US20080253973A1 - Sensation modifying topical composition foam - Google Patents
Sensation modifying topical composition foam Download PDFInfo
- Publication number
- US20080253973A1 US20080253973A1 US11/971,197 US97119708A US2008253973A1 US 20080253973 A1 US20080253973 A1 US 20080253973A1 US 97119708 A US97119708 A US 97119708A US 2008253973 A1 US2008253973 A1 US 2008253973A1
- Authority
- US
- United States
- Prior art keywords
- sensation
- agents
- agent
- composition
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SFSLWUCWGJUOAC-NRDTZQLNSA-N C=C(C)[C@@H]1CC[C@@H](C)C[C@H]1O.CC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)CCC(=O)O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)CCCC(=O)O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)OCC(O)CO.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)OCCO.C[C@@H]1CC[C@@H](C(C)(C)O)[C@@H](O)C1.C[C@@H]1CC[C@@H](C(C)(C)O)[C@H](O)C1 Chemical compound C=C(C)[C@@H]1CC[C@@H](C)C[C@H]1O.CC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)CCC(=O)O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)CCCC(=O)O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)OCC(O)CO.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)OCCO.C[C@@H]1CC[C@@H](C(C)(C)O)[C@@H](O)C1.C[C@@H]1CC[C@@H](C(C)(C)O)[C@H](O)C1 SFSLWUCWGJUOAC-NRDTZQLNSA-N 0.000 description 1
- YZPGDFPKPUBFFS-JFKAKTETSA-N CC(C)[C@@H]1CC[C@@H](C)C2(CC[C@H](C)O)C[C@@H]12 Chemical compound CC(C)[C@@H]1CC[C@@H](C)C2(CC[C@H](C)O)C[C@@H]12 YZPGDFPKPUBFFS-JFKAKTETSA-N 0.000 description 1
- DUMNSKCQOBMGNC-DHPBMWFESA-N CC(C)[C@@H]1CC[C@@H](C)CC1=O.CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O.CC(C)[C@@H]1CC[C@H](C)C[C@@H]1O.CC(C)[C@@H]1CC[C@H](C)C[C@H]1O.CC(C)[C@@]12CC[C@](C)(C(=O)C1)C2(C)C.CC(C)[C@H]1CC[C@@H](C)C[C@@H]1O.CC(C)[C@H]1CC[C@@H](C)C[C@H]1O.CC(C)[C@H]1CC[C@H](C)C[C@@H]1O.CC(C)[C@H]1CC[C@H](C)C[C@H]1O.CC(C)[C@H]1CC[C@H](C)[C@@H](O)C1.CC12CCC(CC1)C(C)(C)O2.CC1=CC=C(C(C)C)C(O)=C1.CC1=CC[C@@H](C(C)C)CC1=O Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1=O.CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O.CC(C)[C@@H]1CC[C@H](C)C[C@@H]1O.CC(C)[C@@H]1CC[C@H](C)C[C@H]1O.CC(C)[C@@]12CC[C@](C)(C(=O)C1)C2(C)C.CC(C)[C@H]1CC[C@@H](C)C[C@@H]1O.CC(C)[C@H]1CC[C@@H](C)C[C@H]1O.CC(C)[C@H]1CC[C@H](C)C[C@@H]1O.CC(C)[C@H]1CC[C@H](C)C[C@H]1O.CC(C)[C@H]1CC[C@H](C)[C@@H](O)C1.CC12CCC(CC1)C(C)(C)O2.CC1=CC=C(C(C)C)C(O)=C1.CC1=CC[C@@H](C(C)C)CC1=O DUMNSKCQOBMGNC-DHPBMWFESA-N 0.000 description 1
- LDKYIDMKQBHBHN-GYGKXAALSA-N CC(C)[C@@H]1CC[C@@H](C)C[C@@]12OCC(CO)O2.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)CCC(=O)O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)CCCC(=O)O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)OCCO.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(C)(O)CO.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(O)CO Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@]12OCC(CO)O2.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)CCC(=O)O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)CCCC(=O)O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)OCCO.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(C)(O)CO.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(O)CO LDKYIDMKQBHBHN-GYGKXAALSA-N 0.000 description 1
- TWGJSVDRHUMVOR-YNLFINFISA-N CC(C)[C@@H]1CC[C@@H](C)C[C@@]12OCC(CO)O2.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)OCCO.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O.CC(O)COC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@]12OCC(CO)O2.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)OCCO.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O.CC(O)COC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C TWGJSVDRHUMVOR-YNLFINFISA-N 0.000 description 1
- VMQASNTXXRJQRI-UTYLMDFPSA-N CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(C)(O)CO.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(O)CO Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(C)(O)CO.CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(O)CO VMQASNTXXRJQRI-UTYLMDFPSA-N 0.000 description 1
- FLYJSXDJKBHQAU-IBSWDFHHSA-N CC(O)COC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C Chemical compound CC(O)COC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C FLYJSXDJKBHQAU-IBSWDFHHSA-N 0.000 description 1
- VVTFZFCQDDVRTF-UHFFFAOYSA-N CC1=C(N2CCCC2)C(=O)CO1.CC1=C(N2CCCC2)C(=O)OC1.CC1=C(N2CCCC2)C(=O)OC1.CC1=C(N2CCCC2)C(=O)OC1C.CC1=CC(C2=CCN(C3=CC=CC=C3O)C(=O)N2)=CC=C1.CCCNC(=O)C(C)(C(C)C)C(C)C.CNC(=O)C(C)(C(C)C)C(C)C.O=C1NC(C2=CC=CC([N+](=O)[O-])=C2)=CCN1C1=CC=CC=C1O.[S-23]=[W] Chemical compound CC1=C(N2CCCC2)C(=O)CO1.CC1=C(N2CCCC2)C(=O)OC1.CC1=C(N2CCCC2)C(=O)OC1.CC1=C(N2CCCC2)C(=O)OC1C.CC1=CC(C2=CCN(C3=CC=CC=C3O)C(=O)N2)=CC=C1.CCCNC(=O)C(C)(C(C)C)C(C)C.CNC(=O)C(C)(C(C)C)C(C)C.O=C1NC(C2=CC=CC([N+](=O)[O-])=C2)=CCN1C1=CC=CC=C1O.[S-23]=[W] VVTFZFCQDDVRTF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/16—Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/87—Polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
- A61K2800/242—Exothermic; Self-heating; Heating sensation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
- A61K2800/244—Endothermic; Cooling; Cooling sensation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
Definitions
- compositions of various types have incorporated within them components or agents which provide a sensation to mucosal membranes and/or to skin.
- the sensation may be a warming, cooling, relaxation stimulation or refreshing feeling or a combination of two or more feelings.
- the sensation or feeling may be real or artificial.
- Compositions which include a sensation agent include, inter alia, toothpastes, mouthwashes, perfumes, lotions, shaving cream, shampoos, antiperspirants, deodorants, beverages, chewing gum, tobacco products, and pharmaceutical products.
- compositions known to date comprising one or more sensation agents, cannot retain the sensation at the site of application thereof in a subject over extended periods of time.
- topical formulations do not retain the sensational effect for more than a few seconds.
- the sensation agent may be volatile, such as menthol, used for providing a topical cooling effect, and the formulation may not retain the active agent for more than a few seconds.
- cooling and warming sensation or sensation modification for example is poorly understood at present. It has been suggested that, among other options, the action of menthol and other cooling agents and capsaicin, camphor and other heat compounds occurs via “thermoreceptors” that register “cool” and “hot” sensation, respectively. It has been suggested that the ‘cooling’ effect of menthol is a physiological effect due to the direct action of menthol on the nerve endings of the human body responsible for the detection of hot or cold and is not due to latent heat of evaporation such that menthol acts as a direct stimulus on the cold receptors at the nerve endings which, in turn, stimulate the central nervous system.
- Substances which are known to provide a sensation of warmth or warmth modulation on application and are called “warming agents” include polyhydric alcohols, capsicum (red pepper) powder, a capsicum tincture, capsicum extract, capsaicin, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives, such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal,
- Foams are considered a more convenient vehicle for topical delivery of active agents.
- topical foams including aqueous foams, such as commonly available shaving foams; hydroalcoholic foams, emulsion-based foams, comprising oil and water components and oleaginous foams, which consist of high oil content, and which are foamable compositions having a specific surfactant selected from the group consisting of ethoxylated lanolin oil, propoxylated lanolin oil, and mixtures thereof and high levels of water that produce fast breaking foams that disappears rapidly into the skin with cooling sensation is described.
- Some formulations make a sound or crackling effect when foam is dispensed.
- Dimethyl ether is a substance which evaporates very rapidly and its use with an aqueous non emollient gel composition, lotion composition and a solution in producing a cooling effect (as opposed to mere sensation without cooling).
- High levels of propellant have also been used to provide a solid or semi ointment deposit with a temperature between minus to plus 5° C.
- Foam forming refrigerant compositions suitable for emergency treatment of burns have also been described.
- Foams and, in particular, foam emulsions are complicated systems which do not form under all circumstances. Changes in foam emulsion composition, such as by the addition of active ingredients may destabilize the foam. There is, therefore, a need for a foam composition, which provides desirable properties to the skin and can remain stable whilst accommodating a variety of sensation agents or active ingredients.
- Formulations based on oil or ointment or emollients have a number of useful attributes making them suitable candidates for topical pharmaceutical and cosmetic compositions including foamable compositions. They are inherently stable and inert which are clearly desirable characteristics. They are able to moisturize and soften the skin and in appropriate amounts can act as a protective or barrier layer and can form a barrier to water. By appropriate formulation they can act to improve agent delivery to the skin and yet remain resistant to being washed off. On the other hand they are by their nature greasy materials and can be difficult to formulate particularly into a topical foamable composition that can deliver substantially uniform and stable composition or foam that ameliorates or overcomes the look and feel of a greasy material, especially where that composition is waterless or substantially so. It is further a problem to incorporate into such a vehicle, effective amounts of one or more active sensation and/or pharmaceutical ingredients such that they are uniformly present throughout the formulation and are effectively delivered without the use of a lower alcohol in the formulation.
- the application relates to aqueous foamable vehicles capable of delivering one or more sensation agents to a body surface in a breakable foam of quality.
- the aqueous vehicles may be emulsion or gel vehicles.
- the application also relates to non aqueous foamable vehicles capable of delivering one or more sensation agents to a body surface in a breakable foam of quality. Upon contact with the body surface an effective amount of one or more sensory agents are capable of causing a perceived sensory effect.
- the formulations are resistant to aging as indicated by their ability to withstand centrifugation. In other embodiments the formulations have a significant and suitable collapse time of 300 or more seconds.
- the formulations are considered to be pleasant for use.
- foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a cooling or warming sensation over a sustained period of time.
- the sustained period of time is at least five minutes, more preferably, at least 15 minutes, yet more preferably, at least 30 minutes, still more preferably, at least one hour.
- the sensation may be felt for up to two hours or more.
- a stable foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing, soothing, stimulating or refreshing sensation.
- a stable foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is a combination of two or more sensations.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is further modulated, potentiated, increased, reduced, or ameliorated by the presence of a sensation modifying agent.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is complementary, supplementary or in addition to or superimposed on a cosmetic, therapeutic or pharmaceutical effect.
- foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially non aqueous carrier.
- foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially aqueous emollient carrier.
- This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to foamable pharmaceutical and cosmetic compositions, containing an active agent, having a sensation or sensation modifying affect on a body surface, upon application.
- a stable foamable composition that is stable on a surface at the delivery site for at least one minute, more preferably, at least two minutes, yet more preferably, for at least five minutes.
- compositions for providing a subject with at least one sensation at a delivery site for a sustained period of time including:
- the composition does not effect a substantial temperature change to the surface.
- the cooling agent is selected from menthol; an isomer of menthol, a menthol derivative; 4-Methyl-3-(1-pyrrolidinyl)-2[5H]-furanone; WS-23, Icilin, Icilin Unilever Analog, 5-methyl-4-(1-pyrrolidinyl)-3-[2H]-furanone; 4,5-dimethyl-3-(1-pyrrolidinyl)-2[5H]-furanone; isopulegol, 3-(I-menthoxy)propane-1,2-diol, 3-(I-menthoxy)-2-methylpropane-1,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6-isopropyl-9-methyl-1,4-dioxas-piro[4,5]decane-2-methanol, menthyl succinate and its alkaline earth metal salt
- the menthol derivative is selected from the group consisting of: menthol ethylene glycol carbonate, which is now known as Frescolat® type MGC, menthol Propylene Glycol Carbonate (Frescolat® type MPC), menthyl lactate (Frescolat ML®) and Menthone Glycerin Acetal (Frescolat MGA®) and 3-(I-Menthoxy)-1,2-propanediol.
- Frescolat® type MGC menthol Propylene Glycol Carbonate
- Frescolat ML® menthyl lactate
- Menthone Glycerin Acetal Fescolat MGA®
- the warming agent is selected from polyhydric alcohols, capsaicin, capsicum powder, a capsicum tincture, capsicum extract, capsaicin, hamamalis, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives, such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal, ginger extract, ginger oil, gingeo
- the relaxing or soothing agent is selected from a herb extracts, selected from the group consisting of aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, yarrow; calendula , comfrey, witch hazel and other astringents, sea weed, and oat extracts; oils, selected from the group consisting of: almond oil, avocado oil, and comfrey; and essential oils, selected from the group consisting of: cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary; waxy or unctuous substances selected from the group consisting of: lanolin or vaselline jelly, minerals, selected from the group consisting of: zinc oxide, calamine and selenium; vitamins, selected from the group consisting of: tocopheryl acetate (vitamin E), and pharmaceutical agents selected from the group consisting of: analges
- compositions wherein the stimulating or refreshing agent is selected from an alcohol, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate, acetyl choline, serotonin, histamine, a prostaglandin, a neurotransmitter; a CNS stimulant, caffeine and quinine.
- the stimulating or refreshing agent is selected from an alcohol, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate, acetyl choline, serotonin, histamine, a prostaglandin, a neurotransmitter; a CNS stimulant, caffeine and quinine.
- the short term stable foam is stable at the delivery site for at least one minute. In some further cases, the short term stable foam is stable at the delivery site for at least five minutes.
- the sustained period of time is at least 15 minutes. According to some further embodiments, the sustained period of time is at least 30 minutes. In some further cases, the sustained period of time is at least one hour.
- compositions wherein the foamable carrier is at a concentration of about 40% to about 99% by weight of the total composition excluding propellant and is selected from the group consisting of an aqueous emulsion, and aqueous gel and a non aqueous carrier
- the carrier includes:
- At least one surface active agent at a concentration of about 0.1% to about 10% by weight of the carrier
- At least one polymeric agent at a concentration of about 0.1% to about 5% by weight of the total composition
- the non aqueous solvent is in the case of the aqueous emulsion, a hydrophobic emollient; in the case of the aqueous gel, a penetration enhancer; and in the case of the non aqueous carrier, a polyol.
- compositions wherein the at least one emollient is selected from the group consisting of: avocado oil, isopropyl myristate, mineral oil; capric triglyceride, capryllic triglyceride mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl
- the at least one stabilizing surface active agent is selected from the group consisting of: stearyl alcohol; steareth-2, steareth-21; polysorbate 80, PEG-40 stearate, glyceryl monostearate, cetostearyl alcohol, laureth 4, and Ceteareth-20, or is a combination of at least two surfactants selected from the group consisting of combinations of polyoxyethylene alkyl ethers, particularly Brij 59/Brij10; Brij 52/Brij 10; Steareth 2/Steareth 20; Steareth 2/Steareth 21 (Brij 72/BRIJ 721); Myrj 52/Myrj 59; combinations of sucrose esters, particularly Surphope 1816/Surphope 1807; combinations of sorbitan esters, particularly Span 20/Span 80; Span 20/Span 60; combinations of sucrose esters and sorbitan esters, particularly Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG compounds
- the at least one polymeric agent is selected from the group consisting of: locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hypromellose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl
- the foamable carrier further includes one or more of the following:
- a co-emulsifier or foam stabilizer at a concentration of about 0.1% to about 5% by weight of the total composition
- a wax, viscosity, bulking or firming agent at a concentration of about 0.1% to about 15% by weight of the total composition
- a penetration enhancer or potent solvent at a concentration of about 0.1% to about 25% by weight of the total composition
- a foam adjuvant agent selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain at a concentration of about 0.1% to about 25% by weight of the total composition;
- a stabilizer at a concentration of about 5% to about 30% by weight of the total composition
- an agent capable of having an occlusive effect at a concentration of about 5% to about 30% by weight of the total composition is an agent capable of having an occlusive effect at a concentration of about 5% to about 30% by weight of the total composition.
- the propellant is a cooling agent.
- the composition further includes at least one additional active agent.
- the at least one additional active agent includes, according to some embodiments, a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
- the at least one additional active agent is selected from the group consisting of active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antiburn agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, cal tar
- compositions wherein the foamable carrier includes at least one carrier medium, selected from the group consisting of water, an oil, a silicone oil, an alcohol, a polyol, a polyethylene glycol (PEG), a propylene glycol, and a solvent or combinations thereof.
- carrier medium selected from the group consisting of water, an oil, a silicone oil, an alcohol, a polyol, a polyethylene glycol (PEG), a propylene glycol, and a solvent or combinations thereof.
- the foamable carrier further includes a polar solvent.
- compositions further including an additional component selected from the group consisting of an anti-perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, moisturizer, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamin.
- an additional component selected from the group consisting of an anti-perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant,
- compositions wherein the sensation or sensation modifying is selected from the group consisting of:
- a combination of a cooling; a warming and stimulating or refreshing agent a combination of a cooling; a warming and stimulating or refreshing agent.
- compositions wherein the propellant provides an initial cooling sensation combined with a sensation agent to provide a prolonged sensation.
- the foamable carrier further contains a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
- a foam adjuvant agent selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
- the composition includes:
- the at least one sensation or sensation modifying agent including menthol in a concentration of 0.5 to about 3% by weight
- the at least one active agent includes:
- coal tar extract in a concentration of around 2% up to around 20% by weight
- the menthol is adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar extract.
- compositions wherein:
- the at least one sensation or sensation modifying agent includes menthol crystals in a concentration of 0.5 to about 3% by weight;
- the at least one active agent includes:
- coal tar in a concentration of around 2% up to around 20% by weight
- hydrocortisone butyrate in a concentration of around 0.5% up to around 10% by weight
- the menthol crystals are adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar.
- a method for providing a subject with at least one sensation at a delivery site including administering to the delivery site of the subject a composition including:
- At least one sensation or sensation modifying agent selected from the group of
- composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam
- the method allows for the foam being stable at the delivery site for at least one minute. In some cases, the foam is stable at the delivery site for at least five minutes.
- the method allows for the subject to sense the at least one sensation at the delivery site for at least at least 15 minutes. In some cases, the subject senses the at least one sensation at the delivery site for at least 30 minutes. In some further cases, the subject senses the at least one sensation at the delivery site for at least one hour. In yet some further cases, the subject senses the at least one sensation as increasing, peaking and decreasing over the sustained period of time.
- the method allows for the subject to sense at least one sensation at the delivery site selected from a cooling sensation, a warming sensation, a heating sensation, a soothing sensation, a relaxing sensation, a stimulating sensation and a refreshing sensation.
- the administration step further includes spreading the foam over a surface at the delivery site.
- the delivery site is selected from the group consisting of the skin, a body cavity, a mucosal surface, the nose, the mouth, the eye, the ear canal, the respiratory system, the vagina and the rectum.
- the method includes administering compositions further including at least one additional active agent.
- the at least one additional active agent includes a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
- the at least one additional active agent is selected from the group consisting of active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antiburn agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, cal tar,
- the method further includes treating a disorder selected from the group consisting of dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, eethyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post-surgical skin conditions
- the foamable composition includes:
- a foamable base composition for use with a sensation or sensation modifying agent comprising
- the foamable composition further comprises at least one component, selected from the group consisting of:
- the foamable composition further comprises at least one component, selected from the group consisting of:
- the foamable waterless carrier composition comprises:
- foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a cooling or warming sensation.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing or soothing sensation.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing, soothing, stimulating or refreshing sensation.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is a combination of two or more sensations.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is further modulated, potentiated, increased, reduced, or ameliorated by the presence of a sensation modifying agent.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is complementary, supplementary or in addition to or superimposed on a cosmetic, therapeutic or pharmaceutical effect.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially non-aqueous carrier.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially aqueous emollient carrier.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that the sensation or sensation modifying effect is of short, medium or long term duration or grades thereof.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that onset of sensation or sensation modifying effect is of a quick, medium or slow onset or grades thereof.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that the relative overall magnitude of sensation or sensation modifying effect is of a mild, medium or strong magnitude or grades thereof.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect increases peaks and then decreases.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect is with no or little skin irritation.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect comprises a fragrance.
- a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect can be useful, beneficial or therapeutic in cosmetic, toiletry, bath additive, and pharmaceutical compositions.
- the composition further contains a compatible fragrance so as for example to provide in addition aromatherapy on application of the sensation foam.
- the composition further contains a compatible washable pigment so as to provide an attractive color to the dispensed foam.
- the composition is a waterless composition with hygroscopic ingredients, which upon absorbing water present on a body surface give an initial warming sensation in addition to the prolonged sensation of the sensation agent.
- foamable compositions using more than one different foamable platforms or carriers. More specifically it was discovered, for example, that effective foamable compositions can be produced with a sensation or sensation modifying effect with a substantially waterless carrier and can also be produced with a substantially aqueous carrier.
- the ability to produce sensation or sensation modifying foam in waterless and aqueous environments allows the production of foams to suit, benefit or improve a wide variety of skin, mucosa and body cavity conditions. Based on this discovery it is possible to develop and create a multitude of foams, which provide a sensation or sensation modifying feeling with the following advantages:
- the propellant is at a concentration from about 3% to about 25% by weight of the total composition.
- the propellant is at a concentration from about 25% to about 45% by weight of the total composition.
- the foamable base composition is flowable.
- the main carrier solvent is at a concentration of about 40% to about 90% by weight of the total composition.
- the foamable composition further comprises at least one component, selected from the group consisting of:
- the surface active agent is a stabilizing combination of at least two surface active agents.
- the surface active agent is at a concentration of about 0.1% to about 10% by weight of the total composition.
- the polymeric agent is at a concentration of about 0.05% to about 5% by weight of the total composition.
- the surface active agent is combination of at least two surfactants.
- the polymeric agent is preferably a combination of hydroxy propylmethyl cellulose and xantham gum.
- the polymeric agent is sodium carboxymethyl-cellulose, hydroxyethyl-cellulose, microcrystalline-cellulose, aluminum starch octyl succinate, and polyacrylates such as carbopol.
- the polymeric agent is preferably a hydroxypropyl-cellulose such as Klucel EF, aluminum starch octyl succinate, and polyacrylates such as carbopol.
- the co-emulsifier is at a concentration of about 0.05% to about 10% by weight of the total composition.
- the viscosity, bulking or firming agent is at a concentration of about 0.1% to about 15% by weight of the total composition.
- the stabilizer is at a concentration of about 0.1% to about 10% by weight of the total composition.
- the co-solvent is at a concentration of about 0.1% to about 30% by weight of the total composition.
- the penetration enhancer is at a concentration of about 0.1% to about 30% by weight of the total composition.
- the agent capable of having an occlusive effect is at a concentration of about 0.1% to about 30% by weight of the total composition.
- a sensation or sensation modifying topical composition wherein the resultant foam has a density of about 0.01 to about 0.2 g/ml.
- a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 60 seconds or more.
- a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 120 seconds or more.
- a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 300 seconds or more.
- the foamable sensation modifying topical composition is an aqueous composition, containing water and further comprises a surface active agent.
- the foamable sensation modifying topical composition comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent.
- the foamable sensation modifying topical composition is an emulsion, comprising water, a hydrophobic solvent, a surface-active agent and a polymeric agent.
- the emulsion-type foamable composition further contains a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
- a foam adjuvant agent selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
- the emulsion is an oil in water emulsion, while in additional embodiments the emulsion is a water in oil emulsion.
- the hydrophobic carrier is an oil.
- oils include mineral oil, silicone oil, a triglyceride and an ester of a fatty acid.
- the hydrophobic solvent is occlusive, such as petrolatum, while in other embodiments the hydrophobic carrier in non-occlusive.
- the foamable sensation modifying topical composition is an oleaginous foamable composition, including at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a polar solvent and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent and at least one polymeric agent.
- the foamable sensation modifying topical composition includes more than 50% of a polar solvent (as used herein, the term “polar solvent” shall mean a material that produces a uniform, clear or hazy, mixture when combined with at least a weight equivalent of water), a surface-active agent and a polymeric agent.
- a polar solvent shall mean a material that produces a uniform, clear or hazy, mixture when combined with at least a weight equivalent of water
- the foamable composition contains up to 80% water, while in additional embodiments the foamable composition contains up to 25% water.
- the composition is substantially alcohol free
- the composition is substantially non-aqueous.
- a method of treating, alleviating or preventing a dermatological reaction, sensation or disorder of a mammalian subject comprising:
- a method of treating, alleviating or preventing a dermatological reaction, sensation or disorder of a mammalian subject comprising:
- hydrophobic solvent refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL.
- the hydrophobic organic carrier is an oil, such as mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl ison
- oil such as mineral
- a “polar solvent” is an organic solvent, typically soluble both in water and oil but is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition.
- the emollient emulsion and waterless formulations may contain polar solvents, which may contribute to the penetration of an active or therapeutic agent including a sensation or sensation modifying agent.
- a polymeric agent can be selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methyl hydroxyeth
- the solvent is a polyol.
- a polyol is an organic substance that contains at least two hydroxy groups in its molecular structure.
- the foamable carrier contains at least one diol (a compound that contains two hydroxy groups in its molecular structure).
- diols include propylene glycol (e.g., 1,2-propylene glycol and 1,3-propylene glycol), butanediol (e.g., 1,2-butanediol, 1,3-butanediol, 2,3-butanediol and 1,4-butanediol), butanediol (e.g., 1,3-butanediol and 1,4-butenediol), butynediol, pentanediol (e.g., pentanediol (e.g., pentane-1,2-diol, pentane-1,3-diol, pentane-1,4-diol, pentane-1,5-diol, pentane-2,3-diol and pent
- the foamable carrier contains at least one triol (a compound that contains three hydroxy groups in its molecular structure), such as glycerin, butane-1,2,3-triol, butane-1,2,4-triol and hexane-1,2,6-triol.
- triol a compound that contains three hydroxy groups in its molecular structure
- the polyol is a mixture of polyols.
- the mixture of polyols contains at least one diol and at least one triol. According to certain embodiments the ratio between the diol and triol is between 9:1 and 1:1.
- part of mixture of polyols is a saccharide.
- exemplary saccharides include, but are not limited to monosaccharide, disaccharides, oligosaccharides and sugar alcohols.
- a monosaccharide is a simple sugar that cannot be hydrolysed to smaller units.
- Exemplary monosaccharide compounds are ribose, glucose, fructose and galactose.
- Disaccharides are made up of two monosaccharides joined together, such as sucrose, maltose and lactose.
- a sugar alcohol also known as a polyol, polyhydric alcohol, or polyalcohol
- saccharide whose carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group. They are commonly used for replacing sucrose in foodstuffs, often in combination with high intensity artificial sweeteners to counter the low sweetness.
- Some exemplary sugar alcohols, which are suitable for use according to the present invention are mannitol, sorbitol, xylitol, maltitol, lactitol. (Maltitol and lactitol are not completely hydrogenated compounds—they are a monosaccharide combined with a polyhydric alcohol).
- Mixtures of polyols, including (1) at least one polyol selected from a diol and a triol; and (2) a saccharide are contemplated within the scope of the present invention.
- the solvent consists of a polymerized ethylene glycol, namely polyethylene glycol, which is also termed “PEG”.
- PEG polyethylene glycol
- the PEG is selected from the group consisting of PEG 200, PEG 300, PEG 400, PEG 600, PEG 1000, PEG 4000, PEG 6000 and PEG 8000.
- the foamable carrier according to the present invention can contain a single PEG or a mixture of two or more PEGs.
- the concentration of the PEG should be in a level that results in viscosity, prior to filling of the composition into aerosol canisters, of less than 12,000 CPs, and more preferably, less than 10,000 CPs.
- a secondary solvent is added to the foamable composition of the present invention.
- the secondary solvent is selected from a variety of organic solvents that are typically miscible on both water and oil.
- solvent that can be contained in the foamable carrier of the present invention include dimethyl isosorbide, tetrahydrofurfuryl alcohol polyethyleneglycol ether (glycofurol), DMSO, pyrrolidones, (such as N-Methyl-2-pyrrolidone and 1-Methyl-2-pyrrolidinone), ethyl proxitol, dimethylacetamide (DMAc), PEG-type surfactants and alpha hydroxy acids, such as lactic acid and glycolic acid.
- DMAc dimethylacetamide
- a “skin penetration enhancer”, also termed herein “penetration enhancer,” is an organic solvent, typically soluble in both water and oil.
- penetration enhancer include polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol, 1-menthol, dioxolane, ethylene glycol, hexylene glycol, other glycols, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, dimethylisosorbide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), azone (1-dodecylazacycloheptan
- the penetration enhancer is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature
- polyols, PEGs and solvents possess a high solubilizing power and thus, they can enable increased concentrations of a pharmaceutical active agent.
- Polyols, PEGs and solvents are also known for their skin penetration enhancement properties. These properties enable high drug bioavailability in the target area of treatment, resulting in an enhanced therapeutic effect.
- combinations of a polyol, PEGs and a secondary solvent exhibit an increased permeability across the skin, as suggested, for example, in Eur. J. Pharm. Biopharm. 1998 Nov. 46(3):265-71.
- the foamable carrier contains (1) at least one solvent, selected from a polyol (selected from a diol and a triol) and PEG; and (2) at least one secondary solvent.
- the foamable carrier contains (1) a mixture of at least two polyols; and (2) at least one secondary solvent. In additional embodiments, the foamable carrier contains a mixture of at least one polyol and at least one PEG; yet in other embodiments the foamable carrier contains (1) a mixture of at least one polyol and at least one PEG and (2) at least one secondary solvent.
- the ratio between the polyol and/or PEG and the secondary solvent is between 9:1 and 1:1.
- the polyol is selected from the group consisting of propylene glycol, hexylene glycol and glycerin (and mixtures thereof); and the secondary solvent is selected from the group consisting of dimethyl isosorbide, diethylene glycol monoethyl ether, a liquid polyethylene glycol and glycofurol.
- the foamable carrier contains (1) at least one polyol; and (2) dimethyl isosorbide.
- the foamable composition includes a potent solvent, in addition to, or in place, of one of the hydrophobic solvents, polar solvents or emollients of the composition.
- a potent solvent is a solvent other than mineral oil that solubilizes a specific active agent substantially better than a hydrocarbon solvent such as mineral oil or petrolatum.
- a potent solvent solubilizes the active agent 5 fold better than a hydrocarbon solvent; or even solubilizes the active agent 10-fold better than a hydrocarbon solvent.
- the composition includes at least one active agent in a therapeutically effective concentration; and at least one potent solvent in a sufficient amount to substantially solubilize the at least one active agent in the composition.
- substantially soluble means that at least 95% of the active agent has been solubilized, i.e., 5% or less of the active agent is present in a solid state.
- the concentration of the at least one potent solvent is more than about 40% of the at least one solvent of the composition of the present invention; or even more than about 60%.
- Non-limiting examples of pairs of active agent and potent solvent include: Betamethasone valerate: Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1% in glycofurol; Hydrocortisone butyrate: Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1% in glycofurol; Metronidazole: Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1% in dimethyl isosrbide; Ketoconazole: Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1% in glycofurol, propylene glycol and dimethyl isosrbide; Mupirocin: Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1% in glycofurol, hexylene glycol, dimethyl isosorbide, propylene glycol and polyethylene glycol 400 (PEG 400); Meloxicam, a nonsteroidal anti-inflammatory agent: Practically insoluble in mineral oil ( ⁇ 0.001%); soluble in propylene glyco
- a non-limiting exemplary list of solvents that can be considered as potent solvents includes polyethylene glycol, propylene glycol, hexylene glycol, butaneediols and isomers thereof, glycerol, benzyl alcohol, DMSO, ethyl oleate, ethyl caprylate, diisopropyl adipate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, isosorbide derivatives, such as dimethyl isosorbide, glycofurol and ethoxydiglycol (transcutol) and laurocapram.
- a potent solvent in a foam composition provides an improved method of delivering poorly soluble therapeutic agents to a target area. It is known that low drug solubility results in poor bioavailability, leading to decreased effectiveness of treatment. Foam compositions of the present invention, for which the solvent includes a potent solvent, increase the levels of the active agent in solution and thus, provide high delivery and improved therapy.
- Potent solvents as defined herein, are usually liquid. Formulations comprising potent solvents and active agents are generally disadvantageous as therapeutics, since their usage involves unwanted dripping and inconvenient method of application; resulting in inadequate dosing. Surprisingly, the foams of the present invention, which are drip-free, provide a superior vehicle for such active agents, enabling convenient usage and accurate effective dosing.
- the foamable pharmaceutical composition may additionally include a mixture of two or more of the solvents selected from the group of hydrophobic solvents, silicone oils, emollients, polar solvents and potent solvents in an appropriate proportion as would be appreciated to a person skilled in the art.
- the PPG alkyl ether may act as a potent solvent.
- the composition further contains a surface-active agent.
- Surface-active agents include any agent linking oil and water in the composition, in the form of emulsion.
- a surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. HLB is defined for non-ionic surfactants. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics.
- Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions.
- the HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average).
- a single surfactant may suffice.
- a combination of two or more surfactants is desired.
- Reference to a surfactant in the specification can also apply to a combination of surfactants or a surfactant system. As will be appreciated by a person skilled in the art which surfactant or surfactant system is more appropriate is related to the vehicle and intended purpose. In general terms a combination of surfactants can be significant in producing breakable forms of good quality.
- the composition contains a single surface active agent having an HLB value between about 2 and 9, or more than one surface active agent and the weighted average of their HLB values is between about 2 and about 9.
- the composition contains a single surface active agent having an HLB value between about 7 and 14, (preferably about 7 to about 12) or more than one surface active agent and the weighted average of their HLB values is between about 7 and about 14 (preferably about 7 to about 12).
- the composition contains a single surface active agent having an HLB value between about 9 and about 19, or more than one surface active agent and the weighted average of their HLB values is between about 9 and about 19.
- HLB values may be suitable.
- the composition contains a non-ionic surfactant.
- non-ionic surfactants include a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59; a polyoxyethylene alkyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, steareths such as steareth 2, brij 21, brij 721, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol and its anhydrides, sorbitan monolaurate, sorbitan monolaurate, a monoglyceride, a diglyceride, isoceteth-20 and mono
- the surfactant is an ether for example polyoxyethylene (26) glycerol ether.
- surfactants are selected which can provide a close packed surfactant layer.
- combinations of at least two surfactants are selected.
- they should be complex emulgators and more preferably they should both be of a similar molecular type; for example, a pair of ethers, like steareth 2 and steareth 21, or a pair of esters, for example, PEG-40 stearate and polysorbate 80.
- the surfactants can be ethers.
- POE esters cannot be used and a combination of sorbitan laurate and sorbitan stearate or a combination of sucrose stearic acid ester mixtures and sodium laurate may be used. All these combinations due to their versatility and strength may also be used satisfactorily and effectively with ether formulations, although the amounts and proportion may be varied according to the formulation and its objectives as will be appreciated by a man of the art.
- a series of dextrin derivative surfactants prepared by the reaction of the propylene glycol polyglucosides with a hydrophobic oxirane-containing material of the glycidyl ether are highly biodegradable.
- Non-limiting examples of non-ionic surfactants that have HLB of about 7 to about 12 include steareth 2 (HLB ⁇ 4.9); glyceryl monostearate/PEG 100 stearate (Av HLB ⁇ 11.2); stearate Laureth 4 (HLB ⁇ 9.7) and cetomacrogol ether (e.g., polyethylene glycol 1000 monocetyl ether).
- Non-limiting examples of preferred surfactants which have a HLB of 4-19 are set out in the Table below:
- HLB steareth 2 ⁇ 4.9 glyceryl monostearate/PEG 100 stearate Av ⁇ 11.2 Glyceryl Stearate ⁇ 4 Steareth-21 ⁇ 15.5 peg 40 stearate ⁇ 16.9 polysorbate 80 ⁇ 15 sorbitan stearate ⁇ 4.7 laureth 4 ⁇ 9.7 Sorbitan monooleate (span 80) ⁇ 4.3 ceteareth 20 ⁇ 15.7 steareth 20 ⁇ 15.3 ceteth 20 ⁇ 15.7 Macrogol Cetostearyl Ether ⁇ 15.7 ceteth 2 (Lipocol C-2) ⁇ 5.3 PEG-30 Dipolyhydroxystearate ⁇ 5.5 sucrose distearate (Sisterna SP30) ⁇ 6 polyoxyethylene (100) stearate ⁇ 18.8
- Sepigel 305 Another component of the formulations of the present invention is a compound used in the present invention is Sepigel 305.
- Sepigel 305 comprises Polyacrylamide and C13-14 Isoparaffin and Laureth-7. It acts as a surfactant and as a thickening and emulsifying agent, and comes in a liquid, very easy to handle form. It requires neither premixing, nor high rate of shear nor neutralisation.
- Sepigel 305 can be used to emulsify all types of oil phase without heating, producing gel-cream with a rich, silky texture that are easy to apply and rapidly absorbed by the skin.
- PEG-Fatty Acid Monoester Surfactants such as:
- PEG-Fatty Acid Diester Surfactants such as:
- Polyglycerized Fatty Acids such as:
- PEG-Sorbitan Fatty Acid Esters such as:
- Polyethylene Glycol Alkyl Ethers such as:
- Sorbitan Fatty Acid Ester Surfactants such as:
- the surface active agent is a complex emulgator in which the combination of two or more surface active agents can be more effective than a single surfactant and provides a more stable formulation or improved foam quality than a single surfactant.
- the complex emulgator comprises a combination of surfactants wherein there is a difference of about 4 or more units between the HLB values of the two surfactants or there is a significant difference in the chemical nature or structure of the two or more surfactants.
- surfactant systems are, combinations of polyoxyethylene alkyl ethers, such as Brij 59/Brij10; Brij 52/Brij 10; Steareth 2/Steareth 20; Steareth 2/Steareth 21 (Brij 72/Brij 721); combinations of polyoxyethylene stearates such as Myrj 52/Myrj 59; combinations of sucrose esters, such as Surphope 1816/Surphope 1807; combinations of sorbitan esters, such as Span 20/Span 80; Span 20/Span 60; combinations of sucrose esters and sorbitan esters, such as Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG compounds, such as Tween 80/PEG-40 stearate; methyl glucaso sequistearate; polymeric emulsifiers, such as Permulen (TRI or TR2); liquid crystal systems, such as Arlatone (2121), Stepan (Mild RM1), Nikomules
- the surfactant is preferably one or more of the following: a combination of steareth-2 and steareth-21 on their own or in combination with glyceryl monostearate (GMS); in certain other embodiments the surfactant is a combination of polysorbate 80 and PEG-40 stearate. In certain other embodiments the surfactant is a combination of glyceryl monostearate/PEG 100 stearate. In certain other embodiments the surfactant is a combination of two or more of stearate 21, PEG 40 stearate, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of laureth 4, span80, and polysorbate 80.
- the surfactant is a combination of two or more of GMS and ceteareth. In certain other embodiments the surfactant is a combination of two or more of steareth 21, ceteareth 20, ceteth 2 and laureth 4 In certain other embodiments the surfactant is a combination of ceteareth 20 and polysorbate 40 stearate. In certain other embodiments the surfactant is a combination of span 60 and GMS. In certain other embodiments the surfactant is a combination of two or all of PEG 40 stearate, sorbitan stearate and polysorbate 60
- the surfactant is one or more of sucrose stearic acid esters, sorbitan laureth, and sorbitan stearate.
- non-ionic surfactants with significant hydrophobic and hydrophilic components, increase the emulsifier or foam stabilization characteristics of the composition.
- using combinations of surfactants with high and low HLB's to provide a relatively close packed surfactant layer may strengthen the formulation.
- the stability of the composition can be improved when a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed.
- the ratio between the at least one non-ionic surfactant having HLB of less than 9 and the at least one non-ionic surfactant having HLB of equal or more than 9, is between 1:8 and 8:1, or at a ratio of 4:1 to 1:4.
- the resultant HLB of such a blend of at least two emulsifiers is preferably between about 9 and about 14.
- a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed, at a ratio of between 1:8 and 8:1, or at a ratio of 4:1 to 1:4, wherein the HLB of the combination of emulsifiers is preferably between about 5 and about 18.
- the surface active agent is selected from the group of cationic, zwitterionic, amphoteric and ampholytic surfactants, such as sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
- amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two incompatible components on a nanometer scale. Soap is an everyday example of a lyotropic liquid crystal.
- surfactants tend to form lyotropic liquid crystals in emulsions interface (oil-in-water) and exert a stabilizing effect
- the surfactant is a surfactant or surfactant combination is capable of or which tends to form liquid crystals.
- Surfactants which tend to form liquid crystals may improve the quality of foams.
- Non limiting examples of surfactants with postulated tendency to form interfacial liquid crystals are: phospholipids, alkyl glucosides, sucrose esters, sorbitan esters.
- the at least one surface active agent is liquid. Moreover for the purposes of formulating with liquid ethers a liquid surfactant is preferred.
- the liquid surfactant is a polysorbate, preferably polysorbate 80 or 60.
- the at least one surface active agent is solid, semi solid or waxy. In a further embodiment they are soluble in oil and in another embodiment have a HLB of less than about 12.
- HLB values may not be so applicable to non ionic surfactants, for example, with liquid crystals or with silicones. Also HLB values may be of lesser significance in a waterless or substantially non-aqueous environment.
- the surfactant can be, a surfactant system comprising of a surfactant and a co surfactant, a waxy emulsifier, a liquid crystal emulsifier, an emulsifier which is solid or semi solid at room temperature and pressure, or combinations of two or more agents in an appropriate proportion as will be appreciated a person skilled in the art.
- a solid or semi solid emulsifier combination it can also comprise a solid or semi solid emulsifier and a liquid emulsifier.
- at least one surfactant is a liquid.
- the surface-active agent includes at least one non-ionic surfactant.
- Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed. Non-ionic surfactants alone can provide formulations and foams of good or excellent quality in the carriers and compositions of the present invention.
- the composition contains a non-ionic surfactant.
- the composition includes a mixture of non-ionic surfactants as the sole surface active agent.
- the foamable composition includes a mixture of at least one non-ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1.
- the non-ionic to ionic surfactant ratio is greater than about 6:1, or greater than about 8:1; or greater than about 14:1, or greater than about 16:1, or greater than about 20:1.
- surface active agent comprises a combination of a non-ionic surfactant and an ionic surfactant, at a ratio of between 1:1 and 20:1.
- a combination of a non-ionic surfactant and an ionic surfactant is employed, at a ratio of between 1:1 and 20:1, or at a ratio of 4:1 to 10:1; for example, about 1:1, about 4:1, about 8:1, about 12:1, about 16:1 and about 20:1 or at a ratio of 4:1 to 10:1, for example, about 4:1, about 6:1, about 8:1 and about 10:1.
- the upper amount of surfactant that may be used may be limited by the shakability of the composition. If the surfactant is non liquid, it can make the formulation to viscous or solid. Subject to its miscibility, solid surfactants may be added first, and may require gentle warming and then cooling before being combined with the other ingredients. In general terms, as the amount of non-liquid surfactant is increased the shakability of the formulation reduces until a limitation point is reached where the formulation can become non shakable and unsuitable. Thus in one embodiment, any effective amount of surfactant may be used provided the formulation remains shakable.
- the upper limit for foamable formulations may be determined by flowability such that any effective amount can be used provided the formulation is sufficiently flowable to be able to flow through an actuator valve and be released and still expand to form a good quality foam. This may be due without being bound by any theory to one or more of a number of factors such as the viscosity, the softness, the lack of crystals, the pseudoplastic or semi pseudo plastic nature of the composition and the dissolution of the propellant into the composition.
- the amount of surfactant or combination of surfactants is between about 0.05% to about 20%; between about 0.05% to about 15%. or between about 0.05% to about 10%.
- the concentration of surface active agent is between about 0.2% and about 8%. In a more preferred embodiments the concentration of surface active agent is between about 1% and about 6% or between about 1% and about 4%.
- the surface active agent does not contain a polyoxyethylene (POE) moiety, such as polysorbate surfactants, POE fatty acid esters, and POE alkyl ethers, because the active agent is incompatible with such surface active agents.
- POE polyoxyethylene
- the active agent pimecrolimus is not stable the presence of POE moieties, yet benefits greatly from the use of dicarboxylic esters as penetration enhancers. In such cases, alternative surface active agents are employed.
- POE—free surfactants include non-ethoxylated sorbitan esters, such as sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate and sorbitan sesquioleate; glycerol fatty acid esters, such as glycerol monostearate and glycerol monooleate; mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), sucrose stearate, sucrose distearate sucrose palmitate and sucrose laurate; and alkyl polyglycosides, such as lauryl diglucoside.
- non-ethoxylated sorbitan esters such as sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate, sorbitan mono
- a humectant is a substance that helps retain moisture and also prevents rapid evaporation.
- Non limiting examples are propylene glycol, propylene glycol derivatives, glycerin, hydrogenated starch hydrosylate, hydrogenated lanolin, lanolin wax, D manitol, sorbitol, sodium 2-pyrrolidone-5-carboxylate, sodium lactate, sodium PCA, soluble collagen, dibutyl phthalate, and gelatin.
- Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
- a moisturizer is a substance that helps retain moisture or add back moisture to the skin.
- examples are allantoin, petrolatum, urea, lactic acid, sodium PCV, glycerin, shea butter, caprylic/capric/stearic triglyceride, candelilla wax, propylene glycol, lanolin, hydrogenated oils, squalene, sodium hyaluronate and lysine PCA.
- Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
- compositions of the present invention may in one or more embodiments usefully comprise in addition a heumectant or a moisturizer or combinations thereof.
- modulating agent is used to describe an agent which can improve the stability of or stabilize a carrier or a foamable composition and or an active agent by modulating the effect of a substance or residue present in the carrier or composition.
- the substance or residue may for example be acidic or basic and potentially alter an artificial pH in a waterless or substantially non aqueous environment or it may be one or more metal ions which may act as a potential catalyst in a waterless or substantially non aqueous environment or it may be an ionisation agent or it may be an oxidizing agent.
- the modulating agent is used in a waterless composition. In one or more embodiments the modulating agent is used to describe an agent which can affect pH in an aqueous solution.
- the agent can be any of the known buffering systems used in pharmaceutical or cosmetic formulations as would be appreciated by a man of the art. It can also be an organic acid, a carboxylic acid, a fatty acid an amino acid, an aromatic acid, an alpha or beta hydroxyl acid an organic base or a nitrogen containing compound.
- the modulating agent is used to describe an agent, which is a chelating or sequestering or complexing agent that is sufficiently soluble or functional in the waterless solvent to enable it to “mop up” or “lock” metal ions.
- modulating agent is used to describe an agent which can effect pH in an aqueous solution
- modulating agent more particularly means an acid or base or buffer system or combinations thereof, which is introduced into or is present in and acts to modulate the ionic or polar characteristics and any acidity or basisity balance of a waterless or substantially non aqueous carrier, composition, foamable carrier or foamable composition or resultant foam described herein.
- pH, pKa, and pKb buffers such measurements and terms are artificial in a waterless environment.
- sufficient modulating agent is added to achieve an artificial pH in which the active agent is preferably stable.
- Such artificial pH may be acidic, maybe basic or may be neutral.
- the modulating or additional component is a pH adjusting agent or a buffering agent.
- the chelating agent is selected from the group consisting of ethylenediaminetetraacetic acid (“EDTA”) and salts thereof such as disodium EDTA, tetrasodium EDTA and calsium disodium EDTA; diethylenetriaminepentaacetic acid (“DTPA”) and salts thereof; hydroxyethlethylenediaminetriacetic acid (“HEDTA”) and salts thereof and nitrilotriacetic acid (“NTA”); more preferably EDTA, HEDTA and their salts; most preferably EDTA and its salts.
- EDTA ethylenediaminetetraacetic acid
- DTPA diethylenetriaminepentaacetic acid
- HEDTA hydroxyethlethylenediaminetriacetic acid
- NTA nitrilotriacetic acid
- a preferred non limiting example of the chelating agent is EDTA.
- the chelating and sequestering agent is present in the composition at a level of up to about 5.0%, preferably 1.0 percent, by weight, of the composition.
- Combinations of Modulating Agents may be a useful for example chelating agents may be usefully used in combination with another modulating agent such as an acid, a base or a buffer system or with various combinations of modulating agents.
- the modulating agent to the foamable composition of the present invention is further useful for adjusting the pH of the target area of application.
- the modulating agent may also be a preservative or an antioxidant or an ionization agent. Any preservative, antioxidant or ionization agents suitable for pharmaceutical or cosmetic application may be used. Non limiting examples of antioxidants are tocopherol succinate, propyl galate, butylated hydroxy toluene and butyl hydroxy anisol. In one or more embodiments the modulating agent is a flavonoid. Ionization agents may be positive or may be negative depending on the environment and the active agent or composition that is to be protected. Ionization agents may for example act to protect or reduce sensitivity of active agents. Non limiting examples of positive ionization agents are benzyl conium chloride, and cetyl pyridium chloride. Non limiting examples of negative ionization agents are sodium lauryl sulphate, sodium lauryl lactylate and phospholipids.
- formulations described herein may further contain a modulating agent.
- the Microsponges are rigid, porous and spongelike round microscopic particles of cross-linked polymer beads (e.g., polystyrene or copolymers thereof), each defining a substantially noncollapsible pore network.
- the Microsponges can be loaded with an active ingredient and can provide a controlled time release of the active ingredient to skin or to a mucosal membrane upon application of the formulation. The slow release is intended to reduce irritation by the active.
- Microsponge® delivery technology was developed by Advanced Polymer Systems.
- the composition comprises one or more active agents loaded into Microponges with an aqueous carrier or with a waterless carrier described herein which may comprise a modulating agent.
- Suitable propellants include volatile hydrocarbons such as butane, propane, isobutane and fluorocarbon gases, or mixtures thereof.
- the propellant is 1681, which is a mixture of propane, isobutene and butane. In another embodiment it is AP 70, which is a mixture of propane, isobutene and butane with a higher pressure.
- the propellant makes up about 5-25 wt % of the foamable composition. In some circumstances the propellant may be up to 35%.
- the propellants are used to generate and administer the foamable composition as a foam.
- the total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable composition.
- Such propellants include, but are not limited to, hydrofluorocarbon (HFC) propellants, which contain no chlorine atoms, and as such, fall completely outside concerns about stratospheric ozone destruction by chlorofluorocarbons or other chlorinated hydrocarbons.
- HFC hydrofluorocarbon
- Exemplary non-flammable propellants include propellants made by DuPont under the registered trademark Dymel, such as 1,1,1,2 tetrafluorethane (Dymel 134), and 1,1,1,2,3,3,3 heptafluoropropane (Dymel 227) 1,1, difluoro ethane (Dymel 152) and 1,1,1,3,3,3 hexafluoropropane HFCs possess Ozone Depletion Potential of 0.00 and thus, they are allowed for use as propellant in aerosol products.
- Dymel 1,1,1,2 tetrafluorethane
- Dymel 227 1,1,1,2,3,3,3 heptafluoropropane
- Dymel 152 1,1,1,2,3,3,3 heptafluoropropane
- Dymel 152 1,1,1,2,3,3,3 heptafluoropropane
- Dymel 152 1,1,1,2,3,3,3 heptafluoropropane
- Dymel 152 1,
- the non inflammbale propellants are used in combination with the more traditional hydrocarbon propellants.
- Dymel is used in such levels that the sensation effect is not primarily due to the propellant.
- foamable emulsions including HFC as the propellant can be improved in comparison with the same composition made with a hydrocarbon propellant.
- foamable compositions comprise a combination of a HFC and a hydrocarbon propellant such as n-butane or mixtures of hydrocarbon propellants such as propane, isobutane and butane.
- a hydrocarbon propellant such as n-butane or mixtures of hydrocarbon propellants such as propane, isobutane and butane.
- Some propellants may have a cooling effect.
- the evaporation of the propellant from newly released foam that has been applied to a body surface can, depending on the nature of the foam and the type and amount of propellant provide a cooling effect.
- the sensation is mild and in other cases the propellant can actually produce physical cooling on the skin surface.
- such cooling effect may increase relative to the ability of the formulation to deliver increasing levels of propellant in contact with the skin.
- Dimethyl ether is a product which evaporates very rapidly to produce a cooling effect and in one or more embodiments is used as part of the propellant system.
- the propellant is a mixture of propane, butane and isobutene.
- the propellant is a mixture of propane, butane and isobutene together with dimethyl ether.
- the propellant makes up about 5-25 wt % of the foamable composition.
- the amount of propellant can be increased to up to less than half of the composition, for example, where it is desired to produce a cooling effect in addition to a cooling sensation or where it is sought to produce an initial cooling effect followed by a cooling or other sensation.
- Additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamin or derivative thereof.
- the additional component is one or more of a colored active agent, a colored excipient, a pigment, a dye, a colorant and a coloring agent.
- the additional component is a fragrance or fragrance masking agent
- the sensation modifying agent is selected from a cooling agent, a warming agent a relaxing or soothing agent; a stimulating agent; a refreshing agent; or mixtures thereof.
- two or more soothing, relaxing, cooling, stimulating, refreshing, and warming agents may be effectively combined in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
- cooling agents substances, which are known to provide a “cool” sensation or cooling effect on or following application to a body surface; and substances that, on or following topical application can ameliorate a hot sensation or a heating effect are called “cooling agents”. Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a cooling sensation or effect or to ameliorate a hot sensation or heating effect, is suitable for use a cooling agent in accordance with the present invention.
- the cooling agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or a propellant or combinations of two or more agents.
- cooling agents which are all incorporated herein by reference are provided in U.S. Pat. Nos. 3,419,543, 4,020,153, 4,032,661, 4,033,994, 4,034,109, 4,059,118, 4,060,091, 4,070,449, 4,070,496, 4,136,163, 4,150,052, 4, 4,153,679, 157,384, 4,178,459, 4,193,936, 4,226,988, 4,230,688, 4,296,255, 4,459,425, 5,266,592, 5,608,119, 5,725,865, 5,773,410, 5,843,466, 5,959,161, 6,214,788, 6,267,974, 6,303,817, 6,328,982, 6,359,168, 6,482,983, 6,592,884, 6,884,906 and 7,030,273 US Patent Application 20040067970, DE 2,202,535, DE 2,205,255, DE 2,503,555, DE 2,608,226, DE 4,22
- the cooling agent has a further sensation or sensation modifying feeling or effect.
- the cooling agent is menthol.
- the cooling agent is an isomer or a derivative of menthol, as exemplifies in the following schemes:
- menthol derivatives are monomenthyl esters of di- and polycarboxylic acids:
- Useful exemplary menthol derivatives are menthol ethylene glycol carbonate, which is now known as Frescolat® type MGC, enthol Propylene Glycol Carbonate (Frescolat® type MPC), menthyl lactate (Frescolat ML®) and Menthone Glycerin Acetal (Frescolat MGA®).
- Cooling Agent 10 3-(/-Menthoxy)-1,2-propanediol, known as Cooling Agent 10; and the same structure with an additional methyl group in the glycerin part of the molecule:
- Menthoxy-coolants are additional cooling menthol derivatives:
- Cubebol is an example of a coolant with a C—C bond in the 3d position of p-menthane.
- Cooling agents which are not menthol derivatives, are also suitable for use in accordance with the present invention. Examples of such cooling agents are provided below:
- Exemplary cooling agents which can be used in the invention include, but are not limited to, menthol, isopulegol, 3-(1-menthoxy)propane-1,2-diol, 3-(1-menthoxy)-2-methylpropane-1,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6-isopropyl-9-methyl-1,4-dioxas-piro[4,5]decane-2-methanol, menthyl succinate and its alkaline earth metal salts, trimethylcyclohexanol, N-ethyl-2-isopropyl-5-methylcyclohexanecarb-oxamide, Japanese mint ( Mentha arvensis ) oil, peppermint oil, menthone, menthone glycerol ketal, menthyl lactate, 3-(1-menthoxy)ethan-1-ol, 3-(I-menthoxy)prop
- the cooling agent is incorporated in the composition in a concentration which, on one side is safe and on the other side provides a cooling sensation or cooling effect upon application of the cooling foamable composition onto a body surface.
- the cooling agent also possesses therapeutic properties.
- menthol is being used in the therapy of psoriasis; relief of nasal complaints and sore throats; and WS-3 (N-Ethyl-p-menthane-3-carboxamide) and related N-substituted p-menthane carboxamides, as well as p-Menthane-3,8-diols are known insect repellents
- warming agents substances, which are known to provide a warming sensation or warming effect on or following application to a body surface; and substances that, upon or following topical application can ameliorate a cold sensation or a cooling effect are called “warming agents”. Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a warming sensation or warming effect or to ameliorate a cold sensation or cooling effect, is suitable for use a warming agent in accordance with the present invention.
- the warming agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or combinations of two or more agents.
- Exemplary substances which are known to provide a sensation of warmth on application and called “warming agents”.
- the warming agent is incorporated in the composition in a concentration which, on one side is safe and on the other side provides a warming sensation or warming effect upon application of the warming foamable composition onto a body surface.
- the warming agent also possesses therapeutic properties.
- capsicum powder, capsicum tincture and extract, as well as capsaicin and homocapsaicin are used for topically treating muscle and joint pain.
- the sensation effect or sensation induced by a first sensation or sensation modifying agent maybe reduced by addition of a second sensation or sensation modifying agent in the composition.
- the cooling sensation of a cooling formulation may be reduced by the presence of a warming or warming modifying agent.
- the warming sensation of a warming formulation may be reduced by the presence of a cooling or cooling modifying agent.
- the composition comprises an effective amount of cooling peppermint oil and a lesser effective amount of capsaicin warming agent such that the cooling sensation is the predominant sensation.
- the composition comprises an effective amount capsaicin of and a lesser effective amount of peppermint oil cooling agent such that the warming sensation is the predominant sensation.
- the cooling and warming agents are selected so that the cooling and warming effects or sensations are staggered.
- the composition comprises an effective amount capsaicin of and an effective amount of dimethyl ether cooling agent such that the cooling sensation is the initial predominant sensation and the warming sensation follows on as the subsequent predominant sensation.
- Other cooling and warming agents may be effectively combined as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
- agents which have a soothing effect there are many different categories of agents which have a soothing effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other soothing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
- Non limiting examples of soothing agents are herb extracts, such as, aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, yarrow; calendula , comfrey, witch hazel and other astringents, sea weed, and oat extracts; oils, such as, almond oil, avocado oil, and comfrey; and essential oils, such as, cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary; waxy or unctuous substances such as lanolin or vaselline jelly, minerals, such as, zinc oxide, calamine and selenium; vitamins, such as, tocopheryl acetate (vitamin E), and drugs, such as, analgesics, anesthetics, anti-inflammatory agents, and anti-histamines, muscle relaxants and the like.
- herb extracts such as, aloe vera,
- menthol camphor
- eugenol eucalyptol
- safrol methyl salicylate
- menthyl lactate menthyl ethoxyacetate
- menthone glycerinacetal 3-I-menthoxypropane-1,2-diol
- ethyl I-menthyl carbonate 1,3S,4R
- menthyl pyrrolidone carboxylate 1, N-substituted-p-menthane-3-carboxamides (as described in U.S. Pat. No.
- ketal coolants as described in WO 93/23005, which is also incorporated herein by reference
- I-menthon-Id-isomenthon glycerin ketal examples include, for example, I-menthon-Id-isomenthon glycerin ketal.
- the composition comprises an effective amount of soothing hamamelis and a lesser effective amount of frescolate cooling agent such that the soothing sensation is the predominant sensation.
- the composition comprises an effective amount capsaicin of and a lesser effective amount of hamamelis soothing agent such that the warming sensation is the predominant sensation.
- the soothing and warming agents are selected so that the soothing and warming effects or sensations are staggered or partially overlapping.
- the soothing and cooling agents are selected so that the soothing and cooling effects or sensations are staggered or partially overlapping.
- agents which have a stimulating or refreshing sensation or effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other stimulating or refreshing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
- Non limiting examples are alcohols, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate, acetyl choline, serotonin, histamine, prostaglandins, other neurotransmitters; CNS stimulants; caffeine, quinine, and the like might be suitable stimulants in dosages or delivery systems where they essentially or primarily have a local or topical as opposed to systemic effect.
- Ginger is said to have several pharmacological activities, including anti-emetic, antithrombotic, antimicrobial, anticancer, antioxidant and anti-inflammatory properties. Also, ginger has been reported to have hypoglycaemic, hypo- and hypertensive, cardiac, prostaglandin and platelet aggregation inhibition, antihypercholesterolaemic, cholagogic and stomachic properties. Ginger has carminative properties and has also been tried for the prophylaxis of motion sickness and nausea and vomiting in pregnancy. In vitro studies have demonstrated that constituents of ginger, such as 6-, 8- and 10-gingerols and galanolactone, have antiserotonergic activity. Ginger oil is used in aromatherapy. Capsicum
- capsaicinoids are principally responsible for the biological activity of capsicum . These pungent principles are thought to stimulate and aid digestion and to act as a counter-irritant when applied externally. Capsaicin has also been used as a neurochemical tool for studying sensory neurotransmission. Topical creams containing capsaicin 0.025% and 0.075% are used for symptomatic relief of osteoarthritis, and post-herpetic neuralgia, respectively. Capsicum oleoresin and capsaicin are ingredients of a number of over-the-counter topical preparations for relief of pain in muscle, tendon and joints. Capsaicin has effects on nervous, cardiovascular, respiratory, thermoregulatory and gastrointestinal systems. Capsaicin has been used as a neurochemical tool for studying sensory neurotransmission.
- Witch hazel is characterized by its tannin constituents and astringent properties. It is also said to have haemostatic properties. The documented herbal uses are related to these astringent properties. It has been used topically in the treatment of haemorrhoids, eczema and dermatitis. Vasoconstriction was reduced in the hindquarters of rabbits. A fraction of an aqueous ethanolic bark extract was significantly active against herpes simplex virus type 1 (HSV-1). Topical applications of a hydroglycolic extract of witch hazel leaf reduced skin temperature perhaps due to a vasoconstrictor effect. After-sun lotion containing 10% hamamelis was reported to have suppressed erythema.
- Peppermint oil is an aromatic carminative that relaxes gastrointestinal smooth muscle and relieves flatulence and colic. Peppermint oil is also used with other volatile agents in preparations for respiratory-tract disorders. It is also used in aromatherapy.
- Menthol is chiefly used to relieve symptoms of bronchitis, sinusitis, and similar conditions. For this purpose it may be used as an inhalation, usually with benzoin or eucalyptus oil, as pastilles, or as an ointment with camphor and eucalyptus oil for application to the chest or. When applied to the skin menthol dilates the blood vessels, causing a sensation of coldness followed by an analgesic effect. It relieves itching and is used in creams, lotions, or ointments in pruritus and urticaria. It has also been applied to the forehead, presumably as a counter-irritant, for the relief of headache. Menthol has a carminative action.
- the foamable carrier is an ideal vehicle for active pharmaceutical ingredients and active cosmetic ingredients.
- active pharmaceutical ingredients and active cosmetic ingredients are collectively termed “additional active agent” or “additional active agents”.
- Suitable additional active agents include but are not limited to active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antiburn agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, antiyeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, corticosteroids, dicarboxylic acids, disinfectants,
- foamable composition is suitable for treating any inflicted surface.
- foamable carrier is suitable for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the cavity and/or the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (severally and interchangeably termed herein “target site”).
- a sensation modifying foamable composition can be used in any condition that can benefit from the modification of a cold or warm sensation, and in any condition that can benefit from stabilizing a cold or warm sensation, by applying a cooling or a warming foam on the target site.
- Examples of uses of a cooling foam composition include:
- Examples of uses of a warming foam composition include:
- the foamable composition is useful in treating an animal or a human patient having any one of a variety of dermatological disorders, including dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythras
- dermatological pain including dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopus
- the foamable composition is suitable for treating a disorder of a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum.
- a disorder of a body cavity or mucosal surface e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum.
- Non limiting examples of such conditions include chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders,
- the composition is useful for the treatment of an infection.
- the composition is suitable for the treatment of an infection, selected from the group of a bacterial infection, a fungal infection, a yeast infection, a viral infection and a parasitic infection.
- the composition is useful for the treatment of wound, ulcer and burn.
- composition is also suitable for administering a hormone to the skin or to a mucosal membrane or to a body cavity, in order to deliver the hormone into the tissue of the target organ, in any disorder that responds to treatment with a hormone.
- compositions and carriers comprise one or more higher alcohols. These generally exclude “lower alcohols”.
- the fatty alcohols are typically liquid at ambient temperature.
- Fatty alcohols may defined as follows:
- the fatty alcohols hereof have a melting point of 30° C. or less, preferably about 25° C. or less, more preferably about 22° C. or less.
- the unsaturated fatty alcohols hereof are also nonvolatile.
- nonvolatile what is meant is they have a boiling point at 1.0 atmospheres of at least about 260° C., preferably at least about 275° C., more preferably at least about 300° C.
- Suitable fatty alcohols include unsaturated monohydric straight chain fatty alcohols, saturated branched chain fatty alcohols, saturated C8-C12 straight chain fatty alcohols, and mixtures thereof.
- the unsaturated straight chain fatty alcohols will typically have one degree of unsaturation.
- Di- and tri-unsaturated alkenyl chains may be present at low levels, preferably less than about 5% by total weight of the unsaturated straight chain fatty alcohol, more preferably less than about 2%, most preferably less than about 1%.
- the unsaturated straight chain fatty alcohols will have an aliphatic chain size of from C112-C22, more preferably from C12-C18, most preferably from C116-C18.
- Especially preferred alcohols of this type include oleyl alcohol and palmitoleic alcohol.
- the branched chain alcohols will typically have aliphatic chain sizes of from C12-C22, preferably C14-C20, more preferably C16-C18.
- Exemplary branched chain alcohols for use herein include isostearyl alcohol, octyl dodecanol, and octyl decanol.
- Examples of saturated C8-C12 straight chain alcohols include octyl alcohol, caprylic alcohol, decyl alcohol, and lauryl alcohol.
- the higher alcohols may be selected from straight chain fatty alcohols, having 6 or more carbon atoms, which are liquid at ambient temperature, such as, but not limited to Hexanol, Octanol, Nonanol, Decanol; branched alcohols, such as: 2 Octanol (Capryl Alcohol), Undecanol (Undecyl Alcohol), 2 Butyl Octanol (Isolauryl Alcohol), Tridecyl Alcohol (Isotridecyl Alcohol), 2 Butyl Decanol, 2 Hexyl Octanol, Isomyristyl Alcohol, 2 Hexyl Decanol, Isocetyl Alcohol, 2 Octyl Decanol, 2 Hexyl Dodecanol, Isostearyl Alcohol, Isooctadecanol, Isooleyl Alcohol (unsaturated and branched), Isoarachidyl Alcohol, 2 Decyl Tetradecanol, Isolignoceryl Alcohol,
- the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols.
- Short chain alcohols having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butaneol, iso-butaneol, t-butaneol and pentanol, are considered less desirable solvents or solvents due to their skin-irritating effect.
- the composition is substantially alcohol-free and includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1%.
- foamable compositions are described in: U.S. Publication No. 05-0232869, published on Oct. 20, 2005, entitled NONSTEROIDAL IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0205086, published on Sep. 22, 2005, entitled RETINOID IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0018937, published on Jan. 26, 2006, entitled STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0271596, published on Dec.
- any of the active ingredients; the solvents; the surfactants; foam adjuvants; polymeric agents, penetration enhancers; preservatives, humectants; moisturizers; and other excipients as well as the propellants and methods listed therein can be applied herein and are incorporated by reference.
- the formulas of the present invention may be made in the following general way with appropriate adjustments for each formulation as will be appreciated by someone skilled in the art.
- Polymers if any, are mixed, swelled and solubilized in the waterless medium, when necessary, with appropriate heat until it forms a clear solution.
- Stabilizing surfactants added usually with heat, until a homogeneous mixture is obtained, the mixture is then allowed to cool. The remainder of the ingredients, are then added with mixing until they have dissolved in the medium.
- the active agent is usually added at the end once the modulating agent, if present, has been incorporated.
- the canisters are then filled with the above waterless formula, sealed and crimped with a valve and pressurized with the propellant.
- a pharmaceutical or cosmetic composition manufactured using the foamable carrier of the present invention is very easy to use. When applied onto the body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
- the foamable composition of the present invention is stable, having an acceptable shelf-life of at least one year, or preferably, at least two years at ambient temperature, as revealed in accelerated stability tests or aging tests.
- a product may satisfy stability tests if upon light shaking a homogenous formulation is restored and remains stable until well after dispensing.
- Organic carriers and propellants tend to impair the stability of emulsions and to interfere with the formation of stable foam upon release from a pressurized container. It has been observed, however, that the foamable compositions according to the present invention are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
- composition should also be free flowing, to allow it to flow through the aperture of the container, e.g., and aerosol container, and create an acceptable foam.
- Foam quality can be graded as follows:
- Grade E excellent: very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
- Grade G (good): rich and creamy in appearance, very small bubble size, “dulls” more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
- Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
- Grade F very little creaminess noticeable, larger bubble structure than a “fairly good” foam, upon spreading on the skin it becomes thin in appearance and watery.
- Grade P no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
- Grade VP dry foam, large very dull bubbles, difficult to spread on the skin.
- Topically administrable foams are typically of quality grade E or G, or occasionally FG, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
- an acceptable foam is one, that exhibits the following characteristics:
- a “stable foam” is defined herein as a composition, which upon release from an aerosol can, creates a foam mass, which is sustained on a surface for at least one minute, more preferably at least two minutes, and yet more preferably for at least 5 minutes.
- a period of minutes is regarded as a short term, but nevertheless it allows a good and more than sufficient period of time for a subject to receive foam dispensed on a body surface and to spread it or to transfer it to another region and to spread it.
- Foam texture should vary from a very fine creamy foam to a fine bubble structure.
- Foam has to have specific gravity in the range of about 0.02 gr/mL to about 0.5 gr/mL, more preferably between about 0.04 gr/mL and about 0.2 gr/mL.
- an acceptable foam is one, that does not readily collapse upon dispensing on the skin; spreads easily on a skin surface; at least partially absorbed following rubbing onto the skin, and more preferably, substantially absorbed following rubbing on the skin.
- an acceptable foam is one, that: creates a pleasant feeling after application; leaves minimal oily residue; and leaves minimal shiny residual look.
- ‘Shakability’ means that the composition contains some or sufficient flow to allow the composition to be mixed or remixed on shaking. That is, it has fluid or semi fluid properties. In some very limited cases it may still be possible to have a foamable composition which is flowable but not apparently shakable.
- a breakable foam is thermally stable or substantially so, yet breaks under sheer force.
- the breakable foam of the present invention is not “quick breaking”, i.e., it does not readily collapse upon exposure to body temperature environment. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability, (due to, for example, the presence of alcohol) since it allows comfortable application and well directed administration to the target area.
- a further aspect of the foam is breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
- the foam of the present invention has several notable advantages, when compared with hydroalcoholic foam compositions, such as
- the foam of the present invention is thermally stable and breakable under sheer force but is not “quick breaking which allows comfortable application and well directed administration to the target area.
- Short chain alcohols are known to dry the skin and impair the integrity of the skin barrier.
- including a film forming agent in the composition of the present invention foes not cause unwanted skin barrier damage.
- foams Another property of the foam is specific gravity, as measured upon release from the aerosol can.
- foams typically have specific gravity of less than 0.12 g/mL; or less than 0.10 g/mL; or less than 0.08 g/mL, depending on their composition and on the propellant concentration.
- formulations are expressed in amounts up to 100% including the propellant. In other cases the formulations are expressed in amounts up to 100% not including the propellant, which is then added to the composition.
- sensation or sensation modifying topical compositions can be prepared according to the general methodology set out below with appropriate changes as would be well appreciated by a man of the art.
- Emulsion Mint Oil
- the foamable formulation may be produced under nitrogen and under vacuum. Whilst the whole process can be carried out under an oxygen free environment, it can be sufficient to apply a vacuum after heating and mixing all the ingredients to obtain an emulsion or homogenous liquid.
- the production chamber is equipped to apply a vacuum but if not the formulation can be for example placed in a dessicator to remove oxygen prior to filing and crimping.
- Each aerosol canister is filled with PFF and crimped with valve using vacuum crimping machine.
- the process of applying a vacuum will cause most of the oxygen present to be eliminated.
- Addition of hydrocarbon propellant may without being bound by any theory further help to reduce the likelihood of any remaining oxygen reacting with the active ingredient. It may do so, without being bound by any theory, by one or more of dissolving in the oil or hydrophobic phase of the formulation, by dissolving to a very limited extent in the aqueous phase, by competing with some oxygen from the formulation, by diluting out any oxygen, by a tendency of oxygen to occupy the dead space, and by oxygen occupying part of the space created by the vacuum being the unfilled volume of the canister or that remaining oxygen is rendered substantially ineffective in the formulation.
- Pressurizing is carried out using a hydrocarbon gas or gas mixture. Canisters are filled and then warmed for 30 sec in a warm bath at 50° C. and well shaken immediately thereafter.
- Each pressurized canister is subjected to bubble and crimping integrity testing by immersing the canister in a 60° C. water bath for 2 minutes. Canisters are observed for leakage as determined by the generation of bubbles. Canisters releasing bubbles are rejected.
- LFRA100 instrument is used to characterize hardness.
- a probe is inserted into the test material.
- the resistance of the material to compression is measured by a calibrated load cell and reported in units of grams on the texture analyzer instrument display.
- Preferably at least three repeat tests are made.
- the textural characteristics of a dispensed foam can affect the degree of dermal penetration, efficacy, spreadability and acceptability to the user. The results can also be looked at as an indicator of softness. Note: the foam sample is dispensed into an aluminum sample holder and filled to the top of the holder.
- Collapse time is examined by dispensing a given quantity of foam and photographing sequentially its appearance with time during incubation at 36° C. It is useful for evaluating foam products, which maintain structural stability at skin temperature for at least 1 min.
- Viscosity is measured with Brookfield LVDV-II+PRO with spindle SC 4-25 at ambient temperature and 10, 5 and 1 RPM. Viscosity is usually measured at 10 RPM. However, at about the apparent upper limit for the spindle of ⁇ >50,000 CP, the viscosity at 1 RPM may be measured, although the figures are of a higher magnitude.
- the amount of active agent present is analyzed in foam expelled from various pressurized canisters containing foam formulations using HPLC. Analysis is carried out at zero time and at appropriate time intervals thereafter.
- the canisters are stored in controlled temperature incubators at 5° C., at 25° C., at, 40° C. and at 50° C. At appropriate time intervals canisters are removed and the amount of active agent in the foam sample is measured.
- the centrifugation used in this procedure serves as a stress condition simulating the aging of the liquid dispersion under investigation. Under these conditions, the centrifugal force applied facilitates the coalescence of dispersed globules or sedimentation of dispersed solids, resulting in loss of the desired properties of the formulated dispersion.
- Foams are made of gas bubbles entrapped in liquid.
- the bubble size and distribution reflects in the visual texture and smoothness of the foam.
- Foam bubbles size is determined by dispensing a foam sample on a glass slide, taking a picture of the foam surface with a digital camera equipped with a macro lens. The diameter of about 30 bubbles is measured manually relatively to calibration standard template. Statistical parameters such as mean bubble diameter, standard deviation and quartiles are then determined. Measuring diameter may also be undertaken with image analysis software.
- the camera used was a Nikon D40X Camera (resolution 10 MP) equipped with Sigma Macro Lens (ref: APO MACRO 150 mm F2.8 EX DG HSM). Pictures obtained are cropped to keep a squared region of 400 pixels ⁇ 400 pixels.
- compositions of the present invention were separately applied to clean skin of a group of human subjects. After 5 minutes tested subjects were asked to provide a gauge of their satisfaction relating to the following parameters: Ease of application, skin absorption, stickiness, odor, oily residue, skin surface shiny appearance, composition stability; overall satisfaction; sensation change, such as cooling, relaxing, heating etc. The subjects gauged their response according to the following scoring system:
- the sensation was observed over a prolonged or sustained period of time.
- Prolonged period of time or “sustained period of time” or “substantial period of time” (used interchangeably herein), is meant a period of time of about five or more minutes, more typically, at least 15 minutes in which the subject senses a sensation pertaining to a sensation agent applied to a target or delivery site on/in the subject.
- thermometer Place a thermometer in a clean glass vial and allow it to come to equilibrium.
- a main aim is to deliver a sensation via a foam vehicle, where the prime sensation is due to pharmaceutical stimulation rather than an actual physical effect.
- the sensation may be a combination of pharmaceutical stimulation and physical effect.
- an excess of propellant may provide an initial physical cooling and the sensation agent provides a prolonged sensation, without further cooling.
- the vehicles disclosed herein are adapted to provide the main sensation with or without an initial physical cooling sensation.
- Emollient emulsion foam provided a reasonable and prolonged cooling sensation; excellent foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents.
- the co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art.
- the propellant can be added at a concentration of about 3% to about 25% or more.
- Emollient Emulsion Foamable Composition with 10% Menthol Crystals and Avocado Oil and 15% Ethanol
- Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, water phase, surfactant combination supported by co emulsifiers and a combination of polymeric agents plus a polar solvent as a penetration enhancer. Menthol in the above formulation achieves good penetration on its own so the presence of 15% ethanol is of only marginal effect. Ethanol is not essential and may be omitted or replaced by other penetrating agents such as transcutol; DMI; and the like. See section on penetration agents.
- the propellant can be added at a concentration of about 3% to about 25% or more.
- Emollient foam provided excellent and prolonged cooling sensation; good foam quality; moisturizing.
- the propylene glycol is non essential.
- the propellant can be added at a concentration of about 3% to about 25% or more.
- Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by a co-emulsifier and a combination of polymeric agents.
- the propylene glycol is non-essential.
- the peppermint oil reduces the viscosity of the emulsion and is matrix destabilizing.
- the propellant can be added at a concentration of about 3% to about 25% or more.
- Emollient Emulsion Foamable Composition with 15% Menthol Crystals and 25% propellant
- Emollient foam provided good cooling sensation; good foam quality; doesn't require preservative.
- the propellant can be added at a concentration of about 3% to about 25% or more.
- the propellant can be added at a concentration of about 3% to about 25% or more.
- Waterless foam provided reasonable and medium term cooling sensation with delayed onset; fairly good foam quality; moisturizing; doesn't require preservative.
- Any high molecular weight PEG for example 1500, 2000, 4000, 6000 or 8000
- combinations of high molecular weight PEG with lower molecular weight PEG for example 200, 400, 600
- the peppermint oil has a thinning effect on the composition, which is to some extent counterbalanced or ameliorated by the high molecular weight PEG.
- the propellant can be added at a concentration of about 3% to about 25% or more.
- Emollient Emulsion Foamable Relaxing or Soothing Composition with Hamamelis Emollient Emulsion Foamable Relaxing or Soothing Composition with Hamamelis
- Emollient foam capable of providing a soothing sensation; excellent foam quality; moisturizing. It comprises an oil phase, water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents, plus a preservative and a chelating agent.
- the chelating agent is non essential.
- the co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art.
- the propellant can be added at a concentration of about 3% to about 25% or more.
- Foamable Oil in Water Emulsion Foamable Compositions Containing Menthol as Cooling Agent and Coal Tar Extract and Salicylic Acid as Additional Therapeutic Agents
- CTR005 CTR006 Ingredient name % W/W % W/W Menthol (Sensation modifying agent) 1 1 Coal tar extract (Additional therapeutic agent) 10 10 Salicylic acid (Additional therapeutic agent) 5 Hydrocortisone (Additional therapeutic agent) 1 PPG-15 Stearyl ether — 3 Isopropyl Myristate 10 5 Octyldodecanol 12 12 Stearyl Alcohol 2 1 Glycerin — 3 Lanolin — 2 Laureth-4 — 2 Emulgin B2 — 1.5 Glyceryl Stearate 1.5 — PEG-40 Stearate 3 — CMC — 0.5 Methocel K100M 0.28 — Xanthan gum 0.28 — Propylene Glycol — 5 Polysorbate 60 1 — Water, purified To 100 To 100 Propellant 8 8 8
- This waterless single phase formulation provides a stable vehicle for peppermint oil that can generate good quality foam and which can withstand 300 rpm.
- the surfactants and a polymeric agent provide viscosity support and aid foaming. On forming foam there is no significant temperature change when measured on a glass surface.
- the peppermint oil provides a sensation of cooling, which may be potentiated by the evaporation of propellant and the lower temperature of the foam compared to the skin.
- SMTC006-071205 SMTC007-071211 SMTC005-071205 cf example 3 cf example 12
- MCT 6.00 Isopropyl myristate 10.00 Octyldodecanol 10.00 Stearic acid 2.00 Stearyl alcohol 2.00 Cetostearyl alcohol 2.00 Steareth 2 2.00 4.20 Steareth-21 1.40 polysorbate 80 2.00 Glyceryl monostearate 2.00 1.40 PEG-40 stearate 3.10 Polysorbate 60 1.20 Xanthan gum 0.30 0.28 Methocell k100M 0.30 0.28 Hydroxypropyl cellulose 1.00 Water 67.80 59.74 menthol crystals 10.00 15.00 1.00 Propylene Glycol 81.00 3.00 Coal tar 10.00 Hydrocortisone butyrate 1.00 Total: 100.00 100.00 100.00 100.00 Propellant (AP-70) 8.00 8.00 8.00 Results PFF Viscosity 4447.05 4527.04 2037.57 Centrifgation 1
- Formulation 5 is a single phase composition that provides a stable vehicle for menthol crystals that can generate good quality foam capable of withstanding 3000 rpm and having a collapse time in excess of 5 minutes.
- the surfactants, adjuvant and a polymeric agent provide viscosity support and aid foaming.
- the other two formulations 6 and 7 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000 rpm and have a collapse time in excess of 5 minutes. All the formulations can accommodate substantial amounts of cooling sensation agent.
- the cooling agent is a combination of at least two cooling agents.
- the cooling agent may be used in combination with a soothing agent.
- the coal tar formulation is yellow prior to addition of the propellant but upon discharge from the canister and release as a foam the color is dissipated such that the foam is only slightly yellow, which may be an advantage for its use.
- Formulation 3 is a waterless single phase composition that provides a stable vehicle for capsaicin that can generate good quality foam capable of withstanding 3000 rpm and having a collapse time in excess of 5 minutes.
- the surfactants, adjuvant and a polymeric agent provide viscosity support and aid foaming.
- the other two formulations 1 and 2 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000 rpm and have a collapse time in excess of 5 minutes. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the capsaicin should provide a sensation of warming.
- the warming agent is a combination of at least two warming agents. In a further embodiment the warming agent may be used in combination with a soothing agent.
- SMTC012-071225 SMTC013-071225 polysorbate 80 2.00 4.00 Avicel RC581 2.00 4.00 Water 94.00 65.00 Aloe vera 2.00 2.00 Diethylene glycol monoethyl 25.00 ether Total: 100.00 100.00 Propellant (AP-70) 8.00 Results PFF Viscosity 39.99 2273.51 Centrifgation 1K not stable not stable Centrifgation 3K not stable not stable FOAM Quality G-E G-E Color White White Collapse time (sec.) 95/F 140/F Density (gr/ml) 0.044 0.034 Bubble size ( ⁇ m) 131 113 Bubble size 0.00 0.00 (%-above 500 ⁇ m)
- these water gel formulations are single phase compositions that provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 1.5 minutes.
- the aloe vera should provide a sensation of soothing.
- the soothing agent is a combination of at least two soothing agents.
- the soothing agent may be used in combination with a cooling agent or with a warming agent.
- these emollient emulsion formulations provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 5 minutes and is stable to centrifugation.
- the aloe vera should provide a sensation of soothing.
- the soothing agent is a combination of at least two soothing agents.
- the soothing agent may be used in combination with a cooling agent or with a warming agent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- This application claims the benefit of priority under 35 U.S.C. §119(e) to co-pending U.S. application No. 60/879,213, filed on Jan. 8, 2007, entitled “Sensation Modifying Topical Composition Foam,” which is incorporated in its entirety by reference.
- This application is a continuation-in-part application of co-pending U.S. patent application Ser. No. 10/532,618, filed on Dec. 22, 2005, which is a 371 National application of International Patent Application No. IB03/005527, designating the United States and filed on Oct. 24, 2003, which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Patent Application Ser. No. 60/429,546, filed on Nov. 29, 2002, all entitled “Cosmetic and Pharmaceutical Foam,” and which claims the benefit of priority under 35 USC §119(a) to Israeli Patent Application No. 152486, filed Oct. 25, 2002, all of which are hereby incorporated in their entirety by reference.
- This application is a continuation-in-part application of co-pending U.S. patent application Ser. No. 10/911,367, filed on Aug. 4, 2004, which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Patent Application Ser. No. 60/492,385, filed on Aug. 4, 2003, both entitled “Foam Carrier Containing Amphiphilic Copolymer Gelling Agent” and both hereby incorporated in their entirety by reference.
- This application is a continuation-in-part application of co-pending U.S. patent application Ser. No. 10/835,505, filed on Apr. 28, 2004, which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Patent Application Ser. No. 60/530,015, filed on Dec. 16, 2003, and U.S. Patent Application Ser. No. 60/492,385, filed on Aug. 4, 2003, all entitled “Oleaginous Pharmaceutical Foam” and all hereby incorporated in their entirety by reference.
- Compositions of various types have incorporated within them components or agents which provide a sensation to mucosal membranes and/or to skin. The sensation may be a warming, cooling, relaxation stimulation or refreshing feeling or a combination of two or more feelings. The sensation or feeling may be real or artificial.
- Compositions which include a sensation agent include, inter alia, toothpastes, mouthwashes, perfumes, lotions, shaving cream, shampoos, antiperspirants, deodorants, beverages, chewing gum, tobacco products, and pharmaceutical products.
- Most compositions known to date, comprising one or more sensation agents, cannot retain the sensation at the site of application thereof in a subject over extended periods of time. Typically, topical formulations do not retain the sensational effect for more than a few seconds. Additionally, the sensation agent may be volatile, such as menthol, used for providing a topical cooling effect, and the formulation may not retain the active agent for more than a few seconds.
- The mechanism of cooling and warming sensation or sensation modification for example is poorly understood at present. It has been suggested that, among other options, the action of menthol and other cooling agents and capsaicin, camphor and other heat compounds occurs via “thermoreceptors” that register “cool” and “hot” sensation, respectively. It has been suggested that the ‘cooling’ effect of menthol is a physiological effect due to the direct action of menthol on the nerve endings of the human body responsible for the detection of hot or cold and is not due to latent heat of evaporation such that menthol acts as a direct stimulus on the cold receptors at the nerve endings which, in turn, stimulate the central nervous system.
- Substances which are known to provide a sensation of warmth or warmth modulation on application and are called “warming agents” include polyhydric alcohols, capsicum (red pepper) powder, a capsicum tincture, capsicum extract, capsaicin, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives, such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal, ginger extract, ginger oil, gingeol, and gingeron.
- Foams are considered a more convenient vehicle for topical delivery of active agents. There are several types of topical foams, including aqueous foams, such as commonly available shaving foams; hydroalcoholic foams, emulsion-based foams, comprising oil and water components and oleaginous foams, which consist of high oil content, and which are foamable compositions having a specific surfactant selected from the group consisting of ethoxylated lanolin oil, propoxylated lanolin oil, and mixtures thereof and high levels of water that produce fast breaking foams that disappears rapidly into the skin with cooling sensation is described. Some formulations make a sound or crackling effect when foam is dispensed. Dimethyl ether is a substance which evaporates very rapidly and its use with an aqueous non emollient gel composition, lotion composition and a solution in producing a cooling effect (as opposed to mere sensation without cooling). High levels of propellant have also been used to provide a solid or semi ointment deposit with a temperature between minus to plus 5° C.
- Foam forming refrigerant compositions, suitable for emergency treatment of burns have also been described.
- Foams and, in particular, foam emulsions are complicated systems which do not form under all circumstances. Changes in foam emulsion composition, such as by the addition of active ingredients may destabilize the foam. There is, therefore, a need for a foam composition, which provides desirable properties to the skin and can remain stable whilst accommodating a variety of sensation agents or active ingredients.
- Formulations based on oil or ointment or emollients have a number of useful attributes making them suitable candidates for topical pharmaceutical and cosmetic compositions including foamable compositions. They are inherently stable and inert which are clearly desirable characteristics. They are able to moisturize and soften the skin and in appropriate amounts can act as a protective or barrier layer and can form a barrier to water. By appropriate formulation they can act to improve agent delivery to the skin and yet remain resistant to being washed off. On the other hand they are by their nature greasy materials and can be difficult to formulate particularly into a topical foamable composition that can deliver substantially uniform and stable composition or foam that ameliorates or overcomes the look and feel of a greasy material, especially where that composition is waterless or substantially so. It is further a problem to incorporate into such a vehicle, effective amounts of one or more active sensation and/or pharmaceutical ingredients such that they are uniformly present throughout the formulation and are effectively delivered without the use of a lower alcohol in the formulation.
- On one level it is far from simple or obvious to produce waterless foamable compositions that when released produce foams of quality suitable for sensation, pharmaceutical or cosmetic application. On a further level having realized a carrier that will produce a waterless foam of quality there is an additional difficulty to be overcome, namely how to adapt the formula and achieve a formulation, which can accept a range of various active sensation, pharmaceutical and cosmetic agents such that the composition and active agent are stable and the foam produced remains of quality. Specifically, one of the challenges in preparing such waterless or substantially waterless foamable compositions is ensuring that the one or more active sensation, pharmaceutical or therapeutic agents does not react, isomerize or otherwise break down to any significant extent during is storage and use. Particularly, there remains an unmet need for improved, easy to use, stable and non-irritating foam formulations, with unique sensation, therapeutic or beneficial properties containing a stable or stabilized active sensation, pharmaceutical or cosmetic agent.
- There remains an unmet need for improved, easy to use, stable and non-irritating topical foam formulations containing a stable or stabilized active sensation, pharmaceutical or cosmetic agent having a therapeutic or beneficial effect, intended for treatment of dermal and mucosal tissues.
- There is still a need to provide stable aqueous and non-aqueous compositions comprising one or more sensation agents for sustained provision of at least one sensation from the sensation agent(s).
- The application relates to aqueous foamable vehicles capable of delivering one or more sensation agents to a body surface in a breakable foam of quality. The aqueous vehicles may be emulsion or gel vehicles. The application also relates to non aqueous foamable vehicles capable of delivering one or more sensation agents to a body surface in a breakable foam of quality. Upon contact with the body surface an effective amount of one or more sensory agents are capable of causing a perceived sensory effect.
- In one or more embodiments the formulations are resistant to aging as indicated by their ability to withstand centrifugation. In other embodiments the formulations have a significant and suitable collapse time of 300 or more seconds.
- In one or more embodiments the formulations are considered to be pleasant for use.
- There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface.
- There is further provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a cooling or warming sensation over a sustained period of time. The sustained period of time is at least five minutes, more preferably, at least 15 minutes, yet more preferably, at least 30 minutes, still more preferably, at least one hour. According to some embodiments the sensation may be felt for up to two hours or more.
- There is further provided a stable foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing, soothing, stimulating or refreshing sensation.
- There is provided a stable foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is a combination of two or more sensations.
- There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is further modulated, potentiated, increased, reduced, or ameliorated by the presence of a sensation modifying agent.
- There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is complementary, supplementary or in addition to or superimposed on a cosmetic, therapeutic or pharmaceutical effect.
- There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially non aqueous carrier.
- There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially aqueous emollient carrier.
- This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to foamable pharmaceutical and cosmetic compositions, containing an active agent, having a sensation or sensation modifying affect on a body surface, upon application.
- There is provided a stable foamable composition that is stable on a surface at the delivery site for at least one minute, more preferably, at least two minutes, yet more preferably, for at least five minutes.
- There is thus provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition including:
-
- at least one sensation or sensation modifying agent, selected from the group of
- a cooling agent;
- a warming agent;
- a relaxing or soothing agent; and
- a stimulating or refreshing agent;
- or mixtures thereof;
- a foamable carrier resistant to aging suitable for delivery of at least one sensation or sensation modifying agent; and
- a propellant at a concentration of about 3% to about 45% by weight of the total composition,
- wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam; and
- wherein upon contact with a surface at the delivery site the prolonged sensation is not primarily due to the propellant or an exothermic reaction.
- According to some embodiments, the composition does not effect a substantial temperature change to the surface.
- According to some further embodiments, the cooling agent is selected from menthol; an isomer of menthol, a menthol derivative; 4-Methyl-3-(1-pyrrolidinyl)-2[5H]-furanone; WS-23, Icilin, Icilin Unilever Analog, 5-methyl-4-(1-pyrrolidinyl)-3-[2H]-furanone; 4,5-dimethyl-3-(1-pyrrolidinyl)-2[5H]-furanone; isopulegol, 3-(I-menthoxy)propane-1,2-diol, 3-(I-menthoxy)-2-methylpropane-1,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6-isopropyl-9-methyl-1,4-dioxas-piro[4,5]decane-2-methanol, menthyl succinate and its alkaline earth metal salts, trimethylcyclohexanol, N-ethyl-2-isopropyl-5-methylcyclohexanecarb-oxamide, Japanese mint (Mentha arvensis) oil, peppermint oil, menthone, menthone glycerol ketal, menthyl lactate, 3-(1-menthoxy)ethan-1-ol, 3-(I-menthoxy)propan-1-ol, 3-(I-menthoxy)butan-1-ol, 1-menthylacetic acid N-ethylamide, I-menthyl-4-hydroxypentanoate, I-menthyl-3-hydroxybutyrate, N,2,3-trimethyl-2-(1-methylethyl)-butanamide and spearmint oil.
- According to some embodiments, the menthol derivative is selected from the group consisting of: menthol ethylene glycol carbonate, which is now known as Frescolat® type MGC, menthol Propylene Glycol Carbonate (Frescolat® type MPC), menthyl lactate (Frescolat ML®) and Menthone Glycerin Acetal (Frescolat MGA®) and 3-(I-Menthoxy)-1,2-propanediol.
- According to some further embodiments, the warming agent is selected from polyhydric alcohols, capsaicin, capsicum powder, a capsicum tincture, capsicum extract, capsaicin, hamamalis, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives, such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal, ginger extract, ginger oil, gingeol and gingeron.
- According to some additional embodiments, the relaxing or soothing agent is selected from a herb extracts, selected from the group consisting of aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, yarrow; calendula, comfrey, witch hazel and other astringents, sea weed, and oat extracts; oils, selected from the group consisting of: almond oil, avocado oil, and comfrey; and essential oils, selected from the group consisting of: cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary; waxy or unctuous substances selected from the group consisting of: lanolin or vaselline jelly, minerals, selected from the group consisting of: zinc oxide, calamine and selenium; vitamins, selected from the group consisting of: tocopheryl acetate (vitamin E), and pharmaceutical agents selected from the group consisting of: analgesics, anesthetics, anti-inflammatory agents, and anti-histamines, and muscle relaxants; menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-I-menthoxypropane-1,2-diol, ethyl I-menthylcarbonate, (1S,3S,4R)-p-menth-8-en-3-ol, menthyl pyrrolidone carboxylate, N-substituted-p-menthane-3-carboxamides hamamelis extract and ginger oil.
- Further provided, according to some embodiments, are compositions wherein the stimulating or refreshing agent is selected from an alcohol, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate, acetyl choline, serotonin, histamine, a prostaglandin, a neurotransmitter; a CNS stimulant, caffeine and quinine.
- In some cases, the short term stable foam is stable at the delivery site for at least one minute. In some further cases, the short term stable foam is stable at the delivery site for at least five minutes.
- According to some embodiments, the sustained period of time is at least 15 minutes. According to some further embodiments, the sustained period of time is at least 30 minutes. In some further cases, the sustained period of time is at least one hour.
- Further provided, according to some embodiments, are compositions, wherein the foamable carrier is at a concentration of about 40% to about 99% by weight of the total composition excluding propellant and is selected from the group consisting of an aqueous emulsion, and aqueous gel and a non aqueous carrier
- wherein the carrier includes:
- at least one surface active agent at a concentration of about 0.1% to about 10% by weight of the carrier;
- at least one polymeric agent at a concentration of about 0.1% to about 5% by weight of the total composition; and
- at least one non aqueous solvent.
- According to some embodiments, the non aqueous solvent is in the case of the aqueous emulsion, a hydrophobic emollient; in the case of the aqueous gel, a penetration enhancer; and in the case of the non aqueous carrier, a polyol.
- Further provided, according to some embodiments, are compositions, wherein the at least one emollient is selected from the group consisting of: avocado oil, isopropyl myristate, mineral oil; capric triglyceride, capryllic triglyceride mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils; essential oils; and silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane).
- According to some embodiments, the at least one stabilizing surface active agent is selected from the group consisting of: stearyl alcohol; steareth-2, steareth-21; polysorbate 80, PEG-40 stearate, glyceryl monostearate, cetostearyl alcohol, laureth 4, and Ceteareth-20, or is a combination of at least two surfactants selected from the group consisting of combinations of polyoxyethylene alkyl ethers, particularly Brij 59/Brij10; Brij 52/Brij 10; Steareth 2/Steareth 20; Steareth 2/Steareth 21 (Brij 72/BRIJ 721); Myrj 52/Myrj 59; combinations of sucrose esters, particularly Surphope 1816/Surphope 1807; combinations of sorbitan esters, particularly Span 20/Span 80; Span 20/Span 60; combinations of sucrose esters and sorbitan esters, particularly Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG compounds, particularly Twin 80/PEG-40 stearate/methyl glucaso sequistearate.
- Further provided, according to some embodiments, the at least one polymeric agent is selected from the group consisting of: locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hypromellose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose carboxymethylhydroxyethylcellulose, a cationic cellulose, methocel K100M, PEG 1000, PEG 4000, PEG 6000 and PEG 8000 xanthan gum; sodium carboxymethyl-cellulose, hydroxypropyl-cellulose, microcrystalline-cellulose, Avicel RC581, aluminum starch octyl succinate and a polyacrylate.
- Additionally, according to some embodiments, the foamable carrier further includes one or more of the following:
- a co-emulsifier or foam stabilizer at a concentration of about 0.1% to about 5% by weight of the total composition;
- a wax, viscosity, bulking or firming agent at a concentration of about 0.1% to about 15% by weight of the total composition;
- a co-solvent at a concentration of about 0.1% to about 20% by weight of the total composition;
- a penetration enhancer or potent solvent at a concentration of about 0.1% to about 25% by weight of the total composition;
- a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain at a concentration of about 0.1% to about 25% by weight of the total composition;
- a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and
- an agent capable of having an occlusive effect at a concentration of about 5% to about 30% by weight of the total composition.
- In some cases, the propellant is a cooling agent.
- According to some embodiments, the composition further includes at least one additional active agent. The at least one additional active agent includes, according to some embodiments, a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
- Additionally, according to some further embodiments, the at least one additional active agent is selected from the group consisting of active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antiburn agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, cal tar, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, vasoconstrictors, vasodilators, vitamins, vitamin derivatives, vitamin A and derivatives, vitamin D and derivatives, wound healing agents and wart removers.
- Further provided, according to some embodiments, are compositions, wherein the foamable carrier includes at least one carrier medium, selected from the group consisting of water, an oil, a silicone oil, an alcohol, a polyol, a polyethylene glycol (PEG), a propylene glycol, and a solvent or combinations thereof.
- According to some embodiments, the foamable carrier further includes a polar solvent.
- Further provided, according to some embodiments, are compositions further including an additional component selected from the group consisting of an anti-perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, moisturizer, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamin.
- Further provided, according to some embodiments, are compositions, wherein the sensation or sensation modifying is selected from the group consisting of:
- a combination of a cooling and a warming agent;
- a combination of a cooling and a soothing or relaxing agent;
- a combination of a cooling and a stimulating or refreshing agent;
- a combination of a warming and a stimulating or refreshing agent;
- a combination of a warming and a soothing or relaxing agent;
- a combination of a cooling; a warming and a soothing or relaxing agent; and
- a combination of a cooling; a warming and stimulating or refreshing agent.
- Further provided, according to some embodiments, are compositions, wherein the propellant provides an initial cooling sensation combined with a sensation agent to provide a prolonged sensation.
- Additionally, according to some embodiments, the foamable carrier further contains a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
- Further provided, according to some embodiments, the composition includes:
- the at least one sensation or sensation modifying agent including menthol in a concentration of 0.5 to about 3% by weight;
- the at least one active agent includes:
- coal tar extract in a concentration of around 2% up to around 20% by weight; and
- at least one other active agent selected from salicylic acid and hydrocortisone in a concentration of around 0.5% up to around 10% by weight; and
- the menthol is adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar extract.
- Further provided, according to some embodiments, are compositions, wherein:
- the at least one sensation or sensation modifying agent includes menthol crystals in a concentration of 0.5 to about 3% by weight;
- the at least one active agent includes:
- coal tar in a concentration of around 2% up to around 20% by weight; and
- hydrocortisone butyrate in a concentration of around 0.5% up to around 10% by weight; and
- the menthol crystals are adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar.
- Additionally, there is thus provided according to some further embodiments of the present invention, a method for providing a subject with at least one sensation at a delivery site, the method including administering to the delivery site of the subject a composition including:
- at least one sensation or sensation modifying agent, selected from the group of
-
- i. a cooling agent;
- ii. a warming agent;
- iii. a relaxing or soothing agent; and
- iv. a stimulating or refreshing agent;
- or mixtures thereof;
- a foamable carrier resistant to aging suitable for delivery of at least one sensation or sensation modifying agent; and
- a propellant at a concentration of about 3% to about 45% by weight of the total composition,
- wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam; and
- wherein upon contact with a surface at the delivery site the prolonged sensation is not primarily due to the propellant or an exothermic reaction,
- so as to provide the subject with the at least one sensation for the sustained period of time.
- According to some embodiments, the method allows for the foam being stable at the delivery site for at least one minute. In some cases, the foam is stable at the delivery site for at least five minutes.
- Additionally, according to some further embodiments, the method allows for the subject to sense the at least one sensation at the delivery site for at least at least 15 minutes. In some cases, the subject senses the at least one sensation at the delivery site for at least 30 minutes. In some further cases, the subject senses the at least one sensation at the delivery site for at least one hour. In yet some further cases, the subject senses the at least one sensation as increasing, peaking and decreasing over the sustained period of time.
- According to some embodiments, the method allows for the subject to sense at least one sensation at the delivery site selected from a cooling sensation, a warming sensation, a heating sensation, a soothing sensation, a relaxing sensation, a stimulating sensation and a refreshing sensation.
- According to some further embodiments, the administration step further includes spreading the foam over a surface at the delivery site.
- According to yet some further embodiments, the delivery site is selected from the group consisting of the skin, a body cavity, a mucosal surface, the nose, the mouth, the eye, the ear canal, the respiratory system, the vagina and the rectum.
- According to some embodiments, the method includes administering compositions further including at least one additional active agent. In some cases, the at least one additional active agent includes a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
- According to yet some further embodiments, the at least one additional active agent is selected from the group consisting of active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antiburn agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, cal tar, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, vasoconstrictors, vasodilators, vitamins, vitamin derivatives, vitamin A and derivatives, vitamin D and derivatives, wound healing agents and wart removers.
- The method, according to some embodiments, further includes treating a disorder selected from the group consisting of dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, eethyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post-surgical skin conditions, scabies, pediculosis, creeping eruption, eczemas, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, edematous, erythema multiforme, erythema nodosum, grannuloma annulare, epidermal necrolysis, sunburn, photosensitivity, pemphigus, bullous pemphigoid, dermatitis herpetiformis, keratosis pilaris, callouses, corns, ichthyosis, skin ulcers, ischemic necrosis, miliaria, hyperhidrosis, moles, Kaposi's sarcoma, melanoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, poison ivy, poison oak, contact dermatitis, atopic dermatitis, rosacea, purpura, moniliasis, candidiasis, baldness, alopecia, Behcet's syndrome, cholesteatoma, Dercum disease, ectodermal dysplasia, gustatory sweating, nail patella syndrome, lupus, hives, hair loss, Hailey-Hailey disease, chemical or thermal skin burns, scleroderma, aging skin, wrinkles, sun spots, necrotizing fasciitis, necrotizing myositis, gangrene, scarring, and vitiligo, chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum; and wherein the at least one active agent is suitable for treating the disorder.
- Thus, according to one or more embodiments, the foamable composition, includes:
-
- a. a foamable carrier;
- b. at least one sensation or sensation modifying agent, selected from the group of
- i. a cooling agent;
- ii. a warming agent;
- iii. a relaxing or soothing agent;
- iv. stimulating or refreshing agent;
- or mixtures thereof;
- c. a propellant at a concentration of about 3% to about 45% by weight of the total composition
- wherein the composition is stored in an aerosol container and upon release expands to form a foam.
- In accordance with one or more embodiments, there is provided a foamable base composition for use with a sensation or sensation modifying agent comprising
-
- i. a foamable carrier; and
- ii. a propellant at a concentration of about 3% to about 45% by weight of the total composition;
- wherein the composition is stored in an aerosol container and upon release expands to form a foam.
- In accordance with one or more embodiments, the foamable composition further comprises at least one component, selected from the group consisting of:
-
- a. a surface active agent; and
- b. a polymeric agent;
- wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
- In accordance with one or more embodiments, the foamable composition further comprises at least one component, selected from the group consisting of:
-
- a. a co-emulsifier and foam stabilizer;
- b. a viscosity, bulking or firming agent;
- c. a stabilizer;
- d. a co-solvent;
- e. a penetration enhancer; and
- f. an agent capable of having an occlusive effect.
- In accordance with one or more embodiments the foamable emollient emulsion carrier composition comprises:
-
- a. an aqueous carrier;
- b. an emollient; and
- c. a surfactant; or polymeric agent and optionally
- d. a co-emulsifier and foam stabilizer; a viscosity, bulking or firming agent; a stabilizer; a co-solvent; a penetration enhancer and or an agent capable of having an occlusive effect
- wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
- In accordance with one or more embodiments, the foamable waterless carrier composition comprises:
-
- a. a non-aqueous carrier;
- b. a surfactant; and or a polymeric agent and optionally
- c. a co-emulsifier and foam stabilizer; and a viscosity, bulking or firming agent
- wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
- In the detailed description, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be understood by those skilled in the art that these are specific embodiments and that the present invention may be practiced also in different ways that embody the characterizing features of the invention as described and claimed herein.
- There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a cooling or warming sensation.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing or soothing sensation.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing, soothing, stimulating or refreshing sensation.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is a combination of two or more sensations.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is further modulated, potentiated, increased, reduced, or ameliorated by the presence of a sensation modifying agent.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is complementary, supplementary or in addition to or superimposed on a cosmetic, therapeutic or pharmaceutical effect.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially non-aqueous carrier.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially aqueous emollient carrier.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that the sensation or sensation modifying effect is of short, medium or long term duration or grades thereof.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that onset of sensation or sensation modifying effect is of a quick, medium or slow onset or grades thereof.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that the relative overall magnitude of sensation or sensation modifying effect is of a mild, medium or strong magnitude or grades thereof.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect increases peaks and then decreases.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect is with no or little skin irritation.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect comprises a fragrance.
- There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect can be useful, beneficial or therapeutic in cosmetic, toiletry, bath additive, and pharmaceutical compositions.
- In one or more embodiments, the composition further contains a compatible fragrance so as for example to provide in addition aromatherapy on application of the sensation foam.
- In one or more embodiments, the composition further contains a compatible washable pigment so as to provide an attractive color to the dispensed foam.
- In one or more embodiments, the composition is a waterless composition with hygroscopic ingredients, which upon absorbing water present on a body surface give an initial warming sensation in addition to the prolonged sensation of the sensation agent.
- It was discovered that incorporating a sensation or sensation modifying agent in a foamable composition results in a product that, when compared with the composition which is not foamed provides an improved effect.
- While not wishing to be limited to any particular theory, it is presently believed that the expansion of the formulations caused by the presence of a propellant causes the product to spread in the form of a thin film on the skin or delivery site, thereby giving a soft, silky, and cosmetically elegant feel. The observed effect is analogous to a comparison between whipped cream and butter. While both of these products are produced from cream, butter is a dense, greasy water in oil emulsion, whereas whipped cream is a light air in oil emulsion in which the oil is extended over a much greater volume, thereby masking its greasy properties to a substantial extent. In the present invention, by foaming the oils with a propellant to produce a low density aerated foam, the greasy property of the oil in the formulation is ameliorated or minimized.
- Moreover it was further discovered that it is possible to prepare such foamable compositions using more than one different foamable platforms or carriers. More specifically it was discovered, for example, that effective foamable compositions can be produced with a sensation or sensation modifying effect with a substantially waterless carrier and can also be produced with a substantially aqueous carrier. The ability to produce sensation or sensation modifying foam in waterless and aqueous environments allows the production of foams to suit, benefit or improve a wide variety of skin, mucosa and body cavity conditions. Based on this discovery it is possible to develop and create a multitude of foams, which provide a sensation or sensation modifying feeling with the following advantages:
-
- 1. Improvement of user compliance especially in children or sensitive patients;
- 2. Enhancement of user comfort;
- 3. Improvement of skin absorption, due to the foam texture;
- 4. Improvement of skin appearance due to the non-shiny appearance thereof, after administration of the composition;
- 5. Easier spreading on the body surface, without the need of extensive rubbing;
- 6. Remains substantially intact for a sufficient period to facilitate convenience of application;
- 7. Sensation agent may mask, neutralize, ameliorate or hide one or more undesired properties of other ingredients of the composition;
- 8. Improvement in absorption through skin of one or more active agents;
- 9. The evaporation of the propellant from newly released foam that has been applied to a body surface can, depending on the nature of the foam and the type and amount of propellant provide a cooling effect.
- In accordance with one or more further embodiments, the propellant is at a concentration from about 3% to about 25% by weight of the total composition.
- In accordance with one or more further embodiments, the propellant is at a concentration from about 25% to about 45% by weight of the total composition.
- In accordance with one or more embodiments, the foamable base composition is flowable.
- In accordance with one or more embodiments, the main carrier solvent is at a concentration of about 40% to about 90% by weight of the total composition.
- In accordance with one or more embodiments, the foamable composition further comprises at least one component, selected from the group consisting of:
- a. a surface active agent;
- b. a polymeric agent
-
- wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
- In accordance with one or more embodiments, the surface active agent is a stabilizing combination of at least two surface active agents.
- In accordance with one or more embodiments, the surface active agent is at a concentration of about 0.1% to about 10% by weight of the total composition.
- In accordance with one or more embodiments, the polymeric agent is at a concentration of about 0.05% to about 5% by weight of the total composition.
- In accordance with one or more embodiments, the surface active agent is combination of at least two surfactants.
- In accordance with one or more embodiments, where the composition is an emollient emulsion the polymeric agent is preferably a combination of hydroxy propylmethyl cellulose and xantham gum. In certain other embodiments the polymeric agent is sodium carboxymethyl-cellulose, hydroxyethyl-cellulose, microcrystalline-cellulose, aluminum starch octyl succinate, and polyacrylates such as carbopol.
- In accordance with one or more embodiments, wherein the composition is an emollient emulsion, the polymeric agent is preferably a hydroxypropyl-cellulose such as Klucel EF, aluminum starch octyl succinate, and polyacrylates such as carbopol.
- In accordance with one or more embodiments, the co-emulsifier is at a concentration of about 0.05% to about 10% by weight of the total composition.
- In accordance with one or more embodiments, the viscosity, bulking or firming agent is at a concentration of about 0.1% to about 15% by weight of the total composition.
- In accordance with one or more embodiments, the stabilizer is at a concentration of about 0.1% to about 10% by weight of the total composition.
- In accordance with one or more embodiments, the co-solvent is at a concentration of about 0.1% to about 30% by weight of the total composition.
- In accordance with one or more embodiments, the penetration enhancer is at a concentration of about 0.1% to about 30% by weight of the total composition.
- In accordance with one or more embodiments, the agent capable of having an occlusive effect is at a concentration of about 0.1% to about 30% by weight of the total composition.
- In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam has a density of about 0.01 to about 0.2 g/ml.
- In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 60 seconds or more.
- In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 120 seconds or more.
- In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 300 seconds or more.
- In an exemplary embodiment, the foamable sensation modifying topical composition is an aqueous composition, containing water and further comprises a surface active agent.
- In an exemplary embodiment, the foamable sensation modifying topical composition comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent.
- In an exemplary embodiment, the foamable sensation modifying topical composition is an emulsion, comprising water, a hydrophobic solvent, a surface-active agent and a polymeric agent.
- Optionally, in one or more embodiments the emulsion-type foamable composition further contains a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
- In certain embodiments, the emulsion is an oil in water emulsion, while in additional embodiments the emulsion is a water in oil emulsion.
- In certain embodiments the hydrophobic carrier is an oil. Exemplary oils include mineral oil, silicone oil, a triglyceride and an ester of a fatty acid. In certain embodiments, the hydrophobic solvent is occlusive, such as petrolatum, while in other embodiments the hydrophobic carrier in non-occlusive.
- In an exemplary embodiment, the foamable sensation modifying topical composition is an oleaginous foamable composition, including at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a polar solvent and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent and at least one polymeric agent.
- In an exemplary embodiment, the foamable sensation modifying topical composition includes more than 50% of a polar solvent (as used herein, the term “polar solvent” shall mean a material that produces a uniform, clear or hazy, mixture when combined with at least a weight equivalent of water), a surface-active agent and a polymeric agent.
- In certain embodiments the foamable composition contains up to 80% water, while in additional embodiments the foamable composition contains up to 25% water.
- In one or more embodiments, the composition is substantially alcohol free
- In one or more embodiments, the composition is substantially non-aqueous.
- In accordance with one or more embodiments, there is provided a method of treating, alleviating or preventing a dermatological reaction, sensation or disorder of a mammalian subject, comprising:
-
- a. administering an effective amount of a sensation or sensation modifying topical emollient emulsion carrier composition to a target site on a mammalian subject, comprising:
- i. an aqueous carrier at a concentration of about 40% to about 90% by weight of the total composition;
- ii. an emollient at a concentration of about 5% to about 15% by weight of the total composition;
- iii. a surfactant at a concentration of about 0.1% to about 10% by weight of the total composition;
- iv. a polymeric agent at a concentration of about 0.1% to about 5% by weight of the total composition;
- v. a propellant at a concentration of about 3% to about 45% by weight of the total composition;
- vi. at least one active agent in an effective amount which is intended to prevent, alleviate, treat or cure said reaction, sensation or disorder; and optionally;
- vii. a co-emulsifier and foam stabilizer at a concentration of about 0.1% to about 5% by weight of the total composition; a viscosity, bulking or firming agent at a concentration of about 0.1% to about 15% by weight of the total composition; a stabilizer; a co-solvent at a concentration of about 0.1% to about 20% by weight of the total composition; a penetration enhancer at a concentration of about 0.1% to about 20% by weight of the total composition; and or an agent capable of having an occlusive effect at a concentration of about 5% to about 30% by weight of the total composition;
- wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
- b. applying mechanical shear break to the applied foam such that it is spread at, about and within the target site.
- a. administering an effective amount of a sensation or sensation modifying topical emollient emulsion carrier composition to a target site on a mammalian subject, comprising:
- In accordance with one or more embodiments, there is provided a method of treating, alleviating or preventing a dermatological reaction, sensation or disorder of a mammalian subject, comprising:
-
- a. administering an effective amount of a sensation or sensation modifying topical substantially waterless foamable composition to a target site on a mammalian subject, comprising:
- aa. a non-aqueous carrier at a concentration of about 40% to about 90% by weight of the total composition;
- bb. a surfactant at a concentration of about 0.1% to about 10% by weight of the total composition; and or a polymeric agent at a concentration of about 0.1% to about 5% by weight of the total composition;
- cc. at least one active agent in an effective amount which is intended to prevent, alleviate, treat or cure said reaction, sensation or disorder;
- dd. a propellant at a concentration of about 3% to about 25% by weight of the total composition and optionally;
- ee. a co-emulsifier and foam stabilizer at a concentration of about 0.1% to about 5% by weight of the total composition; and a viscosity, bulking or firming agent at a concentration of about 0.1% to about 15% by weight of the total composition.
- wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
- b. applying mechanical shear break to the applied foam such that it is spread at, about and within the target site.
- a. administering an effective amount of a sensation or sensation modifying topical substantially waterless foamable composition to a target site on a mammalian subject, comprising:
- A “hydrophobic solvent” as used herein refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL.
- In one or more embodiments, the hydrophobic organic carrier is an oil, such as mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils; essential oils; and silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane) copolymer.
- A “polar solvent” is an organic solvent, typically soluble both in water and oil but is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition. The emollient emulsion and waterless formulations may contain polar solvents, which may contribute to the penetration of an active or therapeutic agent including a sensation or sensation modifying agent.
- A polymeric agent can be selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methyl hydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose, carboxymethylhydroxyethylcellulose, a cationic cellulose PEG 1000, PEG1500, PEG2000, PEG 4000, PEG 6000 and PEG 8000.
- In an embodiment of the present invention, the solvent is a polyol. A polyol is an organic substance that contains at least two hydroxy groups in its molecular structure.
- In one or more embodiments, the foamable carrier contains at least one diol (a compound that contains two hydroxy groups in its molecular structure). Examples of diols include propylene glycol (e.g., 1,2-propylene glycol and 1,3-propylene glycol), butanediol (e.g., 1,2-butanediol, 1,3-butanediol, 2,3-butanediol and 1,4-butanediol), butanediol (e.g., 1,3-butanediol and 1,4-butenediol), butynediol, pentanediol (e.g., pentane-1,2-diol, pentane-1,3-diol, pentane-1,4-diol, pentane-1,5-diol, pentane-2,3-diol and pentane-2,4-diol), hexanediol (e.g., hexane-1,6-diol hexane-2,3-diol and hexane-2,56-diol), octanediol (e.g., 1,8-octanediol), neopentyl glycol, 2-methyl-1,3-propanediol, diethylene glycol, triethylene glycol, tetraethylene glycol, dipropylene glycol and dibutylene glycol.
- In one or more embodiments, the foamable carrier contains at least one triol (a compound that contains three hydroxy groups in its molecular structure), such as glycerin, butane-1,2,3-triol, butane-1,2,4-triol and hexane-1,2,6-triol.
- In one or more embodiments, the polyol is a mixture of polyols. In one or more embodiments, the mixture of polyols contains at least one diol and at least one triol. According to certain embodiments the ratio between the diol and triol is between 9:1 and 1:1.
- In one or more embodiments, part of mixture of polyols is a saccharide. Exemplary saccharides include, but are not limited to monosaccharide, disaccharides, oligosaccharides and sugar alcohols.
- A monosaccharide is a simple sugar that cannot be hydrolysed to smaller units. Empirical formula is (CH2O)n and range in size from trioses (n=3) to heptoses (n=7). Exemplary monosaccharide compounds are ribose, glucose, fructose and galactose.
- Disaccharides are made up of two monosaccharides joined together, such as sucrose, maltose and lactose.
- A sugar alcohol (also known as a polyol, polyhydric alcohol, or polyalcohol) is a hydrogenated form of saccharide, whose carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group. They are commonly used for replacing sucrose in foodstuffs, often in combination with high intensity artificial sweeteners to counter the low sweetness. Some exemplary sugar alcohols, which are suitable for use according to the present invention are mannitol, sorbitol, xylitol, maltitol, lactitol. (Maltitol and lactitol are not completely hydrogenated compounds—they are a monosaccharide combined with a polyhydric alcohol). Mixtures of polyols, including (1) at least one polyol selected from a diol and a triol; and (2) a saccharide are contemplated within the scope of the present invention.
- In an embodiment of the present invention, the solvent consists of a polymerized ethylene glycol, namely polyethylene glycol, which is also termed “PEG”. Exemplary PEGs are provided in the following table.
-
Composition Av. Molecular weight Appearance Melting point (° C.) PEG 200 190~210 Oily liquid ? PEG 300 285~315 Oily liquid PEG 400 380~420 Oily liquid ? PEG 600 570~630 Oily liquid 17~22 PEG 1000 950~1050 Solid 35~40 PEG 4000 3800~4400 Solid 53~58 PEG 6000 5600~6400 Solid 55~60 PEG 8000 7500~8500 Solid 58~65 - Thus, in an embodiment of the present invention, the PEG is selected from the group consisting of PEG 200, PEG 300, PEG 400, PEG 600, PEG 1000, PEG 4000, PEG 6000 and PEG 8000. The foamable carrier according to the present invention can contain a single PEG or a mixture of two or more PEGs. PEGs having molecular weight of more that about 1000 possess gelling properties; i.e., they increase the viscosity of a composition. Therefore, by combining PEGs with different molecular weights/melting points, one can attain varying levels of flowability as desirable for the treatment of a given target site. The concentration of the PEG should be in a level that results in viscosity, prior to filling of the composition into aerosol canisters, of less than 12,000 CPs, and more preferably, less than 10,000 CPs.
- Optionally, a secondary solvent is added to the foamable composition of the present invention. The secondary solvent is selected from a variety of organic solvents that are typically miscible on both water and oil. Examples of solvent that can be contained in the foamable carrier of the present invention include dimethyl isosorbide, tetrahydrofurfuryl alcohol polyethyleneglycol ether (glycofurol), DMSO, pyrrolidones, (such as N-Methyl-2-pyrrolidone and 1-Methyl-2-pyrrolidinone), ethyl proxitol, dimethylacetamide (DMAc), PEG-type surfactants and alpha hydroxy acids, such as lactic acid and glycolic acid.
- A “skin penetration enhancer”, also termed herein “penetration enhancer,” is an organic solvent, typically soluble in both water and oil. Examples of penetration enhancer include polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol, 1-menthol, dioxolane, ethylene glycol, hexylene glycol, other glycols, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, dimethylisosorbide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane, esters, such as isopropyl myristate/palmitate, ethyl acetate, butyl acetate, methyl proprionate, capric/caprylic triglycerides, octylmyristate, dodecyl-myristate; myristyl alcohol, lauryl alcohol, lauric acid, lauryl lactate ketones; amides, such as acetamide oleates such as triolein; various alkanoic acids such as caprylic acid; lactam compounds, such as azone; alkanols, such as dialkylamino acetates, and admixtures thereof.
- According to one or more embodiments, the penetration enhancer is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature
- In many cases, polyols, PEGs and solvents possess a high solubilizing power and thus, they can enable increased concentrations of a pharmaceutical active agent. Polyols, PEGs and solvents are also known for their skin penetration enhancement properties. These properties enable high drug bioavailability in the target area of treatment, resulting in an enhanced therapeutic effect. Occasionally, combinations of a polyol, PEGs and a secondary solvent, exhibit an increased permeability across the skin, as suggested, for example, in Eur. J. Pharm. Biopharm. 1998 Nov. 46(3):265-71.
- Thus, in one or more embodiments, the foamable carrier contains (1) at least one solvent, selected from a polyol (selected from a diol and a triol) and PEG; and (2) at least one secondary solvent.
- In one or more embodiments, the foamable carrier contains (1) a mixture of at least two polyols; and (2) at least one secondary solvent. In additional embodiments, the foamable carrier contains a mixture of at least one polyol and at least one PEG; yet in other embodiments the foamable carrier contains (1) a mixture of at least one polyol and at least one PEG and (2) at least one secondary solvent.
- According to certain embodiments the ratio between the polyol and/or PEG and the secondary solvent is between 9:1 and 1:1.
- In certain embodiments, the polyol is selected from the group consisting of propylene glycol, hexylene glycol and glycerin (and mixtures thereof); and the secondary solvent is selected from the group consisting of dimethyl isosorbide, diethylene glycol monoethyl ether, a liquid polyethylene glycol and glycofurol.
- In certain embodiments, the foamable carrier contains (1) at least one polyol; and (2) dimethyl isosorbide.
- In one or more embodiments of the present invention, the foamable composition includes a potent solvent, in addition to, or in place, of one of the hydrophobic solvents, polar solvents or emollients of the composition. A potent solvent is a solvent other than mineral oil that solubilizes a specific active agent substantially better than a hydrocarbon solvent such as mineral oil or petrolatum. For example, a potent solvent solubilizes the active agent 5 fold better than a hydrocarbon solvent; or even solubilizes the active agent 10-fold better than a hydrocarbon solvent.
- In one or more embodiments of the present invention, the composition includes at least one active agent in a therapeutically effective concentration; and at least one potent solvent in a sufficient amount to substantially solubilize the at least one active agent in the composition. The term “substantially soluble” means that at least 95% of the active agent has been solubilized, i.e., 5% or less of the active agent is present in a solid state. In one or more embodiments, the concentration of the at least one potent solvent is more than about 40% of the at least one solvent of the composition of the present invention; or even more than about 60%.
- Non-limiting examples of pairs of active agent and potent solvent include: Betamethasone valerate: Practically insoluble in mineral oil (<0.01%); soluble more than 1% in glycofurol; Hydrocortisone butyrate: Practically insoluble in mineral oil (<0.01%); soluble more than 1% in glycofurol; Metronidazole: Practically insoluble in mineral oil (<0.01%); soluble more than 1% in dimethyl isosrbide; Ketoconazole: Practically insoluble in mineral oil (<0.01%); soluble more than 1% in glycofurol, propylene glycol and dimethyl isosrbide; Mupirocin: Practically insoluble in mineral oil (<0.01%); soluble more than 1% in glycofurol, hexylene glycol, dimethyl isosorbide, propylene glycol and polyethylene glycol 400 (PEG 400); Meloxicam, a nonsteroidal anti-inflammatory agent: Practically insoluble in mineral oil (<0.001%); soluble in propylene glycol: 0.3 mg/mL; and in PEG 400: 3.7 mg/mL; and Progesterone: Practically insoluble in mineral oil (<0.001%); soluble in PEG 400: 15.3 mg/mL.
- A non-limiting exemplary list of solvents that can be considered as potent solvents includes polyethylene glycol, propylene glycol, hexylene glycol, butaneediols and isomers thereof, glycerol, benzyl alcohol, DMSO, ethyl oleate, ethyl caprylate, diisopropyl adipate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, isosorbide derivatives, such as dimethyl isosorbide, glycofurol and ethoxydiglycol (transcutol) and laurocapram.
- The use of a potent solvent in a foam composition provides an improved method of delivering poorly soluble therapeutic agents to a target area. It is known that low drug solubility results in poor bioavailability, leading to decreased effectiveness of treatment. Foam compositions of the present invention, for which the solvent includes a potent solvent, increase the levels of the active agent in solution and thus, provide high delivery and improved therapy.
- Potent solvents, as defined herein, are usually liquid. Formulations comprising potent solvents and active agents are generally disadvantageous as therapeutics, since their usage involves unwanted dripping and inconvenient method of application; resulting in inadequate dosing. Surprisingly, the foams of the present invention, which are drip-free, provide a superior vehicle for such active agents, enabling convenient usage and accurate effective dosing.
- In one or more embodiments of the present invention the present invention the foamable pharmaceutical composition may additionally include a mixture of two or more of the solvents selected from the group of hydrophobic solvents, silicone oils, emollients, polar solvents and potent solvents in an appropriate proportion as would be appreciated to a person skilled in the art.
- In one or more embodiments of the present invention, the PPG alkyl ether may act as a potent solvent.
- The composition further contains a surface-active agent. Surface-active agents (also termed “surfactants”) include any agent linking oil and water in the composition, in the form of emulsion. A surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. HLB is defined for non-ionic surfactants. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics. Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions. The HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average). In many cases a single surfactant may suffice. In other cases a combination of two or more surfactants is desired. Reference to a surfactant in the specification can also apply to a combination of surfactants or a surfactant system. As will be appreciated by a person skilled in the art which surfactant or surfactant system is more appropriate is related to the vehicle and intended purpose. In general terms a combination of surfactants can be significant in producing breakable forms of good quality. It has been further discovered that the generally thought considerations for HLB values for selecting a surfactant or surfactant combination are not always binding for emulsions and moreover for waterless and substantially non aqueous carriers the usual guidelines are less applicable. Surfactants also play a significant role in foam formation where the foamable formulation is a single phase composition.
- According to one or more embodiments the composition contains a single surface active agent having an HLB value between about 2 and 9, or more than one surface active agent and the weighted average of their HLB values is between about 2 and about 9.
- According to one or more embodiments the composition contains a single surface active agent having an HLB value between about 7 and 14, (preferably about 7 to about 12) or more than one surface active agent and the weighted average of their HLB values is between about 7 and about 14 (preferably about 7 to about 12).
- According to one or more other embodiments the composition contains a single surface active agent having an HLB value between about 9 and about 19, or more than one surface active agent and the weighted average of their HLB values is between about 9 and about 19.
- In a waterless or substantially waterless environment a wide range of HLB values may be suitable.
- Preferably, the composition contains a non-ionic surfactant. Nonlimiting examples of possible non-ionic surfactants include a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59; a polyoxyethylene alkyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, steareths such as steareth 2, brij 21, brij 721, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol and its anhydrides, sorbitan monolaurate, sorbitan monolaurate, a monoglyceride, a diglyceride, isoceteth-20 and mono-, di- and tri-esters of sucrose with fatty acids. In certain embdiments, suitable sucrose esters include those having high monoester content, which have higher HLB values.
- In an embodiment the surfactant is an ether for example polyoxyethylene (26) glycerol ether.
- In certain embodiments, surfactants are selected which can provide a close packed surfactant layer. To achieve such objectives combinations of at least two surfactants are selected. Preferably, they should be complex emulgators and more preferably they should both be of a similar molecular type; for example, a pair of ethers, like steareth 2 and steareth 21, or a pair of esters, for example, PEG-40 stearate and polysorbate 80. Ideally, the surfactants can be ethers. In certain circumstances POE esters cannot be used and a combination of sorbitan laurate and sorbitan stearate or a combination of sucrose stearic acid ester mixtures and sodium laurate may be used. All these combinations due to their versatility and strength may also be used satisfactorily and effectively with ether formulations, although the amounts and proportion may be varied according to the formulation and its objectives as will be appreciated by a man of the art.
- It has been discovered also that by using a derivatized hydrophilic polymer with hydrophobic alkyl moieties as a polymeric emulsifier such as pemulen it is possible to stabilize the emulsion better about or at the region of phase reversal tension. Other types of derivatized polymers like silicone copolymers, derivatized starch [Aluminum Starch Octenylsuccinate (ASOS)]/[DRY-FLO AF Starch], and derivatized dexrin may also a similar stabilizing effect.
- A series of dextrin derivative surfactants prepared by the reaction of the propylene glycol polyglucosides with a hydrophobic oxirane-containing material of the glycidyl ether are highly biodegradable. [Hong-Rong Wang and Keng-Ming Chen, Colloids and Surfaces A: Physicochemical and Engineering Aspects Volume 281, Issues 1-3, 15 Jun. 2006, Pages 190-.
- Non-limiting examples of non-ionic surfactants that have HLB of about 7 to about 12 include steareth 2 (HLB˜4.9); glyceryl monostearate/PEG 100 stearate (Av HLB˜11.2); stearate Laureth 4 (HLB˜9.7) and cetomacrogol ether (e.g., polyethylene glycol 1000 monocetyl ether).
- Non-limiting examples of preferred surfactants, which have a HLB of 4-19 are set out in the Table below:
-
Surfactant HLB steareth 2 ~4.9 glyceryl monostearate/PEG 100 stearate Av ~11.2 Glyceryl Stearate ~4 Steareth-21 ~15.5 peg 40 stearate ~16.9 polysorbate 80 ~15 sorbitan stearate ~4.7 laureth 4 ~9.7 Sorbitan monooleate (span 80) ~4.3 ceteareth 20 ~15.7 steareth 20 ~15.3 ceteth 20 ~15.7 Macrogol Cetostearyl Ether ~15.7 ceteth 2 (Lipocol C-2) ~5.3 PEG-30 Dipolyhydroxystearate ~5.5 sucrose distearate (Sisterna SP30) ~6 polyoxyethylene (100) stearate ~18.8 - Another component of the formulations of the present invention is a compound used in the present invention is Sepigel 305. Sepigel 305 comprises Polyacrylamide and C13-14 Isoparaffin and Laureth-7. It acts as a surfactant and as a thickening and emulsifying agent, and comes in a liquid, very easy to handle form. It requires neither premixing, nor high rate of shear nor neutralisation. Sepigel 305 can be used to emulsify all types of oil phase without heating, producing gel-cream with a rich, silky texture that are easy to apply and rapidly absorbed by the skin.
- More exemplary stabilizing surfactants which may be suitable for use in the present invention are found below.
- PEG-Fatty Acid Monoester Surfactants, such as:
-
Chemical name Product example name HLB PEG-30 stearate Myrj 51 >10 PEG-40 laurate Crodet L40 (Croda) 17.9 PEG-40 oleate Crodet O40 (Croda) 17.4 PEG-45 stearate Nikkol MYS-45 (Nikko) 18 PEG-50 stearate Myrj 53 >10 PEG-100 stearate Myrj 59, Arlacel 165 (ICI) 19 - PEG-Fatty Acid Diester Surfactants, such as:
-
Chemical name Product example name HLB PEG-4 dilaurate Mapeg .RTM. 200 DL (PPG), 7 Kessco .RTM.PEG 200 DL (Stepan), LIPOPEG 2-DL (Lipo Chem.) PEG-4 distearate Kessco .RTM. 200 DS 5 (Stepan.sub) PEG-32 dioleate Kessco .RTM. PEG 1540 DO 15 (Stepan) PEG-400 dioleate Cithrol 4DO series (Croda) >10 PEG-400 disterate Cithrol 4DS series (Croda) >10 PEG-20 glyceryl oleate Tagat .RTM. O (Goldschmidt) >10 - Transesterification Products of Oils and Alcohols, such as:
-
Chemical name Product example name HLB PEG-30 castor oil Emalex C-30 (Nihon Emulsion) 11 PEG-40 hydrogenated castor Cremophor RH 40 (BASF), 13 oil Croduret (Croda), Emulgin HRE 40 (Henkel) - Polyglycerized Fatty Acids, such as:
-
Chemical name Product example name LB Polyglyceryl-6 dioleate Caprol .RTM. 6G20 (ABITEC); 8.5 PGO-62 (Calgene), PLUROL OLEIQUE CC 497 (Gattefosse)Hodag - PEG-Sorbitan Fatty Acid Esters, such as:
-
Chemical name Product example name HLB PEG-20 sorbitan monolaurate Tween-20 (Atlas/ICI), Crillet 1 17 (Croda), DACOL MLS 20 (Condea) PEG-20 sorbitan Tween 40 (Atlas/ICI), Crillet 2 16 Monopalmitate (Croda) PEG-20 sorbitan Tween-60 (Atlas/ICI), Crillet 3 15 monostearate (Croda) PEG-20 sorbitan monooleate Tween-80 (Atlas/ICI), Crillet 4 15 (Croda) - Polyethylene Glycol Alkyl Ethers, such as:
-
Chemical name Product example name HLB PEG-2 oleyl ether oleth-2 Brij 92/93 (Atlas/ICI) 4.9 PEG-3 oleyl ether oleth-3 Volpo 3 (Croda) <10 PEG-5 oleyl ether oleth-5 Volpo 5 (Croda) <10 PEG-10 oleyl ether oleth-10 Volpo 10 (Croda), Brij 12 96/97 (Atlas/ICI) PEG-20 oleyl ether oleth-20 Volpo 20 (Croda), Brij 15 98/99 (Atlas/ICI) PEG-4 lauryl ether laureth-4Brij 30 (Atlas/ICI) 9.7 PEG-23 lauryl ether laureth-23Brij 35 (Atlas/ICI) 17 PEG-10 stearyl ether Brij 76 (ICI) 12 PEG-2 cetyl ether Brij 52 (ICI) 5.3 - Sugar Ester Surfactants, such as:
-
Chemical name Product example name HLB Sucrose distearate Sisterna SP50, Surfope 1811 11 - Sorbitan Fatty Acid Ester Surfactants, such as:
-
Chemical name Product example name HLB Sorbitan monolaurate Span-20 (Atlas/ICI), Crill 1 8.6 (Croda), Arlacel 20 (ICI) Sorbitan monopalmitate Span-40 (Atlas/ICI), Crill 2 6.7 (Croda), Nikkol SP-10 (Nikko) Sorbitan monooleate Span-80 (Atlas/ICI), Crill 4 4.3 (Croda), Crill 50 (Croda) Sorbitan monostearate Span-60 (Atlas/ICI), Crill 3 4.7 (Croda), Nikkol SS-10 (Nikko) - In one or more embodiments the surface active agent is a complex emulgator in which the combination of two or more surface active agents can be more effective than a single surfactant and provides a more stable formulation or improved foam quality than a single surfactant. For example and by way of non-limiting explanation it has been found that by choosing say two surfactants, one hydrophobic and the other hydrophilic the combination can produce a more stable emulsion than a single surfactant. Preferably, the complex emulgator comprises a combination of surfactants wherein there is a difference of about 4 or more units between the HLB values of the two surfactants or there is a significant difference in the chemical nature or structure of the two or more surfactants.
- Specific non limiting examples of surfactant systems are, combinations of polyoxyethylene alkyl ethers, such as Brij 59/Brij10; Brij 52/Brij 10; Steareth 2/Steareth 20; Steareth 2/Steareth 21 (Brij 72/Brij 721); combinations of polyoxyethylene stearates such as Myrj 52/Myrj 59; combinations of sucrose esters, such as Surphope 1816/Surphope 1807; combinations of sorbitan esters, such as Span 20/Span 80; Span 20/Span 60; combinations of sucrose esters and sorbitan esters, such as Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG compounds, such as Tween 80/PEG-40 stearate; methyl glucaso sequistearate; polymeric emulsifiers, such as Permulen (TRI or TR2); liquid crystal systems, such as Arlatone (2121), Stepan (Mild RM1), Nikomulese (41) and Montanov (68) and the like.
- In certain embodiments the surfactant is preferably one or more of the following: a combination of steareth-2 and steareth-21 on their own or in combination with glyceryl monostearate (GMS); in certain other embodiments the surfactant is a combination of polysorbate 80 and PEG-40 stearate. In certain other embodiments the surfactant is a combination of glyceryl monostearate/PEG 100 stearate. In certain other embodiments the surfactant is a combination of two or more of stearate 21, PEG 40 stearate, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of laureth 4, span80, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of GMS and ceteareth. In certain other embodiments the surfactant is a combination of two or more of steareth 21, ceteareth 20, ceteth 2 and laureth 4 In certain other embodiments the surfactant is a combination of ceteareth 20 and polysorbate 40 stearate. In certain other embodiments the surfactant is a combination of span 60 and GMS. In certain other embodiments the surfactant is a combination of two or all of PEG 40 stearate, sorbitan stearate and polysorbate 60
- In certain other embodiments the surfactant is one or more of sucrose stearic acid esters, sorbitan laureth, and sorbitan stearate.
- Without being bound by any particular theory or mode of operation, it is believed that the use of non-ionic surfactants with significant hydrophobic and hydrophilic components, increase the emulsifier or foam stabilization characteristics of the composition. Similarly, without being bound by any particular theory or mode of operation, using combinations of surfactants with high and low HLB's to provide a relatively close packed surfactant layer may strengthen the formulation.
- In one or more embodiments the stability of the composition can be improved when a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed. The ratio between the at least one non-ionic surfactant having HLB of less than 9 and the at least one non-ionic surfactant having HLB of equal or more than 9, is between 1:8 and 8:1, or at a ratio of 4:1 to 1:4. The resultant HLB of such a blend of at least two emulsifiers is preferably between about 9 and about 14.
- Thus, in an exemplary embodiment, a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed, at a ratio of between 1:8 and 8:1, or at a ratio of 4:1 to 1:4, wherein the HLB of the combination of emulsifiers is preferably between about 5 and about 18.
- In certain cases, the surface active agent is selected from the group of cationic, zwitterionic, amphoteric and ampholytic surfactants, such as sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
- Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two incompatible components on a nanometer scale. Soap is an everyday example of a lyotropic liquid crystal. Certain types of surfactants tend to form lyotropic liquid crystals in emulsions interface (oil-in-water) and exert a stabilizing effect In one or more embodiments the surfactant is a surfactant or surfactant combination is capable of or which tends to form liquid crystals. Surfactants which tend to form liquid crystals may improve the quality of foams. Non limiting examples of surfactants with postulated tendency to form interfacial liquid crystals are: phospholipids, alkyl glucosides, sucrose esters, sorbitan esters.
- In one or more embodiments the at least one surface active agent is liquid. Moreover for the purposes of formulating with liquid ethers a liquid surfactant is preferred.
- In one or more embodiments the liquid surfactant is a polysorbate, preferably polysorbate 80 or 60.
- In one or more embodiments the at least one surface active agent is solid, semi solid or waxy. In a further embodiment they are soluble in oil and in another embodiment have a HLB of less than about 12.
- It should be noted that HLB values may not be so applicable to non ionic surfactants, for example, with liquid crystals or with silicones. Also HLB values may be of lesser significance in a waterless or substantially non-aqueous environment.
- In one or more embodiments the surfactant can be, a surfactant system comprising of a surfactant and a co surfactant, a waxy emulsifier, a liquid crystal emulsifier, an emulsifier which is solid or semi solid at room temperature and pressure, or combinations of two or more agents in an appropriate proportion as will be appreciated a person skilled in the art. Where a solid or semi solid emulsifier combination is used it can also comprise a solid or semi solid emulsifier and a liquid emulsifier. In a preferred embodiment at least one surfactant is a liquid.
- In one or more embodiments, the surface-active agent includes at least one non-ionic surfactant. Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed. Non-ionic surfactants alone can provide formulations and foams of good or excellent quality in the carriers and compositions of the present invention.
- Thus, in a preferred embodiment, the surface active agent, the composition contains a non-ionic surfactant. In another preferred embodiment the composition includes a mixture of non-ionic surfactants as the sole surface active agent. Yet, in additional embodiments, the foamable composition includes a mixture of at least one non-ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1. In one or more embodiments, the non-ionic to ionic surfactant ratio is greater than about 6:1, or greater than about 8:1; or greater than about 14:1, or greater than about 16:1, or greater than about 20:1. In further embodiments, surface active agent comprises a combination of a non-ionic surfactant and an ionic surfactant, at a ratio of between 1:1 and 20:1.
- In one or more embodiments, a combination of a non-ionic surfactant and an ionic surfactant (such as sodium lauryl sulphate and cocamidopropylbetaine) is employed, at a ratio of between 1:1 and 20:1, or at a ratio of 4:1 to 10:1; for example, about 1:1, about 4:1, about 8:1, about 12:1, about 16:1 and about 20:1 or at a ratio of 4:1 to 10:1, for example, about 4:1, about 6:1, about 8:1 and about 10:1.
- For foams in selecting a suitable surfactant or combination thereof it should be borne in mind that the upper amount of surfactant that may be used may be limited by the shakability of the composition. If the surfactant is non liquid, it can make the formulation to viscous or solid. Subject to its miscibility, solid surfactants may be added first, and may require gentle warming and then cooling before being combined with the other ingredients. In general terms, as the amount of non-liquid surfactant is increased the shakability of the formulation reduces until a limitation point is reached where the formulation can become non shakable and unsuitable. Thus in one embodiment, any effective amount of surfactant may be used provided the formulation remains shakable. In other certain limited embodiments the upper limit for foamable formulations may be determined by flowability such that any effective amount can be used provided the formulation is sufficiently flowable to be able to flow through an actuator valve and be released and still expand to form a good quality foam. This may be due without being bound by any theory to one or more of a number of factors such as the viscosity, the softness, the lack of crystals, the pseudoplastic or semi pseudo plastic nature of the composition and the dissolution of the propellant into the composition.
- In certain embodiments the amount of surfactant or combination of surfactants is between about 0.05% to about 20%; between about 0.05% to about 15%. or between about 0.05% to about 10%. In a preferred embodiment the concentration of surface active agent is between about 0.2% and about 8%. In a more preferred embodiments the concentration of surface active agent is between about 1% and about 6% or between about 1% and about 4%.
- In some embodiments, it is desirable that the surface active agent does not contain a polyoxyethylene (POE) moiety, such as polysorbate surfactants, POE fatty acid esters, and POE alkyl ethers, because the active agent is incompatible with such surface active agents. For example, the active agent pimecrolimus is not stable the presence of POE moieties, yet benefits greatly from the use of dicarboxylic esters as penetration enhancers. In such cases, alternative surface active agents are employed. In an exemplary manner, POE—free surfactants include non-ethoxylated sorbitan esters, such as sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate and sorbitan sesquioleate; glycerol fatty acid esters, such as glycerol monostearate and glycerol monooleate; mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), sucrose stearate, sucrose distearate sucrose palmitate and sucrose laurate; and alkyl polyglycosides, such as lauryl diglucoside.
- A humectant is a substance that helps retain moisture and also prevents rapid evaporation. Non limiting examples are propylene glycol, propylene glycol derivatives, glycerin, hydrogenated starch hydrosylate, hydrogenated lanolin, lanolin wax, D manitol, sorbitol, sodium 2-pyrrolidone-5-carboxylate, sodium lactate, sodium PCA, soluble collagen, dibutyl phthalate, and gelatin. Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
- A moisturizer, is a substance that helps retain moisture or add back moisture to the skin. Examples are allantoin, petrolatum, urea, lactic acid, sodium PCV, glycerin, shea butter, caprylic/capric/stearic triglyceride, candelilla wax, propylene glycol, lanolin, hydrogenated oils, squalene, sodium hyaluronate and lysine PCA. Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
- Pharmaceutical compositions of the present invention may in one or more embodiments usefully comprise in addition a heumectant or a moisturizer or combinations thereof.
- The term modulating agent is used to describe an agent which can improve the stability of or stabilize a carrier or a foamable composition and or an active agent by modulating the effect of a substance or residue present in the carrier or composition. The substance or residue may for example be acidic or basic and potentially alter an artificial pH in a waterless or substantially non aqueous environment or it may be one or more metal ions which may act as a potential catalyst in a waterless or substantially non aqueous environment or it may be an ionisation agent or it may be an oxidizing agent.
- In one or more other embodiments the modulating agent is used in a waterless composition. In one or more embodiments the modulating agent is used to describe an agent which can affect pH in an aqueous solution.
- The agent can be any of the known buffering systems used in pharmaceutical or cosmetic formulations as would be appreciated by a man of the art. It can also be an organic acid, a carboxylic acid, a fatty acid an amino acid, an aromatic acid, an alpha or beta hydroxyl acid an organic base or a nitrogen containing compound.
- In one or more further embodiments the modulating agent is used to describe an agent, which is a chelating or sequestering or complexing agent that is sufficiently soluble or functional in the waterless solvent to enable it to “mop up” or “lock” metal ions.
- In the embodiment modulating agent is used to describe an agent which can effect pH in an aqueous solution the term modulating agent more particularly means an acid or base or buffer system or combinations thereof, which is introduced into or is present in and acts to modulate the ionic or polar characteristics and any acidity or basisity balance of a waterless or substantially non aqueous carrier, composition, foamable carrier or foamable composition or resultant foam described herein.
- The terms pH, pKa, and pKb, buffers such measurements and terms are artificial in a waterless environment. In an embodiment of the present invention sufficient modulating agent is added to achieve an artificial pH in which the active agent is preferably stable. Such artificial pH may be acidic, maybe basic or may be neutral.
- In an embodiment of the present invention, the modulating or additional component is a pH adjusting agent or a buffering agent.
- In one or more preferred embodiments of the present invention the chelating agent is selected from the group consisting of ethylenediaminetetraacetic acid (“EDTA”) and salts thereof such as disodium EDTA, tetrasodium EDTA and calsium disodium EDTA; diethylenetriaminepentaacetic acid (“DTPA”) and salts thereof; hydroxyethlethylenediaminetriacetic acid (“HEDTA”) and salts thereof and nitrilotriacetic acid (“NTA”); more preferably EDTA, HEDTA and their salts; most preferably EDTA and its salts.
- In one or more embodiments of the present invention a preferred non limiting example of the chelating agent is EDTA. Typically, the chelating and sequestering agent is present in the composition at a level of up to about 5.0%, preferably 1.0 percent, by weight, of the composition.
- Combinations of Modulating Agents may be a useful for example chelating agents may be usefully used in combination with another modulating agent such as an acid, a base or a buffer system or with various combinations of modulating agents.
- The modulating agent to the foamable composition of the present invention is further useful for adjusting the pH of the target area of application.
- In one or more embodiments, the modulating agent may also be a preservative or an antioxidant or an ionization agent. Any preservative, antioxidant or ionization agents suitable for pharmaceutical or cosmetic application may be used. Non limiting examples of antioxidants are tocopherol succinate, propyl galate, butylated hydroxy toluene and butyl hydroxy anisol. In one or more embodiments the modulating agent is a flavonoid. Ionization agents may be positive or may be negative depending on the environment and the active agent or composition that is to be protected. Ionization agents may for example act to protect or reduce sensitivity of active agents. Non limiting examples of positive ionization agents are benzyl conium chloride, and cetyl pyridium chloride. Non limiting examples of negative ionization agents are sodium lauryl sulphate, sodium lauryl lactylate and phospholipids.
- In one or more embodiments the formulations described herein may further contain a modulating agent.
- The Microsponges are rigid, porous and spongelike round microscopic particles of cross-linked polymer beads (e.g., polystyrene or copolymers thereof), each defining a substantially noncollapsible pore network. The Microsponges can be loaded with an active ingredient and can provide a controlled time release of the active ingredient to skin or to a mucosal membrane upon application of the formulation. The slow release is intended to reduce irritation by the active. Microsponge® delivery technology was developed by Advanced Polymer Systems. In one or more embodiments the composition comprises one or more active agents loaded into Microponges with an aqueous carrier or with a waterless carrier described herein which may comprise a modulating agent.
- Examples of suitable propellants include volatile hydrocarbons such as butane, propane, isobutane and fluorocarbon gases, or mixtures thereof.
- In an embodiment the propellant is 1681, which is a mixture of propane, isobutene and butane. In another embodiment it is AP 70, which is a mixture of propane, isobutene and butane with a higher pressure.
- The propellant makes up about 5-25 wt % of the foamable composition. In some circumstances the propellant may be up to 35%. The propellants are used to generate and administer the foamable composition as a foam. The total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable composition.
- Alcohol and organic solvents render foams inflammable. It has been surprisingly discovered that fluorohydrocarbon propellants, other than chloro-fluoro carbons (CMCs), which are non-ozone-depleting propellants, are particularly useful in the production of a non-flammable foamable composition. A test according to European Standard prEN 14851, titled “Aerosol containers—Aerosol foam flammability test” revealed that compositions containing an organic carrier that contains a hydrophobic organic carrier and/or a solvent, which are detected as inflammable when a hydrocarbon propellant is used, become non-flammable, while the propellant is an HFC propellant.
- Such propellants include, but are not limited to, hydrofluorocarbon (HFC) propellants, which contain no chlorine atoms, and as such, fall completely outside concerns about stratospheric ozone destruction by chlorofluorocarbons or other chlorinated hydrocarbons. Exemplary non-flammable propellants according to this aspect of the invention include propellants made by DuPont under the registered trademark Dymel, such as 1,1,1,2 tetrafluorethane (Dymel 134), and 1,1,1,2,3,3,3 heptafluoropropane (Dymel 227) 1,1, difluoro ethane (Dymel 152) and 1,1,1,3,3,3 hexafluoropropane HFCs possess Ozone Depletion Potential of 0.00 and thus, they are allowed for use as propellant in aerosol products.
- In one or more embodiments, the non inflammbale propellants are used in combination with the more traditional hydrocarbon propellants.
- In one or more embodiments, where Dymel is used, it is used in such levels that the sensation effect is not primarily due to the propellant.
- Notably, the stability of foamable emulsions including HFC as the propellant can be improved in comparison with the same composition made with a hydrocarbon propellant.
- In one or more embodiments foamable compositions comprise a combination of a HFC and a hydrocarbon propellant such as n-butane or mixtures of hydrocarbon propellants such as propane, isobutane and butane.
- Some propellants may have a cooling effect. The evaporation of the propellant from newly released foam that has been applied to a body surface can, depending on the nature of the foam and the type and amount of propellant provide a cooling effect. In some cases the sensation is mild and in other cases the propellant can actually produce physical cooling on the skin surface. As will be appreciated such cooling effect may increase relative to the ability of the formulation to deliver increasing levels of propellant in contact with the skin.
- Dimethyl ether is a product which evaporates very rapidly to produce a cooling effect and in one or more embodiments is used as part of the propellant system.
- In one or more embodiments the propellant is a mixture of propane, butane and isobutene.
- In one or more embodiments the propellant is a mixture of propane, butane and isobutene together with dimethyl ether.
- In one or more embodiments the propellant makes up about 5-25 wt % of the foamable composition.
- In certain other embodiments the amount of propellant can be increased to up to less than half of the composition, for example, where it is desired to produce a cooling effect in addition to a cooling sensation or where it is sought to produce an initial cooling effect followed by a cooling or other sensation.
- Additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamin or derivative thereof.
- In addition to the sensations and sensation agents and sensation modifying effects described herein it is possible to enhance the sensation of the user and to increase compliance, by for example making the product visually attractive. Thus, in certain further embodiments the additional component is one or more of a colored active agent, a colored excipient, a pigment, a dye, a colorant and a coloring agent. Similarly, in other certain embodiments the additional component is a fragrance or fragrance masking agent
- The sensation modifying agent is selected from a cooling agent, a warming agent a relaxing or soothing agent; a stimulating agent; a refreshing agent; or mixtures thereof.
- As will be appreciated by someone in the art two or more soothing, relaxing, cooling, stimulating, refreshing, and warming agents may be effectively combined in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
- In the context and without degradating from explanations given elsewhere, substances, which are known to provide a “cool” sensation or cooling effect on or following application to a body surface; and substances that, on or following topical application can ameliorate a hot sensation or a heating effect are called “cooling agents”. Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a cooling sensation or effect or to ameliorate a hot sensation or heating effect, is suitable for use a cooling agent in accordance with the present invention. The cooling agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or a propellant or combinations of two or more agents.
- Hence, non limiting examples of cooling agents, which are all incorporated herein by reference are provided in U.S. Pat. Nos. 3,419,543, 4,020,153, 4,032,661, 4,033,994, 4,034,109, 4,059,118, 4,060,091, 4,070,449, 4,070,496, 4,136,163, 4,150,052, 4, 4,153,679, 157,384, 4,178,459, 4,193,936, 4,226,988, 4,230,688, 4,296,255, 4,459,425, 5,266,592, 5,608,119, 5,725,865, 5,773,410, 5,843,466, 5,959,161, 6,214,788, 6,267,974, 6,303,817, 6,328,982, 6,359,168, 6,482,983, 6,592,884, 6,884,906 and 7,030,273 US Patent Application 20040067970, DE 2,202,535, DE 2,205,255, DE 2,503,555, DE 2,608,226, DE 4,226,043, GB 1,351,761, GB 1,351,762, GB 1,421,744, JP 2004059474 and WO 2005049553; and in Watson et al, J. Soc. Cosmet. Chem. 29, 185-200 (1978); and Ottinger et al in J. Agric. Food Chem., 49, 5383-5390 (2001).
- In an embodiment, the cooling agent has a further sensation or sensation modifying feeling or effect.
- In an embodiment, the cooling agent is menthol. In additional embodiment, the cooling agent is an isomer or a derivative of menthol, as exemplifies in the following schemes:
- Additional examples of menthol derivatives are monomenthyl esters of di- and polycarboxylic acids:
- Some derivatives have been developed to be substantially without smell.
- Useful exemplary menthol derivatives are menthol ethylene glycol carbonate, which is now known as Frescolat® type MGC, enthol Propylene Glycol Carbonate (Frescolat® type MPC), menthyl lactate (Frescolat ML®) and Menthone Glycerin Acetal (Frescolat MGA®).
- Additional widely used menthol derivatives are 3-(/-Menthoxy)-1,2-propanediol, known as Cooling Agent 10; and the same structure with an additional methyl group in the glycerin part of the molecule:
- Menthoxy-coolants are additional cooling menthol derivatives:
- Cubebol is an example of a coolant with a C—C bond in the 3d position of p-menthane.
- Cooling agents, which are not menthol derivatives, are also suitable for use in accordance with the present invention. Examples of such cooling agents are provided below:
- Exemplary cooling agents which can be used in the invention include, but are not limited to, menthol, isopulegol, 3-(1-menthoxy)propane-1,2-diol, 3-(1-menthoxy)-2-methylpropane-1,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6-isopropyl-9-methyl-1,4-dioxas-piro[4,5]decane-2-methanol, menthyl succinate and its alkaline earth metal salts, trimethylcyclohexanol, N-ethyl-2-isopropyl-5-methylcyclohexanecarb-oxamide, Japanese mint (Mentha arvensis) oil, peppermint oil, menthone, menthone glycerol ketal, menthyl lactate, 3-(1-menthoxy)ethan-1-ol, 3-(I-menthoxy)propan-1-ol, 3-(I-menthoxy)butan-1-ol, I-menthylacetic acid N-ethylamide, I-menthyl-4-hydroxypentanoate, I-menthyl-3-hydroxybutyrate, N,2,3-trimethyl-2-(1-methylethyl)-butanamide, and spearmint oil.
- The cooling agent is incorporated in the composition in a concentration which, on one side is safe and on the other side provides a cooling sensation or cooling effect upon application of the cooling foamable composition onto a body surface.
- In an embodiment, the cooling agent also possesses therapeutic properties. For example, menthol is being used in the therapy of psoriasis; relief of nasal complaints and sore throats; and WS-3 (N-Ethyl-p-menthane-3-carboxamide) and related N-substituted p-menthane carboxamides, as well as p-Menthane-3,8-diols are known insect repellents
- In the context and without degradating from explanations given elsewhere, substances, which are known to provide a warming sensation or warming effect on or following application to a body surface; and substances that, upon or following topical application can ameliorate a cold sensation or a cooling effect are called “warming agents”. Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a warming sensation or warming effect or to ameliorate a cold sensation or cooling effect, is suitable for use a warming agent in accordance with the present invention. The warming agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or combinations of two or more agents.
- Exemplary substances, which are known to provide a sensation of warmth on application and called “warming agents”. include polyhydric alcohols, capsicum (red pepper) powder, a capsicum tincture, capsicum extract, capsaicin, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives (JP-A-57-9729), such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal, ginger extract, ginger oil, gingeol, and gingeron.
- The warming agent is incorporated in the composition in a concentration which, on one side is safe and on the other side provides a warming sensation or warming effect upon application of the warming foamable composition onto a body surface.
- In an embodiment, the warming agent also possesses therapeutic properties. For example, capsicum powder, capsicum tincture and extract, as well as capsaicin and homocapsaicin are used for topically treating muscle and joint pain.
- It is also possible to modulate, potentate, increase, reduce, or ameliorate the sensation effect by introducing into the composition a sensation modifying agent. Thus, the sensation effect or sensation induced by a first sensation or sensation modifying agent maybe reduced by addition of a second sensation or sensation modifying agent in the composition. For example, the cooling sensation of a cooling formulation may be reduced by the presence of a warming or warming modifying agent. Likewise, the warming sensation of a warming formulation may be reduced by the presence of a cooling or cooling modifying agent. Thus in one exemplary embodiment the composition comprises an effective amount of cooling peppermint oil and a lesser effective amount of capsaicin warming agent such that the cooling sensation is the predominant sensation. In another exemplary embodiment the composition comprises an effective amount capsaicin of and a lesser effective amount of peppermint oil cooling agent such that the warming sensation is the predominant sensation. In another embodiment the cooling and warming agents are selected so that the cooling and warming effects or sensations are staggered. For example, in one exemplary embodiment the composition comprises an effective amount capsaicin of and an effective amount of dimethyl ether cooling agent such that the cooling sensation is the initial predominant sensation and the warming sensation follows on as the subsequent predominant sensation. Other cooling and warming agents may be effectively combined as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
- There are many different categories of agents which have a soothing effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other soothing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
- Non limiting examples of soothing agents are herb extracts, such as, aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, yarrow; calendula, comfrey, witch hazel and other astringents, sea weed, and oat extracts; oils, such as, almond oil, avocado oil, and comfrey; and essential oils, such as, cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary; waxy or unctuous substances such as lanolin or vaselline jelly, minerals, such as, zinc oxide, calamine and selenium; vitamins, such as, tocopheryl acetate (vitamin E), and drugs, such as, analgesics, anesthetics, anti-inflammatory agents, and anti-histamines, muscle relaxants and the like.
- Other non limiting examples are menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-I-menthoxypropane-1,2-diol, ethyl I-menthyl carbonate, (1S,3S,4R)-p-menth-8-en-3-ol, menthyl pyrrolidone carboxylate, N-substituted-p-menthane-3-carboxamides (as described in U.S. Pat. No. 4,136,163, which is incorporated herein by reference) and ketal coolants (as described in WO 93/23005, which is also incorporated herein by reference) including, for example, I-menthon-Id-isomenthon glycerin ketal.
- In one exemplary embodiment the composition comprises an effective amount of soothing hamamelis and a lesser effective amount of frescolate cooling agent such that the soothing sensation is the predominant sensation. In another exemplary embodiment the composition comprises an effective amount capsaicin of and a lesser effective amount of hamamelis soothing agent such that the warming sensation is the predominant sensation. In another embodiment, the soothing and warming agents are selected so that the soothing and warming effects or sensations are staggered or partially overlapping. In another embodiment, the soothing and cooling agents are selected so that the soothing and cooling effects or sensations are staggered or partially overlapping.
- There are many different categories of agents which have a stimulating or refreshing sensation or effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other stimulating or refreshing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
- Non limiting examples are alcohols, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate, acetyl choline, serotonin, histamine, prostaglandins, other neurotransmitters; CNS stimulants; caffeine, quinine, and the like might be suitable stimulants in dosages or delivery systems where they essentially or primarily have a local or topical as opposed to systemic effect.
- Ginger is said to have several pharmacological activities, including anti-emetic, antithrombotic, antimicrobial, anticancer, antioxidant and anti-inflammatory properties. Also, ginger has been reported to have hypoglycaemic, hypo- and hypertensive, cardiac, prostaglandin and platelet aggregation inhibition, antihypercholesterolaemic, cholagogic and stomachic properties. Ginger has carminative properties and has also been tried for the prophylaxis of motion sickness and nausea and vomiting in pregnancy. In vitro studies have demonstrated that constituents of ginger, such as 6-, 8- and 10-gingerols and galanolactone, have antiserotonergic activity. Ginger oil is used in aromatherapy. Capsicum
- The capsaicinoids are principally responsible for the biological activity of capsicum. These pungent principles are thought to stimulate and aid digestion and to act as a counter-irritant when applied externally. Capsaicin has also been used as a neurochemical tool for studying sensory neurotransmission. Topical creams containing capsaicin 0.025% and 0.075% are used for symptomatic relief of osteoarthritis, and post-herpetic neuralgia, respectively. Capsicum oleoresin and capsaicin are ingredients of a number of over-the-counter topical preparations for relief of pain in muscle, tendon and joints. Capsaicin has effects on nervous, cardiovascular, respiratory, thermoregulatory and gastrointestinal systems. Capsaicin has been used as a neurochemical tool for studying sensory neurotransmission.
- Witch hazel is characterized by its tannin constituents and astringent properties. It is also said to have haemostatic properties. The documented herbal uses are related to these astringent properties. It has been used topically in the treatment of haemorrhoids, eczema and dermatitis. Vasoconstriction was reduced in the hindquarters of rabbits. A fraction of an aqueous ethanolic bark extract was significantly active against herpes simplex virus type 1 (HSV-1). Topical applications of a hydroglycolic extract of witch hazel leaf reduced skin temperature perhaps due to a vasoconstrictor effect. After-sun lotion containing 10% hamamelis was reported to have suppressed erythema.
- Peppermint oil is an aromatic carminative that relaxes gastrointestinal smooth muscle and relieves flatulence and colic. Peppermint oil is also used with other volatile agents in preparations for respiratory-tract disorders. It is also used in aromatherapy.
- Menthol is chiefly used to relieve symptoms of bronchitis, sinusitis, and similar conditions. For this purpose it may be used as an inhalation, usually with benzoin or eucalyptus oil, as pastilles, or as an ointment with camphor and eucalyptus oil for application to the chest or. When applied to the skin menthol dilates the blood vessels, causing a sensation of coldness followed by an analgesic effect. It relieves itching and is used in creams, lotions, or ointments in pruritus and urticaria. It has also been applied to the forehead, presumably as a counter-irritant, for the relief of headache. Menthol has a carminative action.
- The foamable carrier is an ideal vehicle for active pharmaceutical ingredients and active cosmetic ingredients. In the context herein, active pharmaceutical ingredients and active cosmetic ingredients are collectively termed “additional active agent” or “additional active agents”.
- Suitable additional active agents include but are not limited to active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antiburn agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, antiyeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, asoconstrictors, vasodilators, vitamins, vitamin derivatives, vitamin A, vitamin A derivatives, vitamin D, vitamin D derivatives, flavanoids, wound healing agents and wart removers. As is known to one skilled in the art, in some instances a specific active agent may have more than one activity, function or effect.
- The foamable composition is suitable for treating any inflicted surface. In one or more embodiments, foamable carrier is suitable for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the cavity and/or the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (severally and interchangeably termed herein “target site”).
- A sensation modifying foamable composition can be used in any condition that can benefit from the modification of a cold or warm sensation, and in any condition that can benefit from stabilizing a cold or warm sensation, by applying a cooling or a warming foam on the target site.
- Examples of uses of a cooling foam composition include:
-
- Treatment of over-heated body surface;
- Treatment of the skin after sun-burn;
- Treatment of the skin after blistering;
- Treatment of the skin after radiation treatment, burn or injury;
- Treatment of the skin after friction burn;
- Treatment of the skin after inflammation;
- Treatment of the skin after insect bite or sting;
- Treatment of the skin after shaving;
- Treatment of the skin after hair removal;
- Treatment of the skin after laser treatment, burn or injury;
- Treatment or preparation of the skin prior to radiation, laser, or heat treatment or hair removal;
- Treatment of the skin after, during or before acupuncture;
- Treatment of the skin after or during stress;
- Treatment of the skin upon pain.
- Examples of uses of a warming foam composition include:
-
- Treatment of over-cooled body surface;
- Treatment of the skin after exposure to cold environment;
- Treatment of the skin with inadequate circulation;
- Treatment of the skin after wind exposure;
- Treatment of the skin after liquid gas treatment, burn, or injury;
- Treatment or preparation of the skin prior to liquid gas treatment;
- Treatment of the skin after, during or before massage;
- Treatment of the skin after or during stress.
- By selecting a suitable sensation modifying agent, or a combination of at least two sensation modifying agents, or a combination of at lease one sensation modifying agent and at least one additional therapeutic agent, the foamable composition is useful in treating an animal or a human patient having any one of a variety of dermatological disorders, including dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, eethyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post-surgical skin conditions, scabies, pediculosis, creeping eruption, eczemas, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, edematous, erythema multiforme, erythema nodosum, grannuloma annulare, epidermal necrolysis, sunburn, photosensitivity, pemphigus, bullous pemphigoid, dermatitis herpetiformis, keratosis pilaris, callouses, corns, ichthyosis, skin ulcers, ischemic necrosis, miliaria, hyperhidrosis, moles, Kaposi's sarcoma, melanoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, poison ivy, poison oak, contact dermatitis, atopic dermatitis, rosacea, purpura, moniliasis, candidiasis, baldness, alopecia, Behcet's syndrome, cholesteatoma, Dercum disease, ectodermal dysplasia, gustatory sweating, nail patella syndrome, lupus, hives, hair loss, Hailey-Hailey disease, chemical or thermal skin burns, scleroderma, aging skin, wrinkles, sun spots, necrotizing fasciitis, necrotizing myositis, gangrene, scarring, and vitiligo.
- Likewise, the foamable composition is suitable for treating a disorder of a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. Non limiting examples of such conditions include chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum.
- In an embodiment, the composition is useful for the treatment of an infection. In one or more embodiments, the composition is suitable for the treatment of an infection, selected from the group of a bacterial infection, a fungal infection, a yeast infection, a viral infection and a parasitic infection.
- In an embodiment, the composition is useful for the treatment of wound, ulcer and burn.
- The composition is also suitable for administering a hormone to the skin or to a mucosal membrane or to a body cavity, in order to deliver the hormone into the tissue of the target organ, in any disorder that responds to treatment with a hormone.
- In some embodiments of the present invention, the compositions and carriers comprise one or more higher alcohols. These generally exclude “lower alcohols”. The fatty alcohols are typically liquid at ambient temperature.
- Fatty alcohols may defined as follows:
- The fatty alcohols hereof have a melting point of 30° C. or less, preferably about 25° C. or less, more preferably about 22° C. or less.
- The unsaturated fatty alcohols hereof are also nonvolatile. By nonvolatile what is meant is they have a boiling point at 1.0 atmospheres of at least about 260° C., preferably at least about 275° C., more preferably at least about 300° C.
- Suitable fatty alcohols include unsaturated monohydric straight chain fatty alcohols, saturated branched chain fatty alcohols, saturated C8-C12 straight chain fatty alcohols, and mixtures thereof. The unsaturated straight chain fatty alcohols will typically have one degree of unsaturation. Di- and tri-unsaturated alkenyl chains may be present at low levels, preferably less than about 5% by total weight of the unsaturated straight chain fatty alcohol, more preferably less than about 2%, most preferably less than about 1%.
- Preferably, the unsaturated straight chain fatty alcohols will have an aliphatic chain size of from C112-C22, more preferably from C12-C18, most preferably from C116-C18. Especially preferred alcohols of this type include oleyl alcohol and palmitoleic alcohol.
- The branched chain alcohols will typically have aliphatic chain sizes of from C12-C22, preferably C14-C20, more preferably C16-C18. Exemplary branched chain alcohols for use herein include isostearyl alcohol, octyl dodecanol, and octyl decanol. Examples of saturated C8-C12 straight chain alcohols include octyl alcohol, caprylic alcohol, decyl alcohol, and lauryl alcohol. Furthermore, the higher alcohols may be selected from straight chain fatty alcohols, having 6 or more carbon atoms, which are liquid at ambient temperature, such as, but not limited to Hexanol, Octanol, Nonanol, Decanol; branched alcohols, such as: 2 Octanol (Capryl Alcohol), Undecanol (Undecyl Alcohol), 2 Butyl Octanol (Isolauryl Alcohol), Tridecyl Alcohol (Isotridecyl Alcohol), 2 Butyl Decanol, 2 Hexyl Octanol, Isomyristyl Alcohol, 2 Hexyl Decanol, Isocetyl Alcohol, 2 Octyl Decanol, 2 Hexyl Dodecanol, Isostearyl Alcohol, Isooctadecanol, Isooleyl Alcohol (unsaturated and branched), Isoarachidyl Alcohol, 2 Decyl Tetradecanol, Isolignoceryl Alcohol, 2 Decyl Tetradecanol, 2 Tetradecyl Octadecanol, 2 Tetradecyl Eicosanol, 2 Hexadecyl Octadecanol, 2 Hexadecyl Eicosanol; additionally unsaturated alcohols, such as Erucyl Alcohol, Linoleyl Alcohol, oleyl alcohol may be employed.
- According to one or more embodiments, the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols. Short chain alcohols, having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butaneol, iso-butaneol, t-butaneol and pentanol, are considered less desirable solvents or solvents due to their skin-irritating effect. Thus, the composition is substantially alcohol-free and includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1%.
- Other foamable compositions are described in: U.S. Publication No. 05-0232869, published on Oct. 20, 2005, entitled NONSTEROIDAL IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0205086, published on Sep. 22, 2005, entitled RETINOID IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0018937, published on Jan. 26, 2006, entitled STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0271596, published on Dec. 8, 2005, entitled VASOACTIVE KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0269485, published on Nov. 30, 2006, entitled ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 07-0020304, published on Jan. 25, 2007, entitled NON-FLAMMABLE INSECTICIDE COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0193789, published on Aug. 31, 2006, entitled FILM FORMING FOAMABLE COMPOSITION; U.S. patent application Ser. No. 11/732,547, filed on Apr. 4, 2007, entitled ANTI-INFECTION AUGMENTATION OF FOAMABLE COMPOSITIONS AND KIT AND USES THEREOF; U.S. patent application Ser. No. 11/732,547, filed on Apr. 4, 2007, KERATOLYTIC ANTIFUNGAL FOAM; U.S. patent application Ser. No. 11/767,442, filed on Jun. 22, 2007, entitled FOAMABLE COMPOSITIONS AND KITS COMPRISING ONE OR MORE OF A CHANNEL AGENT, A CHOLINERGIC AGENT, A NITRIC OXIDE DONOR, AND RELATED AGENTS AND THEIR USES; U.S. patent application Ser. No. 11/825,406, filed on Jul. 5, 2007, entitled DICARBOXYLIC ACID FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF; U.S. patent application Ser. No. 11/900,072, filed on Sep. 10, 2006, entitled FOAMABLE VEHICLE AND VITAMIN AND FLAVONOID PHARMACEUTICAL COMPOSITIONS THEREOF; and U.S. patent application Ser. No. 11/947,751, filed Nov. 29, 2007, entitled COMPOSITIONS WITH MODULATING AGENTS, all of which are incorporated herein by reference in their entirety. More particularly any of the active ingredients; the solvents; the surfactants; foam adjuvants; polymeric agents, penetration enhancers; preservatives, humectants; moisturizers; and other excipients as well as the propellants and methods listed therein can be applied herein and are incorporated by reference.
- The invention is described with reference to the following examples. This invention is not limited to these examples and experiments. Many variations will suggest themselves and are within the full intended scope of the appended claims.
- The formulas of the present invention may be made in the following general way with appropriate adjustments for each formulation as will be appreciated by someone skilled in the art. Polymers, if any, are mixed, swelled and solubilized in the waterless medium, when necessary, with appropriate heat until it forms a clear solution. Stabilizing surfactants added usually with heat, until a homogeneous mixture is obtained, the mixture is then allowed to cool. The remainder of the ingredients, are then added with mixing until they have dissolved in the medium. The active agent is usually added at the end once the modulating agent, if present, has been incorporated. For foam the canisters are then filled with the above waterless formula, sealed and crimped with a valve and pressurized with the propellant.
- A general procedure for preparing foamable compositions is set out in WO 2004/037225, which is incorporated herein by reference.
- A pharmaceutical or cosmetic composition manufactured using the foamable carrier of the present invention is very easy to use. When applied onto the body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
- The foamable composition of the present invention is stable, having an acceptable shelf-life of at least one year, or preferably, at least two years at ambient temperature, as revealed in accelerated stability tests or aging tests. In certain embodiments a product may satisfy stability tests if upon light shaking a homogenous formulation is restored and remains stable until well after dispensing. Organic carriers and propellants tend to impair the stability of emulsions and to interfere with the formation of stable foam upon release from a pressurized container. It has been observed, however, that the foamable compositions according to the present invention are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
- The composition should also be free flowing, to allow it to flow through the aperture of the container, e.g., and aerosol container, and create an acceptable foam.
- Foam quality can be graded as follows:
- Grade E (excellent): very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
- Grade G (good): rich and creamy in appearance, very small bubble size, “dulls” more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
- Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
- Grade F (fair): very little creaminess noticeable, larger bubble structure than a “fairly good” foam, upon spreading on the skin it becomes thin in appearance and watery.
- Grade P (poor): no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
- Grade VP (very poor): dry foam, large very dull bubbles, difficult to spread on the skin.
- Topically administrable foams are typically of quality grade E or G, or occasionally FG, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
- In terms of foam consistency and texture an acceptable foam is one, that exhibits the following characteristics:
- A “stable foam” is defined herein as a composition, which upon release from an aerosol can, creates a foam mass, which is sustained on a surface for at least one minute, more preferably at least two minutes, and yet more preferably for at least 5 minutes. A period of minutes is regarded as a short term, but nevertheless it allows a good and more than sufficient period of time for a subject to receive foam dispensed on a body surface and to spread it or to transfer it to another region and to spread it.
- Foam texture should vary from a very fine creamy foam to a fine bubble structure.
- Foam has to have specific gravity in the range of about 0.02 gr/mL to about 0.5 gr/mL, more preferably between about 0.04 gr/mL and about 0.2 gr/mL.
- In terms of spreadability and absorption an acceptable foam is one, that does not readily collapse upon dispensing on the skin; spreads easily on a skin surface; at least partially absorbed following rubbing onto the skin, and more preferably, substantially absorbed following rubbing on the skin.
- In terms of tactile properties an acceptable foam is one, that: creates a pleasant feeling after application; leaves minimal oily residue; and leaves minimal shiny residual look.
- ‘Shakability’ means that the composition contains some or sufficient flow to allow the composition to be mixed or remixed on shaking. That is, it has fluid or semi fluid properties. In some very limited cases it may still be possible to have a foamable composition which is flowable but not apparently shakable.
- A breakable foam is thermally stable or substantially so, yet breaks under sheer force. The breakable foam of the present invention is not “quick breaking”, i.e., it does not readily collapse upon exposure to body temperature environment. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability, (due to, for example, the presence of alcohol) since it allows comfortable application and well directed administration to the target area.
- A further aspect of the foam is breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
- The foam of the present invention has several notable advantages, when compared with hydroalcoholic foam compositions, such as
- Breakability. The foam of the present invention is thermally stable and breakable under sheer force but is not “quick breaking which allows comfortable application and well directed administration to the target area.
- sSkin drying and skin barrier function. Short chain alcohols are known to dry the skin and impair the integrity of the skin barrier. By contrast, including a film forming agent in the composition of the present invention foes not cause unwanted skin barrier damage.
- Irritability. Due to the lack of lower alcohols (C1-C5) and improvement in skin barrier function, skin irritability is eliminated.
- Another property of the foam is specific gravity, as measured upon release from the aerosol can. Typically, foams have specific gravity of less than 0.12 g/mL; or less than 0.10 g/mL; or less than 0.08 g/mL, depending on their composition and on the propellant concentration.
- The invention is described with reference to the following examples. This invention is not limited to these examples and experiments. Many variations will suggest themselves and are within the full intended scope of the appended claims
- All % values are provided on a weight (w/w) basis.
- In some cases the formulations are expressed in amounts up to 100% including the propellant. In other cases the formulations are expressed in amounts up to 100% not including the propellant, which is then added to the composition.
- In one or more various embodiments the sensation or sensation modifying topical compositions can be prepared according to the general methodology set out below with appropriate changes as would be well appreciated by a man of the art.
-
-
- 1. Mix oily phase ingredients and heat to 75° C. to melt all ingredients and obtain homogeneous mixture.
- 2. Mix polymers in water with heating or cooling as appropriate for specific polymer.
- 3. Add all other water soluble ingredients to water-polymer solution and heat to 75° C.
- 4. Add slowly internal phase to external phase at 75° C. under vigorous mixing and homogenize to obtain fine emulsion.
- 5. Cool to below 40° C. and add sensitive ingredients with mild mixing.
- 6. Cool to room temperature.
This methodology is suitable, for example, for the preparation of the hamamelis, and also for the capsaicin emollient emulsion compositions exemplified below.
-
-
- 1. Dissolve the polymers in the main solvent with heating or cooling as appropriate for specific polymer. Add the all other ingredients and heat to 75° C. to melt and dissolve the various ingredients.
- 2. Cool to below 40° C. and add sensitive ingredients with mild mixing.
- 3. Cool to room temperature.
This methodology is suitable, for example, for the preparation of the capsaicin waterless compositions exemplified below.
-
-
- 1. Mix oily phase ingredients and heat to 75° C. to melt all ingredients and obtain homogeneous mixture.
- 2. Mix polymers in water with heating or cooling as appropriate for specific polymer.
- 3. Add all other water soluble ingredients to water-polymer solution and heat to 75° C.
- 4. Add internal phase to external phase at 75° C. under vigorous mixing and homogenize to obtain fine emulsion.
- 5. Cool to below 40° C.
- 6. Add sensitizing agents and any other active ingredient with mild mixing.
- 7. Cool to room temperature.
- 8. In case of Pemulene® stabilizer, dissolve the Pemulene® in the Mint oil and add to the emulsion.
-
-
- 1. Dissolve the polymers in the main solvent with heating or cooling as appropriate for specific polymer. Add the all other ingredients and heat to 75° C. to melt and dissolve the various ingredients.
- 2. Cool to below 40° C.
- 3. Add sensitizing agents and any other active ingredient with mild mixing.
- 4. Cool to room temperature.
- Optionally, the foamable formulation may be produced under nitrogen and under vacuum. Whilst the whole process can be carried out under an oxygen free environment, it can be sufficient to apply a vacuum after heating and mixing all the ingredients to obtain an emulsion or homogenous liquid. Preferably the production chamber is equipped to apply a vacuum but if not the formulation can be for example placed in a dessicator to remove oxygen prior to filing and crimping.
- Each aerosol canister is filled with PFF and crimped with valve using vacuum crimping machine. The process of applying a vacuum will cause most of the oxygen present to be eliminated. Addition of hydrocarbon propellant may without being bound by any theory further help to reduce the likelihood of any remaining oxygen reacting with the active ingredient. It may do so, without being bound by any theory, by one or more of dissolving in the oil or hydrophobic phase of the formulation, by dissolving to a very limited extent in the aqueous phase, by competing with some oxygen from the formulation, by diluting out any oxygen, by a tendency of oxygen to occupy the dead space, and by oxygen occupying part of the space created by the vacuum being the unfilled volume of the canister or that remaining oxygen is rendered substantially ineffective in the formulation.
- Pressurizing is carried out using a hydrocarbon gas or gas mixture. Canisters are filled and then warmed for 30 sec in a warm bath at 50° C. and well shaken immediately thereafter.
- Each pressurized canister is subjected to bubble and crimping integrity testing by immersing the canister in a 60° C. water bath for 2 minutes. Canisters are observed for leakage as determined by the generation of bubbles. Canisters releasing bubbles are rejected.
- By way of non limiting example the objectives of hardness, collapse time and FTC stability tests are briefly set out below as would be appreciated by a person of the art.
- LFRA100 instrument is used to characterize hardness. A probe is inserted into the test material. The resistance of the material to compression is measured by a calibrated load cell and reported in units of grams on the texture analyzer instrument display. Preferably at least three repeat tests are made. The textural characteristics of a dispensed foam can affect the degree of dermal penetration, efficacy, spreadability and acceptability to the user. The results can also be looked at as an indicator of softness. Note: the foam sample is dispensed into an aluminum sample holder and filled to the top of the holder.
- Collapse time (CT) is examined by dispensing a given quantity of foam and photographing sequentially its appearance with time during incubation at 36° C. It is useful for evaluating foam products, which maintain structural stability at skin temperature for at least 1 min.
- Viscosity is measured with Brookfield LVDV-II+PRO with spindle SC4-25 at ambient temperature and 10, 5 and 1 RPM. Viscosity is usually measured at 10 RPM. However, at about the apparent upper limit for the spindle of ˜>50,000 CP, the viscosity at 1 RPM may be measured, although the figures are of a higher magnitude.
- To check the foam appearance under extreme conditions of repeated cycles of cooling, heating, (first cycle) cooling, heating (second cycle) etc., commencing with −100° C. (24 hours) followed by +400° C. (24 hours) measuring the appearance and again repeating the cycle for up to three times.
- The amount of active agent present is analyzed in foam expelled from various pressurized canisters containing foam formulations using HPLC. Analysis is carried out at zero time and at appropriate time intervals thereafter. The canisters are stored in controlled temperature incubators at 5° C., at 25° C., at, 40° C. and at 50° C. At appropriate time intervals canisters are removed and the amount of active agent in the foam sample is measured.
- The centrifugation used in this procedure serves as a stress condition simulating the aging of the liquid dispersion under investigation. Under these conditions, the centrifugal force applied facilitates the coalescence of dispersed globules or sedimentation of dispersed solids, resulting in loss of the desired properties of the formulated dispersion.
- Following preparation of the experimental formulation/s, allow to stand at room temperature for ≧24 h. Handle pentane in the chemical hood. Add to each experimental formulation in a 20-mL glass vial a quantity of pentane equivalent to the specified quantity of propellant for that formulation, mix and allow formulation to stand for at least 1 h and not more than 24 h.
- Transfer each mixture to 1.5 mL microtubes. Tap each microtube on the table surface to remove entrapped air bubbles.
- Place visually balanced microtubes in the centrifuge rotor and operate the centrifuge at one or more of 10,000 rpm for 10 min, 3,000 rpm for 10 min or at 1,000 rpm for 10 min.
- Foams are made of gas bubbles entrapped in liquid. The bubble size and distribution reflects in the visual texture and smoothness of the foam. Foam bubbles size is determined by dispensing a foam sample on a glass slide, taking a picture of the foam surface with a digital camera equipped with a macro lens. The diameter of about 30 bubbles is measured manually relatively to calibration standard template. Statistical parameters such as mean bubble diameter, standard deviation and quartiles are then determined. Measuring diameter may also be undertaken with image analysis software. The camera used was a Nikon D40X Camera (resolution 10 MP) equipped with Sigma Macro Lens (ref: APO MACRO 150 mm F2.8 EX DG HSM). Pictures obtained are cropped to keep a squared region of 400 pixels×400 pixels.
- Compositions of the present invention were separately applied to clean skin of a group of human subjects. After 5 minutes tested subjects were asked to provide a gauge of their satisfaction relating to the following parameters: Ease of application, skin absorption, stickiness, odor, oily residue, skin surface shiny appearance, composition stability; overall satisfaction; sensation change, such as cooling, relaxing, heating etc. The subjects gauged their response according to the following scoring system:
- 1—very bad feeling
2—Bad feeling
3—feels “OK”
4—Feels good
5—Feels excellent, want more
The scores assigned by the subjects were added and an average result was recorded. - In cases where a sensation agent was added to the composition, the above test was repeated after 15, 30, 60, 120 minutes and after washing off the composition from the skin surface (after 120 minutes). The subjects were asked to gauge their feeling of a sensation, such as sensation change, such as cooling, relaxing, heating etc. The scores assigned by the subjects were added and an average result was recorded.
- In some cases, as exemplified below, the sensation was observed over a prolonged or sustained period of time.
- By “prolonged period of time” or “sustained period of time” or “substantial period of time” (used interchangeably herein), is meant a period of time of about five or more minutes, more typically, at least 15 minutes in which the subject senses a sensation pertaining to a sensation agent applied to a target or delivery site on/in the subject.
- In the Examples hereinbelow, the following test was performed to see if there were any temperature changes to a surface onto which a foam was placed:
- 1. Place a thermometer in a clean glass vial and allow it to come to equilibrium.
- 2. Measure and record the temperature.
- 3. Release foam about 5 gm onto the thermometer.
- 4. Observe temperature for 300 sec.
- The procedure was performed on regular; different cooling and heating foam formulations (per examples below).
- Results: For all foams tested by the above method as seen in the examples hereinbelow, no detectable significant temperature difference was noted between the surface temperature, foam temperature and ambient initial temperature. This is indicative that the foams produced in the examples below did not exhibit a measurable exothermic or endothermic reaction. Thus, the foams tested should not induce a significant temperature effect at the target site primarily due to the cooling effect of the propellant. In certain embodiments, it may be possible for there to be an interaction between chemicals in the skin or other target site and the foam composition, particularly for the non-aqueous compositions. For example, by moisture in the skin being absorbed by hygroscopic pharmaceutical recipients, like glycols. Nevertheless, a main aim is to deliver a sensation via a foam vehicle, where the prime sensation is due to pharmaceutical stimulation rather than an actual physical effect. In one or more embodiments, the sensation may be a combination of pharmaceutical stimulation and physical effect. For example, where an excess of propellant may provide an initial physical cooling and the sensation agent provides a prolonged sensation, without further cooling. The vehicles disclosed herein are adapted to provide the main sensation with or without an initial physical cooling sensation.
-
-
Ingredient Name Function % w/w Avocado oil emollient and solvent 10 PEG 40 Stearate Stabilizing emulsifier 2.31 Stearyl Alcohol Co-emulsifier and foam stabilizer 0.77 Isopropyl myristate emollient 4.62 Mineral Oil Emollient 4.62 Hypromellose Stabilizing polymers 0.23 Xanthan gum Stabilizing polymers 0.23 Polysorbate 80 Stabilizing emulsifier 0.77 GMS Co-emulsifier foam stabilizer 0.39 Menthol Cooling agent 10 Water Solvent to 100 TOTAL 100 Propane/butane/isobutane 8 -
Foam quality Excellent Color White Odor Menthol Density [g/cm3] 0.045 Shakability Good pH 6.63 Collapse time [seconds] >300 -
-
Time Score 0 2.00 5′ 1.33 15′ 2.33 30′ 2.00 60′ 2.00 120′ 1.33 after washing 1.67 Sum total of points for this formulation for all subjects is: 38 -
-
Ease skin oily foam Shiny overall of application absorption stickiness odor residue stability Look satisfaction 3.3 2.7 4.0 3.0 3.7 3.3 3.3 3.7 Sum total of points for this formulation for all subjects is: 107 - Comments: Emollient emulsion foam provided a reasonable and prolonged cooling sensation; excellent foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents. The co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art.
- Note: The propellant can be added at a concentration of about 3% to about 25% or more.
-
-
Ingredient Name Function % w/w Avocado oil emollient and solvent 10 PEG 40 Stearate Stabilizing emulsifier 2.31 Stearyl Alcohol Co-emulsifier and foam stabilizer 0.77 Isopropyl myristate emollient 4.62 Mineral Oil Emollient 4.62 hypromellose Stabilizing polymers 0.23 xanthan gum Stabilizing polymers 0.23 Polysorbate 80 Stabilizing emulsifier 0.77 GMS Co-emulsifier foam stabilizer 0.39 Menthol Cooling agent 10 ETHANOL Solvent - penetration enhancer 15 Water Solvent to 100 TOTAL 100 Propane/butane/isobutane 8 -
Foam quality Good Color White Odor Menthol Density [g/cm3] 0.044 Shakability Moderate pH 5.89 Collapse time [seconds] 300 -
-
Time Score 0 1.75 5′ 1.875 15′ 2.5 30′ 2.75 60′ 2.25 120′ 1.25 after washing 1 Sum total of points for this formulation for all subjects is: 53.5 -
-
Ease skin oily foam Shiny overall of application absorption stickiness odor residue stability Look satisfaction 4.25 3.75 5 4 4.25 3.75 2 4 Sum total of points for this formulation for all subjects is: 124 - Comments: Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, water phase, surfactant combination supported by co emulsifiers and a combination of polymeric agents plus a polar solvent as a penetration enhancer. Menthol in the above formulation achieves good penetration on its own so the presence of 15% ethanol is of only marginal effect. Ethanol is not essential and may be omitted or replaced by other penetrating agents such as transcutol; DMI; and the like. See section on penetration agents.
- Note: The propellant can be added at a concentration of about 3% to about 25% or more.
-
-
Ingredient Name Function % w/w Capric/caprilic triglyceride Emollient and solvent 6 Stearic acid Co-emulsifier and foam stabilizer 2 hypromellose Stabilizing polymers 0.3 xanthan gum Stabilizing polymers 0.3 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 Menthol Cooling agent 15 Propylene Glycol Solvent; moisturizer; penetration 3 enhancer Water solvent To 100 TOTAL 100 Propane/butane/isobutane 8 -
Foam quality Good Color White Odor Menthol Density [g/cm3] 0.025 Shakability Moderate pH 6.26 Collapse time [seconds] >300 -
-
Time Score 0 1.375 5′ 2 15′ 3.25 30′ 3.5 60′ 2.5 120′ 1.25 after washing 1.25 Sum total of points for this formulation for all subjects is 60.5 -
-
Ease skin oily foam Shiny overall of application absorption stickiness odor residue stability Look satisfaction 4 4 3.5 3.75 3.5 4.5 2.75 3.75 Sum total of points for this formulation for all subjects is: 119 - Comments: Emollient foam provided excellent and prolonged cooling sensation; good foam quality; moisturizing. Comprises an oil phase, a water phase, a surfactant combination supported by a co-emulsifier and a combination of polymeric agents. The propylene glycol is non essential.
- Note: The propellant can be added at a concentration of about 3% to about 25% or more.
-
-
CTFA Name Function % w/w Capric/caprilic Triglyceride Emollient and solvent 6 Stearic acid Co-emulsifier and foam stabilizer 2 hypromellose Stabilizing polymers 0.3 xanthan gum Stabilizing polymers 0.3 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 PEPPERMINT OIL Cooling agent 15 Propylene Glycol Solvent/moisturizer/penetration 3 enhancer Permulen 0.1 TEA To pH 7 Water solvent To 100 TOTAL 100 Propane/butane/isobutane 8 -
Foam quality Good Color White Odor Menthol Density [g/cm3] 0.028 Shakability Low pH 6.17 Collapse time [seconds] >300 -
-
Time Score 0 1.75 5′ 1.5 15′ 2.25 30′ 2.5 60′ 1.75 120′ 1 after washing 1 Sum total of points for this formulation for all subjects is: 47 -
-
Ease skin oily foam Shiny overall of application absorption stickiness odor residue stability Look satisfaction 4 3.75 4 3.25 3.75 4.5 3.25 3.75 Sum total of points for this formulation for all subjects is: 121 - Comments: Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by a co-emulsifier and a combination of polymeric agents. The propylene glycol is non-essential. The peppermint oil reduces the viscosity of the emulsion and is matrix destabilizing.
- Note: The propellant can be added at a concentration of about 3% to about 25% or more.
-
-
Ingredient name Function % w/w Stearic acid * Co-emulsifier and foam stabilizer 3 Steareth-2 * Stabilizing emulsifier 2 Steareth-21 * Stabilizing emulsifier 3 Methylcellulose * Co-emulsifier and foam stabilizer 0.3 Xanthan gum * Co-emulsifier and foam stabilizer 0.3 Menthol crystal Cooling agent 15 Water * Solvent To 100 Glyceryl monostearete Co-emulsifier foam stabilizer 2 Propellant 25 (Propane/Butane/Isobutane) -
-
Time Score 0 1.7 5′ 1.0 15′ 2.3 30′ 2.7 60′ 1.7 120′ 1.3 after washing 1.0 Sum total of points for this formulation for all subjects is: 37 -
-
Ease skin oily foam Shiny overall of application absorption stickiness odor residue stability Look satisfaction 4.0 3.3 3.0 3.0 3.0 3.0 4.0 3.7 Sum total of points for this formulation for all subjects is: 76 - Comments: Emollient foam provided good cooling sensation; good foam quality; doesn't require preservative.
- Note: The propellant can be added at a concentration of about 3% to about 25% or more.
-
-
Ingredient Name Function % w/w PEG 4000 Firming wax 7.5 Stearic acid Co-emulsifier and foam stabilizer 2 Hydroxupropyl cellulose Stabilizing polymers 2 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 Menthol Cooling agent 15 Propylene Glycol Solvent/moisturizer/penetration 68 enhancer TOTAL 100 Propane/butane/isobutane 8 -
Foam quality Fairly good Color White Odor Menthol -
-
Time Score 0 1 5′ 1.125 15′ 1.375 30′ 2 60′ 2.5 120′ 1.5 after washing 1 Sum total of points for this formulation for all subjects is: 42
c) Foam satisfaction Parameters -
Ease skin oily foam Shiny overall of application absorption stickiness odor residue stability Look satisfaction 4 2.5 3.25 3.75 2 1 1.75 2.25 Sum total of points for this formulation for all subjects is: 82 - Comments: Waterless foam provided reasonable and prolonged cooling sensation with a delayed onset; fairly good foam quality; moisturizing; doesn't require preservative. Any high molecular weight PEG (for example 1500, 2000, 4000, 6000 or 8000) or combinations of high molecular weight PEG with lower molecular weight PEG (for example 200, 400, 600) may be used.
- Note: The propellant can be added at a concentration of about 3% to about 25% or more.
-
-
Ingredient Name Function % w/w PEG 4000 Firming wax 7.5 Stearic acid Co-emulsifier and foam stabilizer 2 Hydroxypropyl cellulose Stabilizing polymers 2 Steareth-2 Stabilizing emulsifier 2.5 Steareth-21 Stabilizing emulsifier 3 PEPPERMINT OIL Cooling agent 10 Propylene Glycol Solvent/moisturizer - penetration 73 enhancer TOTAL 100 Propane/butane/isobutane 8 -
Foam quality Fairy good Color White Odor Menthol Cooling score (Σ of total points for 36 this formulation from all people) -
-
Time Score 0 1 5′ 1 15′ 1.75 30′ 2 60′ 1.25 120′ 1 after washing 1 Sum total of points for this formulation for all subjects is: 36 -
-
Ease skin oily foam Shiny overall of application absorption stickiness odor residue stability Look satisfaction 4 3 3.25 3.5 2.25 3.5 2.5 3 Sum total of points for this formulation for all subjects is: 100 - Comments: Waterless foam provided reasonable and medium term cooling sensation with delayed onset; fairly good foam quality; moisturizing; doesn't require preservative. Any high molecular weight PEG (for example 1500, 2000, 4000, 6000 or 8000) or combinations of high molecular weight PEG with lower molecular weight PEG (for example 200, 400, 600) may be used. The peppermint oil has a thinning effect on the composition, which is to some extent counterbalanced or ameliorated by the high molecular weight PEG.
- Note: The propellant can be added at a concentration of about 3% to about 25% or more.
-
-
% w/w Mineral oil 6.00 Isopropyl myristate 6.00 Glyceryl monostearate 0.50 Stearyl alcohol 1.00 Xanthan gum 0.30 Methocel K100M 0.30 Polysorbate 80 1.00 PEG-40 stearate 3.00 Hamamelis glycerin fluid extract (Alban Muller, France) 10.00 EDTA disodium 0.20 Phenonip 0.30 Water pure to 100.0 Propellant (propane and butane 20:80) 8.0 -
Foam quality Excellent Density [g/cm3] 0.04 Collapse time >120 Shakability Yes Odor slight - Comments: Emollient foam capable of providing a soothing sensation; excellent foam quality; moisturizing. It comprises an oil phase, water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents, plus a preservative and a chelating agent. The chelating agent is non essential. The co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art.
- Note: The propellant can be added at a concentration of about 3% to about 25% or more.
-
-
Ingredient name % w/w Mineral oil 4.62 Isopropyl myristate 4.62 Glyceryl monostearate 0.39 Polysorbate 80 0.77 PEG-40 stearate 2.31 Stearyl alcohol 0.77 Hydroxypropyl methylcellulose 0.23 Xanthan 0.23 Water TO 100 Capsaicin 0.025 Total: 100.00 Propellant (Propane/Butane/Isobutane) 8 -
-
Ingredient name % w/w PEG 4000 7.5 Capsaicin 0.025 Hydroxypropyl cellulose 2 Stearic acid 2 Steareth-2 2.5 Steareth-21 3 Propylene glycol To 100 Propellant (Propane/Butane/Isobutane) 8 -
-
Ingredient name % w/w MCT 6 Stearic acid 2 Steareth 2 2.5 Steareth-21 3 Capsaicin 0.025 Propylene Glycol 3 Xanthan gum 0.3 Hypromellose 0.3 Water To 100 Propellant (Propane/Butane/Isobutane) 8 - Comments:
-
- It is possible to use any of the above exemplary warming formulations with other warming agents, for example, methyl salicylate. Apart from its warming effect methyl salicylate is an analgesic and counter irritant. Lists of applicable warming agents are described in the specification. An effective amount of the warming agent is introduced into the formulation in place of capsaicin and the amount of the main carrier is adjusted to bring the formulation to 100%, which in the case of the waterless composition is propylene glycol and in the case of the emollient emulsion composition is water. The amount of methyl salicylate is of the order of 5 to 10%.
- It is also possible to use combinations of warming agents. The combination of capsaicin with methyl salicylate, for example, may be useful. Methyl salicylate has a quick onset whilst capsaicin does not so a combination may be helpful in cases where pain relief is sought.
- It is also possible to modulate, potentate, increase, reduce, or ameliorate the warming effect by introducing into the composition a sensation modifying agent. I an embodiment the warming effect or sensation maybe reduced by addition of a cooling agent in the composition.
- The formulations may contain polar solvents, which contribute to skin penetration of an active agent
Foam with Additional Therapeutic Agents
-
-
CTR005 CTR006 Ingredient name % W/W % W/W Menthol (Sensation modifying agent) 1 1 Coal tar extract (Additional therapeutic agent) 10 10 Salicylic acid (Additional therapeutic agent) 5 Hydrocortisone (Additional therapeutic agent) 1 PPG-15 Stearyl ether — 3 Isopropyl Myristate 10 5 Octyldodecanol 12 12 Stearyl Alcohol 2 1 Glycerin — 3 Lanolin — 2 Laureth-4 — 2 Emulgin B2 — 1.5 Glyceryl Stearate 1.5 — PEG-40 Stearate 3 — CMC — 0.5 Methocel K100M 0.28 — Xanthan gum 0.28 — Propylene Glycol — 5 Polysorbate 60 1 — Water, purified To 100 To 100 Propellant 8 8 - Comments: The above formulations provided excellent moisturizing emollient foams with improved sensation by ameliorating the negative sensation effect of coal tar.
- A) Waterless Propylene Glycol Formulation Containing Peppermint Oil as Cooling Agent
-
SMTC004-071205 Steareth 2 2.00 polysorbate 80 2.00 Glyceryl monostearate 2.00 Hydroxypropyl cellulose 1.00 peppermint oil 10.00 Propylene Glycol 83.00 Total: 100.00 Propellant (AP-70) 8.00 Results PFF Viscosity 148.97 Centrifgation 1K stable Centrifgation 3K stable FOAM Quality G-E Color White Collapse time (sec.) 95/F Density (gr/ml) 0.070 Bubble size (μm) 180 Bubble size (%-above 500 μm) 6.30 temperature change T-0 MINUTES = 13° C. T-5 MINUTES = 12° C. *G-E = Good to Excellent - Comments: This waterless single phase formulation provides a stable vehicle for peppermint oil that can generate good quality foam and which can withstand 300 rpm. The surfactants and a polymeric agent provide viscosity support and aid foaming. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the peppermint oil provides a sensation of cooling, which may be potentiated by the evaporation of propellant and the lower temperature of the foam compared to the skin.
- B) A Waterless PG Formulation and Two Oil in Water Emulsion Formulations Containing Menthol Crystals as Cooling Agent
-
SMTC006-071205 SMTC007-071211 SMTC005-071205 cf example 3 cf example 12 MCT 6.00 Isopropyl myristate 10.00 Octyldodecanol 10.00 Stearic acid 2.00 Stearyl alcohol 2.00 Cetostearyl alcohol 2.00 Steareth 2 2.00 4.20 Steareth-21 1.40 polysorbate 80 2.00 Glyceryl monostearate 2.00 1.40 PEG-40 stearate 3.10 Polysorbate 60 1.20 Xanthan gum 0.30 0.28 Methocell k100M 0.30 0.28 Hydroxypropyl cellulose 1.00 Water 67.80 59.74 menthol crystals 10.00 15.00 1.00 Propylene Glycol 81.00 3.00 Coal tar 10.00 Hydrocortisone butyrate 1.00 Total: 100.00 100.00 100.00 Propellant (AP-70) 8.00 8.00 8.00 Results PFF Viscosity 4447.05 4527.04 2037.57 Centrifgation 1K stable Stable stable Centrifgation 3K stable Stable stable FOAM Quality G-E G-E G-E Color White White Slightly Yellow Collapse time (sec.) >300/G >300/FG >300/FG Density (gr/ml) 0.060 0.043 0.039 Bubble size (μm) 62 99 112 Bubble size (%-above 500 μm) 0.00 0.00 0.00 - Comments: Formulation 5 is a single phase composition that provides a stable vehicle for menthol crystals that can generate good quality foam capable of withstanding 3000 rpm and having a collapse time in excess of 5 minutes. The surfactants, adjuvant and a polymeric agent provide viscosity support and aid foaming. The other two formulations 6 and 7 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000 rpm and have a collapse time in excess of 5 minutes. All the formulations can accommodate substantial amounts of cooling sensation agent. In an embodiment the cooling agent is a combination of at least two cooling agents. In a further embodiment the cooling agent may be used in combination with a soothing agent. The coal tar formulation is yellow prior to addition of the propellant but upon discharge from the canister and release as a foam the color is dissipated such that the foam is only slightly yellow, which may be an advantage for its use.
-
-
SMTC001-071204 SMTC002-071204 cf example 11 cf example 9 SMTC003-071204 MCT 8.00 Mineral oil 5.00 Isopropyl myristate 5.00 Stearic acid 2.00 Stearyl alcohol 1.00 Cetostearyl alcohol Steareth 2 6.70 2.00 Steareth-21 1.80 Glyceryl monostearate 1.80 PEG-40 stearate 1.50 Xanthan gum 0.30 0.23 Methocell k100M 0.30 0.23 Water 77.87 82.21 Capsaicin 0.03 0.03 0.03 Propylene Glycol 3.00 3.00 97.97 Total: 100.00 100.00 100.00 Propellant (AP-70) 8.00 8.00 8.00 Results PFF Viscosity 18636.03 1085.77 4367.07 Centrifgation 1K stable Stable stable Centrifgation 3K stable Stable stable FOAM Quality G-E G-E G-E Color White White White Collapse time (sec.) >300/FG >300/FG >300/G Density (gr/ml) 0.078 0.036 0.048 Bubble size (μm) 78 96 85 Bubble size (%-above 500 μm) 0.00 0.00 0.00 temperature change T-0 MINUTES = 13 C. T-5 MINUTES = 14 C. - Comments: Formulation 3 is a waterless single phase composition that provides a stable vehicle for capsaicin that can generate good quality foam capable of withstanding 3000 rpm and having a collapse time in excess of 5 minutes. The surfactants, adjuvant and a polymeric agent provide viscosity support and aid foaming. The other two formulations 1 and 2 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000 rpm and have a collapse time in excess of 5 minutes. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the capsaicin should provide a sensation of warming.
- In an embodiment the warming agent is a combination of at least two warming agents. In a further embodiment the warming agent may be used in combination with a soothing agent.
-
-
SMTC010-071218 SMTC011-071223 Cetostearyl alcohol 2.00 Steareth 2 1.40 Steareth-21 4.50 polysorbate 80 1.40 Glyceryl monostearate 1.30 PEG-40 stearate 1.80 Xanthan gum 0.30 0.30 Methocell k100M 0.30 0.30 Avicel RC581 Water 84.90 81.50 ginger oil 10.00 10.00 Total: 100.00 100.00 Propellant (AP-70) 8.00 8.00 Results PFF Viscosity 4399.06 1150.75 Centrifgation 1K stable stable Centrifgation 3K stable stable FOAM Quality FG G-E Color slight yellow Off-white Collapse time (sec.) 30/F >300/G Density (gr/ml) 0.034 Bubble size (μm) 105 Bubble size 0.00 (%-above 500 μm) temperature change T-0 MINUTES = 13 C. T-5 MINUTES = 13 C. - Comments: By altering the surfactant mix a good quality foam was generated that is resistant to centrifugation and has a collapse time in excess of 5 minutes. The vehicle is capable of supporting substantial amounts of ginger oil. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the ginger oil should provide a sensation of soothing.
-
-
SMTC012-071225 SMTC013-071225 polysorbate 80 2.00 4.00 Avicel RC581 2.00 4.00 Water 94.00 65.00 Aloe vera 2.00 2.00 Diethylene glycol monoethyl 25.00 ether Total: 100.00 100.00 Propellant (AP-70) 8.00 Results PFF Viscosity 39.99 2273.51 Centrifgation 1K not stable not stable Centrifgation 3K not stable not stable FOAM Quality G-E G-E Color White White Collapse time (sec.) 95/F 140/F Density (gr/ml) 0.044 0.034 Bubble size (μm) 131 113 Bubble size 0.00 0.00 (%-above 500 μm) - Comments: These water gel formulations are single phase compositions that provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 1.5 minutes. When the formulation is applied to the skin, the aloe vera should provide a sensation of soothing. In an embodiment the soothing agent is a combination of at least two soothing agents. In a further embodiment the soothing agent may be used in combination with a cooling agent or with a warming agent.
-
-
SMTC014-080103 Mineral oil 11.00 Cetostearyl alcohol 2.00 Steareth 2 4.30 Steareth-21 2.90 Xanthan gum 0.30 Methocell k100M 0.30 Water 77.20 Aloe vera 2.00 Total: 100.00 Propellant (AP-70) 8.00 Results PFF Viscosity 18300.10 Centrifgation 1K stable Centrifgation 3K Stable FOAM Quality G-E Color White Odor Characteris.odor Collapse time (sec.) >300/G Density (gr/ml) 0.070 Bubble size (μm) 48 Bubble size (%-above 500 μm) 0.00 - Comments: These emollient emulsion formulations provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 5 minutes and is stable to centrifugation. When the formulation is applied to the skin, the aloe vera should provide a sensation of soothing. In an embodiment the soothing agent is a combination of at least two soothing agents. In a further embodiment the soothing agent may be used in combination with a cooling agent or with a warming agent.
- The references cited herein teach many principles that are applicable to the present invention. Therefore the full contents of these publications are incorporated by reference herein where appropriate for teachings of additional or alternative details, features and/or technical background.
- It is appreciated that certain features, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art.
Claims (44)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/971,197 US20080253973A1 (en) | 2002-10-25 | 2008-01-08 | Sensation modifying topical composition foam |
US12/350,650 US9320705B2 (en) | 2002-10-25 | 2009-01-08 | Sensation modifying topical composition foam |
CA2711703A CA2711703A1 (en) | 2008-01-08 | 2009-01-08 | Sensation modifying topical composition foam |
PCT/IB2009/005005 WO2009087578A2 (en) | 2008-01-08 | 2009-01-08 | Sensation modifying topical composition foam |
ZA2010/05630A ZA201005630B (en) | 2008-01-08 | 2010-08-04 | Sensation modifying topical composition foam |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL152486 | 2002-10-25 | ||
IL15248602A IL152486A0 (en) | 2002-10-25 | 2002-10-25 | Alcohol-free cosmetic and pharmaceutical foam carrier |
US49238503P | 2003-08-04 | 2003-08-04 | |
US10/532,618 US20060140984A1 (en) | 2002-10-25 | 2003-10-24 | Cosmetic and pharmaceutical foam |
US53001503P | 2003-12-16 | 2003-12-16 | |
US10/835,505 US7820145B2 (en) | 2003-08-04 | 2004-04-28 | Oleaginous pharmaceutical and cosmetic foam |
US10/911,367 US20050069566A1 (en) | 2003-08-04 | 2004-08-04 | Foam carrier containing amphiphilic copolymeric gelling agent |
US87921307P | 2007-01-08 | 2007-01-08 | |
US11/971,197 US20080253973A1 (en) | 2002-10-25 | 2008-01-08 | Sensation modifying topical composition foam |
Related Parent Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2003/005527 Continuation-In-Part WO2004037225A2 (en) | 2002-10-24 | 2003-10-24 | Cosmetic and pharmaceutical foam |
US10/532,618 Continuation-In-Part US20060140984A1 (en) | 2002-10-24 | 2003-10-24 | Cosmetic and pharmaceutical foam |
US10532618 Continuation-In-Part | 2003-10-24 | ||
US10/911,367 Continuation-In-Part US20050069566A1 (en) | 2002-10-25 | 2004-08-04 | Foam carrier containing amphiphilic copolymeric gelling agent |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/350,650 Continuation US9320705B2 (en) | 2002-10-25 | 2009-01-08 | Sensation modifying topical composition foam |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080253973A1 true US20080253973A1 (en) | 2008-10-16 |
Family
ID=29765086
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/971,197 Abandoned US20080253973A1 (en) | 2002-10-25 | 2008-01-08 | Sensation modifying topical composition foam |
US12/350,650 Expired - Fee Related US9320705B2 (en) | 2002-10-25 | 2009-01-08 | Sensation modifying topical composition foam |
US13/795,831 Abandoned US20130189196A1 (en) | 2002-10-25 | 2013-03-12 | Foamable Composition |
US15/903,275 Expired - Lifetime US10821077B2 (en) | 2002-10-25 | 2018-02-23 | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US17/072,243 Active US11033491B2 (en) | 2002-10-25 | 2020-10-16 | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/350,650 Expired - Fee Related US9320705B2 (en) | 2002-10-25 | 2009-01-08 | Sensation modifying topical composition foam |
US13/795,831 Abandoned US20130189196A1 (en) | 2002-10-25 | 2013-03-12 | Foamable Composition |
US15/903,275 Expired - Lifetime US10821077B2 (en) | 2002-10-25 | 2018-02-23 | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US17/072,243 Active US11033491B2 (en) | 2002-10-25 | 2020-10-16 | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Country Status (4)
Country | Link |
---|---|
US (5) | US20080253973A1 (en) |
CN (1) | CN1713891A (en) |
IL (1) | IL152486A0 (en) |
ZA (2) | ZA200503298B (en) |
Cited By (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080069924A1 (en) * | 2006-09-19 | 2008-03-20 | Bary Lyn Zeller | Gasified Food Products and Methods of Preparation Thereof |
US20080089850A1 (en) * | 2006-10-11 | 2008-04-17 | Ariel Haskel | Compositions Comprising Combinations of Sensates |
US20090253973A1 (en) * | 2008-04-04 | 2009-10-08 | Eran Bashan | Apparatus for optimizing a patient's insulin dosage regimen |
US7645803B2 (en) | 2005-05-09 | 2010-01-12 | Foamix Ltd. | Saccharide foamable compositions |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20100278991A1 (en) * | 2009-04-29 | 2010-11-04 | John Christian Haught | Methods for Improving Taste and Oral Care Compositions With Improved Taste |
WO2011009972A1 (en) * | 2009-07-21 | 2011-01-27 | Zuazo Gauger, S.L. | Foaming composition for creating indications for a limited duration of time |
WO2011085053A2 (en) | 2010-01-07 | 2011-07-14 | The Gillette Company | Personal care compositions comprising a multi-active system for down regulating cytokines irritation |
WO2011088073A2 (en) | 2010-01-15 | 2011-07-21 | The Gillette Company | Personal care compositions comprising a methyl naphthalenyl ketone or a derivative thereof |
US20110236321A1 (en) * | 2010-03-26 | 2011-09-29 | Precision Dermatology, Inc. | Aerosol Foams Comprising Clindamycin Phosphate |
US20110263715A1 (en) * | 2010-04-21 | 2011-10-27 | Adchara Pongpeerapat | Local Anesthetic Emulsion Compositions and Methods of Making and Using the Same |
EP2381926A1 (en) * | 2008-12-10 | 2011-11-02 | Roc Lebel | Topical foaming composition and method of application |
US20120004305A1 (en) * | 2009-03-11 | 2012-01-05 | Kowa Co., Ltd. | External preparation containing analgesic/anti-inflammatory agent |
US8114385B2 (en) | 2003-08-04 | 2012-02-14 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US8119106B2 (en) | 2003-04-28 | 2012-02-21 | Foamix Ltd | Foamable iodine compositions |
US20120213717A1 (en) * | 2011-02-18 | 2012-08-23 | Mcneil-Ppc, Inc. | Soothing Agents |
US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US8298515B2 (en) | 2005-06-01 | 2012-10-30 | Stiefel Research Australia Pty Ltd. | Vitamin formulation |
US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
WO2012104164A3 (en) * | 2011-02-04 | 2013-01-17 | Beiersdorf Ag | Self-heating, surfactant-containing cleansing gel featuring a combination of low and high molecular mass pegs |
JP2013505967A (en) * | 2009-09-30 | 2013-02-21 | スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド | Beauty form |
US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
EP2614860A2 (en) * | 2010-09-08 | 2013-07-17 | Universidad Miguel Hernández De Elche | Pharmaceutical composition for the treatment of dry eye |
US20130202543A1 (en) * | 2010-06-14 | 2013-08-08 | Symrise Ag | Use of polyols for enhancing the cooling effect of a cooling substance and cooling mixtures having an enhanced cooling effect |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2013165481A1 (en) * | 2012-05-01 | 2013-11-07 | Amberwing Solutions Inc. | Method and product for headache relief |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
KR101351841B1 (en) | 2013-08-28 | 2014-01-15 | 윤경 | Cellulose patch having cooling and heating function |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
DE102012218733A1 (en) * | 2012-10-15 | 2014-04-17 | Beiersdorf Ag | Cosmetic or dermatological preparation for the prophylaxis and / or treatment of atopic dermatitis |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
WO2014204008A1 (en) * | 2013-06-18 | 2014-12-24 | L'oreal | Foam aerosol cosmetic composition |
US20140378360A1 (en) * | 2011-06-23 | 2014-12-25 | The Procter & Gamble Company | Perfume systems |
US8936814B2 (en) * | 2012-11-30 | 2015-01-20 | Zuri A. Murrell | Skin cream |
EP2862442A1 (en) * | 2013-10-16 | 2015-04-22 | Fulltec GmbH | Insect repellent |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
WO2016109517A1 (en) * | 2014-12-29 | 2016-07-07 | Kimberly-Clark Worldwide, Inc. | Cosmetic emulsions |
EP3045171A1 (en) * | 2009-06-24 | 2016-07-20 | Strategic Science & Technologies, LLC | Topical composition |
US9427605B2 (en) | 2005-03-24 | 2016-08-30 | Novan, Inc. | Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9463159B2 (en) * | 2012-12-06 | 2016-10-11 | Colgate-Palmolive Company | Oral gel for relief of tooth pain |
US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9695292B2 (en) | 2013-11-26 | 2017-07-04 | Ansell Limited | Effervescent texturing |
US9757397B2 (en) | 2011-07-05 | 2017-09-12 | Novan, Inc. | Methods of manufacturing topical compositions and apparatus for the same |
KR101793818B1 (en) | 2016-03-04 | 2017-11-06 | 서영아 | Hair improving composition for preventing hair loss and promoting a growth hair, and the hair improving material using the composition |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9919072B2 (en) | 2009-08-21 | 2018-03-20 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US10206947B2 (en) | 2013-08-08 | 2019-02-19 | Novan, Inc. | Topical compositions and methods of using the same |
US10226483B2 (en) | 2013-08-08 | 2019-03-12 | Novan, Inc. | Topical compositions and methods of using the same |
CN109475120A (en) * | 2016-10-11 | 2019-03-15 | 西姆莱斯股份公司 | Antimicrobial compositions |
US10265334B2 (en) | 2011-07-05 | 2019-04-23 | Novan, Inc. | Anhydrous compositions |
US20190175739A1 (en) * | 2017-12-08 | 2019-06-13 | Church & Dwight Co., Inc. | Non-medicated, teething, cooling composition |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US10322081B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
CN110035663A (en) * | 2016-05-11 | 2019-07-19 | 拜耳医药保健有限责任公司 | The heat-staple preparation for breaking into foam |
US10398731B2 (en) * | 2017-06-12 | 2019-09-03 | James H Southard, Jr. | Treatment for warts |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10406081B2 (en) | 2014-12-29 | 2019-09-10 | Kimberly-Clark Worldwide, Inc. | Multifunctional base emulsion |
CN110475473A (en) * | 2016-08-23 | 2019-11-19 | 奇特利奇公司 | Containing monoterpene/Phenylpropanoid Glycosides compound and preparation method thereof and as the purposes of insecticide |
US10849864B2 (en) | 2015-07-28 | 2020-12-01 | Novan, Inc. | Combinations and methods for the treatment and/or prevention of fungal infections |
US10912743B2 (en) | 2016-03-02 | 2021-02-09 | Novan, Inc. | Compositions for treating inflammation and methods of treating the same |
US10925689B2 (en) | 2014-07-14 | 2021-02-23 | Novan, Inc. | Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same |
US11077194B2 (en) | 2012-03-14 | 2021-08-03 | Novan, Inc. | Nitric oxide releasing pharmaceutical compositions |
US11147761B2 (en) | 2018-01-12 | 2021-10-19 | Nicole Akmenkalns | Topical supplement composition and method of use |
US11166980B2 (en) | 2016-04-13 | 2021-11-09 | Novan, Inc. | Compositions, systems, kits, and methods for treating an infection |
US20220000825A1 (en) * | 2018-10-01 | 2022-01-06 | Wintermute Biomedical, Inc. | Therapeutic compositions |
US20220008461A1 (en) * | 2020-07-13 | 2022-01-13 | Nsc-Nano Sono Cooperation Ltd | Anhydrous antimicrobial topical formulations and methods of use thereof |
US11285171B2 (en) | 2018-03-01 | 2022-03-29 | Novan, Inc. | Nitric oxide releasing suppositories and methods of use thereof |
US11602493B2 (en) | 2017-05-11 | 2023-03-14 | Beiersdorf Ag | Gel formulations |
US11612551B2 (en) | 2016-05-11 | 2023-03-28 | Formulated Solutions, Llc | Whipped formulations |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
WO2024189661A1 (en) * | 2023-03-13 | 2024-09-19 | Jordan University Of Science And Technology | A topical composition comprising a ternary metal oxide nanoparticle preservative |
RU2829491C1 (en) * | 2024-05-09 | 2024-10-30 | Борис Юльевич Чебураков | Cellulite treatment gel |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080031907A1 (en) * | 2002-10-25 | 2008-02-07 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
ES2364692T3 (en) * | 2008-12-23 | 2011-09-12 | Intendis Gmbh | ESSENTIALLY FREE FOAM COMPOSITION OF PHARMACEUTICALLY ACTIVE INGREDIENTS FOR HUMAN SKIN TREATMENT. |
DE102009028156A1 (en) * | 2009-07-31 | 2011-02-03 | Evonik Stockhausen Gmbh | Foamable O / W emulsion |
CN102319188B (en) * | 2011-09-28 | 2012-11-21 | 上海交通大学 | Water-soluble silicone oil microemulsion and preparation method and application thereof |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
EP2711414B1 (en) * | 2012-09-19 | 2019-05-15 | Symrise AG | Stabilisation of capsule systems in detergent and cleaning compositions |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
RU2015140498A (en) * | 2013-03-08 | 2017-04-13 | Сипла Лимитед | Pharmaceutical compositions for rectal administration |
ES2857602T3 (en) * | 2014-03-11 | 2021-09-29 | Promius Pharma Llc | Topical corticosteroid compositions |
CN104030992B (en) * | 2014-03-20 | 2016-03-23 | 东南大学 | A kind of Dicyclanil drug crystal forms II and preparation method thereof |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2016020861A2 (en) * | 2014-08-05 | 2016-02-11 | Palmeira De Oliveira Ana Cristina | Vaginal composition for the treatment and prevention of urogenital infections, method for producing the same and uses thereof |
JP6696768B2 (en) * | 2014-12-24 | 2020-05-20 | 株式会社ポーラファルマ | External composition for screen former |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
KR20180098300A (en) * | 2015-12-15 | 2018-09-03 | 테라퓨틱스 인코퍼레이티드 | Halobetasol foam composition and method of use thereof |
DE102016204685A1 (en) * | 2016-03-22 | 2017-09-28 | Beiersdorf Ag | Antiperspirant stick in the form of an O / W emulsion |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
JP2019513709A (en) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US20170368564A1 (en) * | 2016-06-28 | 2017-12-28 | William Christopher Baker | Foam formula and dispensing apparatus |
GB201620701D0 (en) * | 2016-12-06 | 2017-01-18 | Glaxosmithkline Consumer Healthcare (Uk) Ip Ltd | Novel composition |
CN108030737B (en) * | 2017-11-24 | 2021-01-15 | 卢镇东 | Concentrated spray for promoting white hair to turn black, fixing hair and growing hair and preparation method thereof |
WO2019100362A1 (en) * | 2017-11-27 | 2019-05-31 | Wise Ally Holdings Ltd | Vaporizer system |
US11337904B2 (en) | 2017-12-28 | 2022-05-24 | Honeywell International Inc. | Personal care compositions and methods comprising trans-1-chloro-3,3,3-trifluoropropene |
JP2019151566A (en) * | 2018-03-01 | 2019-09-12 | ロレアル | Sprayable composition |
FR3090357B1 (en) * | 2018-12-20 | 2022-10-07 | Oreal | Foam aerosol device containing a composition rich in fatty substances |
US12097186B2 (en) | 2019-04-30 | 2024-09-24 | Bayer Healthcare Llc | Topical analgesic compositions |
CA3138194A1 (en) | 2019-04-30 | 2020-11-05 | Bayer Healthcare Llc | Topical analgesic gel compositions |
US11590073B2 (en) | 2020-06-09 | 2023-02-28 | The Procter & Gamble Company | Methods and compositions for reducing the feeling of vaginal dryness |
US20240041726A1 (en) | 2020-10-23 | 2024-02-08 | Chattem, Inc. | Foamable composition, use thereof, and process for its preparation |
KR20220149828A (en) | 2021-04-30 | 2022-11-09 | 삼성전자주식회사 | Semiconductor devices |
CN115252549B (en) * | 2022-07-12 | 2023-09-08 | 科辉智药生物科技(无锡)有限公司 | Composition for improving efficacy of hair-growing active substance and preparation method thereof |
CN115463091B (en) * | 2022-10-27 | 2023-04-07 | 新基元(北京)医药科技有限公司 | Minocycline foaming agent with improved stability |
WO2024209065A1 (en) * | 2023-04-06 | 2024-10-10 | Biofrontera Bioscience Gmbh | Pressurized nanoemulsion |
Citations (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2586287A (en) * | 1948-12-11 | 1952-02-19 | Colagte Palmolive Peet Company | Aluminum sulfamate antiperspirant preparation |
US2968628A (en) * | 1958-10-17 | 1961-01-17 | Shulton Inc | Propellant composition |
US3236457A (en) * | 1963-08-21 | 1966-02-22 | John R Kennedy | Composite spray container assembly |
US3298919A (en) * | 1962-12-26 | 1967-01-17 | Dow Corning | Shaving cream containing polysiloxanes |
US3301444A (en) * | 1965-08-12 | 1967-01-31 | Oel Inc | Aerosol metering valve |
US3303970A (en) * | 1964-07-14 | 1967-02-14 | Jerome Marrow | Device for simultaneously dispensing from plural sources |
US3366494A (en) * | 1967-02-15 | 1968-01-30 | Du Pont | Pressurized aerosol food emulsions |
US3369034A (en) * | 1964-04-27 | 1968-02-13 | Eversharp Inc | Process for separating saponifiables and unsaponifiables in marine animal oils |
US3559890A (en) * | 1968-09-03 | 1971-02-02 | William R Brooks | Foam dispenser |
US3561262A (en) * | 1967-10-26 | 1971-02-09 | Magnaflux Corp | Water soluble developer |
US3563098A (en) * | 1968-06-28 | 1971-02-16 | Rex Chainbelt Inc | Automatic quick release mechanism |
US3787566A (en) * | 1969-07-29 | 1974-01-22 | Holliston Labor Inc | Disinfecting aerosol compositions |
US3865275A (en) * | 1973-07-30 | 1975-02-11 | Raymond Lee Organization Inc | Apparatus for operating an aerosol can |
US3866800A (en) * | 1969-02-12 | 1975-02-18 | Alberto Culver Co | Non-pressurized package containing self-heating products |
US4001391A (en) * | 1969-04-18 | 1977-01-04 | Plough, Inc. | Means for depositing aerosol sprays in buttery form |
US4001442A (en) * | 1973-07-18 | 1977-01-04 | Elastin-Werk Aktiengesellschaft | Collagen-containing preparations |
US4252787A (en) * | 1976-12-27 | 1981-02-24 | Cambridge Research And Development Group | Anti-fertility composition and method |
US4309995A (en) * | 1980-01-28 | 1982-01-12 | Sacco Susan M | Vaginal irrigation apparatus |
US4310510A (en) * | 1976-12-27 | 1982-01-12 | Sherman Kenneth N | Self administrable anti-fertility composition |
US4427670A (en) * | 1980-03-27 | 1984-01-24 | Mitsubishi Chemical Industries Limited | Skin preparation |
US4725609A (en) * | 1983-11-21 | 1988-02-16 | Burroughs Wellcome Co. | Method of promoting healing |
US4798682A (en) * | 1985-06-18 | 1989-01-17 | Henkel Kommanditgesellschaft Auf Aktien | Oil-in-water emulsions with increased viscosity under shear stress |
US4804674A (en) * | 1986-03-26 | 1989-02-14 | Euroceltique, S.A. | Vaginal pharmaceutical composition |
US4806262A (en) * | 1985-08-14 | 1989-02-21 | The Procter & Gamble Company | Nonlathering cleansing mousse with skin conditioning benefits |
US4808388A (en) * | 1986-08-20 | 1989-02-28 | Merz + Co. Gmbh & Co. | Foamable creams |
US4847068A (en) * | 1987-08-06 | 1989-07-11 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions |
US4897262A (en) * | 1988-03-22 | 1990-01-30 | Playtex Jhirmack, Inc. | Non-aerosol hair spray composition |
US4902281A (en) * | 1988-08-16 | 1990-02-20 | Corus Medical Corporation | Fibrinogen dispensing kit |
US4981679A (en) * | 1983-06-08 | 1991-01-01 | Briggs Joseph H | Method and composition for the treatment of burns |
US4981677A (en) * | 1987-09-23 | 1991-01-01 | L'oreal | Petrolatum-containing aerosol foam concentrate |
US4981367A (en) * | 1989-07-28 | 1991-01-01 | Stranco, Inc. | Portable mixing apparatus |
US4981845A (en) * | 1988-09-09 | 1991-01-01 | Chesebrough Pond's U.S.A. Co., Division Of Conopco, Inc. | Cosmetic composition |
US4985459A (en) * | 1984-02-08 | 1991-01-15 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
US4992478A (en) * | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4993496A (en) * | 1987-07-06 | 1991-02-19 | Total Walther Feuerschutz Gmbh | Quick release valve for sprinkler head |
US5082651A (en) * | 1989-04-26 | 1992-01-21 | Smith Kline & French Laboratories Limited | Pharmaceutical compositions |
US5087618A (en) * | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
US5089252A (en) * | 1982-01-15 | 1992-02-18 | L'oreal | Cosmetic composition for treating keratin fibres, and process for treating the latter |
US5091111A (en) * | 1990-09-19 | 1992-02-25 | S. C. Johnson & Son, Inc. | Aqueous emulsion and aersol delivery system using same |
US5279819A (en) * | 1991-03-18 | 1994-01-18 | The Gillette Company | Shaving compositions |
US5286475A (en) * | 1990-11-09 | 1994-02-15 | L'oreal | Anhydrous cosmetic composition in the aerosol form forming a foam |
US5378451A (en) * | 1989-10-19 | 1995-01-03 | Dow B. Hickam, Inc. | Topical medicinal pressurized aerosol compositions and method of preparation, method of use and article of manufacture thereof |
US5378730A (en) * | 1988-06-09 | 1995-01-03 | Alza Corporation | Permeation enhancer comprising ethanol and monoglycerides |
US5380761A (en) * | 1991-04-15 | 1995-01-10 | Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. | Transdermal compositions |
US5384308A (en) * | 1993-06-14 | 1995-01-24 | Henkin; R. I. | Composition and method for enhancing wound healing |
US5385943A (en) * | 1988-03-30 | 1995-01-31 | Schering Aktiengesellschaft | Use of topically applicable preparations for treatment of presbyderma |
US5389676A (en) * | 1991-03-22 | 1995-02-14 | E. B. Michaels Research Associates, Inc. | Viscous surfactant emulsion compositions |
US5482965A (en) * | 1991-03-19 | 1996-01-09 | Rajadhyaksha; Vithal J. | Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active agents |
US5491245A (en) * | 1993-03-26 | 1996-02-13 | Th. Goldschmidt Ag | Method for the synthesis of amphoteric surfactants |
US5597560A (en) * | 1994-05-17 | 1997-01-28 | Laboratorios Cusi, S.A. | Diclofenac and tobramycin formulations for ophthalmic and otic topicaluse |
US5603940A (en) * | 1993-10-08 | 1997-02-18 | L'oreal | Oil-in-water emulsion which may be used for obtaining a cream |
US5605679A (en) * | 1994-06-03 | 1997-02-25 | L'oreal | Photoprotective/cosmetic compositions comprising at least one solid organic sunscreen compound and diphenylacrylate solvent therefor |
US5716611A (en) * | 1996-01-02 | 1998-02-10 | Euro-Celtique, S.A. | Emollient antimicrobial formulations containing povidone iodine |
US5716621A (en) * | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
US5719122A (en) * | 1992-10-20 | 1998-02-17 | Smithkline Beecham Farmaceutici S.P.A. | Pharmaceutical compositions containing a calcitonin |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5856452A (en) * | 1996-12-16 | 1999-01-05 | Sembiosys Genetics Inc. | Oil bodies and associated proteins as affinity matrices |
US5858371A (en) * | 1997-02-05 | 1999-01-12 | Panacea Biotech Limited | Pharmaceutical composition for the control and treatment of anorectal and colonic diseases |
US5865347A (en) * | 1997-10-27 | 1999-02-02 | William T. Wilkinson | Multi-chamber dispenser for flowable materials |
US5866040A (en) * | 1990-06-15 | 1999-02-02 | Shiseido Company, Ltd. | Complex and emulsified composition |
US5869529A (en) * | 1994-07-20 | 1999-02-09 | Agis Industries (1983) Ltd. | Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus |
US5871720A (en) * | 1997-11-20 | 1999-02-16 | Colgate-Palmolive Company | Cosmetic compositions with DBS and functionalized silicones |
US6168576B1 (en) * | 1999-05-24 | 2001-01-02 | Irene N. Reynolds | Device for dispensing vaginal medication |
US6171347B1 (en) * | 1996-11-16 | 2001-01-09 | Wella Aktiengesellschaft | Compositions, methods and kits for reductively removing color from dyed hair |
US6180669B1 (en) * | 1996-11-12 | 2001-01-30 | Tamarkin Pharmaceutical Innovation Ltd. | Method for treatment of dermatological disorders |
US6214318B1 (en) * | 1997-10-02 | 2001-04-10 | Oms Holdings Llc | Aerosol ointment compositions for topical use |
US6335022B1 (en) * | 1998-12-17 | 2002-01-01 | L'oreal | Nanoemulsion based on oxyethylenated or non-oxyethylenated sorbitan fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields |
US20020002151A1 (en) * | 2000-05-23 | 2002-01-03 | Showa Yakuhin Kako Co., Ltd. | Minocycline-containing compositions |
US20020004063A1 (en) * | 1999-09-28 | 2002-01-10 | Jie Zhang | Methods and apparatus for drug delivery involving phase changing formulations |
US6341717B2 (en) * | 2000-04-01 | 2002-01-29 | Megaplast Gmbh & Co. Kg | Metering pump dispenser with at least two metering pumps |
US20020013481A1 (en) * | 1998-02-24 | 2002-01-31 | Uwe Schonrock | Use of flavones flavanones and flavonoids for protecting ascorbic acid and/or ascorbyl compounds from oxidation |
US20020048798A1 (en) * | 2000-03-15 | 2002-04-25 | Avery Mitchell Allen | Novel antioxidants |
US20020122811A1 (en) * | 2000-10-04 | 2002-09-05 | Bernd Stein | Hair wax products containing waxes, non-volatile oils and volatile hydrophobic materials |
US20030006193A1 (en) * | 1999-09-06 | 2003-01-09 | Katsunori Ikeda | Apparatus for purifying nucleic acids and proteins |
US6511655B1 (en) * | 1999-08-16 | 2003-01-28 | Beiersdorf Ag | Cosmetic or dermatological preparations of the oil-in-water type |
US6672483B1 (en) * | 1999-02-05 | 2004-01-06 | Rexam Sofab | Dispenser for chemically unstable products |
US6682750B2 (en) * | 2001-03-03 | 2004-01-27 | Clariant Gmbh | Surfactant-free cosmetic, dermatological and pharmaceutical compositions |
US6682726B2 (en) * | 2001-04-30 | 2004-01-27 | The Gillette Company | Self-foaming shaving lotion |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
US20050002976A1 (en) * | 2003-06-19 | 2005-01-06 | The Procter & Gamble Company | Polyol-in-silicone emulsions |
US6843390B1 (en) * | 2003-03-17 | 2005-01-18 | Joe G. Bristor | Multiple fluid closed system dispensing device |
US20050013853A1 (en) * | 2000-11-29 | 2005-01-20 | Irit Gil-Ad | Anti-proliferative drugs |
US6897195B2 (en) * | 2002-07-24 | 2005-05-24 | Nanjing Zhongshi Chemical Co. | Composition of menthol and menthyl lactate, its preparation method and its applications as a cooling agent |
US20060008432A1 (en) * | 2004-07-07 | 2006-01-12 | Sebastiano Scarampi | Gilsonite derived pharmaceutical delivery compositions and methods: nail applications |
US20060014990A1 (en) * | 2004-07-14 | 2006-01-19 | Kuechler Keith H | Process for producing olefins |
US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
US20060018938A1 (en) * | 1997-08-18 | 2006-01-26 | Stephanie Neubourg | Foam skin cream, use of the foam skin protection cream and a process of its preparation |
USRE38964E1 (en) * | 1995-01-09 | 2006-01-31 | Becton Dickinson And Company | One hand needle release system |
US20070010580A1 (en) * | 2003-05-30 | 2007-01-11 | Gianfranco De Paoli Ambrosi | Formulation for chemical peeling |
US20070009607A1 (en) * | 2005-07-11 | 2007-01-11 | George Jones | Antibacterial/anti-infalmmatory composition and method |
US20070017696A1 (en) * | 2005-07-22 | 2007-01-25 | Hon Hai Precision Industry Co., Ltd. | Multi-layer printed circuit board |
US20070020213A1 (en) * | 2002-10-25 | 2007-01-25 | Foamix Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US20070020304A1 (en) * | 2002-10-25 | 2007-01-25 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US20070224143A1 (en) * | 2006-03-21 | 2007-09-27 | Kamedis Ltd. | Cosmetic and pharmaceutical foam carrier |
US20080008397A1 (en) * | 2006-07-04 | 2008-01-10 | Pavel Kisilev | Feature-aware image defect removal |
US20080015263A1 (en) * | 2002-02-27 | 2008-01-17 | Bolotin Elijah M | Compositions for delivery of therapeutics and other materials |
US20080015271A1 (en) * | 2006-07-14 | 2008-01-17 | Stiefel Research Austrialia Pty Ltd | Fatty acid pharmaceutical foam |
US7645803B2 (en) * | 2005-05-09 | 2010-01-12 | Foamix Ltd. | Saccharide foamable compositions |
US20110002857A1 (en) * | 2003-08-04 | 2011-01-06 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20110002969A1 (en) * | 2008-02-29 | 2011-01-06 | Lipotec, S.A. | Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors |
US20110008266A1 (en) * | 2008-01-14 | 2011-01-13 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8343945B2 (en) * | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US20130011342A1 (en) * | 2009-10-02 | 2013-01-10 | Foamix Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US8362091B2 (en) * | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
Family Cites Families (1112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1159250A (en) | 1914-05-01 | 1915-11-02 | Frank Moulton | Vaginal irrigator. |
US1666684A (en) | 1926-01-15 | 1928-04-17 | Carstens Mfg Co H | Vaginal douche |
US1924972A (en) | 1929-04-15 | 1933-08-29 | Carl J Beckert | Stabilized egg product |
US2085733A (en) | 1935-07-15 | 1937-07-06 | John C Bird | Shaving cream |
US2390921A (en) | 1943-03-23 | 1945-12-11 | Ethel Hudson Clark | Applicator for facial creams |
US2524590A (en) | 1946-04-22 | 1950-10-03 | Carsten F Boe | Emulsion containing a liquefied propellant gas under pressure and method of spraying same |
US2617754A (en) | 1949-08-29 | 1952-11-11 | Procter & Gamble | Cosmetic cream |
US3062715A (en) | 1953-11-18 | 1962-11-06 | George S Pfaus | Vaginal tablet |
US2767712A (en) | 1954-03-01 | 1956-10-23 | Neil S Waterman | Medicinal applicator |
GB808104A (en) | 1955-01-04 | 1959-01-28 | Udylite Res Corp | Electrodeposition of copper from aqueous alkaline cyanide solutions |
GB808105A (en) | 1956-06-15 | 1959-01-28 | Ici Ltd | New pharmaceutical compositions |
US3092555A (en) | 1958-04-21 | 1963-06-04 | Roy H Horn | Relatively collapsible aerosol foam compositions |
US3144386A (en) | 1958-05-09 | 1964-08-11 | Merck & Co Inc | Mastitis aerosol foam |
US3178352A (en) | 1959-02-27 | 1965-04-13 | Erickson Roy | Shaving method and composition therefor |
US3141821A (en) | 1959-03-17 | 1964-07-21 | Lehn & Fink Products Corp | Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis |
US3004894A (en) | 1959-04-07 | 1961-10-17 | Upjohn Co | Therapeutic composition comprising tetracycline and a dioxolane |
GB922930A (en) | 1959-09-21 | 1963-04-03 | Sunnen Joseph | Spermicidal composition and method of making same |
US3142420A (en) | 1959-11-09 | 1964-07-28 | Neotechnic Eng Ltd | Metering dispenser for aerosol with fluid pressure operated piston |
US3092255A (en) | 1960-02-05 | 1963-06-04 | Robert F Hohman | Sorting apparatus |
US3067784A (en) | 1960-04-14 | 1962-12-11 | Esta Medical Lab Inc | Adapter connecting aerosol container valve stem to dispenser for filling said dispenser |
NL270627A (en) | 1960-10-26 | |||
US3154075A (en) | 1960-11-02 | 1964-10-27 | Norwich Pharma Co | Vaginal applicator |
GB998490A (en) | 1961-06-03 | 1965-07-14 | Albert Fritz Albach | A foam projector |
DE1926796U (en) | 1961-10-12 | 1965-11-11 | Heidolph Elektro K G | FAN. |
NL285082A (en) | 1962-02-28 | |||
US3261695A (en) | 1962-12-24 | 1966-07-19 | Gen Foods Corp | Process for preparing dehydrated foods |
US3330730A (en) | 1962-08-03 | 1967-07-11 | Colgate Palmolive Co | Pressurized emulsion quick breaking foam compositions |
US3252859A (en) | 1962-10-24 | 1966-05-24 | Masti Kure Company Inc | Colloidal silica-oil composition and method of using same |
US3244589A (en) | 1962-10-26 | 1966-04-05 | Sunnen | Alkyl phenoxy polyethoxy ether spermicidal aerosol |
US3383280A (en) | 1963-01-09 | 1968-05-14 | Miles Lab | Dermatological abradant stick-type applicator |
FR1355607A (en) | 1963-01-22 | 1964-03-20 | Improvements to cannula probes and their applications | |
US3149543A (en) | 1963-03-04 | 1964-09-22 | Ingersoll Rand Co | Non-lubricated piston |
GB1026831A (en) | 1963-05-31 | 1966-04-20 | Mediline Ag | Preparations for use in feminine hygiene |
US3824303A (en) | 1963-07-24 | 1974-07-16 | Yardley Of London Inc | Collapsible foam pre-electric shave lotion containing diester lubricants |
GB1081949A (en) | 1963-08-12 | 1967-09-06 | Avon Prod Inc | Improvements in cosmetic mask |
US3333333A (en) | 1963-08-14 | 1967-08-01 | Rca Corp | Method of making magnetic material with pattern of embedded non-magnetic material |
US3263867A (en) | 1963-12-26 | 1966-08-02 | Valve Corp Of America | Metering button-type aerosol actuator |
US3395214A (en) | 1964-01-09 | 1968-07-30 | Scholl Mfg Co Inc | Antiperspirant composition providing a readily collapsible sprayable foam |
US3278093A (en) | 1964-01-13 | 1966-10-11 | Valve Corp Of America | Metering and non-metering aerosol actuator button |
US3395215A (en) | 1964-10-15 | 1968-07-30 | Colgate Palmolive Co | Pressurized lotion composition |
US3384541A (en) | 1964-10-28 | 1968-05-21 | William G. Clark | Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants |
US3263869A (en) | 1964-11-03 | 1966-08-02 | Calmar Inc | Liquid dispenser with overcap |
US3342845A (en) | 1964-11-05 | 1967-09-19 | Upjohn Co | Terphenyl triisocyanates |
US3419658A (en) | 1965-01-25 | 1968-12-31 | Du Pont | Nonaqueous aerosol foams containing mineral oil |
US3346451A (en) | 1965-01-27 | 1967-10-10 | S E Massengill Company | Concentrated liquid lactic acid douche preparation containing aromatics |
US3456052A (en) | 1965-09-28 | 1969-07-15 | Garrett Lab Inc | Aerosol composition containing butoxymonoether of a polyoxyalkylene glycol |
GB1121358A (en) | 1965-10-21 | 1968-07-24 | Bristol Myers Co | Aerosol manufacture |
US3849569A (en) | 1965-12-02 | 1974-11-19 | Glaxo Lab Ltd | Composition containing procaine penicillin |
BE692228A (en) | 1966-01-10 | 1967-07-05 | ||
US3401849A (en) | 1966-05-24 | 1968-09-17 | Robert L. Weber | Low force metering valve |
US3886084A (en) | 1966-09-29 | 1975-05-27 | Champion Int Corp | Microencapsulation system |
US3377004A (en) | 1966-10-03 | 1968-04-09 | Gen Mills Inc | Metered dispensing container |
GB1201918A (en) | 1966-12-21 | 1970-08-12 | Bespak Industries Ltd | Improvements in or relating to valves for pressurised dispensers |
US3527559A (en) | 1967-01-05 | 1970-09-08 | Standard Pharmacal Corp | Dense aqueous aerosol foam depilatory compositions containing a mixture of alkaline metal and alkali metal thioglycolates and a fatty alcohol-alkylene oxide wax emulsifying agent |
US3540448A (en) | 1968-01-17 | 1970-11-17 | Joseph Sunnen | Rechargeable applicator for dispensing substances in a foam condition |
DE1926796A1 (en) | 1968-05-27 | 1970-03-19 | Dudiuyt Jean Paul | Aerosol compsn. and container |
US3878118A (en) | 1968-09-06 | 1975-04-15 | Wilkinson Sword Ltd | Self-heating chemical compositions |
US3667461A (en) | 1968-11-05 | 1972-06-06 | Paul A Zamarra | Disposable syringe |
CA975500A (en) | 1969-02-06 | 1975-09-30 | Joseph G. Spitzer | Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same, and process |
US3966090A (en) | 1969-02-17 | 1976-06-29 | Dart Industries Inc. | Package for dispensing an antiseptic composition |
US3819524A (en) | 1969-06-17 | 1974-06-25 | Colgate Palmolive Co | Cosmetic composition for thermal dispensing |
US3577518A (en) | 1969-07-18 | 1971-05-04 | Nat Patent Dev Corp | Hydrophilic hairspray and hair setting preparations |
BE759520A (en) | 1969-11-28 | 1971-04-30 | Aspro Nicholas Ltd | ASPIRIN COMPOSITIONS |
GB1351761A (en) | 1971-02-04 | 1974-05-01 | Wilkinson Sword Ltd | Substituted p-menthane carboxamides and compositions containing them |
GB1353381A (en) | 1971-02-04 | 1974-05-15 | Wilkinson Sword Ltd | Substituted p-menthanes and compositions containing them |
GB1351762A (en) | 1971-02-14 | 1974-05-01 | Wilkinson Sword Ltd | Tobacco and tobacco-containing manufactures |
CA958338A (en) | 1971-03-08 | 1974-11-26 | Chung T. Shin | Antiperspirant powder aerosol compositions containing aluminum chloride and water soluble aluminum compounds and methods of preparation |
US3770648A (en) | 1971-07-12 | 1973-11-06 | Bristol Myers Co | Anhydrous aerosol foam |
BE788788A (en) | 1971-09-13 | 1973-03-13 | Treuhandvereinigung Ag | PRODUCT FOR PRESERVING, PROMOTING AND RESTORING HAIR AND METHOD OF MANUFACTURING THIS PRODUCT |
US3912667A (en) | 1971-09-13 | 1975-10-14 | Spitzer Joseph G | Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same and process |
US3997467A (en) | 1971-11-26 | 1976-12-14 | Pharmacia Aktiebolag | Foam forming composition |
SE358308B (en) | 1971-11-26 | 1973-07-30 | Pharmacia Ab | |
CH554911A (en) | 1971-12-30 | 1974-10-15 | Ciba Geigy Ag | USE OUTSIDE THE TEXTILE INDUSTRY OF NEW 4,4'-DIVINYLDIPHENYL COMPOUNDS AS OPTICAL LIGHTENING AGENTS FOR ORGANIC MATERIALS. |
JPS4892282U (en) | 1972-02-05 | 1973-11-06 | ||
US3963833A (en) | 1972-06-02 | 1976-06-15 | Colgate-Palmolive Company | Antiperspirant composition and method containing a dihydro-benzofuran and an astringent metal salt |
US3841525A (en) | 1972-06-14 | 1974-10-15 | N Siegel | Aerosol spray device with cam activator |
US3849580A (en) | 1972-09-05 | 1974-11-19 | American Home Prod | Aerosol dispensing system for anhydrous edible fat compositions |
US3751562A (en) | 1972-09-22 | 1973-08-07 | Princeton Biomedix | Medicated gelled oils |
US3970584A (en) | 1973-02-14 | 1976-07-20 | S. C. Johnson & Son, Inc. | Aerosol package containing a foam-forming emulsion and propellent system |
US4439416A (en) | 1973-03-23 | 1984-03-27 | Colgate-Palmolive Company | Self-heating shaving composition |
GB1423179A (en) | 1973-05-16 | 1976-01-28 | Wilkinson Sword Ltd | Pressurised shaving foam dispensers |
US4110426A (en) | 1973-07-24 | 1978-08-29 | Colgate-Palmolive Company | Method of treating skin and hair with a self-heated cosmetic |
US3929985A (en) | 1974-01-18 | 1975-12-30 | Richardson Merrell Inc | Anhydrous candicidin foam compositions |
DE2501548A1 (en) | 1974-01-25 | 1975-07-31 | Procter & Gamble | ORAL TREATMENT PRODUCTS |
GB1457671A (en) | 1974-01-31 | 1976-12-08 | Wilkinson Sword Ltd | Flavour |
US3923970A (en) | 1974-03-29 | 1975-12-02 | Carter Wallace | Stable aerosol shaving foams containing mineral oil |
US3962150A (en) | 1974-04-10 | 1976-06-08 | Richardson-Merrell Inc. | Foam producing cleansing compositions |
US3953591A (en) | 1974-04-29 | 1976-04-27 | The Procter & Gamble Company | Fatty acid, polysiloxane and water-soluble polymer containing skin conditioning emulsion |
US3966632A (en) | 1974-06-06 | 1976-06-29 | G. D. Searle & Co. | Vegetable oil emulsion |
US4145411A (en) | 1974-09-05 | 1979-03-20 | Colgate-Palmolive Company | Pressurized foaming shaving composition |
JPS5729213B2 (en) | 1974-11-12 | 1982-06-21 | ||
US4052513A (en) | 1974-12-13 | 1977-10-04 | Plough, Inc. | Stable topical anesthetic compositions |
US3952916A (en) | 1975-01-06 | 1976-04-27 | Warner-Lambert Company | Automatic dispenser for periodically actuating an aerosol container |
US4019657A (en) | 1975-03-03 | 1977-04-26 | Spitzer Joseph G | Aerosol containers for foaming and delivering aerosols |
US3970219A (en) | 1975-03-03 | 1976-07-20 | Spitzer Joseph G | Aerosol containers for foaming and delivering aerosols and process |
US4018396A (en) | 1975-05-05 | 1977-04-19 | Bechtel International Corporation | Embedded housing for ore crusher |
US3993224A (en) | 1975-09-08 | 1976-11-23 | Aerosol Investments, Ltd. | Spout for two-component resin dispenser |
DE2608226A1 (en) | 1976-02-28 | 1977-09-08 | Haarmann & Reimer Gmbh | AGENTS WITH PHYSIOLOGICAL COOLING EFFECT |
US4100426A (en) | 1976-03-10 | 1978-07-11 | Square D Company | Load controlling means |
IL49491A (en) | 1976-04-29 | 1979-09-30 | Rosenberg Peretz | Quickly-attachable connector for plastic pipes |
US4102995A (en) | 1976-05-13 | 1978-07-25 | Westwood Pharmaceuticals Inc. | Tar gel formulation |
US4124149A (en) | 1976-07-19 | 1978-11-07 | Spitzer Joseph G | Aerosol container with position-sensitive shut-off valve |
CA1089368A (en) | 1976-08-02 | 1980-11-11 | Daniel C. Geary | Polyethoxylated fatty alcohol in antiperspirant sticks |
IL52045A (en) | 1976-08-25 | 1979-12-30 | Mundipharma Ag | Sprayable germicidal foam compositions |
US4083974A (en) | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
JPS5744429Y2 (en) | 1977-04-14 | 1982-10-01 | ||
IT1114950B (en) | 1977-12-30 | 1986-02-03 | Porro Marcella | COMPOSITIONS FOR ACNE TREATMENT AND THERAPY |
US4386104A (en) | 1977-04-19 | 1983-05-31 | Nazzaro Porro Marcella | Process for the treatment of acne |
GB2004746B (en) | 1977-10-03 | 1982-03-10 | Scherico Ltd | Stable hopical anaesthetic compositions |
JPS5639815Y2 (en) | 1977-11-25 | 1981-09-17 | ||
SE7713618L (en) | 1977-12-01 | 1979-06-02 | Astra Laekemedel Ab | LOCAL ANESTHETIC MIXTURE |
US4160827A (en) | 1978-02-06 | 1979-07-10 | The Upjohn Company | Metronidazole phosphate and salts |
US4229432A (en) | 1978-04-19 | 1980-10-21 | Bristol-Myers Company | Antiperspirant stick composition |
US4603812A (en) | 1978-06-27 | 1986-08-05 | The Dow Chemical Company | Foam-generating pump sprayer |
US4178373A (en) | 1978-08-21 | 1979-12-11 | William H. Rorer, Inc. | Coal tar gel composition |
US4214000A (en) | 1978-10-30 | 1980-07-22 | Johnson & Johnson | Zinc salt of all-trans-retinoic acid for the treatment of acne |
JPS5569682U (en) | 1978-11-08 | 1980-05-13 | ||
JPS5569682A (en) | 1978-11-20 | 1980-05-26 | Toyo Aerosol Kogyo Kk | Foam shrinkable composition |
US4213979A (en) | 1978-12-18 | 1980-07-22 | Plough, Inc. | Stable sprayable hydrocortisone product |
US4954487A (en) | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
US4439441A (en) | 1979-01-11 | 1984-03-27 | Syntex (U.S.A.) Inc. | Contraceptive compositions and methods employing 1-substituted imidazole derivatives |
US4226344A (en) | 1979-02-06 | 1980-10-07 | Booth, Inc. | Constant flow valve actuator |
CH639913A5 (en) | 1979-03-16 | 1983-12-15 | Aerosol Service Ag | Container for receiving and delivering a liquid substance |
US4230701A (en) | 1979-03-21 | 1980-10-28 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
US4335120A (en) | 1979-03-21 | 1982-06-15 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
US4278206A (en) | 1979-04-13 | 1981-07-14 | Ae Development Corporation | Non-pressurized dispensing system |
US4241048A (en) | 1979-05-01 | 1980-12-23 | Bristol-Myers Company | Suspension composition of benzocaine |
JPS55153712A (en) | 1979-05-18 | 1980-11-29 | Kao Corp | Insulin pharmaceutical preparation and its production |
US4268499A (en) | 1979-06-07 | 1981-05-19 | Dow Corning Corporation | Antiperspirant emulsion compositions |
US4241149A (en) | 1979-07-20 | 1980-12-23 | Temple University | Canal clathrate complex solid electrolyte cell |
DE2931469A1 (en) | 1979-08-02 | 1981-02-26 | Bayer Ag | SURFACE SEALED MOLDED BODIES MADE OF CELLED POLYURETHANE ELASTOMERS AND METHOD FOR THE PRODUCTION THEREOF |
JPS5854931B2 (en) | 1979-09-04 | 1983-12-07 | トヨタ自動車株式会社 | broaching machine |
US4271149A (en) | 1979-09-21 | 1981-06-02 | West Agro-Chemical, Inc. | Germicidal iodine compositions with enhanced iodine stability |
US4299826A (en) | 1979-10-12 | 1981-11-10 | The Procter & Gamble Company | Anti-acne composition |
EP0032309A3 (en) | 1980-01-10 | 1981-08-05 | Imperial Chemical Industries Plc | Production of catalyst component, catalyst and use thereof |
SE8004580L (en) | 1980-06-19 | 1981-12-20 | Draco Ab | PHARMACEUTICAL PREPARATION |
US4338211A (en) | 1980-06-30 | 1982-07-06 | The Procter & Gamble Company | Liquid surfactant skin cleanser with lather boosters |
US4508705A (en) | 1980-07-02 | 1985-04-02 | Lever Brothers Company | Skin treatment composition |
US4323582A (en) | 1980-07-21 | 1982-04-06 | Siegel Norman H | Method of treating animals and humans for internal and external parasites |
JPS601113Y2 (en) | 1980-07-22 | 1985-01-12 | 三菱電機株式会社 | Round lighting equipment packaging |
JPS5914282B2 (en) | 1980-07-31 | 1984-04-04 | 株式会社神戸製鋼所 | Tube expansion drawing method |
US4329990A (en) | 1980-08-07 | 1982-05-18 | Sneider Vincent R | Expanding swab applicator |
US4325939A (en) | 1980-09-22 | 1982-04-20 | Richardson-Vicks Inc. | Zinc derivatives and their use in dental compositions |
US4305936A (en) | 1980-10-09 | 1981-12-15 | Dermik Laboratories | Topical corticosteroid formulations |
US4292250A (en) | 1980-11-17 | 1981-09-29 | Wisconsin Alumni Research Foundation | Vitamin D derivatives |
EP0052404B1 (en) | 1980-11-19 | 1987-05-27 | THE PROCTER & GAMBLE COMPANY | Non-yellowing topical pharmaceutical composition |
JPS57501845A (en) | 1980-11-27 | 1982-10-14 | ||
DE3147726A1 (en) | 1980-12-03 | 1982-06-24 | Leo Pharmaceutical Products Ltd. A/S (Loevens kemiske Fabrik Produktionsaktieselskab), 2750 Ballerup | ANTIBIOTIC COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS THAT CONTAIN THESE COMPOUNDS |
US4352808A (en) | 1980-12-12 | 1982-10-05 | Schering Corporation | 3-Aralkyloxy-2,3-dihydro-2-(imidazolylmethyl)benzo(b)thiophenes and related derivatives, their use as antimicrobials and pharmaceutical formulations useful therefore |
US4323694A (en) | 1981-04-13 | 1982-04-06 | Finetex, Inc. | Benzoic acid esters |
US4522948A (en) | 1981-04-24 | 1985-06-11 | Syntex (U.S.A.) Inc. | Spermicidal substituted 1-(cycloalkyl)alkylimidazoles |
US4393066A (en) | 1981-06-05 | 1983-07-12 | Garrett David M | Method for treatment of herpetic lesions |
US4607101A (en) | 1981-08-27 | 1986-08-19 | Jaye-Boern Laboratories, Inc. | Method of treating acne vulgaris with a composition containing carbamide peroxide |
US4877805A (en) | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
US4469674A (en) | 1981-09-03 | 1984-09-04 | Richardson-Vicks Inc. | Stable oral compositions containing zinc and fluoride compounds |
US4440320A (en) | 1981-11-30 | 1984-04-03 | Wernicke Steven A | Foam dispensing apparatus |
LU83949A1 (en) | 1982-02-16 | 1983-09-02 | Oreal | COMPOSITION FOR THE TREATMENT OF KERATINIC MATERIALS CONTAINING AT LEAST ONE CATIONIC POLYMER AND AT LEAST ONE ANIONIC LATEX |
US4529605A (en) | 1983-01-12 | 1985-07-16 | Una E. Lynch | Bathing oil composition |
US4661340A (en) | 1983-06-06 | 1987-04-28 | Interkemia Vegyipari Gazdasagi Tarsasag | Quail egg based stabilized foam compositions for cosmetic purposes |
JPS601113A (en) | 1983-06-20 | 1985-01-07 | Kao Corp | Hair-nourishing and hair-growing agent |
US4552872A (en) | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
US4612193A (en) | 1983-12-23 | 1986-09-16 | Del Laboratories, Inc. | Sty ointment and method of using the same |
GB8402748D0 (en) | 1984-02-02 | 1984-03-07 | Dunlop Ltd | Intravaginal device |
US4912124A (en) | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
NZ207341A (en) | 1984-03-01 | 1988-02-29 | Harvey Alex Ind Ltd | Device containing chemical impregnants for insertion into a body cavity of an animal |
US4628063A (en) | 1984-03-08 | 1986-12-09 | Dana P. Brigham | Antiviral pharmaceutical preparations and methods for their use |
US4574052A (en) | 1984-05-31 | 1986-03-04 | Richardson-Vicks Inc. | Crackling aerosol foam |
GB8416638D0 (en) | 1984-06-29 | 1984-08-01 | Beecham Group Plc | Topical treatment and composition |
ATE37209T1 (en) | 1984-08-06 | 1988-09-15 | Ciba Geigy Ag | PROCESS FOR SIZING PAPER WITH ANIONIC, HYDROPHOBIC SIZES AND CATIONIC RETENTION AGENTS. |
US4595526A (en) | 1984-09-28 | 1986-06-17 | Colgate-Palmolive Company | High foaming nonionic surfacant based liquid detergent |
SE8404895L (en) | 1984-10-01 | 1986-03-17 | Torkel Ingemar Fischer | MEANS OF A SENSITIVITY TEST |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
CA1261276A (en) | 1984-11-09 | 1989-09-26 | Mark B. Grote | Shampoo compositions |
US4701320A (en) | 1984-11-29 | 1987-10-20 | Lederle (Japan), Ltd. | Composition stably containing minocycline for treating periodontal diseases |
US4627973A (en) * | 1984-12-14 | 1986-12-09 | Charles Of The Ritz Group Ltd. | Skin mousse |
AU5078885A (en) | 1984-12-20 | 1986-06-26 | Warner-Lambert Company | Non-irritant detergent |
US4673569A (en) | 1985-02-12 | 1987-06-16 | Faberge Incorporated | Mousse hair composition |
US5002680A (en) | 1985-03-01 | 1991-03-26 | The Procter & Gamble Company | Mild skin cleansing aerosol mousse with skin feel and moisturization benefits |
EP0194097B1 (en) | 1985-03-01 | 1990-04-25 | The Procter & Gamble Company | Mild cleansing mousse |
WO1986005389A1 (en) | 1985-03-18 | 1986-09-25 | Product Resources International, Inc. | Exothermic stable foam compositions |
US4752465A (en) | 1985-09-20 | 1988-06-21 | Product Resources International, Inc. | Aerosol foam |
US4639367A (en) | 1985-03-18 | 1987-01-27 | Product Resources International, Inc. | Aerosol foam |
US5094853A (en) | 1985-04-26 | 1992-03-10 | S. C. Johnson & Son, Inc. | Method of preparing a water-soluble stable arthropodicidally-active foam matrix |
US4965063A (en) | 1985-05-24 | 1990-10-23 | Irene Casey | Cleaner and disinfectant with dye |
US4672078A (en) | 1985-07-03 | 1987-06-09 | Schering-Plough Corporation | Urea stabilized with a lactone in various pharmaceutical and cosmetic preparations |
GB8519426D0 (en) | 1985-08-01 | 1985-09-04 | Ici Plc | Composition for personal care products |
EP0213827A3 (en) | 1985-08-14 | 1988-04-06 | The Procter & Gamble Company | Nonfoaming cleansing mousse with skin conditioning benefits |
AU6175586A (en) | 1985-09-11 | 1987-03-12 | Chesebrough-Pond's Inc. | Petroleum jelly, mild detergent anhydrous base compositions |
FR2591331A1 (en) | 1985-12-10 | 1987-06-12 | Drevet Jean Baptiste | Device for dispensing metered portions of a product contained in a pressurised receptacle |
US4837378A (en) | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
JPS62241701A (en) | 1986-04-11 | 1987-10-22 | Maeda Kogyo Kk | Quick releasing device for hub for bicycle |
CA1291036C (en) | 1986-04-23 | 1991-10-22 | Edwin I. Stoltz | Nasal administration of drugs |
DE3614515A1 (en) | 1986-04-29 | 1987-11-05 | Pfeiffer Erich Gmbh & Co Kg | DISCHARGE DEVICE FOR MEDIA |
FR2598392B1 (en) | 1986-05-09 | 1988-08-26 | Oreal | PACKAGING FOR TWO PRESSURIZED CONTAINERS |
PH25150A (en) | 1986-06-05 | 1991-03-13 | Ciba Geigy Ag | Novel pharmaceutical preparation for topical application |
US4770634A (en) | 1986-06-11 | 1988-09-13 | Pellico Michael A | Method for treating teeth with foamable fluoride compositions |
JPS62299423A (en) | 1986-06-18 | 1987-12-26 | Mazda Motor Corp | Air-conditioner for vehicle |
US4837019A (en) | 1986-08-11 | 1989-06-06 | Charles Of The Ritz Group Ltd. | Skin treatment composition and method for treating burned skin |
US4906453A (en) | 1986-08-12 | 1990-03-06 | Jumpeer Nails, Inc. | Mousse product |
DE3778027D1 (en) | 1986-09-05 | 1992-05-07 | Upjohn Co | SEBUM SOLVING, NOT AQUEOUS MINOXIDIL FORMULATION. |
AU8025787A (en) | 1986-09-12 | 1988-04-07 | Upjohn Company, The | Foams for delivery of minoxidil |
LU86585A1 (en) | 1986-09-15 | 1988-04-05 | Oreal | COMPOSITION IN THE FORM OF AN AEROSOL FOAM BASED ON A POLYMER DERIVED FROM QUATERNIZED CELLULOSE AND ANIONIC POLYMER |
JPH0778019B2 (en) | 1986-11-08 | 1995-08-23 | 久光製薬株式会社 | Foamed anti-inflammatory analgesic preparation |
EP0270316A3 (en) | 1986-12-04 | 1989-12-06 | Pfizer Inc. | Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne |
US4822613A (en) | 1986-12-15 | 1989-04-18 | S. C. Johnson & Son, Inc. | Water-soluble foamable insecticidally-active compositions |
US4822614A (en) | 1986-12-19 | 1989-04-18 | S. C. Johnson & Son, Inc. | Bioactive film-forming composition for control of crawling insects and the like |
US5389677B1 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of treating wrinkles using glycalic acid |
US4863900A (en) | 1987-01-15 | 1989-09-05 | The Research Foundation Of State University Of New York | Method for reducing viral transmission with poly-L-histidine |
JPS63119420U (en) | 1987-01-30 | 1988-08-02 | ||
DE3704907A1 (en) | 1987-02-17 | 1988-08-25 | Bayer Ag | TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS |
US4828837A (en) | 1987-03-30 | 1989-05-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition, its production and application |
US4933330A (en) | 1987-04-01 | 1990-06-12 | Dak-Laboratoriet | Benzoic acid derivatives and use thereof |
LU86839A1 (en) | 1987-04-10 | 1988-12-13 | Oreal | DETERGENT AND FOAMING COSMETIC COMPOSITION, DELAYING RE-LUBRICATION OF HAIR |
WO1988008316A1 (en) | 1987-04-21 | 1988-11-03 | Chattan Nominees Pty. Ltd. | Vaginal douche |
FR2615173B1 (en) | 1987-05-13 | 1989-08-18 | Valois | DOSING VALVE FOR LIQUID LOADED WITH A LIQUID OR LIQUEFIED GAS PROPELLER, FOR USE IN THE REVERSE POSITION |
US4867967A (en) | 1987-06-04 | 1989-09-19 | Crutcher Wilbert L | Method for the treatment of pseudofolliculitis barbae |
US4780309A (en) | 1987-06-16 | 1988-10-25 | Warner-Lambert Company | Edible aerosol foam compositions and method of preparing same |
US4849117A (en) | 1987-06-17 | 1989-07-18 | Sanitek Products, Inc. | Concentrated composition for forming an aqueous foam |
US4885282A (en) | 1987-07-02 | 1989-12-05 | Thornfeldt Carl R | Treatment of hyperhidrosis, ichthyosis and wrinkling |
US5196405A (en) | 1987-07-08 | 1993-03-23 | Norman H. Oskman | Compositions and methods of treating hemorrhoids and wounds |
US4913893A (en) | 1987-08-28 | 1990-04-03 | Clairol Incorporated | Aerosol hair setting composition containing an alginate |
CA1273576A (en) | 1987-09-16 | 1990-09-04 | Patrick A. Beauchamp | Topical treatment for diseased skin disorders |
EP0309353B1 (en) | 1987-09-23 | 1994-07-27 | L'oreal | Aerosol foam skin-treating composition containing petrolatum |
US4784842A (en) | 1987-09-25 | 1988-11-15 | Jean London | Therapeutic composition for treatment of cuts, burns and abrasions |
US4772427A (en) | 1987-12-01 | 1988-09-20 | Colgate-Palmolive Co. | Post-foaming gel shower product |
JPH01100111U (en) | 1987-12-24 | 1989-07-05 | ||
US5143717A (en) | 1987-12-30 | 1992-09-01 | Code Blue Medical Corporation | Burn foam and delivery system |
ATE74003T1 (en) | 1988-01-14 | 1992-04-15 | Akzo Nv | AQUEOUS PHARMACEUTICAL PREPARATION. |
US5536743A (en) | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
JP2643217B2 (en) | 1988-01-22 | 1997-08-20 | エーザイ株式会社 | Aqueous liquid of fat-soluble substance |
US4849211A (en) | 1988-03-16 | 1989-07-18 | Schrauzer Gerhard N | Product and method for the treatment of acne and other skin disorders |
LU87187A1 (en) | 1988-03-31 | 1989-10-26 | Oreal | COMBINATION OF PYRIMIDINE DERIVATIVES AND SALICYLIC ACID DERIVATIVES FOR INDUCING AND STIMULATING HAIR GROWTH AND REDUCING HAIR LOSS |
US4873078A (en) | 1988-04-22 | 1989-10-10 | Plough, Inc. | High-gloss, high-shine lipstick |
GB8811409D0 (en) | 1988-05-13 | 1988-06-15 | Unilever Plc | Cosmetic composition |
GB8813766D0 (en) | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
US4827378A (en) | 1988-06-15 | 1989-05-02 | Rockwell International Corporation | Jack coaxial connector EMI shielding apparatus |
US5217707A (en) | 1988-06-16 | 1993-06-08 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Pharmaceutical composition and process for the preparation thereof |
US4950420A (en) | 1988-08-31 | 1990-08-21 | Nalco Chemical Company | Antifoam/defoamer composition |
US4855294A (en) | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
JPH02191223A (en) | 1988-10-04 | 1990-07-27 | Otsuka Pharmaceut Co Ltd | Iron-supplying preparation |
US5135915A (en) | 1988-10-14 | 1992-08-04 | Genentech, Inc. | Method for the treatment of grafts prior to transplantation using TGF-.beta. |
US5186857A (en) | 1988-11-14 | 1993-02-16 | Imaginative Research Associates, Inc. | Self-foaming oil compositions and process for making and using same |
GB8828013D0 (en) | 1988-12-01 | 1989-01-05 | Unilever Plc | Topical composition |
US4970067A (en) | 1988-12-12 | 1990-11-13 | Helene Curtis, Inc. | Method and composition to condition hair and impart semi-permanent hair set retention properties |
US5262407A (en) | 1988-12-16 | 1993-11-16 | L'oreal | Use of salicylic derivatives for the treatment of skin aging |
FR2640942A1 (en) | 1988-12-23 | 1990-06-29 | Suchard Sa Jacobs | Container of the aerosol type for delivering, in the form of a foam, metered quantities of product, particularly of food product |
DE68913693T3 (en) | 1988-12-27 | 2004-01-22 | Osaka Shipbuilding Co., Ltd. | Aerosol composition. |
JP2960445B2 (en) | 1988-12-28 | 1999-10-06 | 株式会社大阪造船所 | Aerosol composition |
FR2641185B1 (en) | 1988-12-29 | 1991-04-05 | Oreal | SHAVING COMPOSITION FOR THE SKIN BASED ON ACYLOXYALKYL FUNCTIONAL POLYORGANOSILOXANES AND METHOD FOR IMPLEMENTING SAME |
JP2741230B2 (en) | 1989-01-11 | 1998-04-15 | 株式会社コーセー | Foam anhydrous cosmetics |
LU87449A1 (en) | 1989-02-09 | 1990-09-19 | Oreal | PROCESS FOR THE MANUFACTURE OF FOAMS FOR USE IN THE COSMETIC AND PHARMACEUTICAL AREAS AND FOAMS OBTAINED BY THIS PROCESS |
US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
US4996193A (en) | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5019375A (en) | 1989-03-14 | 1991-05-28 | The Procter & Gamble Company | Low residue antiperspirant creams |
JP2903708B2 (en) | 1989-03-17 | 1999-06-14 | 大正製薬株式会社 | Aerosol for external use |
US5221696A (en) | 1989-03-29 | 1993-06-22 | Alcon Laboratories, Inc. | Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs |
ATE123937T1 (en) | 1989-04-05 | 1995-07-15 | Kao Corp | COSMETIC DOUBLE EMULSION COMPOSITION. |
US5204093A (en) | 1989-04-06 | 1993-04-20 | Victor Steven A | Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same |
US5071648A (en) | 1989-04-06 | 1991-12-10 | Merocel Corporation | Polymeric broad-spectrum antimicrobial materials |
US5618798A (en) | 1989-04-20 | 1997-04-08 | Bar-Shalom; Daniel | Use of sucralfate to treat baldness |
US5221534A (en) | 1989-04-26 | 1993-06-22 | Pennzoil Products Company | Health and beauty aid compositions |
US4874794A (en) | 1989-04-28 | 1989-10-17 | Lidak Biopharmaceuticals | Inflammatory disease treatment |
US5322683A (en) | 1989-05-01 | 1994-06-21 | Leonard Mackles | Anhydrous aerosol foam |
US5002540A (en) | 1989-05-22 | 1991-03-26 | Warren Kirschbaum | Intravaginal device and method for delivering a medicament |
GB8911853D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Co2 blown integral skin foams |
CA1337279C (en) | 1989-06-06 | 1995-10-10 | Robert J. Borgman | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
US5208031A (en) | 1989-06-06 | 1993-05-04 | Kelly Patrick D | Sexual lubricants containing zinc as an anti-viral agent |
US5122519A (en) | 1989-06-27 | 1992-06-16 | American Cyanamid Company | Stable, cosmetically acceptable topical gel formulation and method of treatment for acne |
MX21452A (en) | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | PHARMACEUTICAL PREPARATIONS THAT ARE TOPICALLY ADMINISTERED. |
JPH0350289A (en) | 1989-07-17 | 1991-03-04 | Shiseido Co Ltd | Non-emulsion type foam aerosol composition |
US5560859A (en) | 1989-07-26 | 1996-10-01 | Pfizer Inc. | Post foaming gel shaving composition |
CA2042583C (en) | 1989-07-28 | 1995-06-20 | Akira Nakagawa | Foamable aerosol preparation |
JPH0383914A (en) | 1989-08-18 | 1991-04-09 | W R Grace & Co | Drug carrier |
US5219877A (en) | 1989-09-25 | 1993-06-15 | Bristol-Myers Squibb Company | Lauryl alcohol as skin penetration enhancer for topical imidazole agents |
US5439670A (en) | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5508033A (en) | 1989-12-06 | 1996-04-16 | Societe D'engrais Composes Mineraux Et Amendments | Utilization of algae extract for the preparation of pharmaceutical, cosmetic, food or agricultural compositions |
US5295984A (en) | 1989-12-07 | 1994-03-22 | Ultrafem, Inc. | Vaginal discharge collection device and intravaginal drug delivery system |
EP0504301B1 (en) | 1989-12-07 | 2004-03-31 | Instead, Inc. | Method of collecting vaginal discharge |
WO1991008733A1 (en) | 1989-12-20 | 1991-06-27 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
US4966779A (en) | 1989-12-21 | 1990-10-30 | Basf Corporation | Stable, water miscible emulsion comprising a fat-soluble vitamin |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US4963351A (en) | 1989-12-26 | 1990-10-16 | Bhn Associates | Shaving aid |
US5100917A (en) | 1989-12-29 | 1992-03-31 | Merrell Dow Pharmaceuticals Inc. | Novel a-nor-steroid-3-carboxylic acid derivatives |
US5104645A (en) | 1990-02-02 | 1992-04-14 | The Proctor & Gamble Company | Antidandruff shampoo compositions |
SE9000485D0 (en) | 1990-02-09 | 1990-02-09 | Pharmacia Ab | FOAMABLE COMPOSITION FOR PHARMACEUTICAL USE, USE THEREOF AND METHOD OF TREATMENT |
US5164367A (en) | 1990-03-26 | 1992-11-17 | Procyte Corporation | Method of using copper(ii) containing compounds to accelerate wound healing |
US5130121A (en) | 1990-04-17 | 1992-07-14 | Isp Investments Inc. | Skin care compositions containing discrete microdroplets of an oil in water stabilized by in situ polymerization of water-soluble vinyl monomer |
US5007556A (en) | 1990-04-18 | 1991-04-16 | Block Drug Company, Inc. | Metering dispenser |
US5156765A (en) | 1990-05-15 | 1992-10-20 | Fox Valley Systems, Inc. | Aerosol foam marking compositions |
US5112359A (en) | 1990-06-04 | 1992-05-12 | Clairol, Inc. | Hair colorants |
JPH0451958A (en) | 1990-06-18 | 1992-02-20 | Mitsubishi Materials Corp | Treating agent for circulation type toilet filth |
US5034220A (en) | 1990-06-20 | 1991-07-23 | Gaf Chemicals Corporation | Non-aerosol shaving gel |
US5336692A (en) | 1990-06-28 | 1994-08-09 | Medicis Pharmaceutical Corporation | Ointment base and method of use |
IT1243379B (en) | 1990-07-27 | 1994-06-10 | Giuliani Spa | PHARMACEUTICAL COMPOSITION SUITABLE FOR RECTAL ADMINISTRATION OF ACTIVE PRINCIPLES WHICH EXPLICATE A MEDICATION ACTION AT THE LEVEL OF THE COLON, PREVALENTLY TOPICAL |
US5108556A (en) | 1990-09-14 | 1992-04-28 | Minnesota Mining And Manufacturing Company | Process for preparing tertiary perfluoroamines |
US5114718A (en) | 1990-09-20 | 1992-05-19 | The Procter & Gamble Company | Sustained release compositions for treating periodontol disease |
GB9021546D0 (en) | 1990-10-04 | 1990-11-21 | Beecham Group Plc | Novel composition |
US5073371A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
DE9016291U1 (en) | 1990-11-30 | 1991-03-28 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Topically applicable diclofenac preparations |
WO1992011839A1 (en) | 1991-01-08 | 1992-07-23 | Leonard Mackles | Anhydrous aerosol |
AU1411992A (en) | 1991-01-15 | 1992-08-27 | Robert A Bok | A composition containing a tetracycline and use for inhibiting angiogenesis |
US5227163A (en) | 1991-01-18 | 1993-07-13 | Clilco, Ltd. | Lice-repellant compositions |
DE4102506C2 (en) | 1991-01-29 | 1999-11-25 | Pfeiffer Erich Gmbh & Co Kg | Discharge device for media |
WO1992013602A1 (en) | 1991-02-05 | 1992-08-20 | Buil Juergen | Fire extinguishing and protection agent |
US5650554A (en) | 1991-02-22 | 1997-07-22 | Sembiosys Genetics Inc. | Oil-body proteins as carriers of high-value peptides in plants |
US6753167B2 (en) | 1991-02-22 | 2004-06-22 | Sembiosys Genetics Inc. | Preparation of heterologous proteins on oil bodies |
US5948682A (en) | 1991-02-22 | 1999-09-07 | Sembiosys Genetics Inc. | Preparation of heterologous proteins on oil bodies |
US5648380A (en) | 1991-03-01 | 1997-07-15 | Warner-Lambert Company | Anti-inflammatory wound healing compositions and methods for preparing and using same |
US5658956A (en) | 1991-03-01 | 1997-08-19 | Warner-Lambert Company | Bioadhesive-wound healing compositions and methods for preparing and using same |
US5663208A (en) | 1991-03-01 | 1997-09-02 | Warner-Lambert Company | Antifungal wound healing compositions and methods for preparing and using same |
IT1247138B (en) | 1991-03-06 | 1994-12-12 | Dompe Farmaceutici Spa | HYDROPHILE PHARMACEUTICAL COMPOSITION CONTAINING KETOPROFENE LYSINE SALT FOR TOPICAL USE. |
JPH04282311A (en) | 1991-03-08 | 1992-10-07 | Koike Kagaku Kk | Aerosol-type foamable wound-disinfectant |
AU658608B2 (en) | 1991-03-25 | 1995-04-27 | Astellas Pharma Europe B.V. | Topical preparation containing a suspension of solid lipid particles |
US5167950A (en) | 1991-03-28 | 1992-12-01 | S. C. Johnson & Son | High alcohol content aerosol antimicrobial mousse |
DE4110973A1 (en) | 1991-04-05 | 1992-10-08 | Haarmann & Reimer Gmbh | MEDIUM WITH A PHYSIOLOGICAL COOLING EFFECT AND EFFECTIVE COMPOUNDS SUITABLE FOR THIS MEDIUM |
JP3100416B2 (en) | 1991-04-11 | 2000-10-16 | オカモト株式会社 | Moose-like lubricant |
IT1247529B (en) | 1991-04-24 | 1994-12-17 | Poli Ind Chimica Spa | PHARMACEUTICAL COMPOSITIONS IN FOAM FORM FOR INTRAVAGINAL, SKIN AND ORAL ADMINISTRATION |
US5204090A (en) | 1991-05-30 | 1993-04-20 | Bristol Myers Squibb | Waterproof high-SPF sunscreen compositions |
US5164357A (en) | 1991-06-05 | 1992-11-17 | Appleton Papers Inc. | Thermally-responsive record material |
FR2677544B1 (en) | 1991-06-14 | 1993-09-24 | Oreal | COSMETIC COMPOSITION CONTAINING A MIXTURE OF NANOPIGMENTS OF METAL OXIDES AND MELANIC PIGMENTS. |
US5221530A (en) | 1991-06-24 | 1993-06-22 | Helene Curtis, Inc. | Mild conditioning shampoo with a high foam level containing an anionic surfactant-cationic acrylate/acrylamide copolymer conditioning agent |
DE4210165A1 (en) | 1991-07-30 | 1993-02-04 | Schering Ag | TRANSDERMAL THERAPEUTIC SYSTEMS |
GB9118028D0 (en) | 1991-08-21 | 1991-10-09 | Secr Defence Brit | Improved transdrmal formulations |
DE4127630A1 (en) | 1991-08-21 | 1993-02-25 | Bruno Jesswein | TWO-COMPONENT PRESSURE CAN, IN PARTICULAR FOR 2K FOAM |
JP2969398B2 (en) | 1991-09-12 | 1999-11-02 | 花王株式会社 | Anhydrous foam cleaning agent |
US5643600A (en) | 1991-09-17 | 1997-07-01 | Micro-Pak, Inc. | Lipid vesicles containing avocado oil unsaponifiables |
EP0564656B1 (en) | 1991-09-27 | 1999-02-03 | Nof Corporation | Cosmetic composition and emulsion composition |
GB2260079B (en) | 1991-10-01 | 1995-08-09 | American Cyanamid Co | Pharmaceutical composition containing felbinac |
US5230897A (en) | 1991-10-31 | 1993-07-27 | G. D. Searle & Co. | Transdermal pentamidine |
US5236707A (en) | 1991-11-08 | 1993-08-17 | Dallas Biotherapeutics, Inc. | Stabilization of human interferon |
EP0613369A1 (en) | 1991-11-22 | 1994-09-07 | Richardson-Vicks, Inc. | Combined personal cleansing and moisturizing compositions |
DE4140474C2 (en) | 1991-12-09 | 1995-07-13 | Schuelke & Mayr Gmbh | Skincare additive |
US5294365A (en) | 1991-12-12 | 1994-03-15 | Basf Corporation | Hydroxypolyethers as low-foam surfactants |
IT1253711B (en) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | VAGINAL PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS |
US5252246A (en) | 1992-01-10 | 1993-10-12 | Allergan, Inc. | Nonirritating nonionic surfactant compositions |
EP0552612A3 (en) | 1992-01-22 | 1993-10-20 | Hoffmann La Roche | Methods for determining and isolating compounds which bind directly to nucleosolic proteins |
JP3146052B2 (en) | 1992-01-31 | 2001-03-12 | プレスコ株式会社 | Aerosol massage agent |
US5318774A (en) | 1992-02-28 | 1994-06-07 | Richardson-Vicks Inc. | Composition and method for imparting an artificial tan to human skin |
DE69332538T2 (en) | 1992-04-02 | 2003-11-06 | Sembiosys Genetics, Inc. | CIS ELEMENTS OF OIL BODY PROTEIN AS REGULATIONAL SIGNALS |
US5344051A (en) | 1992-04-27 | 1994-09-06 | Insta-Foam Products, Inc. | Two-component foam dispensing apparatus |
ZA932947B (en) | 1992-04-28 | 1993-10-27 | Schering Plough Healthcare | Applicator for semisolid medications |
US5254334A (en) | 1992-05-04 | 1993-10-19 | Imaginative Research Associates, Inc. | Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin amd emollients such as oils and esters |
US5409706A (en) | 1992-05-04 | 1995-04-25 | Imaginative Research Associates, Inc. | Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin and emollients such as oils and esters |
IL105595A0 (en) | 1992-05-15 | 1993-09-22 | Akzo Nv | Applicator for introducing a cream-type substance into a woman's vagina |
WO1993023005A1 (en) | 1992-05-18 | 1993-11-25 | The Procter & Gamble Company | Coolant compositions |
US5389305A (en) | 1992-06-03 | 1995-02-14 | Colgate Palmolive Co. | High foaming nonionic surfactant base liquid detergent |
DK0644746T3 (en) | 1992-06-11 | 1999-12-20 | Theratech Inc | Use of glycerine to moderate transdermal drug delivery |
US5346135A (en) | 1992-06-16 | 1994-09-13 | Vincent Edward C | Spraying apparatus for blending liquids in a gaseous spray system |
US5300286A (en) | 1992-07-14 | 1994-04-05 | Dow Corning Corporation | Silicone emulsion for personal care application |
KR950702436A (en) | 1992-07-28 | 1995-07-29 | 자코부스 코르넬리스 라세르 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER |
CA2105887C (en) | 1992-09-10 | 2004-03-16 | Peter Britton | Bioerodible device for administering active ingredients |
CA2144509C (en) | 1992-09-14 | 1999-05-18 | Walter P. Smith | Skin-conditioning composition, its application and manufacture |
JPH06100414A (en) | 1992-09-18 | 1994-04-12 | Osaka Aerosol Ind Corp | Composition for aerosol |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5413775A (en) | 1992-09-29 | 1995-05-09 | Amerchol Corporation | Hairsprays and acrylic polymer compositions for use therein |
US5527534A (en) | 1992-10-21 | 1996-06-18 | Gynetech Laboratories, Ltd. | Vaginal sponge delivery system |
ES2114993T3 (en) | 1992-10-31 | 1998-06-16 | Goldschmidt Ag Th | COSMETIC OR PHARMACEUTICAL PREPARATIONS. |
DE4238860A1 (en) | 1992-11-19 | 1994-05-26 | Medicon Gmbh | Skin protection products for the protection of human skin |
US5308643A (en) | 1992-11-30 | 1994-05-03 | Osipow Lloyd I | Self-lather generating shaving compositions |
JP3328344B2 (en) | 1992-12-22 | 2002-09-24 | タイホー工業株式会社 | Method of controlling foaming state retention time of foaming type cleaning polishes |
JPH06263630A (en) | 1993-03-10 | 1994-09-20 | Lion Corp | Vitamin as-solubilizing eye drop |
JPH06279228A (en) | 1993-03-30 | 1994-10-04 | Kao Corp | Foaming composition |
US5326557A (en) | 1993-04-06 | 1994-07-05 | Dow Corning Corporation | Moisturizing compositions containing organosilicon compounds |
US5807571A (en) | 1993-05-06 | 1998-09-15 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic systems for administering indole serotonin agonists |
US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
PT698393E (en) | 1993-05-19 | 2002-10-31 | Hisamitsu Pharmaceutical Co | SOLUBILIZATION AGENT AND PREPARATION FOR EXTERNAL USE CONTAINING THE SAME |
CA2161431A1 (en) | 1993-05-21 | 1994-12-08 | Barry A. Salka | Mild shampoo composition |
JP3161869B2 (en) | 1993-05-24 | 2001-04-25 | 株式会社ダイゾー | Water-in-oil aerosol composition and process for producing the same |
US5635469A (en) | 1993-06-10 | 1997-06-03 | The Procter & Gamble Company | Foaming cleansing products |
US5447725A (en) | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
US5398846A (en) | 1993-08-20 | 1995-03-21 | S. C. Johnson & Son, Inc. | Assembly for simultaneous dispensing of multiple fluids |
US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
FR2709666B1 (en) | 1993-09-07 | 1995-10-13 | Oreal | Cosmetic or dermatological composition consisting of an oil-in-water emulsion based on oily globules provided with a lamellar liquid crystal coating. |
JP2978043B2 (en) | 1993-09-16 | 1999-11-15 | 高砂香料工業株式会社 | (2S) -3-{(1R, 2S, 5R)-[5-methyl-2- (1-methylethyl) cyclohexyl] oxy} -1,2-propanediol, its production method and use |
US5766632A (en) | 1993-10-01 | 1998-06-16 | Legere Pharmaceuticals, Ltd. | Method of using lectins for contraception |
US5578315A (en) | 1993-12-01 | 1996-11-26 | Rutgers, The State University Of New Jersey | Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity |
FR2713486B1 (en) | 1993-12-14 | 1996-02-09 | Scophysa | New compositions for foams, in particular rectal foams, and foams thus obtained. |
WO1995017175A1 (en) | 1993-12-23 | 1995-06-29 | The Procter & Gamble Company | Antimicrobial wipe compositions |
US5527822A (en) | 1993-12-29 | 1996-06-18 | Forest Laboratories, Inc. | Method of treatment of traumatic brain injury |
DE9422052U1 (en) | 1994-01-04 | 1997-10-30 | Adolf Würth GmbH & Co. KG, 74653 Künzelsau | Filling device for filling a refillable dispensing container and refillable dispensing container |
JP3530564B2 (en) | 1994-02-03 | 2004-05-24 | 株式会社ノエビア | Aerosol foam cosmetics |
DE4405127A1 (en) | 1994-02-18 | 1995-08-31 | Henkel Kgaa | Hair treatment products |
US5514367A (en) | 1994-02-28 | 1996-05-07 | Estee Lauder, Inc. | Skin tanning compositions and methods for their preparation and use |
US5925669A (en) | 1994-03-22 | 1999-07-20 | Molecular/Structural Bio Technologies, Inc. | Carrier compositions for anti-neoplastic drugs |
IL109230A (en) | 1994-04-05 | 1998-08-16 | Agis Ind 1983 Ltd | Anti-fungal composition containing bifonazole and fluocinonide |
US5658749A (en) | 1994-04-05 | 1997-08-19 | Corning Clinical Laboratories, Inc. | Method for processing mycobacteria |
US5429815A (en) | 1994-04-11 | 1995-07-04 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Stable single-phase self-foaming cleanser |
FR2719467B1 (en) | 1994-05-05 | 1996-05-31 | Oreal | Use of flavonoids to preserve and / or strengthen the mechanical properties of the hair and method of protecting hair using these compounds. |
US5902574A (en) | 1994-05-23 | 1999-05-11 | The Gillette Company | Shaving preparation for improved shaving comfort |
US5545401A (en) | 1994-06-02 | 1996-08-13 | Shanbrom; Edward | Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine |
US6221381B1 (en) | 1994-06-28 | 2001-04-24 | The University Of British Columbia | Enhancing milk production by adding to feed a nonionic surfactant coated on a carrier |
MA23592A1 (en) | 1994-06-30 | 1995-12-31 | Procter & Gamble | COMPOSITIONS FOR BODY CARE CONTAINING THERMOPLASTIC ELASTOMERIC GRAFT COPOLYMERS |
US5679324A (en) | 1994-07-08 | 1997-10-21 | The Procter & Gamble Co. | Aerosol foamable fragrance composition |
FR2722431B1 (en) | 1994-07-12 | 1996-09-13 | Lir France Sa | DOUBLE DISPENSER FOR FLUID PRODUCTS |
US5444092A (en) * | 1994-07-20 | 1995-08-22 | Collins; Jerry | Method and composition for treating psoriasis |
JP3173330B2 (en) | 1994-07-20 | 2001-06-04 | トヨタ自動車株式会社 | Slip control device for vehicle lock-up clutch |
GB9414699D0 (en) | 1994-07-21 | 1994-09-07 | Slagel David | Aqueous foamable composition |
US5512555A (en) | 1994-07-21 | 1996-04-30 | Merck & Co., Inc. | Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one |
JP3241542B2 (en) | 1994-07-29 | 2001-12-25 | 高砂香料工業株式会社 | Method for purifying (-)-n-isopulegol and citrus-based fragrance composition containing (-)-n-isopulegol obtained by the method |
JPH0840899A (en) | 1994-07-29 | 1996-02-13 | Tokyo Tanabe Co Ltd | Aerosol of oxyconazone nitrate |
DE4428096A1 (en) | 1994-08-09 | 1996-02-15 | Wella Ag | Two-chamber container |
US5547989A (en) | 1994-08-19 | 1996-08-20 | Schering-Plough Healthcare Products, Inc. | Compositions for treating corns and calluses |
US5656586A (en) | 1994-08-19 | 1997-08-12 | Rhone-Poulenc Inc. | Amphoteric surfactants having multiple hydrophobic and hydrophilic groups |
WO1996006595A1 (en) | 1994-08-26 | 1996-03-07 | The Procter & Gamble Company | Personal cleansing compositions |
JP3558393B2 (en) | 1994-08-29 | 2004-08-25 | 株式会社ダイゾー | Foamable aerosol composition |
TW460296B (en) | 1994-09-01 | 2001-10-21 | Janssen Pharmaceutica Nv | Topical ketoconazole emulsion compositions without sodium sulfite |
US5976555A (en) | 1994-09-07 | 1999-11-02 | Johnson & Johnson Consumer Products, Inc. | Topical oil-in-water emulsions containing retinoids |
JP3604177B2 (en) | 1994-09-14 | 2004-12-22 | 日東電工株式会社 | Transdermal formulation |
US5500211A (en) | 1994-09-22 | 1996-03-19 | The Gillette Company | Soap-free self-foaming shave gel composition |
US5905092A (en) | 1994-09-27 | 1999-05-18 | Virotex Corporation Reel/Frame | Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction |
US5955414A (en) | 1994-10-05 | 1999-09-21 | S. C. Johnson & Son, Inc. | Cleaning foam having fluorinated stain repellent and low flammability |
US5540853A (en) | 1994-10-20 | 1996-07-30 | The Procter & Gamble Company | Personal treatment compositions and/or cosmetic compositions containing enduring perfume |
CA2180454A1 (en) | 1994-11-08 | 1996-05-17 | Toshihiko Terao | External preparation for skin protection |
US5567420A (en) | 1994-11-16 | 1996-10-22 | Mceleney; John | Lotion which is temporarily colored upon application |
US5788664A (en) | 1994-11-30 | 1998-08-04 | Scalise; Gaspare | Suppository applicator |
GB9424562D0 (en) | 1994-12-06 | 1995-01-25 | Giltech Ltd | Product |
US5641480A (en) | 1994-12-08 | 1997-06-24 | Lever Brothers Company, Division Of Conopco, Inc. | Hair care compositions comprising heteroatom containing alkyl aldonamide compounds |
JP3355257B2 (en) | 1994-12-09 | 2002-12-09 | 太陽化学株式会社 | Cosmetics |
US5529770A (en) | 1994-12-09 | 1996-06-25 | West Agro, Inc. | Viscous liquid conditioning topical germicides |
DE4444238A1 (en) | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides |
FR2728166A1 (en) | 1994-12-19 | 1996-06-21 | Oreal | TOPICAL COMPOSITION CONTAINING AN ANTAGONIST OF SUBSTANCE P |
BR9510478A (en) | 1994-12-21 | 1998-12-15 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
WO1996019921A1 (en) | 1994-12-23 | 1996-07-04 | Commonwealth Scientific And Industrial Research Organisation | Iodine biocidal material |
DE4446891A1 (en) | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stable aqueous budesonide solution |
US5534261A (en) | 1995-01-17 | 1996-07-09 | University Of Southern California | Retinoid-based compositions and method for preventing adhesion formation using the same |
FR2729855A1 (en) | 1995-01-26 | 1996-08-02 | Oreal | USE OF A CGRP ANTAGONIST IN A COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION AND COMPOSITION OBTAINED |
US5523078A (en) | 1995-02-03 | 1996-06-04 | Michael E. Baylin | Method of preparing and composition for treatment of hair and scalp |
US5587149A (en) | 1995-02-06 | 1996-12-24 | R.P. Scherer Corporation | Topical application emulsions |
FR2730932B1 (en) | 1995-02-27 | 1997-04-04 | Oreal | TRANSPARENT NANOEMULSION BASED ON FLUID NON-IONIC AMPHIPHILIC LIPIDS AND USE IN COSMETICS OR DERMOPHARMACY |
FR2730930B1 (en) | 1995-02-27 | 1997-04-04 | Oreal | USE OF NO-SYNTHASE INHIBITORS TO REDUCE THE IRRITANT SKIN EFFECT OF PRODUCTS USED IN THE COSMETIC OR PHARMACEUTICAL FIELD |
GB9504265D0 (en) | 1995-03-03 | 1995-04-19 | Medeva Plc | Corticosteroid-containing pharmaceutical composition |
US5558872A (en) | 1995-03-07 | 1996-09-24 | Healthpoint Medical Limited Partnership | Gelled mineral oil skin protectant |
US5618850A (en) | 1995-03-09 | 1997-04-08 | Focal, Inc. | Hydroxy-acid cosmetics |
US5783202A (en) | 1995-03-14 | 1998-07-21 | Soltec Research Pty. Ltd. | Pediculicidal mousse composition for killing head lice |
EP0818195B1 (en) | 1995-03-29 | 2003-11-26 | Shionogi & Co., Ltd. | Gelatin capsule with adjusted water activity |
JPH08277209A (en) | 1995-04-07 | 1996-10-22 | Taisho Pharmaceut Co Ltd | Revitalizing hair tonic |
US5585104A (en) | 1995-04-12 | 1996-12-17 | The Procter & Gamble Company | Cleansing emulsions |
EP0738510A3 (en) | 1995-04-20 | 2005-12-21 | L'oreal | Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties. |
FR2733417B1 (en) | 1995-04-25 | 1997-06-06 | Oreal | FOAMING OIL-IN-WATER EMULSION BASED ON NON-IONIC SURFACTANTS, A FATTY PHASE AND A CATIONIC OR ANIONIC POLYMER CROSS-LINKED AND USE IN TOPICAL APPLICATION |
GB9510856D0 (en) | 1995-05-27 | 1995-07-19 | Cussons Int Ltd | Cleaning composition |
UY24246A1 (en) | 1995-06-06 | 1996-06-14 | Neutrogena Corp | TROPIC VEHICLES CONTAINING SOLUBILIZED AND STABILIZED AZELAIC ACID |
EP0833605A1 (en) | 1995-06-22 | 1998-04-08 | Minnesota Mining And Manufacturing Company | Stable hydroalcoholic compositions |
JP3542665B2 (en) | 1995-07-07 | 2004-07-14 | 株式会社資生堂 | Anti-aging skin external preparation, collagen cross-linking inhibition skin external preparation and anti-ultraviolet skin external preparation |
US5705472A (en) | 1995-07-18 | 1998-01-06 | Petroferm Inc. | Neutral aqueous cleaning composition |
FR2736824B1 (en) | 1995-07-18 | 1997-10-10 | Fabre Pierre Dermo Cosmetique | MINOXIDIL HAIR COMPOSITION WITH LOW FAT SOLVENT CONTENT |
DE29512760U1 (en) | 1995-08-08 | 1995-11-16 | Wella Ag, 64295 Darmstadt | Pressurized gas container for dispensing foam |
TW504387B (en) | 1995-09-06 | 2002-10-01 | Kao Corp | Emulsified, water-in-oil type composition and skin cosmetic preparation |
CN1062129C (en) | 1995-09-14 | 2001-02-21 | 徐荣祥 | Medicine matrix and its use |
US5881493A (en) | 1995-09-14 | 1999-03-16 | D. B. Smith & Co. Inc. | Methods for applying foam |
JPH0984855A (en) | 1995-09-25 | 1997-03-31 | Kyoto Yakuhin Kogyo Kk | Aerosol preparation for administer medicine to rectum or vagina |
JPH0999553A (en) | 1995-10-09 | 1997-04-15 | Fujitsu Ltd | Ink jet head |
JP3425019B2 (en) | 1995-10-16 | 2003-07-07 | カネボウ株式会社 | Oily foam cleansing cosmetic |
US6221823B1 (en) | 1995-10-25 | 2001-04-24 | Reckitt Benckiser Inc. | Germicidal, acidic hard surface cleaning compositions |
US6133327A (en) | 1995-12-14 | 2000-10-17 | Taisho Pharmaceutical Co., Ltd. | Aerosol preparation |
FR2742986B1 (en) | 1995-12-29 | 1998-01-30 | Rhone Poulenc Chimie | COSMETIC COMPOSITIONS FOR THE HAIR OR THE SKIN BASED ON SULPHONATED COPOLYESTERS WITH POLYORGANOSILOXANE MOTIFS |
US5889028A (en) | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5843411A (en) | 1997-02-06 | 1998-12-01 | Topix Pharmaceuticals Inc. | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5759524A (en) | 1996-02-09 | 1998-06-02 | The Procter & Gamble Company | Photoprotective compositions |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5912007A (en) | 1996-02-29 | 1999-06-15 | Warner-Lambert Company | Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same |
US6251369B1 (en) | 1996-03-05 | 2001-06-26 | Sultan Dental Products | Dental fluoride foam |
FR2745716B1 (en) | 1996-03-07 | 1998-04-17 | Oreal | ULTRAFINE PRESSURIZABLE FOAMING OIL-IN-WATER EMULSIONS |
US6251941B1 (en) | 1996-04-19 | 2001-06-26 | Sloan-Kettering Institute For Cancer Research | Use of inhaled retinoids in the prevention of cancer |
US5910382A (en) | 1996-04-23 | 1999-06-08 | Board Of Regents, University Of Texas Systems | Cathode materials for secondary (rechargeable) lithium batteries |
IT1283042B1 (en) | 1996-05-21 | 1998-04-07 | Condea Augusta Spa | COSMETIC COMPOUNDS DEODORANT AND / OR ANTI-BREATHING |
US5797955A (en) | 1996-06-11 | 1998-08-25 | Walters; David J. | Pressure application unit for positioning vertebra |
US5833961A (en) | 1996-06-25 | 1998-11-10 | Inolex Investment Corporation | Polyester-based suncreen formulations |
EP0932401A1 (en) | 1996-07-01 | 1999-08-04 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
DE69715444T2 (en) | 1996-07-10 | 2003-04-30 | Steris Inc. (N.D.Ges.D. Staates Delaware), Temecula | TRICLOSAN CONTAINING SKIN CLEANSING AGENTS WITH IMPROVED EFFECTIVENESS |
DE19631221C2 (en) | 1996-08-02 | 1999-07-01 | Beiersdorf Ag | Foam-form sunscreen preparations containing water-soluble sunscreen filter substances and surface-active substances |
US6042848A (en) | 1996-08-15 | 2000-03-28 | The Board Of Trustees Of Southern Illinois University | Enhancement of antimicrobial peptide activity by metal ions |
US5833963A (en) | 1996-08-20 | 1998-11-10 | Bristol-Myers Squibb Company | Non-tacky and quick-drying aqueous-based antiperspirant compositions |
US5837270A (en) | 1996-08-26 | 1998-11-17 | Burgess; Nelson Leon | Topical anti-acne composition |
US5741509A (en) | 1996-08-26 | 1998-04-21 | Alvin S. Berlat | Silicone wound dressing |
EP0829259A1 (en) | 1996-09-04 | 1998-03-18 | Warner-Lambert Company | Foam/gel with microbeads and/or fine particles |
US6271295B1 (en) | 1996-09-05 | 2001-08-07 | General Electric Company | Emulsions of silicones with non-aqueous hydroxylic solvents |
US5952392A (en) | 1996-09-17 | 1999-09-14 | Avanir Pharmaceuticals | Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition |
US7060253B1 (en) | 1996-09-20 | 2006-06-13 | Mundschenk David D | Topical formulations and delivery systems |
FR2754451B1 (en) | 1996-10-14 | 1998-11-06 | Oreal | SELF-FOAMING CREAM |
AU4995597A (en) | 1996-10-23 | 1998-05-15 | Vertex Pharmaceuticals Incorporated | Methods of using sucrose octasulfate to treat or prevent enveloped virus infection |
US6093408A (en) | 1996-10-25 | 2000-07-25 | The Procter & Gamble Company | Skin care compositions |
IT1287114B1 (en) | 1996-10-31 | 1998-08-04 | Recordati Chem Pharm | ANTI-HERPETIC PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATORS, CONTAINING ACICLOVIR |
JP2986552B2 (en) | 1996-11-04 | 1999-12-06 | ザ、プロクター、エンド、ギャンブル、カンパニー | Hair mousse composition containing silicone emulsion |
FR2755854B1 (en) | 1996-11-15 | 1998-12-24 | Oreal | NANOEMULSION BASED ON NON-IONIC AND CATIONIC AMPHIPHILIC LIPIDS AND USES |
US5906992A (en) | 1996-11-21 | 1999-05-25 | Colgate Palmolive Company | Foam cleaning compositions |
AUPO379596A0 (en) | 1996-11-22 | 1996-12-19 | Soltec Research Pty Ltd | Percutaneous delivery system |
US5951544A (en) | 1996-12-04 | 1999-09-14 | Laser Industries Ltd. | Handpiece assembly for laser apparatus |
US5759579A (en) | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
US5695551A (en) | 1996-12-09 | 1997-12-09 | Dow Corning Corporation | Water repellent composition |
US5672634A (en) | 1996-12-23 | 1997-09-30 | Isp Investments Inc. | Crosslinked PVP-I2 foam product |
US5879469A (en) | 1997-01-06 | 1999-03-09 | Deeay Technologies Ltd. | Dishwashing method and detergent composition therefor |
US6582711B1 (en) | 1997-01-09 | 2003-06-24 | 3M Innovative Properties Company | Hydroalcoholic compositions thickened using polymers |
SE520811C2 (en) | 1997-01-17 | 2003-08-26 | Ponsus Ab | Skin protection preparations containing lipophilic and hydrophilic components, method of preparation and use thereof |
ES2133090B1 (en) | 1997-02-21 | 2000-04-01 | Uriach & Cia Sa J | NEW APPLICATOR FOR THE ADMINISTRATION OF SEMI-SOLID MEDICATIONS. |
AP9901641A0 (en) | 1997-02-11 | 1999-09-30 | Bernard Salafsky | Anti-parasitic action of N,N-Diethyl-m-toluamide (DEET) and formulations that prolong its activity in the skin. |
EP1250927A3 (en) | 1997-02-24 | 2003-03-26 | S.L.A. Pharma AG | Pharmaceutical composition for topical application comprising nifedipine |
JP3050289B2 (en) | 1997-02-26 | 2000-06-12 | 日本電気株式会社 | Output impedance adjustment circuit of output buffer circuit |
US6433068B1 (en) | 1997-03-07 | 2002-08-13 | David S. Morrison | Hydrocarbon gels as suspending and dispersing agents and products |
FR2760637B1 (en) * | 1997-03-11 | 1999-05-28 | Fabre Pierre Dermo Cosmetique | COAL TAR EXTRACT WITH REDUCED AROMATIC HYDROCARBON CONTENT, PROCESS FOR OBTAINING AND DERMO-COSMETIC PREPARATIONS |
US5922331A (en) | 1997-03-26 | 1999-07-13 | Chanel, Inc. | Skin cream composition |
US5951989A (en) | 1997-04-07 | 1999-09-14 | Heymann; Warren R. | Method for the treatment of dry skin |
USH2043H1 (en) | 1997-05-23 | 2002-08-06 | The Procter & Gamble Company | Skin care compositions |
US6183762B1 (en) | 1997-05-27 | 2001-02-06 | Sembiosys Genetics Inc. | Oil body based personal care products |
DK0986309T3 (en) | 1997-05-27 | 2008-06-09 | Sembiosys Genetics Inc | Use of oil bodies |
US6372234B1 (en) | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US6599513B2 (en) | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US6217887B1 (en) | 1997-06-04 | 2001-04-17 | The Procter & Gamble Company | Leave-on antimicrobial compositions which provide improved immediate germ reduction |
JP3113610B2 (en) | 1997-06-04 | 2000-12-04 | 東洋ガスメーター株式会社 | Mounting fixture for transmission equipment for gas meters |
EP0884045A1 (en) | 1997-06-06 | 1998-12-16 | Pfizer Products Inc. | Self-tanning dihydroxyacetone formulations having improved stability and providing enhanced delivery |
US20050276836A1 (en) | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
WO1998056350A1 (en) | 1997-06-13 | 1998-12-17 | Taisho Pharmaceutical Co., Ltd. | Aerosols |
FR2765799B1 (en) | 1997-07-08 | 1999-08-27 | Oreal | GLOSSY COMPOSITION CONTAINING AROMATIC OILS THICKENED BY A POLYSACCHARIDE ALKYLETHER |
SE9703226D0 (en) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
US5885581A (en) | 1997-09-11 | 1999-03-23 | Merz, Incorporated | Composition and method for improvement of the appearance of scars |
US5939376A (en) | 1997-09-25 | 1999-08-17 | Colgate Palmolive Company | Liquid cleaning compositions containing an organic ester foam control agent |
US6241971B1 (en) | 1997-09-25 | 2001-06-05 | The Procter & Gamble Company | Hair styling compositions comprising mineral salt, lipophilic material, and low levels of surfactant |
US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
FR2769299B1 (en) | 1997-10-03 | 1999-12-31 | Oreal | BI-PRODUCTS PACKAGING AND DISTRIBUTION SET |
AUPO983897A0 (en) | 1997-10-17 | 1997-11-06 | Soltec Research Pty Ltd | Topical antifungal composition |
US5961957A (en) | 1997-10-20 | 1999-10-05 | Mcanalley; Bill H. | Foam compositions |
US5911981A (en) | 1997-10-24 | 1999-06-15 | R.I.T.A. Corporation | Surfactant blends for generating a stable wet foam |
US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
WO1999021562A1 (en) | 1997-10-28 | 1999-05-06 | Asivi, Llc | Treatment of female sexual dysfunction |
JP3450680B2 (en) | 1997-10-28 | 2003-09-29 | 高砂香料工業株式会社 | Method for producing para-menthane-3,8-diol |
IL136042A (en) | 1997-11-10 | 2005-12-18 | Cellegy Pharma Inc | Alcohol-containing composition for topical application |
DE29720316U1 (en) | 1997-11-17 | 1998-01-29 | Raimund Andris Gmbh & Co Kg, 78052 Villingen-Schwenningen | Two-chamber dispenser |
US5849042A (en) | 1997-11-19 | 1998-12-15 | Bristol-Myers Squibb | Hair dye compositions containing 2,3 dialkyl-4-aminophenol and a 2-alkyl-1-naphthol |
EP1049486A4 (en) | 1997-12-05 | 2006-01-04 | Lilly Co Eli | Glp-1 formulations |
TWI225793B (en) | 1997-12-25 | 2005-01-01 | Ajinomoto Kk | Cosmetic composition |
DE19802206A1 (en) | 1998-01-22 | 1999-07-29 | Beiersdorf Ag | Stable cosmetic or dermatological composition with low viscosity |
FR2774595A1 (en) | 1998-02-06 | 1999-08-13 | Rech D Innovation Et De Dev Ce | EMULSION FOR TRANSDERMAL STEROID ADMINISTRATION |
DE19805918A1 (en) | 1998-02-13 | 1999-08-19 | Beiersdorf Ag | Lipidreduced preparations |
US6110966A (en) | 1998-02-20 | 2000-08-29 | Medi-Cell Laboratories, Inc. | Triple action complex |
JP3514105B2 (en) | 1998-02-27 | 2004-03-31 | ティアック株式会社 | Recording medium recording / reproducing device |
US6017912A (en) | 1998-02-27 | 2000-01-25 | Bussell; Letantia | Topical fluoroquinolone antibiotics in an alcohol and acetone vehicle |
DE69926843T2 (en) | 1998-03-04 | 2006-06-22 | Teijin Ltd. | ACTIVE VITAMIN D3 CONTAINING LOTIONS IN THE FORM OF EMULSIONS |
US6121210A (en) | 1998-03-12 | 2000-09-19 | Dap Products Inc. | Foamable silicone oil compositions and methods of use thereof |
AU3276499A (en) | 1998-03-12 | 1999-09-27 | Oji Paper Co. Ltd. | Bactericides |
US5990100A (en) | 1998-03-24 | 1999-11-23 | Panda Pharmaceuticals, L.L.C. | Composition and method for treatment of psoriasis |
AUPP310798A0 (en) | 1998-04-22 | 1998-05-14 | Soltec Research Pty Ltd | Vehicle system for a composition comprising a piperidinopyrimidine derivative |
US5919830A (en) | 1998-04-30 | 1999-07-06 | Gopalkrishnan; Sridhar | Stable non-aqueous blends for personal care compositions |
US6649175B1 (en) | 1998-05-04 | 2003-11-18 | Schering-Plough Healthcare Products, Inc. | Skin barrier composition |
GB9810949D0 (en) | 1998-05-22 | 1998-07-22 | Hewlett Healthcare Limited | Formulation |
FR2779637B1 (en) | 1998-06-15 | 2000-09-01 | Oreal | PHOTOPROTECTIVE COSMETIC COMPOSITIONS CONTAINING A METAL OXIDE NANOPIGMENT AND AN ACRYLIC TERPOLYMER AND USE OF SUCH COMPOSITIONS FOR PROTECTING KERATINIC MATERIALS FROM ULTRAVIOLET RADIATION |
US6706290B1 (en) | 1998-07-06 | 2004-03-16 | Olvai E. Kajander | Methods for eradication of nanobacteria |
FR2780879B1 (en) | 1998-07-09 | 2002-09-20 | Oreal | PHOTOPROTECTOR COSMETIC COMPOSITION CONTAINING AN ANIONIC SURFACTANT, COMPOUND FILTERING ULTRAVIOLET RADIATION AND CATIONIC OR ZPHITTERIONIC AMPHIPHILIC COMPOUND AND USE THEREOF |
US6146664A (en) | 1998-07-10 | 2000-11-14 | Shaklee Corporation | Stable topical ascorbic acid compositions |
US6124362A (en) | 1998-07-17 | 2000-09-26 | The Procter & Gamble Company | Method for regulating hair growth |
US6071541A (en) | 1998-07-31 | 2000-06-06 | Murad; Howard | Pharmaceutical compositions and methods for managing skin conditions |
DE19835239A1 (en) | 1998-08-04 | 2000-02-24 | Johnson & Johnson Gmbh | Foaming oil preparation and its use |
JP4017758B2 (en) | 1998-08-04 | 2007-12-05 | 高砂香料工業株式会社 | Cooling agent composition |
GB9817817D0 (en) | 1998-08-14 | 1998-10-14 | Unilever Plc | Cosmetic composition |
CN1198603C (en) | 1998-08-20 | 2005-04-27 | 3M创新有限公司 | Spray on bandage and drug delivery system |
JP3712868B2 (en) | 1998-09-02 | 2005-11-02 | 株式会社カネボウ化粧品 | Aerosol composition |
AUPP583198A0 (en) | 1998-09-11 | 1998-10-01 | Soltec Research Pty Ltd | Mousse composition |
US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US6087310A (en) | 1998-09-23 | 2000-07-11 | Castrol Limited | Skin cleaning compositions and uses comprising a polymer latex emulsion |
JP2002525298A (en) | 1998-09-28 | 2002-08-13 | メルク エンド カムパニー インコーポレーテッド | Treatment of inflammatory diseases by administration of thrombin inhibitors |
US6914057B1 (en) | 1998-09-28 | 2005-07-05 | The Research Foundation Of State University Of New York | Inhibitor of cataract formation |
US6607716B1 (en) | 1998-09-29 | 2003-08-19 | Tech Labs, Inc. | Pediculicidal compositions, a kit, and methods of use |
RU2134052C1 (en) | 1998-10-07 | 1999-08-10 | Нерушай Сергей Алексеевич | Method and apparatus for aerosol application of perfumery liquids |
US6287546B1 (en) | 1998-10-09 | 2001-09-11 | Colgate-Palmolive Company | Shampoos with stabilizers |
JP3876081B2 (en) | 1998-10-22 | 2007-01-31 | 東洋エアゾール工業株式会社 | Aerosol composition for foam formation |
US6110477A (en) | 1998-10-30 | 2000-08-29 | Topix Pharmaceuticals Inc. | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US5980904A (en) | 1998-11-18 | 1999-11-09 | Amway Corporation | Skin whitening composition containing bearberry extract and a reducing agent |
US6344218B1 (en) | 1998-11-23 | 2002-02-05 | The Procter & Gamble Company | Skin deodorizing and santizing compositions |
DE19855097A1 (en) | 1998-11-28 | 2000-05-31 | Wella Ag | Pigment-containing, foamable gel |
US20010006654A1 (en) | 1998-12-09 | 2001-07-05 | L'oreal | Compositions and methods for treating hair and skin using aqueous delivery systems |
US6087317A (en) | 1998-12-10 | 2000-07-11 | Dow Corning Corporation | Particle size stable silicone emulsions |
US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6262128B1 (en) | 1998-12-16 | 2001-07-17 | 3M Innovative Properties Company | Aqueous foaming compositions, foam compositions, and preparation of foam compositions |
FR2787728B1 (en) | 1998-12-23 | 2001-01-26 | Oreal | NANOEMULSION BASED ON FATTY ESTERS OF PHOSPHORIC ACID, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS |
JP2000191429A (en) | 1998-12-28 | 2000-07-11 | Kao Corp | Foamable cosmetic |
WO2000038731A1 (en) | 1998-12-28 | 2000-07-06 | Taisho Pharmaceutical Co.,Ltd. | External preparation |
FR2787703B1 (en) | 1998-12-29 | 2001-01-26 | Oreal | NANOEMULSION BASED ON ETHOXYL FATHER ETHERS OR ETHOXYL FATTY ESTERS, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS |
FR2788007B1 (en) | 1999-01-05 | 2001-02-09 | Oreal | NANOEMULSION BASED ON BLOCK COPOLYMERS OF ETHYLENE OXIDE AND PROPYLENE OXIDE, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS |
US6270781B1 (en) | 1999-01-08 | 2001-08-07 | Maxim Pharmaceuticals, Inc. | Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
EP1025836A1 (en) | 1999-02-08 | 2000-08-09 | F. Hoffmann-La Roche Ag | Cosmetic light screening composition |
TWI262930B (en) | 1999-02-10 | 2006-10-01 | Mitsui Chemicals Inc | High-durability flexible polyurethane cold molded foam and process for producing the same |
US6224888B1 (en) | 1999-02-12 | 2001-05-01 | The Procter & Gamble Company | Cosmetic compositions |
US6423329B1 (en) | 1999-02-12 | 2002-07-23 | The Procter & Gamble Company | Skin sanitizing compositions |
JP3641152B2 (en) | 1999-02-17 | 2005-04-20 | 株式会社ヤクルト本社 | Topical skin preparation |
EP1075325B1 (en) | 1999-02-26 | 2003-11-05 | Wella Aktiengesellschaft | Device for mixing, foaming and dispensing liquids from separate compressed-gas containers |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
IL129102A0 (en) | 1999-03-22 | 2000-02-17 | J P M E D Ltd | An emulsion |
DE60037689T2 (en) | 1999-03-31 | 2009-01-02 | Firmenich S.A. | Use of Cubebol as a flavoring agent |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6264964B1 (en) | 1999-04-14 | 2001-07-24 | Conopco, Inc. | Foaming cosmetic products |
EP1172105A4 (en) | 1999-04-16 | 2002-09-04 | Fujisawa Pharmaceutical Co | Antifungal compositions |
US6284802B1 (en) | 1999-04-19 | 2001-09-04 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue |
US6433003B1 (en) | 1999-04-23 | 2002-08-13 | Arthur M. Bobrove | Method for treating hyperhidrosis in mammals |
RU2238734C2 (en) | 1999-04-23 | 2004-10-27 | Лео Фармасьютикал Продактс Лтд. А/С (Левенс Кемиске Фабрик Продукционсактиесельскаб) | Pharmaceutical composition |
GB9909711D0 (en) | 1999-04-27 | 1999-06-23 | Unilever Plc | Mousse forming hair treatment composition |
FR2793479B1 (en) | 1999-05-10 | 2001-06-29 | Lir France Sa | DOUBLE DISPENSER FOR FLUID OR PASTY PRODUCTS |
AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
US6518228B1 (en) | 1999-05-27 | 2003-02-11 | Clairol Incorporated | Ultra-mild, clear, aqueous, foamable skin cleanser |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
JP2003500427A (en) | 1999-05-28 | 2003-01-07 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Effervescent shower oil composition |
JP2000351726A (en) | 1999-06-08 | 2000-12-19 | Lion Corp | Aerosol preparation |
JP2000354623A (en) | 1999-06-14 | 2000-12-26 | Shiigeru Kk | Deodorant and deodorizing spray |
US6113888A (en) | 1999-06-15 | 2000-09-05 | Neutrogena Corporation | Self-tanning mousse |
GB9913951D0 (en) | 1999-06-15 | 1999-08-18 | Unilever Plc | Mousse-forming shampoo compositions |
US6190365B1 (en) | 1999-06-21 | 2001-02-20 | Chun Lim Abbott | Vaginal douche applicator and method of vaginal deodorization using the same |
KR100352088B1 (en) | 1999-06-21 | 2002-09-12 | 한미약품공업 주식회사 | Dermal emulsion composition comprising minoxidil |
US6524594B1 (en) | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
NL1012419C2 (en) | 1999-06-23 | 2000-12-28 | Airspray Nv | Aerosol for dispensing a liquid. |
JP2001002526A (en) | 1999-06-23 | 2001-01-09 | Koike Kagaku Kk | Foam aerosol composition |
US6551604B1 (en) | 1999-06-28 | 2003-04-22 | The Procter & Gamble Company | Skin care compositions |
US6762158B2 (en) | 1999-07-01 | 2004-07-13 | Johnson & Johnson Consumer Companies, Inc. | Personal care compositions comprising liquid ester mixtures |
WO2001001949A1 (en) | 1999-07-01 | 2001-01-11 | Johnson And Johnson Consumer Companies, Inc. | Cleansing compositions |
FR2795643B1 (en) | 1999-07-02 | 2004-06-11 | Oreal | FIRMING COSMETIC COMPOSITION INCLUDING AT LEAST ONE HYDROXYSTILBENE IN ASSOCIATION WITH ASCORBIC ACID |
JP4058199B2 (en) | 1999-07-06 | 2008-03-05 | ポーラ化成工業株式会社 | Warm feeling pack |
CA2313955A1 (en) | 1999-07-15 | 2001-01-15 | Playtex Products, Inc. | Sunscreen aerosol composition |
US6548074B1 (en) | 1999-07-22 | 2003-04-15 | Elizabeth Arden Co., Division Of Conopco, Inc. | Silicone elastomer emulsions stabilized with pentylene glycol |
FR2796925B1 (en) | 1999-07-29 | 2001-10-05 | Valois Sa | DISPENSER WITH ARTICULATED DISPENSING HEAD |
WO2001008681A1 (en) | 1999-08-02 | 2001-02-08 | First Horizon Pharmaceutical Corporation | Methods of administration of glycopyrrolate compositions |
US6303552B1 (en) | 1999-08-04 | 2001-10-16 | Napier International Technologies, Inc. | Aerosol paint stripper compositions |
CA2382670A1 (en) | 1999-08-26 | 2001-03-01 | Ganeden Biotech, Inc. | Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications |
US6777591B1 (en) | 1999-08-27 | 2004-08-17 | Sembiosys Genetics Inc. | Legume-like storage protein promoter isolated from flax and methods of expressing proteins in plant seeds using the promoter |
US6308863B1 (en) | 1999-09-02 | 2001-10-30 | Owens-Brockway Plastic Products Inc. | Dual chamber package for pressurized products |
US6479058B1 (en) | 1999-09-02 | 2002-11-12 | Mccadden Michael E. | Composition for the topical treatment of poison ivy and other forms of contact dermatitis |
JP4394775B2 (en) | 1999-09-03 | 2010-01-06 | 株式会社ダイゾー | Water-in-oil foam aerosol composition and method for producing the same |
US6986883B2 (en) | 1999-09-09 | 2006-01-17 | Discus Dental, Inc. | Increased peroxide content tooth bleaching gel |
WO2001021501A1 (en) | 1999-09-20 | 2001-03-29 | The Procter & Gamble Company | Article for the delivery of foam products |
US6437006B1 (en) | 1999-09-27 | 2002-08-20 | American Cyanamid Company | Pharmaceutical carrier formulation |
FR2798849B1 (en) | 1999-09-29 | 2001-11-23 | Oreal | COMPOSITION FOR WASHING KERATIN MATERIALS, BASED ON A DETERGENT SURFACE-ACTIVE AGENT, A DIALKYL DIALLYL AMMONIUM HOMOPOLYMER AND AN ACRYLIC TERPOLYMER |
US6667045B2 (en) | 1999-10-01 | 2003-12-23 | Joseph Scott Dahle | Topical applications for skin treatment |
US6790435B1 (en) | 1999-10-01 | 2004-09-14 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Antiperspirant compositions comprising microemulsions |
FR2799369B1 (en) | 1999-10-08 | 2001-12-21 | Oreal | COMBINATION OF ESCINE AND DEXTRAN SULFATE AND THE USE THEREOF |
US6186367B1 (en) | 1999-10-19 | 2001-02-13 | Valley Design Inc. | Metered liquid squeeze dispenser |
FR2799963B1 (en) | 1999-10-22 | 2002-07-19 | Oreal | EMULSIONS CONTAINING AT LEAST ONE INSOLUBLE ORGANIC UV FILTER AND A NON-FILTERING ORGANOMODIFIED SILICONE |
US6080394A (en) | 1999-11-08 | 2000-06-27 | Dow Corning Corporation | Polar solvent-in-oil emulsions and multiple emulsions |
US20030077301A1 (en) | 1999-12-16 | 2003-04-24 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of inflammatory dermatoses |
UA66796C2 (en) | 1999-12-27 | 2004-06-15 | Univ Nat Pharmaceutical | Composition "profesol foamy" for treating radiation lesions of skin |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
IL133969A0 (en) | 2000-01-10 | 2001-04-30 | Thixo Ltd | Thixotropic compositions containing unsaturated oils and food products containing the same |
US7001690B2 (en) | 2000-01-18 | 2006-02-21 | Valence Technology, Inc. | Lithium-based active materials and preparation thereof |
US6528033B1 (en) | 2000-01-18 | 2003-03-04 | Valence Technology, Inc. | Method of making lithium-containing materials |
FR2804015B1 (en) | 2000-01-21 | 2005-12-23 | Oreal | NANEMULSION CONTAINING AMPHIPHILIC LIPIDS AND NONIONIC POLYMER AND USES THEREOF |
FR2804016B1 (en) | 2000-01-21 | 2006-07-28 | Oreal | NANEMULSION CONTAINING AMPHIPHILIC LIPIDS AND PEG ESTER AND USES THEREOF |
WO2001054679A2 (en) | 2000-01-27 | 2001-08-02 | Children's Hospital Research Foundation | Transdermal composition containing an anesthetic and a vasodilator agent |
US6780443B1 (en) * | 2000-02-04 | 2004-08-24 | Takasago International Corporation | Sensate composition imparting initial sensation upon contact |
FR2804666B1 (en) | 2000-02-04 | 2002-06-14 | Oreal | DISPENSER FOR STORING AT LEAST TWO COMPONENTS AND SELECTIVE DISPENSING EITHER OF A SINGLE CONSTITUENT, EITHER OF THEIR MIXTURE, AND METHOD FOR THE IMPLEMENTATION THEREOF |
NL1014389C2 (en) | 2000-02-15 | 2001-08-16 | Dija Zeist Bv | Tanning preparation for the skin. |
US20040161447A1 (en) | 2000-02-17 | 2004-08-19 | Leonard Paul | Liquid foam producing compositions and dispensing system therefor |
ES2230276T3 (en) | 2000-02-22 | 2005-05-01 | Color Access, Inc. | GELIFIED AQUATIC COSMETIC COMPOSITIONS. |
US7117199B2 (en) | 2000-02-22 | 2006-10-03 | Metacarta, Inc. | Spatially coding and displaying information |
DE10008837A1 (en) | 2000-02-25 | 2001-08-30 | Henkel Kgaa | Dental cleaner containing propellant gas |
DE10008896A1 (en) | 2000-02-25 | 2001-08-30 | Beiersdorf Ag | Improving the solubility and compatibility of benzotriazole UV filters in oils, e.g. in cosmetics or dermatological compositions, by addition of dialkylnaphthalates |
IL135222A (en) | 2000-03-22 | 2005-06-19 | Univ Ben Gurion | Compositions containing molecular iodine |
US6649571B1 (en) | 2000-04-04 | 2003-11-18 | Masi Technologies, L.L.C. | Method of generating gas bubbles in oleaginous liquids |
AU2000258901A1 (en) | 2000-04-06 | 2001-10-23 | Nicholas V. Perricone | Treatment of skin damage using olive oil polyphenols |
FR2807322B1 (en) | 2000-04-10 | 2004-02-20 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, COMPRISING ASCORBIC ACID IN ASSOCIATION WITH AN ASCORBIC ACID DERIVATIVE |
US7758888B2 (en) | 2000-04-21 | 2010-07-20 | Sol-Gel Technologies Ltd. | Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
JP2002012513A (en) | 2000-04-24 | 2002-01-15 | Kanebo Ltd | Urea-containing whipped cosmetic |
US6358541B1 (en) | 2000-05-03 | 2002-03-19 | David S. Goodman | Topical preparation for the treatment of hair loss |
US6410036B1 (en) | 2000-05-04 | 2002-06-25 | E-L Management Corp. | Eutectic mixtures in cosmetic compositions |
AU2001257534A1 (en) | 2000-05-05 | 2001-11-20 | R.P. Scherer Technologies, Inc. | Oil-in-water emulsion formulation containing hydroquinone and retinol |
US6433024B1 (en) | 2000-05-08 | 2002-08-13 | Karl F. Popp | Topical anti-acne composition |
WO2001085128A2 (en) | 2000-05-08 | 2001-11-15 | Pfizer Products Inc. | Skin protectant spray compositions |
FR2808685B1 (en) | 2000-05-12 | 2004-10-08 | Sanofi Synthelabo | PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ANTI-INFLAMMATORY AGENTS |
JP2001326952A (en) | 2000-05-15 | 2001-11-22 | Nec Corp | Broadcast confirmation system, method and device for broadcast confirmation, and recording medium with broadcast confirmation program recorded thereon |
FR2809010B1 (en) | 2000-05-22 | 2002-07-12 | Oreal | NANOEMULSION BASED ON ANIONIC POLYMERS, AND ITS USES IN PARTICULAR IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS |
DE10028638A1 (en) | 2000-06-09 | 2001-12-20 | Schuelke & Mayr Gmbh | Storage-stable composition useful in cosmetic and pharmaceutical compositions comprises combination of glycerol monoalkyl ether with antioxidant |
US6649178B2 (en) | 2000-06-13 | 2003-11-18 | Fatemeh Mohammadi | Cosmetic composition for stressed skin under extreme conditions |
WO2002000820A1 (en) | 2000-06-23 | 2002-01-03 | Combe International Ltd. | Stable foam for use in disposable wipe |
US20020164381A1 (en) | 2000-06-30 | 2002-11-07 | Medicis Pharmaceutical Corporation | Mitocidal compositions and methods |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
CA2313659A1 (en) | 2000-07-06 | 2002-01-06 | Barry J. Barclay | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
DE10033414B4 (en) | 2000-07-08 | 2004-02-19 | Wella Aktiengesellschaft | Clear, two-phase, foam-forming aerosol hair care product |
US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
FR2811564B1 (en) | 2000-07-13 | 2002-12-27 | Oreal | NANOEMULSION CONTAINING NON-IONIC POLYMERS, AND ITS USES IN PARTICULAR IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS |
DE10035930A1 (en) | 2000-07-21 | 2002-01-31 | Clariant Gmbh | fine emulsions |
US20020035070A1 (en) * | 2000-07-26 | 2002-03-21 | The Procter & Gamble Company | Method of regulating hair growth using metal complexes of oxidized carbohydrates |
FR2812191B1 (en) | 2000-07-28 | 2003-10-17 | Oreal | USE OF PROSTAGLANDIN E2 RECEPTOR AGONISTS (EP-3) TO ATTENUATE, DECREASE OR STOP HAIR AND HAIR GROWTH IN COSMETIC PREPARATIONS |
JP4166931B2 (en) | 2000-08-02 | 2008-10-15 | ポーラ化成工業株式会社 | Fever foam cosmetic |
US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US6514487B1 (en) | 2000-08-08 | 2003-02-04 | Teresa Leigh Barr | Foam and gel oat protein complex and method of use |
WO2002015873A2 (en) | 2000-08-22 | 2002-02-28 | The Procter & Gamble Company | Personal care compositions containing adhesive elastomeric polymer and inorganic colloid |
US6299023B1 (en) | 2000-08-24 | 2001-10-09 | Miles Arnone | Device for dispensing two substances in a user selectable ratio with replaceable cartridges |
WO2002015860A1 (en) | 2000-08-24 | 2002-02-28 | Tim Ioannides | Topical antioxidant having vitamin c and method of combination with topical agent by user |
FR2813189B1 (en) | 2000-08-31 | 2003-02-28 | Oreal | COSMETIC FOAMING CREAM FOR THE TREATMENT OF OILY SKIN |
WO2002022086A2 (en) | 2000-09-14 | 2002-03-21 | Quantum Energy Technologies | Application of water nanoclusters to skin |
AU2001288039B2 (en) | 2000-09-21 | 2005-09-15 | Taisho Pharmaceutical Co., Ltd. | Suppositories sustained in the lower rectum |
AUPR048600A0 (en) | 2000-10-02 | 2000-10-26 | Soltec Research Pty Ltd | Pharmaceutical vehicle |
FR2814959A1 (en) | 2000-10-09 | 2002-04-12 | Menarini France | Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve |
US6547063B1 (en) | 2000-10-10 | 2003-04-15 | The Procter & Gamble Company | Article for the delivery of foam products |
GB2367809A (en) | 2000-10-12 | 2002-04-17 | Bespak Plc | Metering valve with collapsible chamber |
FR2815616B1 (en) | 2000-10-20 | 2003-01-24 | Oreal | DISTRIBUTION ASSEMBLY FOR THE EXTEMPORARY DISTRIBUTION OF TWO PRODUCTS |
US6403069B1 (en) | 2000-10-20 | 2002-06-11 | Colgate-Palmolive Company | High oil clear emulsion with elastomer |
DE10058384B4 (en) | 2000-11-24 | 2004-12-16 | Wella Aktiengesellschaft | Cosmetic or dermatological agent in the form of a creamy permanent foam or a stably foamed cream, its use and method for producing the agent |
US6299032B1 (en) | 2000-11-27 | 2001-10-09 | George W. Hamilton | Disposable actuator with cap opener for aerosol cans |
AU2002217896A1 (en) | 2000-11-28 | 2002-06-11 | Avon Products Inc. | Foaming insect repellent compositions |
US6969521B1 (en) | 2000-11-28 | 2005-11-29 | Avon Products, Inc. | Aerosol insect repellent composition having low VOC content and method of applying same to the skin |
US6774100B2 (en) | 2000-12-06 | 2004-08-10 | Imaginative Research Associates, Inc. | Anhydrous creams, lotions and gels |
GB0030068D0 (en) | 2000-12-11 | 2001-01-24 | Lawrence Malcolm | Highway vehicular traffic flow control |
JP3497466B2 (en) | 2000-12-12 | 2004-02-16 | 高砂香料工業株式会社 | Warming composition |
US20060254597A1 (en) | 2000-12-14 | 2006-11-16 | 40J's Llc | Method of treatment of atrophic vaginitis by topical clitoral menthol or a related cooling compound |
DE10063342A1 (en) | 2000-12-19 | 2002-06-20 | Beiersdorf Ag | Cosmetic or dermatological composition contains three-part emulsifier system and gas |
US6749860B2 (en) | 2000-12-22 | 2004-06-15 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with non-aqueous compositions containing botanicals |
US20040079361A1 (en) | 2001-01-17 | 2004-04-29 | Clayton Colin D. | Medicinal aerosols |
FR2819427B1 (en) | 2001-01-18 | 2003-04-11 | Oreal | TRANSLUCENT NANOEMULSION, MANUFACTURING METHOD THEREOF AND USES THEREOF IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS |
US20030013692A1 (en) | 2001-01-19 | 2003-01-16 | Gullans Steven R. | Methods of treating neurological disorders |
US20040063684A1 (en) | 2001-02-05 | 2004-04-01 | Kamm Michael A. | Treatment of oesophageal motility disorders and gastro-oesophageal reflux disease |
EP1383502A4 (en) | 2001-03-06 | 2007-07-25 | Strakan Int Ltd | Compounds and methods for the treatment of urogenital disorders |
JP2004520437A (en) | 2001-03-07 | 2004-07-08 | ザ プロクター アンド ギャンブル カンパニー | Topical composition containing functional aromatic derivative cosmetic binder |
ES2224063T3 (en) | 2001-03-26 | 2005-03-01 | 3M Innovative Properties Company | DOSING VALVE FOR A DOSE INHALER MEASURES THAT HAVE IMPROVED FLOW. |
CA2441893C (en) | 2001-03-26 | 2015-01-20 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
NZ528377A (en) | 2001-03-27 | 2005-05-27 | Galen Chemicals Ltd | Intravaginal drug delivery devices for the administration of an antimicrobial agent |
US6977082B2 (en) | 2001-03-29 | 2005-12-20 | The Dial Corporation | High efficacy antibacterial compositions having enhanced esthetic and skin care properties |
JP2002302419A (en) | 2001-03-30 | 2002-10-18 | Aldeep Cosmetics Japan Inc | Cosmetic composition |
AU2002256092C1 (en) | 2001-04-05 | 2009-10-15 | Collagenex Pharmaceuticals, Inc. | Controlled delivery of tetracycline compounds and tetracycline derivatives |
US6848597B2 (en) | 2001-04-18 | 2005-02-01 | James A. Vlodek | Methods and apparatus for extruding foam through orifices |
US20030053980A1 (en) | 2001-04-30 | 2003-03-20 | The Gillette Company | Shaving compositions containing highly lubricious water soluble polymers |
US20020187181A1 (en) | 2001-05-14 | 2002-12-12 | 3M Innovative Properties Company | System for delivering cosmetics and pharmaceuticals |
ITMI20011019A1 (en) | 2001-05-17 | 2002-11-17 | Carlo Ghisalberti | FURILIC SUBSTANCES FOR TOPICAL USE |
US20030017181A1 (en) | 2001-05-31 | 2003-01-23 | Rood Gloria A. | Dermatological compositions and methods |
CN1520282A (en) | 2001-06-20 | 2004-08-11 | 宝洁公司 | Personal care compsn. comprising polyol-in-silicone emulsion |
US7270828B2 (en) | 2001-06-20 | 2007-09-18 | The Procter & Gamble Company | Personal care composition comprising hydrophobic gel |
FR2826292B1 (en) | 2001-06-22 | 2004-01-23 | Rhodia Chimie Sa | OIL-IN-OIL EMULSIONS COMPRISING A SILICONE, DISPERSIONS OF SUCH EMULSIONS AND USE THEREOF |
US6544562B2 (en) | 2001-06-25 | 2003-04-08 | Blistex Inc. | Acne treatment including dual-package system |
US6428772B1 (en) | 2001-06-25 | 2002-08-06 | Blistex Inc. | Acne treatment composition with cooling effect |
WO2003002082A1 (en) | 2001-06-26 | 2003-01-09 | The Procter & Gamble Company | Pressurized anhydrous antiperspirant emulsions |
JP2003012511A (en) | 2001-06-27 | 2003-01-15 | Rohto Pharmaceut Co Ltd | Aerosol composition |
WO2003002426A1 (en) | 2001-06-27 | 2003-01-09 | Kanebo,Limited | Mixer/extractor |
MXPA04000226A (en) | 2001-07-13 | 2004-05-21 | Procter & Gamble | Mousse forming compositions comprising quaternary ammonium agents. |
US20060194773A1 (en) | 2001-07-13 | 2006-08-31 | Paratek Pharmaceuticals, Inc. | Tetracyline compounds having target therapeutic activities |
DE10134786A1 (en) | 2001-07-17 | 2003-02-06 | Beiersdorf Ag | Foamable preparations |
US7960416B2 (en) | 2001-08-03 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Stable emulsion composition |
DE10138495B4 (en) | 2001-08-04 | 2004-11-11 | Beiersdorf Ag | Foaming preparations and their use |
ATE469639T1 (en) | 2001-08-08 | 2010-06-15 | Dominguez Maria Antonia Garcia-Olmedo | INJECTABLE FOAM AND NEW PHARMACEUTICAL APPLICATIONS THEREOF |
JP4707279B2 (en) | 2001-08-09 | 2011-06-22 | ポーラ化成工業株式会社 | Cosmetics for massage with cool-down effect |
AU2002327437A1 (en) | 2001-08-09 | 2003-02-24 | Croda, Inc. | Anti-irritants |
JP2004537482A (en) | 2001-08-11 | 2004-12-16 | アベンティス・フアーマ・リミテッド | Pressurized aerosol dispenser |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
US20030049218A1 (en) | 2001-08-28 | 2003-03-13 | Amit Patel | Antiperspirant deodorant emulsion |
DE60232178D1 (en) | 2001-08-29 | 2009-06-10 | Pharmakodex Ltd | DEVICE FOR TOPICAL ADMINISTRATION |
US6709663B2 (en) | 2001-08-31 | 2004-03-23 | Healthpoint, Ltd. | Multivesicular emulsion drug delivery systems |
US6479060B1 (en) | 2001-09-04 | 2002-11-12 | Healthpoint, Ltd. | Elegant hydrogenated castor oil ointments |
FR2829693B1 (en) | 2001-09-20 | 2004-02-27 | Oreal | FOAMING COSMETIC CREAM |
DE10147820A1 (en) | 2001-09-27 | 2003-04-10 | Beiersdorf Ag | Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations containing waxes or lipids which are solid and / or semi-solid at room temperature |
US7931533B2 (en) | 2001-09-28 | 2011-04-26 | Igt | Game development architecture that decouples the game logic from the graphics logics |
US20030185839A1 (en) | 2001-10-05 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating dermal lesions |
CA2462291A1 (en) | 2001-10-05 | 2003-04-17 | The General Hospital Corporation | Methods and compositions for treating dermal lesions |
EP1434836B1 (en) | 2001-10-10 | 2013-01-16 | ExxonMobil Research and Engineering Company | Biodegradable non-toxic gear oil |
ATE420619T1 (en) | 2001-10-26 | 2009-01-15 | Taiyo Kagaku Kk | OILY FOAMABLE AEROSOL COMPOSITION |
US20030082120A1 (en) | 2001-10-26 | 2003-05-01 | Milstein Harold J. | Method for reducing systemic effects of aging, effects of aging on the skin, and incidence of skin damage from sun exposure using antibiotics of the tetracycline family |
US7255869B2 (en) | 2001-10-30 | 2007-08-14 | The Procter & Gamble Company | Anhydrous cosmetic compositions containing polyols |
DE10154324A1 (en) | 2001-11-06 | 2003-08-07 | Merz Pharma Gmbh & Co Kgaa | Topically applicable compositions with external active substance depot formation, their production and their use |
DE10155956A1 (en) | 2001-11-09 | 2003-05-22 | Beiersdorf Ag | Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations |
EP1446090A2 (en) | 2001-11-13 | 2004-08-18 | The Procter & Gamble Company | Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care |
DE10155792A1 (en) | 2001-11-14 | 2003-05-22 | Beiersdorf Ag | Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations containing siloxane elastomers |
AU2002356953A1 (en) | 2001-11-16 | 2004-06-03 | Beatrice M. Klysz | Anti-aging skin care composition and uses thereof |
DE10159002A1 (en) | 2001-11-30 | 2003-06-18 | Clariant Gmbh | Use of multi-phase foaming agents from foam dispensers |
FR2833246B1 (en) | 2001-12-06 | 2005-06-24 | Beatrice France Touteau | DEVICE FOR SIMULTANEOUSLY ACTING TWO AEROSOLS CONTAINING TWO PRODUCTS TO BE MIXED AT THE TIME OF USE |
US6531118B1 (en) | 2001-12-11 | 2003-03-11 | Avon Products, Inc. | Topical compositions with a reversible photochromic ingredient |
US8226972B2 (en) | 2001-12-20 | 2012-07-24 | Femmepharma Holding Company, Inc. | Vaginal delivery of drugs |
US6765001B2 (en) | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
SE0104421D0 (en) | 2001-12-21 | 2001-12-21 | Ponsus Pharma Ab | New composition |
US20030118515A1 (en) | 2001-12-21 | 2003-06-26 | Robert Jew | Cosmetic composition containing carbon dioxide |
US20030129259A1 (en) | 2001-12-28 | 2003-07-10 | Avon Products, Inc. | Topical lightening compostitions and methods of use |
JP4549625B2 (en) | 2002-01-05 | 2010-09-22 | 株式會社アモーレパシフィック | Finely emulsified particles containing ginseng saponin metabolites as active ingredients, a method for producing the same, and a cosmetic composition for preventing skin aging containing the same |
US7192601B2 (en) | 2002-01-18 | 2007-03-20 | Walker Edward B | Antimicrobial and sporicidal composition |
US6992049B2 (en) | 2002-01-31 | 2006-01-31 | Exxonmobil Research And Engineering Company | Lubricating oil compositions |
NZ517094A (en) | 2002-02-08 | 2005-03-24 | Advanced Animal Technology Ltd | Improvements in and relating to substance delivery device |
EP1475381A1 (en) | 2002-02-14 | 2004-11-10 | Quimversion, S.L. | Aluminium and hexamethylenetetramine complex and the applications thereof |
US6589216B1 (en) | 2002-02-20 | 2003-07-08 | Abbott Research Group, Inc. | Vaginal douches, vaginal douche applicators and methods of vaginal douching |
US6682511B2 (en) | 2002-02-21 | 2004-01-27 | Robert Wallace Besoyan | Brief protector |
US6691898B2 (en) | 2002-02-27 | 2004-02-17 | Fomo Products, Inc. | Push button foam dispensing device |
AU2003213787A1 (en) | 2002-03-06 | 2003-09-22 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
US20050281766A1 (en) | 2002-03-11 | 2005-12-22 | Avon Products, Inc. | Method of improving the aesthetic appearance of epithelia |
US6736860B2 (en) | 2002-03-12 | 2004-05-18 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Gradual permanent coloring of hair using dye intermediates dissolved in alkaline water with fatty alcohol |
CA2422244A1 (en) | 2002-03-14 | 2003-09-14 | Homax Products, Inc. | Aerosol systems and methods for mixing and dispensing two-part materials |
US20030180347A1 (en) * | 2002-03-19 | 2003-09-25 | W.F. Young, Incorporated | Patch for the delivery of topical agents |
AU2003221262A1 (en) | 2002-03-19 | 2003-09-29 | Airspray International B. V. | Dispensing unit |
AU2003221093A1 (en) | 2002-03-28 | 2003-10-13 | Hakuto Co., Ltd. | Method of foam stabilization for foam cosmetic |
US20040078896A1 (en) | 2002-04-12 | 2004-04-29 | Dreamwell, Ltd. | Cassette bedding system |
US8192749B2 (en) | 2003-04-16 | 2012-06-05 | Galderma Laboratories Inc. | Methods of simultaneously treating ocular rosacea and acne rosacea |
US8846039B2 (en) | 2002-04-26 | 2014-09-30 | Asan Laboratories Company (Cayman), Limited | Method for ameliorating pruritus |
US6875438B2 (en) | 2002-04-27 | 2005-04-05 | Aventis Pharma Deutschland Gmbh | Preparations for topical administration of substances having antiandrogenic activity |
CA2384922C (en) | 2002-05-03 | 2008-09-02 | Purepharm Inc. | Topical glycopyrrolate product for the reduction of sweating |
AU2003243205A1 (en) | 2002-05-06 | 2003-11-17 | Collagenex Pharmaceuticals, Inc. | Methods of simultaneously treating mucositis and fungal infection |
JP4108678B2 (en) | 2002-05-10 | 2008-06-25 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Hair conditioning composition |
US6783027B2 (en) | 2002-05-15 | 2004-08-31 | The Procter & Gamble Company | Metered-dose underarm product and package |
US20030215472A1 (en) | 2002-05-16 | 2003-11-20 | Bonda Craig A | Methods and compositions employing a dialkyl amide |
EP1505961A4 (en) | 2002-05-20 | 2009-09-02 | Collagenex Pharm Inc | Methods of treating allergic reactions |
JP4050094B2 (en) | 2002-05-28 | 2008-02-20 | 株式会社三谷バルブ | Metering valve mechanism and aerosol products |
US6723309B1 (en) | 2002-06-10 | 2004-04-20 | Jeffrey Alan Deane | Hair cleansing conditioner |
FR2840903B1 (en) | 2002-06-13 | 2005-01-28 | Oreal | GLUCOSE AND VITAMIN F DERIVATIVE, COMPOSITIONS COMPRISING THE SAME, AND USES FOR IMPROVING THE CONDITION OF HAIR AND HAIR |
US7763587B2 (en) | 2002-06-13 | 2010-07-27 | L'oreal S.A. | Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process |
US7163669B2 (en) | 2002-06-19 | 2007-01-16 | J.M. Huber Corporation | Cosmetic compositions comprising calcium silicates |
DE60335275D1 (en) | 2002-06-26 | 2011-01-20 | Daizo Co Ltd | PACKAGING CONVEYOR FOR TRANSFERRING MULTIPLE CONTENTS, PACKAGING PRODUCT WITH PACKAGING PRODUCTS |
JP2004026605A (en) | 2002-06-27 | 2004-01-29 | Asahi Fiber Glass Co Ltd | Greige goods for glass fiber yarn and glass fiber yarn made using this |
US20040002550A1 (en) | 2002-06-28 | 2004-01-01 | Mercurio Anthony Fred | Post foaming compositions |
US6785629B2 (en) | 2002-07-02 | 2004-08-31 | Agilent Technologies, Inc. | Accuracy determination in bit line voltage measurements |
JP3833972B2 (en) | 2002-07-08 | 2006-10-18 | 古河電気工業株式会社 | Wire harness assembly system |
DE10233330B4 (en) | 2002-07-22 | 2007-04-26 | Sasol Germany Gmbh | Microemulsion containing UV photoprotective filter and / or anti-dandruff agent |
US7137536B2 (en) | 2002-07-22 | 2006-11-21 | Seaquist Perfect Dispensing Foreign, Inc. | Inverted aerosol dispenser |
US20020182162A1 (en) | 2002-08-07 | 2002-12-05 | Mohsen Shahinpoor | Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth |
FR2843373B1 (en) | 2002-08-12 | 2005-03-04 | Jean Augustin | DEVICE FOR PACKAGING AND APPLYING A PRODUCT IN FLUID FORM |
US7939170B2 (en) | 2002-08-15 | 2011-05-10 | The Rockefeller University | Water soluble metal and semiconductor nanoparticle complexes |
US20060240123A1 (en) | 2002-08-26 | 2006-10-26 | S.L.A. Pharma Ag | Pharmaceutical composition |
US6770607B2 (en) | 2002-09-12 | 2004-08-03 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Viscoelastic cleansing gel with micellar surfactant solutions |
US7906473B2 (en) | 2002-09-13 | 2011-03-15 | Bissell Homecare, Inc. | Manual spray cleaner |
US6968982B1 (en) | 2002-09-18 | 2005-11-29 | Burns Caleb E S | Multiple-mist dispenser |
GB0221697D0 (en) | 2002-09-18 | 2002-10-30 | Unilever Plc | Novel compouds and their uses |
US7179481B2 (en) | 2002-09-19 | 2007-02-20 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
US6949037B2 (en) | 2002-09-27 | 2005-09-27 | Richard A. Enos | Quick-release fastener for releasably attaching lacrosse stick head to shaft |
EP1402784B1 (en) | 2002-09-30 | 2008-11-12 | Kao Corporation | Foamable oil-in-water type emulsion |
FR2845672B1 (en) | 2002-10-09 | 2006-02-10 | Airlessystems | FLUID PRODUCT DISPENSER |
US20060140984A1 (en) | 2002-10-25 | 2006-06-29 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
EP1567113A4 (en) | 2002-10-24 | 2006-11-08 | G & R Pharmaceuticals Llc | Antifungal formulations |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US20050186142A1 (en) | 2002-10-25 | 2005-08-25 | Foamix Ltd. | Kit and composition of imidazole with enhanced bioavailability |
US20080031907A1 (en) | 2002-10-25 | 2008-02-07 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
US20060233721A1 (en) | 2002-10-25 | 2006-10-19 | Foamix Ltd. | Foam containing unique oil globules |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US20160158261A1 (en) | 2002-10-25 | 2016-06-09 | Foamix Pharmaceuticals Ltd. | Antibiotic Kit and Composition and Uses Thereof |
US20070292355A1 (en) | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
US20050271596A1 (en) | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
US20080317679A1 (en) | 2002-10-25 | 2008-12-25 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US20060193789A1 (en) | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20070292359A1 (en) | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
US20080206161A1 (en) | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
US20120156144A1 (en) | 2002-10-25 | 2012-06-21 | Foamix | Foamable Compositions, Kits and Methods for Hyperhidrosis |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US20050069566A1 (en) | 2003-08-04 | 2005-03-31 | Foamix Ltd. | Foam carrier containing amphiphilic copolymeric gelling agent |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US20050205086A1 (en) | 2002-10-25 | 2005-09-22 | Foamix Ltd. | Retinoid immunomodulating kit and composition and uses thereof |
EP1556332B1 (en) | 2002-10-28 | 2016-10-05 | Givaudan SA | Coolant solutions and compositions comprising the same |
JP2004250435A (en) | 2002-11-21 | 2004-09-09 | Dai Ichi Seiyaku Co Ltd | Composition for hair growth |
JP4282311B2 (en) | 2002-11-26 | 2009-06-17 | 三洋電機株式会社 | Ice making equipment |
US20070134167A2 (en) | 2002-12-12 | 2007-06-14 | Neubourg Skin Care Gmbh & Co. Kg | Stable foam cream |
GB0229071D0 (en) | 2002-12-13 | 2003-01-15 | Unilever Plc | Cosmetic method and composition for enhancing attractiveness |
US20040191196A1 (en) | 2002-12-16 | 2004-09-30 | Dov Tamarkin | Novel conjugate compounds and dermatological compositions thereof |
FR2848847B1 (en) | 2002-12-18 | 2005-10-14 | Coletica | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AN AQUEOUS INSOLUBLE ENZYME AND USES THEREOF |
US7842791B2 (en) | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
FR2848998B1 (en) | 2002-12-20 | 2006-04-07 | Oreal | DISPENSING DEVICE HAVING MEANS FOR DISTRIBUTING TWO PRODUCTS IN VARIABLE PROPORTIONS |
EP1578421A4 (en) | 2003-01-02 | 2009-04-22 | Femmepharma Holding Co Inc | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
WO2004064769A2 (en) | 2003-01-21 | 2004-08-05 | Hector Herrera | Methods for making and using topical delivery agents |
MXPA05007722A (en) | 2003-01-24 | 2006-01-31 | Connetics Australia Pty Ltd | Clindamycin phosphate foam. |
US20040151756A1 (en) | 2003-02-04 | 2004-08-05 | Richards Anthony P. | Edible low density high surface area drug vehicle, method of manufacturing low density high surface area drug vehicle |
US7517519B2 (en) | 2003-02-06 | 2009-04-14 | Cipla Limited | Topical immunotherapy and compositions for use therein |
EP1594454B8 (en) | 2003-02-12 | 2016-10-12 | Stiefel Research Australia Pty Ltd | Film forming hydroalcoholic foam |
US6841547B2 (en) | 2003-02-28 | 2005-01-11 | Albert Einstein College Of Medicine Of Yeshevia University | Method for decreasing low density lipoprotein |
US20040175347A1 (en) | 2003-03-04 | 2004-09-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using hexamidine compositions |
GB0305010D0 (en) | 2003-03-05 | 2003-04-09 | Unilever Plc | Changing colours |
US7357950B2 (en) | 2003-03-21 | 2008-04-15 | Elizabeth Anne Mazzio | Topical treatment for dyshidrosis (pompholyx) and dry skin disorders |
US20040192754A1 (en) | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
US7488757B2 (en) | 2003-03-24 | 2009-02-10 | Becton, Dickinson And Company | Invisible antimicrobial glove and hand antiseptic |
DE10315936A1 (en) | 2003-04-03 | 2004-10-28 | Ing. Erich Pfeiffer Gmbh | Discharge device for at least one medium |
GB0308585D0 (en) | 2003-04-14 | 2003-05-21 | Pz Cussons Int Ltd | Cleaning composition |
US20040220187A1 (en) | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders |
US20040229803A1 (en) | 2003-04-22 | 2004-11-18 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
DE10319771B4 (en) | 2003-05-02 | 2005-03-17 | Koenig & Bauer Ag | System for inspecting a printed image |
JP2004353084A (en) | 2003-05-08 | 2004-12-16 | Sanyo Electric Co Ltd | Evaporator fixation member |
FR2854821B1 (en) | 2003-05-16 | 2006-12-08 | Oreal | ASSEMBLY FOR PACKAGING AND DISPENSING A PRODUCT, IN PARTICULAR IN THE FORM OF A SAMPLE |
JP4232535B2 (en) | 2003-05-20 | 2009-03-04 | セイコーエプソン株式会社 | Printer maintenance system, print control server, client, method related thereto and program related thereto |
US7222802B2 (en) | 2003-05-23 | 2007-05-29 | Meadwestvaco Corporation | Dual sprayer with external mixing chamber |
EP1634584A1 (en) | 2003-05-25 | 2006-03-15 | Yuwan Wang | Dimeticone-containing sustained formulation |
US7186416B2 (en) | 2003-05-28 | 2007-03-06 | Stiefel Laboratories, Inc. | Foamable pharmaceutical compositions and methods for treating a disorder |
US20050079228A1 (en) | 2003-05-30 | 2005-04-14 | Ashish Jaiswal | Clear, stable topical compositions of clarithromycin and processes for their preparation |
US20050208083A1 (en) | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
JP4018032B2 (en) | 2003-06-17 | 2007-12-05 | 高砂香料工業株式会社 | Hair and body cleaning composition |
ES2279391T3 (en) | 2003-06-18 | 2007-08-16 | Galderma S.A. | PHARMACEUTICAL COMPOSITION TOPICA OF DYE GREEN BASED METRONIDAZOL. |
US20050042182A1 (en) | 2003-08-13 | 2005-02-24 | Moshe Arkin | Topical compositions of urea |
AU2004253410B2 (en) | 2003-07-03 | 2008-08-21 | Japan Science And Technology Agency | Remedy for sarcoidosis and method of treating the same |
US20070140999A1 (en) | 2003-07-18 | 2007-06-21 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
EP1653932A1 (en) | 2003-07-24 | 2006-05-10 | Ranbaxy Laboratories Limited | Modified release compositions for minocycline |
US7226230B2 (en) | 2003-07-28 | 2007-06-05 | Raymond Liberatore | Spreader |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US20080069779A1 (en) | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
BRPI0412975A (en) | 2003-08-25 | 2006-10-03 | Foamix Ltd | penetrating foam for pharmaceutical use |
US20060140990A1 (en) | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
CN1886126A (en) | 2003-09-25 | 2006-12-27 | Dmi生物科学公司 | Methods and products which utilize N-acyl-L-aspartic acid |
FR2860143B1 (en) | 2003-09-26 | 2008-06-27 | Oreal | COSMETIC COMPOSITION COMPRISING A SEQUENCE POLYMER AND A NON-VOLATILE SILICONE OIL |
US20050084551A1 (en) | 2003-09-26 | 2005-04-21 | Jensen Claude J. | Morinda citrifolia-based oral care compositions and methods |
GB2406330B (en) | 2003-09-29 | 2005-12-07 | Bespak Plc | A dispensing apparatus |
CN1528326A (en) | 2003-09-29 | 2004-09-15 | 中国医学科学院皮肤病研究所 | Complex external medicine mainly for acne |
BRPI0414883A (en) | 2003-09-29 | 2006-12-12 | Ethena Healthcare Inc | composition, composition concentrate, and disinfectant and gel-like alcoholic compositions |
MXPA06003743A (en) | 2003-10-03 | 2006-06-23 | Collegium Pharmaceutical Inc | Topical aerosol foams. |
FR2860502B1 (en) | 2003-10-07 | 2007-09-14 | Valois Sas | DOSING VALVE AND DEVICE FOR DISPENSING FLUID PRODUCT COMPRISING SUCH A VALVE |
GB0323908D0 (en) | 2003-10-11 | 2003-11-12 | Nupharm Lab Ltd | Pharmaceutical foam formulation |
US8278350B2 (en) | 2003-10-14 | 2012-10-02 | Showa Denko K.K. | Agent for skin external use containing salt of ascorbic acid derivative, method for stabilizing the agent for skin external use, and stabilizer |
FR2860976B1 (en) | 2003-10-20 | 2006-02-10 | Ravi Shrivastava | NOVEL SYNERGISTIC COMPOSITIONS FOR IMPROVING THE BIODAVAILABILITY AND EFFICIENCY OF POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF BRAIN FUNCTIONING DISORDERS. |
US7419498B2 (en) | 2003-10-21 | 2008-09-02 | Nmt Medical, Inc. | Quick release knot attachment system |
CN100475184C (en) | 2003-10-31 | 2009-04-08 | 宝洁公司 | Skin care composition containing dehydroacetic acid and skin care actives |
EP1684768A4 (en) | 2003-11-06 | 2007-06-06 | Univ New York State Res Found | Methods of treating eczema |
US8157788B2 (en) | 2003-11-06 | 2012-04-17 | Paolo L. Manfredi | Multi-site drug delivery platform |
JP5019880B2 (en) | 2003-11-06 | 2012-09-05 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Improved cosmetic composition comprising vitamin B3, vitamin B6 and an organic acid |
AU2006246425B2 (en) | 2003-11-06 | 2012-03-22 | Genencor International, Inc. | Personal care compositions and methods for their use |
DE10354051A1 (en) | 2003-11-17 | 2005-06-16 | Beiersdorf Ag | Dispensers containing cosmetic preparations containing aids for keeping the donor in motion |
CA2544215A1 (en) | 2003-11-17 | 2005-06-02 | The Procter & Gamble Company | Antiperspirant composition and applicator therefor |
AU2004290982B2 (en) | 2003-11-21 | 2008-06-19 | Pfizer Products Inc. | The use of anti biotics as vaccine adjuvants |
US20050115988A1 (en) | 2003-12-01 | 2005-06-02 | Brian Law | Multiple liquid foamer |
US20050123496A1 (en) | 2003-12-08 | 2005-06-09 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Self foaming non-aqueous personal wash cleansers with little or no surfactant |
DE10361022A1 (en) | 2003-12-23 | 2005-07-28 | Merckle Gmbh Chem.-Pharm. Fabrik | Topical preparations containing dimethyl sulfoxide and dexpanthenol |
BRPI0418251C1 (en) | 2003-12-30 | 2021-05-25 | Gilead Sciences Inc | phosphonates, monophosphonamidates, bisphosphonamidates, and pharmaceutical composition comprising them |
IL159729A0 (en) | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
EP1727522A2 (en) | 2004-02-04 | 2006-12-06 | Foamix Ltd. | Cosmetic and pharmaceutical foam with solid matter |
US7225518B2 (en) | 2004-02-23 | 2007-06-05 | Boston Scientific Scimed, Inc. | Apparatus for crimping a stent assembly |
JP4381169B2 (en) | 2004-02-27 | 2009-12-09 | 花王株式会社 | Hair cosmetics |
JP5095388B2 (en) | 2004-03-03 | 2012-12-12 | ルバンス セラピュティックス インク. | Compositions and methods for topical application and transdermal delivery of botulinum toxin |
US20050206214A1 (en) | 2004-03-18 | 2005-09-22 | Bodypoint Designs, Inc. | Pivoting side mount for a pelvic stabilization device |
JP4704784B2 (en) * | 2004-03-29 | 2011-06-22 | 株式会社コーセー | Oily foam cleansing cosmetic |
DE102004016710B4 (en) | 2004-04-05 | 2020-11-19 | Greppmayr GmbH | Foot care formulation |
EP1734927B8 (en) | 2004-04-08 | 2013-10-23 | MEDA Pharma S.à.r.l. | Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides |
ES2429443T3 (en) | 2004-04-19 | 2013-11-14 | Strategic Science & Technologies, Llc | Transdermal supply of beneficial substances by means of an environment of high ionic strength |
NL1026031C2 (en) | 2004-04-23 | 2005-10-25 | Airspray Nv | Delivery assembly. |
WO2006131784A1 (en) | 2004-04-28 | 2006-12-14 | Foamix Ltd. | Body cavity foams |
JP2005314323A (en) | 2004-04-30 | 2005-11-10 | Sato Pharmaceutical Co Ltd | Hair growth formulation |
US20050244354A1 (en) | 2004-04-30 | 2005-11-03 | Sam Speron | Oxygenated personal care products |
US20050255048A1 (en) | 2004-05-15 | 2005-11-17 | Collegium Pharmaceutical, Inc. | Sprayable formulations for the treatment of acute inflammatory skin conditions |
US7083125B2 (en) | 2004-05-17 | 2006-08-01 | S.C. Johnson & Son, Inc. | Detachable tube assembly |
US7143909B2 (en) | 2004-05-21 | 2006-12-05 | Sonoco Development, Inc. | Reconfigurable metered material dispenser |
US8394394B2 (en) | 2004-05-26 | 2013-03-12 | L'oréal | Mousse formulations |
ITBO20040338A1 (en) | 2004-05-28 | 2004-08-28 | Progine Farmaceutici Srl | VAGINAL NEBULIZATION DISPENSER |
US20050268416A1 (en) | 2004-06-03 | 2005-12-08 | Sommers J E | Foldable lotion applicator |
JP4368250B2 (en) | 2004-06-09 | 2009-11-18 | ポーラ化成工業株式会社 | Post-form dosage form of warm cosmetic |
FR2871698B1 (en) | 2004-06-17 | 2008-07-04 | Galderma Sa | SPRAY COMPOSITION COMPRISING AN ASSOCIATION OF PHARMACEUTICAL ASSETS AND AN OILY PHASE |
FR2871696B1 (en) | 2004-06-17 | 2006-11-10 | Galderma Sa | TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS |
US8211449B2 (en) | 2004-06-24 | 2012-07-03 | Dpt Laboratories, Ltd. | Pharmaceutically elegant, topical anhydrous aerosol foam |
JP4355264B2 (en) | 2004-06-25 | 2009-10-28 | ポーラ化成工業株式会社 | Warm feeling non-water foam cosmetic |
US7207655B2 (en) | 2004-06-28 | 2007-04-24 | Eastman Kodak Company | Latency stirring in fluid ejection mechanisms |
US6991789B2 (en) | 2004-06-29 | 2006-01-31 | Allergas, Inc. | Methods of modulating intracellular degradation rates of toxins |
UA93354C2 (en) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Topical antiviral formulations |
US20060121073A1 (en) | 2004-07-12 | 2006-06-08 | Sandhya Goyal | Topical gel formulation comprising insecticide and its preparation thereof |
EP1778216A1 (en) | 2004-07-19 | 2007-05-02 | Warner-Lambert Company LLC | Formulation for stimulating hair growth |
WO2006010589A2 (en) | 2004-07-29 | 2006-02-02 | Mipharm S.P.A. | Post foaming gel mousse |
JP4557624B2 (en) | 2004-07-29 | 2010-10-06 | 株式会社吉野工業所 | Quantitative dispenser |
US20060029565A1 (en) | 2004-08-09 | 2006-02-09 | The Gillette Company | Self-heating shave foam product |
WO2006020695A2 (en) | 2004-08-12 | 2006-02-23 | Triaccess Technologies, Inc. | Optical receiver with increased dynamic range |
US8460641B2 (en) | 2004-08-31 | 2013-06-11 | Stiefel Research Australia Pty Ltd | Microemulsion process and composition |
KR100623013B1 (en) | 2004-09-04 | 2006-09-19 | 김영대 | Nano-emulsion, the use thereof, and preparing method thereof |
DK1809303T3 (en) | 2004-09-23 | 2019-06-11 | Arc Medical Devices Inc | PHARMACEUTICAL COMPOSITION AND METHODS IN RELATION TO FIBROSE ADHESION OR INFLAMMATORIC DISEASE USING LOW SULPHATE FUCAN |
EP1791791B1 (en) * | 2004-09-27 | 2019-05-29 | Special Water Patents B.V. | Methods and compositions for treatment of water |
FR2875797B1 (en) | 2004-09-30 | 2006-11-24 | Oreal | DISTRIBUTION ASSEMBLY FOR THE EXTENDED DISTRIBUTION OF TWO PRODUCTS |
BRPI0404595A (en) | 2004-10-26 | 2006-06-13 | Natura Cosmeticos Sa | oil-in-water nanoemulsion, cosmetic composition and cosmetic product comprising same, process for preparing said nanoemulsion |
DE102004052986A1 (en) | 2004-11-02 | 2006-05-04 | Lindal Ventil Gmbh | Device for mixing two different components |
US7350673B2 (en) | 2004-11-19 | 2008-04-01 | Glynntech, Inc. | Metered dose squeeze dispenser |
US20060110415A1 (en) | 2004-11-22 | 2006-05-25 | Bioderm Research | Topical Delivery System for Cosmetic and Pharmaceutical Agents |
US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
FR2880802B1 (en) * | 2005-01-14 | 2008-12-19 | Sederma Soc Par Actions Simpli | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING EUGLENE EXTRACT |
WO2006081327A2 (en) | 2005-01-25 | 2006-08-03 | University Of Vermont And State Agricultural College | Small molecules that reduce fungal growth |
BRPI0607038A2 (en) | 2005-01-28 | 2009-12-01 | Basf Ag | use of polymers cosmetic compositions for hair and skin and dermatological composition |
US20060177392A1 (en) | 2005-02-10 | 2006-08-10 | William Walden | Oil-based composition for acne |
US20060193813A1 (en) | 2005-02-11 | 2006-08-31 | L'oreal | Nanoemulsion containing a hydroxylated urea compound |
WO2006099687A1 (en) | 2005-03-24 | 2006-09-28 | Ensign Laboratories Pty Ltd | Sunscreen aerosol spray |
GB0506141D0 (en) | 2005-03-24 | 2005-05-04 | Transphase Ltd | A topical compostion and its uses |
US20060222675A1 (en) | 2005-03-29 | 2006-10-05 | Sabnis Ram W | Personal care compositions with color changing indicator |
US20060285912A1 (en) | 2005-04-19 | 2006-12-21 | Foamix Ltd. | Apparatus and method for releasing a measured amount of content from a container |
US20070069046A1 (en) | 2005-04-19 | 2007-03-29 | Foamix Ltd. | Apparatus and method for releasing a measure of content from a plurality of containers |
EP1879595B1 (en) | 2005-05-10 | 2014-09-24 | Dermipsor Ltd | Compositions and methods for treating hyperproliferative epidermal diseases |
WO2006122158A2 (en) | 2005-05-10 | 2006-11-16 | Xanthone Plus International, Llc | Skin care compositions containing xanthones |
CA2611147C (en) | 2005-06-01 | 2013-04-09 | Stiefel Research Australia Pty Ltd. | Topical emulsion formulation |
US20060272199A1 (en) | 2005-06-02 | 2006-12-07 | Bmc Manufacturing, Llc | Aqueous gel candle for use with a warming device |
US8211874B2 (en) | 2005-06-03 | 2012-07-03 | Galderma Laboratories Inc. | Inhibition of thrombin generation |
WO2007099396A2 (en) | 2005-06-07 | 2007-09-07 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
WO2007085899A2 (en) * | 2005-07-06 | 2007-08-02 | Foamix Ltd. | Foamable arthropocidal composition for tropical application |
US20070015738A1 (en) | 2005-07-15 | 2007-01-18 | Walker Stephen G | Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells |
EP2862560B1 (en) | 2005-07-18 | 2019-10-30 | The Procter and Gamble Company | Aerosol cream mousse, method of treating hair and use |
WO2007085902A2 (en) | 2005-07-19 | 2007-08-02 | Foamix Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US20080152596A1 (en) | 2005-07-19 | 2008-06-26 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
DE602005010417D1 (en) | 2005-07-22 | 2008-11-27 | Wella Ag | Hair treatment method with a dry foam used as a mechanical vehicle |
DE102005037844A1 (en) | 2005-08-04 | 2007-04-05 | Intendis Gmbh | Anhydrous multi-phase gel system |
CA2618974C (en) | 2005-08-09 | 2014-01-28 | Nanobio Corporation | Nanoemulsion compositions having anti-inflammatory activity |
EP1933941A2 (en) | 2005-08-25 | 2008-06-25 | Philip R. Houle | Treatment systems for delivery of sensitizer solutions |
FR2890559B1 (en) | 2005-09-13 | 2011-06-24 | Galderma Sa | DERMATOLOGICAL FOAMS BASED ON METRONIDAZOLE AND EMULSIONS FOR PREPARATION |
DE202006004676U1 (en) | 2005-09-28 | 2007-02-08 | Neubourg Skin Care Gmbh & Co. Kg | Formulation, useful as foam skin cream and to treat e.g. dermatitis and psoriasis, comprises an aqueous emulsion, propellant gas, urea emulsion, hyaluronic acid, free fatty acid and at least two emulsions |
EP2108360A3 (en) | 2005-10-24 | 2010-06-09 | Collegium Pharmaceutical, Inc. | Topical Pharmaceutical Foam Composition |
US20070134174A1 (en) | 2005-11-03 | 2007-06-14 | Christopher Irwin | Personal care composition |
JP2007131539A (en) | 2005-11-08 | 2007-05-31 | Koike Kagaku Kk | Chilling foam cosmetic |
US20070148194A1 (en) | 2005-11-29 | 2007-06-28 | Amiji Mansoor M | Novel nanoemulsion formulations |
JP4885529B2 (en) | 2005-12-08 | 2012-02-29 | 住友重機械工業株式会社 | Radiation detection unit and radiation inspection apparatus |
US20070160548A1 (en) | 2005-12-13 | 2007-07-12 | Playtex Products, Inc. | Moisturizing sunless tanning composition |
US20070142263A1 (en) | 2005-12-15 | 2007-06-21 | Stahl Katherine D | Color changing cleansing composition |
US20070148112A1 (en) | 2005-12-28 | 2007-06-28 | Avon Products, Inc. | Foaming, color-changing topical composition and method of imparting a cosmetic effect |
CA2637408C (en) | 2006-01-19 | 2013-12-03 | Disphar International B.V. | Foam-forming composition |
US20070166273A1 (en) | 2006-01-19 | 2007-07-19 | Krivulka Joseph J | Skin treatment educational kit |
CA2645073A1 (en) | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
CN101404972B (en) | 2006-03-22 | 2012-11-14 | 宝洁公司 | Aerosol product comprising a foaming concentrate composition comprising particulate materials |
US7252816B1 (en) | 2006-03-29 | 2007-08-07 | Dow Pharmaceutical Sciences | Topical acne vulgairs medication with a sunscreen |
US8158109B2 (en) | 2006-03-31 | 2012-04-17 | Stiefel Research Australia Pty Ltd | Foamable suspension gel |
WO2008075207A2 (en) | 2006-04-04 | 2008-06-26 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
US10278917B2 (en) | 2006-04-14 | 2019-05-07 | Perrigo Israel Pharmaceuticals Ltd. | Pharmaceutical compositions comprising silica microspheres |
US20070264317A1 (en) | 2006-05-15 | 2007-11-15 | Perrigo Israel Pharmaceuticals Ltd. | Imiquimod cream formulation |
US20070281999A1 (en) | 2006-05-31 | 2007-12-06 | The Dial Corporation | Alcohol-containing antimicrobial compositions having improved efficacy |
JP4892282B2 (en) | 2006-06-09 | 2012-03-07 | アルプス電気株式会社 | Lubricating composition for electrical contacts |
WO2008110872A2 (en) | 2006-06-23 | 2008-09-18 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
PT2494959E (en) | 2006-07-05 | 2015-02-20 | Foamix Pharmaceuticals Ltd | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
CA2658031C (en) | 2006-07-18 | 2015-06-02 | Graceway Pharmaceuticals, Llc | Immune response modifier foam formulations comprising imiquimod and a fatty acid |
US20080031908A1 (en) | 2006-07-25 | 2008-02-07 | L'oreal | Oily cosmetic composition in aerosol form |
JP2008040899A (en) | 2006-08-08 | 2008-02-21 | Fuji Xerox Co Ltd | Printing controller, program, and method |
CN101563058A (en) | 2006-09-08 | 2009-10-21 | 弗米克斯有限公司 | Colored or colorable foamable composition and foam |
ES2315123B1 (en) | 2006-09-25 | 2009-12-30 | Divasa-Farmavic, S.A. | STABLE PHARMACEUTICAL COMPOSITIONS OF TETRACICLINES IN SOLUTION, PROCEDURE FOR OBTAINING AND USES. |
HUP0600765A2 (en) | 2006-10-06 | 2008-10-28 | Istvan Piller | Container for stable carbondioxide foam, process for producing stable carbondioxide foam and method for using of foam |
EP2073794A2 (en) | 2006-11-14 | 2009-07-01 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
EP2097065A2 (en) | 2006-11-29 | 2009-09-09 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
JP2010513289A (en) | 2006-12-15 | 2010-04-30 | ザ プロクター アンド ギャンブル カンパニー | Skin care composition |
WO2008083158A2 (en) | 2006-12-26 | 2008-07-10 | Femmepharma Holding Company, Inc. | Topical administration of danazol |
US20080292560A1 (en) | 2007-01-12 | 2008-11-27 | Dov Tamarkin | Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent |
CA2673767A1 (en) | 2007-01-16 | 2008-07-24 | Oystershell N.V. | Foamable composition for killing arthropods and uses thereof |
WO2008097851A1 (en) | 2007-02-02 | 2008-08-14 | Warner Chilcott Company, Inc. | Tetracycline compositions for topical administration |
US20080188445A1 (en) | 2007-02-02 | 2008-08-07 | Warner Chilcott Company Inc. | Tetracycline compositions for topical administration |
PT103661B (en) | 2007-02-23 | 2010-09-07 | Hovione Farmaciencia S A | MINOCYCINE PREPARATION PROCESS CRYSTALLINE |
GB0703909D0 (en) | 2007-02-28 | 2007-04-11 | Neuropharm Ltd | Treatment of anxiety disorders |
FR2915891B1 (en) | 2007-05-10 | 2012-05-11 | Oreal | FOAM COMPOSITION COMPRISING A SILICONE POLYMER |
EP1992323B1 (en) | 2007-05-10 | 2012-02-08 | Neubourg Skin Care GmbH & Co. KG | Tenside-free foam formulae |
US9511016B2 (en) | 2007-06-12 | 2016-12-06 | Epicentrx, Inc. | Topical composition for treating pain |
ES2382890T3 (en) | 2007-06-19 | 2012-06-14 | Neubourg Skin Care Gmbh & Co. Kg | DMS (derma membrane structure) in foam creams. |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8617100B2 (en) | 2007-09-04 | 2013-12-31 | Foamix Ltd. | Device for delivery of a foamable composition |
EA017174B1 (en) | 2007-09-30 | 2012-10-30 | Меда Аб | Silicone gel-based composition and medicament for wound healing and scar reduction |
US20090130029A1 (en) | 2007-11-21 | 2009-05-21 | Foamix Ltd. | Glycerol ethers vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009087578A2 (en) | 2008-01-08 | 2009-07-16 | Foamix Ltd. | Sensation modifying topical composition foam |
US8652443B2 (en) | 2008-02-14 | 2014-02-18 | Precision Dermatology, Inc. | Foamable microemulsion compositions for topical administration |
US20090253660A1 (en) | 2008-03-05 | 2009-10-08 | Paratek Pharmaceuticals, Inc. | Minocycline Compounds and Methods of Use Thereof |
EP2564857B1 (en) | 2008-03-06 | 2017-05-03 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-inflammatory agents |
US20120141384A1 (en) | 2008-05-06 | 2012-06-07 | Dov Tamarkin | Antibacterial conjugated boronic acids and pharmaceutical compositions thereof |
WO2009141406A1 (en) | 2008-05-21 | 2009-11-26 | Galderma Research & Development | Maintenance therapy regimen for treating acne |
CA3042777A1 (en) | 2008-06-26 | 2009-12-30 | Anterios, Inc. | Dermal delivery |
JP5070340B2 (en) | 2008-08-07 | 2012-11-14 | シャープ株式会社 | Display device |
BRPI0921685A2 (en) | 2008-10-31 | 2016-02-16 | Moberg Derma Ab | a topical composition comprising a combination of at least two penetration enhancing agents. |
ES2364692T3 (en) | 2008-12-23 | 2011-09-12 | Intendis Gmbh | ESSENTIALLY FREE FOAM COMPOSITION OF PHARMACEUTICALLY ACTIVE INGREDIENTS FOR HUMAN SKIN TREATMENT. |
JP5213734B2 (en) | 2009-01-22 | 2013-06-19 | サンウエーブ工業株式会社 | Cabinet with flap door |
MX354480B (en) | 2009-02-12 | 2018-03-07 | Prec Dermatology Inc Star | Foamable benzoyl peroxide compositions for topical administration. |
JP6130992B2 (en) | 2009-02-25 | 2017-05-17 | スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド | Topical foam composition |
US20120164087A1 (en) | 2009-04-24 | 2012-06-28 | Carter Daniel C | Human Serum Albumin-Based Topical Ointment for Treatment of Acne, Psoriasis, Egfr-Induced Toxicity, Premature Skin Aging and Other Skin Conditions |
US9814657B2 (en) | 2009-04-27 | 2017-11-14 | Premier Dental Products Company | Buffered microencapsulated compositions and methods |
US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
PT104644B (en) | 2009-06-26 | 2012-11-06 | Hovione Farmaciencia S A | Topical formulation containing a tetracycline and a method of treating skin infections using the same |
US8255186B2 (en) | 2009-07-09 | 2012-08-28 | Air Liquide Large Industries U.S. Lp | Presenting dynamic SCADA data |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US20110052506A1 (en) | 2009-08-31 | 2011-03-03 | Collegium Pharmaceutical, Inc. | Stable Aerosol Topical Foams Comprising a Hypochlorite Salt |
US20140121188A1 (en) | 2009-10-02 | 2014-05-01 | Foamix Ltd. | Compositions for the improved treatment of acne and related disorders |
US20140186269A1 (en) | 2013-01-03 | 2014-07-03 | Foamix Ltd. | Vehicle compositions essentially free of pharmaceutically active agents for the improved treatment of acne and related disorders |
GB2474930B (en) | 2009-10-02 | 2012-07-04 | Foamix Ltd | Topical tetracycline compositions |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8735377B1 (en) | 2010-02-04 | 2014-05-27 | Susan Anna Sipos | Methods of treating herpes zoster |
US20110212035A1 (en) | 2010-02-26 | 2011-09-01 | Collegium Pharmaceutical, Inc. | Emollient foams for treatment of dermatoses |
WO2011115700A2 (en) | 2010-03-18 | 2011-09-22 | Precision Dermatology, Inc. | Emollient foams for treatment of seborrheic dermatitis |
EP2563336A4 (en) | 2010-03-26 | 2014-07-23 | Prec Dermatology Inc | Aerosol foams comprising clindamycin phosphate |
US20120076742A1 (en) | 2010-04-21 | 2012-03-29 | Phillips D Howard | Topical drug delivery system with dual carriers |
US20130053353A1 (en) | 2010-05-04 | 2013-02-28 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses |
ES2918299T3 (en) | 2010-06-11 | 2022-07-15 | Prec Dermatology Inc | High oil content emollient spray foam compositions |
WO2012007843A2 (en) | 2010-07-12 | 2012-01-19 | Foamix Ltd. | Apparatus and method for releasing a unit dose of content from a container |
CN103347517B (en) | 2010-08-11 | 2018-10-02 | 德雷克塞尔大学 | Treat the D of dyskinesia in Parkinson's disease3Dopamine-receptor stimulant |
US20120064136A1 (en) | 2010-09-10 | 2012-03-15 | Nanobio Corporation | Anti-aging and wrinkle treatment methods using nanoemulsion compositions |
US20120093876A1 (en) | 2010-10-13 | 2012-04-19 | Aciex, Inc. | Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions |
US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
FR2969492B1 (en) | 2010-12-23 | 2013-07-05 | Galderma Res & Dev | DERMATOLOGICAL FOAMS OBTAINED FROM GEL OR SUSPENSION CONTAINING ADAPALENE |
SG10201600332TA (en) | 2011-01-19 | 2016-02-26 | Lab Skin Care Inc | Topical minocycline compositions and methods of using the same |
CA2834262C (en) | 2011-04-28 | 2020-08-25 | Borje S. Andersson | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
WO2013009586A1 (en) | 2011-07-08 | 2013-01-17 | The Research Foundation Of State University Of New York | Topical minocycline ointment for suppression of allergic skin responses |
EP2773324A4 (en) | 2011-11-03 | 2015-07-01 | Prec Dermatology Inc | Stable dermatological aerosol foams utilizing reactive propellants |
US8801680B2 (en) | 2012-03-14 | 2014-08-12 | Becton, Dickinson And Company | Angled retracting sheath for safety needle |
IL225246A0 (en) | 2012-03-15 | 2013-06-27 | Meir Eini | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US20130251644A1 (en) | 2012-03-22 | 2013-09-26 | Precision Dermatology, Inc. | Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof |
CA2775393C (en) | 2012-05-02 | 2014-04-29 | Samy Saad | Topical non-aqueous pharmaceutical formulations |
WO2014012094A2 (en) | 2012-07-13 | 2014-01-16 | Paratek Pharmaceuticals, Inc. | Tetracycline compounds for treating neurodegenerative disorders |
PT106679B (en) | 2012-11-27 | 2015-03-25 | Hovione Farmaciencia Sa | TOPICAL FORMULATIONS OF TETRACYCLINES, THEIR PREPARATION AND USES |
US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
WO2014130763A1 (en) | 2013-02-22 | 2014-08-28 | Stiefel Laboratories, Inc. | Non-aqueous solid stabilized emulsions |
WO2014134427A1 (en) | 2013-02-28 | 2014-09-04 | Precision Dermatology, Inc. | Controlling the bioavailability of active ingredients in topical formulations |
WO2014134394A1 (en) | 2013-02-28 | 2014-09-04 | Precision Dermatology, Inc. | Topical formulations of corticosteroids with enhanced bioavailability |
WO2014151347A1 (en) | 2013-03-15 | 2014-09-25 | Revance Therapeutics, Inc. | Minocycline derivatives |
CA2914583C (en) | 2013-06-04 | 2019-06-18 | Vyome Biosciences Pvt. Ltd. | Coated particles and compositions comprising same |
CA2915206A1 (en) | 2013-06-17 | 2014-12-24 | Contract Pharmaceuticals Limited | Non-aerosol foams for topical administration |
US9883848B2 (en) | 2013-09-13 | 2018-02-06 | Maui Imaging, Inc. | Ultrasound imaging using apparent point-source transmit transducer |
US9474720B2 (en) | 2013-11-04 | 2016-10-25 | BioPharmX, Inc. | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers |
US20160287614A1 (en) | 2013-11-20 | 2016-10-06 | Lupin Limited | Stable Pharmaceutical Formulation(s) of Tetracycline Antibiotic |
PT107433B (en) | 2014-01-28 | 2018-12-04 | Hovione Farm S A | PARTICLE SIZE REDUCTION AND CONTROL PROCESS |
WO2015153864A2 (en) | 2014-04-02 | 2015-10-08 | Hopkins Patricia T | Methods for treating inflammatory conditions |
US9841142B2 (en) | 2014-12-22 | 2017-12-12 | Rockwell Automation Technologies, Inc. | Single-wire industrial safety system with safety device diagnostic communication |
JP2018506554A (en) | 2015-02-25 | 2018-03-08 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドSun Pharma Advanced Research Company Limited | Nanoparticle composition |
RU2017134566A (en) | 2015-03-23 | 2019-04-05 | Байофармкс, Инк. | PHARMACEUTICAL TETRACYCLINE COMPOSITION FOR DERMATOLOGICAL USE |
US20160287615A1 (en) | 2015-04-03 | 2016-10-06 | BioPharmX, Inc. | Novel encapsulation of fluorescent, photo-sensitive, or oxygen-sensitive active ingredient for topical application |
DE102015209752A1 (en) | 2015-05-28 | 2016-12-01 | Beiersdorf Ag | Sprayable highly viscous cosmetic preparation |
WO2016205172A1 (en) | 2015-06-15 | 2016-12-22 | Banner Life Sciences Llc | Soft lozenges comprising corticosteroids |
CA2992107A1 (en) | 2015-07-13 | 2017-01-19 | Dr. Reddy's Laboratories Ltd. | Topical retinoid compositions |
US10080763B2 (en) | 2015-08-17 | 2018-09-25 | Sidmak Laboratories (India) Pvt. Ltd. | Topical film delivery system |
US20190307778A1 (en) | 2015-08-20 | 2019-10-10 | Foamix Pharmaceuticals Ltd. | Tetracycline management of egfr inhibitor associated dermatoses |
MX2018002067A (en) | 2015-08-20 | 2018-09-05 | Foamix Pharmaceuticals Ltd | Tetracycline management of egfr inhibitor associated dermatoses. |
PT108978B (en) | 2015-11-24 | 2020-03-09 | Hovione Farm S A | TETRACYCLINE SALTS |
AU2017250267A1 (en) | 2016-04-12 | 2018-11-08 | Illustris Pharmaceuticals, Inc. | Compositions for topical application of compounds |
CA2978573A1 (en) | 2016-09-08 | 2018-03-08 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
AU2017351950A1 (en) | 2016-10-26 | 2019-05-02 | Oxy Solutions As | Formulations |
US10821075B1 (en) | 2017-07-12 | 2020-11-03 | James Blanchard | Compositions for topical application of a medicaments onto a mammalian body surface |
US20200345671A1 (en) | 2017-10-24 | 2020-11-05 | Glenmark Pharmaceuticals Limited | Topical pharmaceutical composition of adapalene and minocycline |
US11690998B2 (en) | 2017-10-31 | 2023-07-04 | Theradep Technologies, Inc. | Methods of treating bacterial infections |
WO2019164984A1 (en) | 2018-02-20 | 2019-08-29 | BioPharmX, Inc. | Topical compositions with stable solubilized selective retinoids and/or tetracycline-class antibiotics |
US10350226B1 (en) | 2018-06-27 | 2019-07-16 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections |
CA3116971A1 (en) | 2018-10-29 | 2020-05-07 | Sol-Gel Technologies Ltd. | Topical minocycline foamable compositions |
WO2020130035A1 (en) | 2018-12-19 | 2020-06-25 | 日東メディック株式会社 | Foamable topical composition |
US20200222358A1 (en) | 2019-01-15 | 2020-07-16 | Derma Research Group Inc. | Topical dermatologic acne treatment cream composition and method of manufacture |
-
2002
- 2002-10-25 IL IL15248602A patent/IL152486A0/en unknown
-
2003
- 2003-10-24 CN CNA2003801039672A patent/CN1713891A/en active Pending
-
2005
- 2005-04-25 ZA ZA200503298A patent/ZA200503298B/en unknown
-
2007
- 2007-07-24 ZA ZA200706383A patent/ZA200706383B/en unknown
-
2008
- 2008-01-08 US US11/971,197 patent/US20080253973A1/en not_active Abandoned
-
2009
- 2009-01-08 US US12/350,650 patent/US9320705B2/en not_active Expired - Fee Related
-
2013
- 2013-03-12 US US13/795,831 patent/US20130189196A1/en not_active Abandoned
-
2018
- 2018-02-23 US US15/903,275 patent/US10821077B2/en not_active Expired - Lifetime
-
2020
- 2020-10-16 US US17/072,243 patent/US11033491B2/en active Active
Patent Citations (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2586287A (en) * | 1948-12-11 | 1952-02-19 | Colagte Palmolive Peet Company | Aluminum sulfamate antiperspirant preparation |
US2968628A (en) * | 1958-10-17 | 1961-01-17 | Shulton Inc | Propellant composition |
US3298919A (en) * | 1962-12-26 | 1967-01-17 | Dow Corning | Shaving cream containing polysiloxanes |
US3236457A (en) * | 1963-08-21 | 1966-02-22 | John R Kennedy | Composite spray container assembly |
US3369034A (en) * | 1964-04-27 | 1968-02-13 | Eversharp Inc | Process for separating saponifiables and unsaponifiables in marine animal oils |
US3303970A (en) * | 1964-07-14 | 1967-02-14 | Jerome Marrow | Device for simultaneously dispensing from plural sources |
US3301444A (en) * | 1965-08-12 | 1967-01-31 | Oel Inc | Aerosol metering valve |
US3366494A (en) * | 1967-02-15 | 1968-01-30 | Du Pont | Pressurized aerosol food emulsions |
US3561262A (en) * | 1967-10-26 | 1971-02-09 | Magnaflux Corp | Water soluble developer |
US3563098A (en) * | 1968-06-28 | 1971-02-16 | Rex Chainbelt Inc | Automatic quick release mechanism |
US3559890A (en) * | 1968-09-03 | 1971-02-02 | William R Brooks | Foam dispenser |
US3866800A (en) * | 1969-02-12 | 1975-02-18 | Alberto Culver Co | Non-pressurized package containing self-heating products |
US4001391A (en) * | 1969-04-18 | 1977-01-04 | Plough, Inc. | Means for depositing aerosol sprays in buttery form |
US3787566A (en) * | 1969-07-29 | 1974-01-22 | Holliston Labor Inc | Disinfecting aerosol compositions |
US4001442A (en) * | 1973-07-18 | 1977-01-04 | Elastin-Werk Aktiengesellschaft | Collagen-containing preparations |
US3865275A (en) * | 1973-07-30 | 1975-02-11 | Raymond Lee Organization Inc | Apparatus for operating an aerosol can |
US4252787A (en) * | 1976-12-27 | 1981-02-24 | Cambridge Research And Development Group | Anti-fertility composition and method |
US4310510A (en) * | 1976-12-27 | 1982-01-12 | Sherman Kenneth N | Self administrable anti-fertility composition |
US4309995A (en) * | 1980-01-28 | 1982-01-12 | Sacco Susan M | Vaginal irrigation apparatus |
US4427670A (en) * | 1980-03-27 | 1984-01-24 | Mitsubishi Chemical Industries Limited | Skin preparation |
US5089252A (en) * | 1982-01-15 | 1992-02-18 | L'oreal | Cosmetic composition for treating keratin fibres, and process for treating the latter |
US5087618A (en) * | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
US4981679A (en) * | 1983-06-08 | 1991-01-01 | Briggs Joseph H | Method and composition for the treatment of burns |
US4725609A (en) * | 1983-11-21 | 1988-02-16 | Burroughs Wellcome Co. | Method of promoting healing |
US4985459A (en) * | 1984-02-08 | 1991-01-15 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
US4798682A (en) * | 1985-06-18 | 1989-01-17 | Henkel Kommanditgesellschaft Auf Aktien | Oil-in-water emulsions with increased viscosity under shear stress |
US4806262A (en) * | 1985-08-14 | 1989-02-21 | The Procter & Gamble Company | Nonlathering cleansing mousse with skin conditioning benefits |
US4804674A (en) * | 1986-03-26 | 1989-02-14 | Euroceltique, S.A. | Vaginal pharmaceutical composition |
US4808388A (en) * | 1986-08-20 | 1989-02-28 | Merz + Co. Gmbh & Co. | Foamable creams |
US4993496A (en) * | 1987-07-06 | 1991-02-19 | Total Walther Feuerschutz Gmbh | Quick release valve for sprinkler head |
US4847068A (en) * | 1987-08-06 | 1989-07-11 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions |
US4981677A (en) * | 1987-09-23 | 1991-01-01 | L'oreal | Petrolatum-containing aerosol foam concentrate |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4897262A (en) * | 1988-03-22 | 1990-01-30 | Playtex Jhirmack, Inc. | Non-aerosol hair spray composition |
US5385943A (en) * | 1988-03-30 | 1995-01-31 | Schering Aktiengesellschaft | Use of topically applicable preparations for treatment of presbyderma |
US4992478A (en) * | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US5378730A (en) * | 1988-06-09 | 1995-01-03 | Alza Corporation | Permeation enhancer comprising ethanol and monoglycerides |
US4902281A (en) * | 1988-08-16 | 1990-02-20 | Corus Medical Corporation | Fibrinogen dispensing kit |
US4981845A (en) * | 1988-09-09 | 1991-01-01 | Chesebrough Pond's U.S.A. Co., Division Of Conopco, Inc. | Cosmetic composition |
US5082651A (en) * | 1989-04-26 | 1992-01-21 | Smith Kline & French Laboratories Limited | Pharmaceutical compositions |
US4981367A (en) * | 1989-07-28 | 1991-01-01 | Stranco, Inc. | Portable mixing apparatus |
US5378451A (en) * | 1989-10-19 | 1995-01-03 | Dow B. Hickam, Inc. | Topical medicinal pressurized aerosol compositions and method of preparation, method of use and article of manufacture thereof |
US5866040A (en) * | 1990-06-15 | 1999-02-02 | Shiseido Company, Ltd. | Complex and emulsified composition |
US5091111A (en) * | 1990-09-19 | 1992-02-25 | S. C. Johnson & Son, Inc. | Aqueous emulsion and aersol delivery system using same |
US5286475A (en) * | 1990-11-09 | 1994-02-15 | L'oreal | Anhydrous cosmetic composition in the aerosol form forming a foam |
US5279819A (en) * | 1991-03-18 | 1994-01-18 | The Gillette Company | Shaving compositions |
US5482965A (en) * | 1991-03-19 | 1996-01-09 | Rajadhyaksha; Vithal J. | Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active agents |
US5389676A (en) * | 1991-03-22 | 1995-02-14 | E. B. Michaels Research Associates, Inc. | Viscous surfactant emulsion compositions |
US5380761A (en) * | 1991-04-15 | 1995-01-10 | Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. | Transdermal compositions |
US5719122A (en) * | 1992-10-20 | 1998-02-17 | Smithkline Beecham Farmaceutici S.P.A. | Pharmaceutical compositions containing a calcitonin |
US5491245A (en) * | 1993-03-26 | 1996-02-13 | Th. Goldschmidt Ag | Method for the synthesis of amphoteric surfactants |
US5384308A (en) * | 1993-06-14 | 1995-01-24 | Henkin; R. I. | Composition and method for enhancing wound healing |
US5603940A (en) * | 1993-10-08 | 1997-02-18 | L'oreal | Oil-in-water emulsion which may be used for obtaining a cream |
US5597560A (en) * | 1994-05-17 | 1997-01-28 | Laboratorios Cusi, S.A. | Diclofenac and tobramycin formulations for ophthalmic and otic topicaluse |
US5605679A (en) * | 1994-06-03 | 1997-02-25 | L'oreal | Photoprotective/cosmetic compositions comprising at least one solid organic sunscreen compound and diphenylacrylate solvent therefor |
US5869529A (en) * | 1994-07-20 | 1999-02-09 | Agis Industries (1983) Ltd. | Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus |
USRE38964E1 (en) * | 1995-01-09 | 2006-01-31 | Becton Dickinson And Company | One hand needle release system |
US5716611A (en) * | 1996-01-02 | 1998-02-10 | Euro-Celtique, S.A. | Emollient antimicrobial formulations containing povidone iodine |
US5716621A (en) * | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
US6180669B1 (en) * | 1996-11-12 | 2001-01-30 | Tamarkin Pharmaceutical Innovation Ltd. | Method for treatment of dermatological disorders |
US6171347B1 (en) * | 1996-11-16 | 2001-01-09 | Wella Aktiengesellschaft | Compositions, methods and kits for reductively removing color from dyed hair |
US5856452A (en) * | 1996-12-16 | 1999-01-05 | Sembiosys Genetics Inc. | Oil bodies and associated proteins as affinity matrices |
US5858371A (en) * | 1997-02-05 | 1999-01-12 | Panacea Biotech Limited | Pharmaceutical composition for the control and treatment of anorectal and colonic diseases |
US20060018938A1 (en) * | 1997-08-18 | 2006-01-26 | Stephanie Neubourg | Foam skin cream, use of the foam skin protection cream and a process of its preparation |
US6214318B1 (en) * | 1997-10-02 | 2001-04-10 | Oms Holdings Llc | Aerosol ointment compositions for topical use |
US5865347A (en) * | 1997-10-27 | 1999-02-02 | William T. Wilkinson | Multi-chamber dispenser for flowable materials |
US5871720A (en) * | 1997-11-20 | 1999-02-16 | Colgate-Palmolive Company | Cosmetic compositions with DBS and functionalized silicones |
US20020013481A1 (en) * | 1998-02-24 | 2002-01-31 | Uwe Schonrock | Use of flavones flavanones and flavonoids for protecting ascorbic acid and/or ascorbyl compounds from oxidation |
US6335022B1 (en) * | 1998-12-17 | 2002-01-01 | L'oreal | Nanoemulsion based on oxyethylenated or non-oxyethylenated sorbitan fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields |
US6672483B1 (en) * | 1999-02-05 | 2004-01-06 | Rexam Sofab | Dispenser for chemically unstable products |
US6168576B1 (en) * | 1999-05-24 | 2001-01-02 | Irene N. Reynolds | Device for dispensing vaginal medication |
US6511655B1 (en) * | 1999-08-16 | 2003-01-28 | Beiersdorf Ag | Cosmetic or dermatological preparations of the oil-in-water type |
US20030006193A1 (en) * | 1999-09-06 | 2003-01-09 | Katsunori Ikeda | Apparatus for purifying nucleic acids and proteins |
US20020004063A1 (en) * | 1999-09-28 | 2002-01-10 | Jie Zhang | Methods and apparatus for drug delivery involving phase changing formulations |
US20020048798A1 (en) * | 2000-03-15 | 2002-04-25 | Avery Mitchell Allen | Novel antioxidants |
US6341717B2 (en) * | 2000-04-01 | 2002-01-29 | Megaplast Gmbh & Co. Kg | Metering pump dispenser with at least two metering pumps |
US20020002151A1 (en) * | 2000-05-23 | 2002-01-03 | Showa Yakuhin Kako Co., Ltd. | Minocycline-containing compositions |
US20020122811A1 (en) * | 2000-10-04 | 2002-09-05 | Bernd Stein | Hair wax products containing waxes, non-volatile oils and volatile hydrophobic materials |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
US20050013853A1 (en) * | 2000-11-29 | 2005-01-20 | Irit Gil-Ad | Anti-proliferative drugs |
US6682750B2 (en) * | 2001-03-03 | 2004-01-27 | Clariant Gmbh | Surfactant-free cosmetic, dermatological and pharmaceutical compositions |
US6682726B2 (en) * | 2001-04-30 | 2004-01-27 | The Gillette Company | Self-foaming shaving lotion |
US20080015263A1 (en) * | 2002-02-27 | 2008-01-17 | Bolotin Elijah M | Compositions for delivery of therapeutics and other materials |
US6897195B2 (en) * | 2002-07-24 | 2005-05-24 | Nanjing Zhongshi Chemical Co. | Composition of menthol and menthyl lactate, its preparation method and its applications as a cooling agent |
US20070020213A1 (en) * | 2002-10-25 | 2007-01-25 | Foamix Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
US20070020304A1 (en) * | 2002-10-25 | 2007-01-25 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US6843390B1 (en) * | 2003-03-17 | 2005-01-18 | Joe G. Bristor | Multiple fluid closed system dispensing device |
US20070010580A1 (en) * | 2003-05-30 | 2007-01-11 | Gianfranco De Paoli Ambrosi | Formulation for chemical peeling |
US20050002976A1 (en) * | 2003-06-19 | 2005-01-06 | The Procter & Gamble Company | Polyol-in-silicone emulsions |
US8362091B2 (en) * | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20110002857A1 (en) * | 2003-08-04 | 2011-01-06 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20060008432A1 (en) * | 2004-07-07 | 2006-01-12 | Sebastiano Scarampi | Gilsonite derived pharmaceutical delivery compositions and methods: nail applications |
US20060014990A1 (en) * | 2004-07-14 | 2006-01-19 | Kuechler Keith H | Process for producing olefins |
US7645803B2 (en) * | 2005-05-09 | 2010-01-12 | Foamix Ltd. | Saccharide foamable compositions |
US20070009607A1 (en) * | 2005-07-11 | 2007-01-11 | George Jones | Antibacterial/anti-infalmmatory composition and method |
US20070017696A1 (en) * | 2005-07-22 | 2007-01-25 | Hon Hai Precision Industry Co., Ltd. | Multi-layer printed circuit board |
US20070224143A1 (en) * | 2006-03-21 | 2007-09-27 | Kamedis Ltd. | Cosmetic and pharmaceutical foam carrier |
US20080008397A1 (en) * | 2006-07-04 | 2008-01-10 | Pavel Kisilev | Feature-aware image defect removal |
US20080015271A1 (en) * | 2006-07-14 | 2008-01-17 | Stiefel Research Austrialia Pty Ltd | Fatty acid pharmaceutical foam |
US8343945B2 (en) * | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US20110008266A1 (en) * | 2008-01-14 | 2011-01-13 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US20110002969A1 (en) * | 2008-02-29 | 2011-01-06 | Lipotec, S.A. | Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors |
US20130011342A1 (en) * | 2009-10-02 | 2013-01-10 | Foamix Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US20130028850A1 (en) * | 2009-10-02 | 2013-01-31 | Foamix Ltd. | Topical tetracycline compositions |
Non-Patent Citations (1)
Title |
---|
Prud'homme et al., Foams: theory, measurements, and applications, Marcel Dekker, Inc., 327-328, 1996. * |
Cited By (193)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8741265B2 (en) | 2002-10-25 | 2014-06-03 | Foamix Ltd. | Penetrating pharmaceutical foam |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8119106B2 (en) | 2003-04-28 | 2012-02-21 | Foamix Ltd | Foamable iodine compositions |
US8486375B2 (en) | 2003-04-28 | 2013-07-16 | Foamix Ltd. | Foamable compositions |
US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8703105B2 (en) | 2003-08-04 | 2014-04-22 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8114385B2 (en) | 2003-08-04 | 2012-02-14 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8518378B2 (en) | 2003-08-04 | 2013-08-27 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8362091B2 (en) | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9427605B2 (en) | 2005-03-24 | 2016-08-30 | Novan, Inc. | Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor |
US7645803B2 (en) | 2005-05-09 | 2010-01-12 | Foamix Ltd. | Saccharide foamable compositions |
US8629128B2 (en) | 2005-06-01 | 2014-01-14 | Stiefel West Coast, Llc | Vitamin formulation |
US8298515B2 (en) | 2005-06-01 | 2012-10-30 | Stiefel Research Australia Pty Ltd. | Vitamin formulation |
US20080069924A1 (en) * | 2006-09-19 | 2008-03-20 | Bary Lyn Zeller | Gasified Food Products and Methods of Preparation Thereof |
US8084050B2 (en) | 2006-10-11 | 2011-12-27 | Colgate-Palmolive Company | Compositions comprising combinations of sensates |
US20080089850A1 (en) * | 2006-10-11 | 2008-04-17 | Ariel Haskel | Compositions Comprising Combinations of Sensates |
US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US9549898B2 (en) | 2007-12-07 | 2017-01-24 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US20090253973A1 (en) * | 2008-04-04 | 2009-10-08 | Eran Bashan | Apparatus for optimizing a patient's insulin dosage regimen |
EP2381926A1 (en) * | 2008-12-10 | 2011-11-02 | Roc Lebel | Topical foaming composition and method of application |
EP2381926A4 (en) * | 2008-12-10 | 2012-12-12 | Roc Lebel | Topical foaming composition and method of application |
US20120004305A1 (en) * | 2009-03-11 | 2012-01-05 | Kowa Co., Ltd. | External preparation containing analgesic/anti-inflammatory agent |
US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US8962057B2 (en) | 2009-04-29 | 2015-02-24 | The Procter & Gamble Company | Methods for improving taste and oral care compositions with improved taste |
US20100278991A1 (en) * | 2009-04-29 | 2010-11-04 | John Christian Haught | Methods for Improving Taste and Oral Care Compositions With Improved Taste |
US9492458B2 (en) | 2009-06-24 | 2016-11-15 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US10898489B2 (en) | 2009-06-24 | 2021-01-26 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9675619B2 (en) | 2009-06-24 | 2017-06-13 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9457092B2 (en) | 2009-06-24 | 2016-10-04 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US10682357B2 (en) | 2009-06-24 | 2020-06-16 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US10172865B2 (en) | 2009-06-24 | 2019-01-08 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9737543B2 (en) | 2009-06-24 | 2017-08-22 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
EP3045171A1 (en) * | 2009-06-24 | 2016-07-20 | Strategic Science & Technologies, LLC | Topical composition |
WO2011009972A1 (en) * | 2009-07-21 | 2011-01-27 | Zuazo Gauger, S.L. | Foaming composition for creating indications for a limited duration of time |
US9572775B2 (en) | 2009-07-29 | 2017-02-21 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9737561B2 (en) | 2009-08-21 | 2017-08-22 | Novan, Inc. | Topical gels and methods of using the same |
US10376538B2 (en) | 2009-08-21 | 2019-08-13 | Novan, Inc. | Topical gels and methods of using the same |
US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
US9919072B2 (en) | 2009-08-21 | 2018-03-20 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US11583608B2 (en) | 2009-08-21 | 2023-02-21 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
JP2013505967A (en) * | 2009-09-30 | 2013-02-21 | スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド | Beauty form |
US20130108557A1 (en) * | 2009-09-30 | 2013-05-02 | Albert Zorko Abram | Cosmetic foam |
US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8992896B2 (en) | 2009-10-02 | 2015-03-31 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
WO2011085053A2 (en) | 2010-01-07 | 2011-07-14 | The Gillette Company | Personal care compositions comprising a multi-active system for down regulating cytokines irritation |
WO2011088073A2 (en) | 2010-01-15 | 2011-07-21 | The Gillette Company | Personal care compositions comprising a methyl naphthalenyl ketone or a derivative thereof |
WO2011119585A3 (en) * | 2010-03-26 | 2012-01-12 | Precision Dermatology, Inc. | Aerosol foams comprising clindamycin phosphate |
US8592380B2 (en) | 2010-03-26 | 2013-11-26 | Precision Dermatology, Inc. | Aerosol foams comprising clindamycin phosphate |
US20110236321A1 (en) * | 2010-03-26 | 2011-09-29 | Precision Dermatology, Inc. | Aerosol Foams Comprising Clindamycin Phosphate |
US20110263715A1 (en) * | 2010-04-21 | 2011-10-27 | Adchara Pongpeerapat | Local Anesthetic Emulsion Compositions and Methods of Making and Using the Same |
US8535692B2 (en) * | 2010-04-21 | 2013-09-17 | Teikoku Pharma Usa, Inc. | Local anesthetic emulsion compositions and methods of making and using the same |
US20130202543A1 (en) * | 2010-06-14 | 2013-08-08 | Symrise Ag | Use of polyols for enhancing the cooling effect of a cooling substance and cooling mixtures having an enhanced cooling effect |
US11491091B2 (en) * | 2010-06-14 | 2022-11-08 | Symrise Ag | Cooling product |
US10028920B2 (en) | 2010-09-08 | 2018-07-24 | Universidad Miguel Hernandez De Elche | Methods for treating occular irritation involving tearing by administering modulators of TRPM8 |
EP2614860A4 (en) * | 2010-09-08 | 2014-01-29 | Univ Miguel Hernandez De Elche | Pharmaceutical composition for the treatment of dry eye |
US9901549B2 (en) | 2010-09-08 | 2018-02-27 | Universidad Miguel Hernández De Elche | Method for treating vaginal dryness by administering transient receptor potential cation channel subfamily M member 8 (TRPM8) receptor agonists |
EP2614860A2 (en) * | 2010-09-08 | 2013-07-17 | Universidad Miguel Hernández De Elche | Pharmaceutical composition for the treatment of dry eye |
EP4268814A3 (en) * | 2010-09-08 | 2024-01-24 | Universidad Miguel Hernández De Elche | Pharmaceutical composition for the treatment of dry eye |
US9833456B2 (en) | 2010-12-29 | 2017-12-05 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9498482B2 (en) | 2010-12-29 | 2016-11-22 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
WO2012104164A3 (en) * | 2011-02-04 | 2013-01-17 | Beiersdorf Ag | Self-heating, surfactant-containing cleansing gel featuring a combination of low and high molecular mass pegs |
US20120213717A1 (en) * | 2011-02-18 | 2012-08-23 | Mcneil-Ppc, Inc. | Soothing Agents |
US9309487B2 (en) * | 2011-06-23 | 2016-04-12 | The Procter & Gamble Company | Perfume systems |
US9822327B2 (en) | 2011-06-23 | 2017-11-21 | The Procter & Gamble Company | Perfume systems |
US20140378360A1 (en) * | 2011-06-23 | 2014-12-25 | The Procter & Gamble Company | Perfume systems |
US10265334B2 (en) | 2011-07-05 | 2019-04-23 | Novan, Inc. | Anhydrous compositions |
US9757397B2 (en) | 2011-07-05 | 2017-09-12 | Novan, Inc. | Methods of manufacturing topical compositions and apparatus for the same |
US10500220B2 (en) | 2011-07-05 | 2019-12-10 | Novan, Inc. | Topical compositions |
US11077194B2 (en) | 2012-03-14 | 2021-08-03 | Novan, Inc. | Nitric oxide releasing pharmaceutical compositions |
WO2013165481A1 (en) * | 2012-05-01 | 2013-11-07 | Amberwing Solutions Inc. | Method and product for headache relief |
WO2014060150A1 (en) * | 2012-10-15 | 2014-04-24 | Beiersdorf Ag | Cosmetic or dermatological preparation for prophylaxis and/or treatment of atopic dermatitis |
US9789099B2 (en) | 2012-10-15 | 2017-10-17 | Beiersdorf Ag | Cosmetic or dermatological preparation for prophylaxis and/or treatment of atopic dermatitis |
DE102012218733A1 (en) * | 2012-10-15 | 2014-04-17 | Beiersdorf Ag | Cosmetic or dermatological preparation for the prophylaxis and / or treatment of atopic dermatitis |
US8936814B2 (en) * | 2012-11-30 | 2015-01-20 | Zuri A. Murrell | Skin cream |
US9463159B2 (en) * | 2012-12-06 | 2016-10-11 | Colgate-Palmolive Company | Oral gel for relief of tooth pain |
US10258564B2 (en) | 2013-02-28 | 2019-04-16 | Novan, Inc. | Topical compositions and methods of using the same |
US11285098B2 (en) | 2013-02-28 | 2022-03-29 | Novan, Inc. | Topical compositions and methods of using the same |
US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
WO2014204008A1 (en) * | 2013-06-18 | 2014-12-24 | L'oreal | Foam aerosol cosmetic composition |
US10226483B2 (en) | 2013-08-08 | 2019-03-12 | Novan, Inc. | Topical compositions and methods of using the same |
US11813284B2 (en) | 2013-08-08 | 2023-11-14 | Novan, Inc. | Topical compositions and methods of using the same |
US10206947B2 (en) | 2013-08-08 | 2019-02-19 | Novan, Inc. | Topical compositions and methods of using the same |
US10828323B2 (en) | 2013-08-08 | 2020-11-10 | Novan, Inc. | Topical compositions and methods of using the same |
KR101351841B1 (en) | 2013-08-28 | 2014-01-15 | 윤경 | Cellulose patch having cooling and heating function |
EP2862442A1 (en) * | 2013-10-16 | 2015-04-22 | Fulltec GmbH | Insect repellent |
US9695292B2 (en) | 2013-11-26 | 2017-07-04 | Ansell Limited | Effervescent texturing |
US11040006B2 (en) | 2014-07-11 | 2021-06-22 | Novan, Inc. | Topical antiviral compositions, delivery systems, and methods of using the same |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US11723858B2 (en) | 2014-07-11 | 2023-08-15 | Novan, Inc. | Topical antiviral compositions, delivery systems, and methods of using the same |
US10736839B2 (en) | 2014-07-11 | 2020-08-11 | Novan, Inc. | Topical antiviral compositions, delivery systems, and methods of using the same |
US10322081B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US10925689B2 (en) | 2014-07-14 | 2021-02-23 | Novan, Inc. | Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same |
GB2548775B (en) * | 2014-12-29 | 2020-09-02 | Kimberly Clark Co | Cosmetic emulsions |
GB2548775A (en) * | 2014-12-29 | 2017-09-27 | Kimberly Clark Co | Cosmetic emulsions |
US10111824B2 (en) | 2014-12-29 | 2018-10-30 | Kimberly-Clark Worldwide, Inc. | Cosmetic emulsions |
WO2016109517A1 (en) * | 2014-12-29 | 2016-07-07 | Kimberly-Clark Worldwide, Inc. | Cosmetic emulsions |
US10406081B2 (en) | 2014-12-29 | 2019-09-10 | Kimberly-Clark Worldwide, Inc. | Multifunctional base emulsion |
US10849864B2 (en) | 2015-07-28 | 2020-12-01 | Novan, Inc. | Combinations and methods for the treatment and/or prevention of fungal infections |
US10912743B2 (en) | 2016-03-02 | 2021-02-09 | Novan, Inc. | Compositions for treating inflammation and methods of treating the same |
KR101793818B1 (en) | 2016-03-04 | 2017-11-06 | 서영아 | Hair improving composition for preventing hair loss and promoting a growth hair, and the hair improving material using the composition |
US11166980B2 (en) | 2016-04-13 | 2021-11-09 | Novan, Inc. | Compositions, systems, kits, and methods for treating an infection |
US11826440B2 (en) | 2016-05-11 | 2023-11-28 | Formulated Solutions, Llc | Thermal-stable whipped formulations |
US11622922B2 (en) | 2016-05-11 | 2023-04-11 | Formulated Solutions, Llc | Whipped formulations |
US11612551B2 (en) | 2016-05-11 | 2023-03-28 | Formulated Solutions, Llc | Whipped formulations |
US11964035B2 (en) | 2016-05-11 | 2024-04-23 | Beiersdorf Ag | Whipped gel formulations |
CN110035663A (en) * | 2016-05-11 | 2019-07-19 | 拜耳医药保健有限责任公司 | The heat-staple preparation for breaking into foam |
CN110475473A (en) * | 2016-08-23 | 2019-11-19 | 奇特利奇公司 | Containing monoterpene/Phenylpropanoid Glycosides compound and preparation method thereof and as the purposes of insecticide |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
CN109475120A (en) * | 2016-10-11 | 2019-03-15 | 西姆莱斯股份公司 | Antimicrobial compositions |
US11116710B2 (en) * | 2016-10-11 | 2021-09-14 | Symrise Ag | Antimicrobial compositions |
US20190282478A1 (en) * | 2016-10-11 | 2019-09-19 | Symrise Ag | Antimicrobial compositions |
US11602493B2 (en) | 2017-05-11 | 2023-03-14 | Beiersdorf Ag | Gel formulations |
US10398731B2 (en) * | 2017-06-12 | 2019-09-03 | James H Southard, Jr. | Treatment for warts |
US20190175739A1 (en) * | 2017-12-08 | 2019-06-13 | Church & Dwight Co., Inc. | Non-medicated, teething, cooling composition |
US11147761B2 (en) | 2018-01-12 | 2021-10-19 | Nicole Akmenkalns | Topical supplement composition and method of use |
US11285171B2 (en) | 2018-03-01 | 2022-03-29 | Novan, Inc. | Nitric oxide releasing suppositories and methods of use thereof |
US20220040135A1 (en) * | 2018-10-01 | 2022-02-10 | Wintermute Biomedical, Inc. | Therapeutic compositions of decanoic acid and arginine |
US20220000825A1 (en) * | 2018-10-01 | 2022-01-06 | Wintermute Biomedical, Inc. | Therapeutic compositions |
US12138311B2 (en) | 2020-02-28 | 2024-11-12 | Journey Medical Corporation | Topical tetracycline compositions |
US20220008461A1 (en) * | 2020-07-13 | 2022-01-13 | Nsc-Nano Sono Cooperation Ltd | Anhydrous antimicrobial topical formulations and methods of use thereof |
US12102650B2 (en) * | 2020-07-13 | 2024-10-01 | Nsc-Nano Sono Cooperation Ltd | Anhydrous antimicrobial topical formulations and methods of use thereof |
WO2024189661A1 (en) * | 2023-03-13 | 2024-09-19 | Jordan University Of Science And Technology | A topical composition comprising a ternary metal oxide nanoparticle preservative |
US12138332B2 (en) | 2023-03-24 | 2024-11-12 | Formulated Solutions, Llc | Whipped formulations |
US12138268B2 (en) | 2023-04-18 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
RU2829491C1 (en) * | 2024-05-09 | 2024-10-30 | Борис Юльевич Чебураков | Cellulite treatment gel |
Also Published As
Publication number | Publication date |
---|---|
US20120237453A1 (en) | 2012-09-20 |
US20190022001A1 (en) | 2019-01-24 |
US20210038517A1 (en) | 2021-02-11 |
ZA200503298B (en) | 2006-08-30 |
US20190247310A9 (en) | 2019-08-15 |
US11033491B2 (en) | 2021-06-15 |
US20130189196A1 (en) | 2013-07-25 |
IL152486A0 (en) | 2003-05-29 |
US9320705B2 (en) | 2016-04-26 |
US10821077B2 (en) | 2020-11-03 |
ZA200706383B (en) | 2008-12-31 |
CN1713891A (en) | 2005-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9320705B2 (en) | Sensation modifying topical composition foam | |
CA2711703A1 (en) | Sensation modifying topical composition foam | |
US11103454B2 (en) | Wax foamable vehicle and pharmaceutical compositions thereof | |
US10322085B2 (en) | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof | |
US8119109B2 (en) | Foamable compositions, kits and methods for hyperhidrosis | |
EP2494959B1 (en) | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof | |
US9439857B2 (en) | Foam containing benzoyl peroxide | |
US20120156144A1 (en) | Foamable Compositions, Kits and Methods for Hyperhidrosis | |
US20080152596A1 (en) | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof | |
US20070292359A1 (en) | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof | |
US9795564B2 (en) | Oil-based foamable carriers and formulations | |
US20150025060A1 (en) | Foamable Compositions and Kits Comprising One or More of a Channel Agent, a Cholinergic Agent, A nitric Oxide Donor and Related Agents and Their Uses | |
US20090130029A1 (en) | Glycerol ethers vehicle and pharmaceutical compositions thereof | |
US20100111879A1 (en) | Saccharide foamable compositions | |
US20120087872A1 (en) | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof | |
WO2008038140A2 (en) | Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FOAMIX LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAMARKIN, DOV;EINI, MEIR;FRIEDMAN, DORON;AND OTHERS;REEL/FRAME:021142/0692;SIGNING DATES FROM 20080428 TO 20080506 |
|
AS | Assignment |
Owner name: FOAMIX LTD.,ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAMARKIN, DOV;EINI, MEIR;FRIEDMAN, DORON;AND OTHERS;SIGNING DATES FROM 20080428 TO 20080506;REEL/FRAME:023947/0316 |
|
AS | Assignment |
Owner name: FOAMIX PHARMACEUTICALS LTD., ISRAEL Free format text: CHANGE OF NAME;ASSIGNOR:FOAMIX LTD.;REEL/FRAME:033445/0249 Effective date: 20140601 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |